

17th June 2026

Ref. No: Union/HQ/2026/003

Request for Proposal for a multi-year agreement to manage elements of the Union World Conference on Lung Health 2027–2029

1. BACKGROUND

- 1.1. **The Union** is a global membership, technical and scientific organisation. We were established in 1920 and are led by people who are committed to our vision, mission and values. Our members are organisations and individuals from all parts of the world. We bring together clinicians, managers, policy makers, front-line workers and implementers, scientists, patients and survivors, advocates and civil society. In collaboration with national Ministries of Health and international partners, we develop, promote and evaluate effective strategies for tuberculosis control in low- and middle-income countries.
- 1.2. The Union provides technical assistance to national tuberculosis control programs, leads various research projects, conducts international and national courses in several languages, organises world conferences, publishes several guides and peer reviewed journals (*International Journal of Tuberculosis and Lung Disease*, *IJTLD Open*, *IJTLD CRD* and *Public Health Action*). In addition to tuberculosis, The Union is also involved in tobacco control and non-communicable diseases. For more information, visit www.theunion.org.

2. PURPOSE

- 2.1. The Union seeks to engage an agency on a multi-year agreement to manage elements of the Union World Conference on Lung Health (WCLH) from 2027–2029.
- 2.2. In pursuance of this objective The Union has decided to carry out the bidding process for hiring of an agency to whom the contract may be awarded. This RFP should not be considered as an agreement or offer by The Union to the prospective bidders. The purpose of this RFP is to provide interested parties with information that may be useful to them in the submission of proposals pursuant to this RFP.
- 2.3. The Applicants must submit their applications in accordance with the requirements contained in this RFP.
- 2.4. The Union reserves the right to update, amend and supplement the information in this document including qualification process before the last date and time of submission of applications.

3. GENERAL TERMS OF BIDDING

- 3.1. All bidders are required to submit their bid in accordance with the terms set forth in this RFP.
- 3.2. Notwithstanding anything to the contrary contained in this RFP, the detailed terms specified in the Agreement shall have overriding effect. Provided that any conditions or obligations imposed on the bidder hereunder shall continue to have effect in addition to its obligations under that Agreement.
- 3.3. The Union reserves the right to invite fresh bids with or without amendment of the RFP at any stage or to terminate at any time the entire bidding/selection process without any liability or any obligation to any of the bidders and without assigning any reason whatsoever.
- 3.4. The Union will not guarantee any minimum quantity of business under any contract. Also, The Union reserves the right to split the business amongst the agencies keeping in mind the interest of the organisation. The Union reserves the right to enter into contract with multiple bidders/agencies at the same time.
- 3.5. Bidder may submit a proposal as a single entity or collaborate with other Service Providers to present a proposal either by submitting a joint proposal or through subcontracting. Proposals may also combine both approaches. The legal status and role of each legal entity shall be clearly described in the proposal.
- 3.6. A bidder shall not have a conflict of interest that affects the bidding process. Any bidder found to have a conflict of interest shall be disqualified.
- 3.7. Also, the bidder should not have been convicted/charge-sheeted for any criminal offence. Any entity which has been convicted for any criminal offence shall not be eligible to submit the bid.
- 3.8. The bidder must have no affiliation with the tobacco industry and/or its agents/associates and currently does not accept and shall not accept financial or other support from any tobacco product manufacturer or the parent, subsidiary or affiliate of a tobacco product manufacturer until at least 12 months after the end of the Agreement period. Failure to comply may constitute grounds for termination of the Agreement.
- 3.9. Any entity which has been convicted for any criminal offence shall not be eligible to submit the bid.

4. GENERAL DISCLOSURES

- 4.1. Respondents must disclose:
 - 4.1.1. If they are or have been the subject of any proceedings or other arrangements relating to bankruptcy, insolvency or the financial standing of the Respondent including but not limited to the appointment of any officer such as a receiver in relation to the Respondent personal or business matters or an arrangement with creditors or of any other similar proceedings.
 - 4.1.2. If they have been convicted of, or are the subject of any proceedings, relating to:

- 4.1.2a. Criminal offence or other offence, a serious offence involving the activities of a criminal organisation or found by any regulator or professional body to have committed professional misconduct.
- 4.1.2b. Corruption including the offer or receipt of any inducement of any kind in relation to obtaining any contract, with The Union or any other contracting body or authority
- 4.2. Failure to fulfil any obligations in any jurisdiction relating to the payment of taxes
- 4.3 If they have any business relationship with or knowingly received payment or other support from any tobacco product manufacturer or wholesaler (the “**Tobacco Industry**”), or any parent, affiliate, subsidiary, organisation, or foundation with majority support from the Tobacco Industry, or any person, interest group, advocacy organisation, or other business or organisation (other than a law firm, advertising agency, or accounting firm) that represents the interests of the Tobacco Industry.

5. SCOPE OF WORK INTRODUCTION

The WCLH is the world’s largest gathering of clinicians and public health workers, health programme managers, policymakers, researchers and advocates working to end the suffering caused by tuberculosis and lung disease, with a focus specifically on the challenges faced by low and lower-middle income populations.

The WCLH is an annual event (typically in the 3rd week of November), attracting 3,000–5,000 delegates, with representatives from over 130 countries.

General information about our conferences is available at: <https://worldlunghealth.org/> and the 2025 Abstract Book is available [here](#)

The 2025 Conference Programme PDF is available on request from the Procurement team. The high-level programme for 2024 is here: <https://conf2024.theunion.org/> and for 2025 here: <https://conf2025.theunion.org/>

Information on TB Science: <https://worldlunghealth.org/tbscience/>

Information on Community Connect: <https://worldlunghealth.org/community-connect/>

As a consequence of the cuts to global funding for public health, we are keen to ensure our conferences are run as effectively as possible, both in terms of costs and the revenue raised. For this reason, we have taken a more long-term approach to countries and venues (see Annexure) and are assessing interest in a multi-year RFP.

In your responses, please highlight any efficiencies this approach presents and describe the specific benefits of partnering with your organisation.

RFP responses must include all costs in detail associated with the delivery and management of the Services covered in this request, including, but not limited to, any national or local taxes that are applicable, permits to operate or permits required by staff to work, and any costs associated with currency requirements. Costs quoted in the RFP response must be in US Dollars.

COMPONENTS TO INCLUDE IN THE RFP RESPONSE

5A. Venue search for the 2028 and 2029 WCLH and venue scoping exercise: **REQUIRED.**

Please advise on your approach to identifying a suitable venue for WCLH 2028 and WCLH 2029:

- For 2028, the venue will be in a high burden TB country, in the African region.
- For 2029, the venue may be in a low burden TB country in WHO Europe Region.

Your response should also incorporate details on the plan for scoping the venue and the key deliverables (e.g., a full set of venue visuals, proposed venue plans for all areas, and mapping of all required space usage for the full conference delivery).

Your plan should include detail on how you would assess the venues, using The Union criteria (see Annexure A) and geographical focus areas (Annexure A), how you would short list the locations and venues, and the level of effort required to conduct a location and venue scoping exercise to allow The Union team to decide on the most appropriate choice.

Please include a specific line item in the financial proposal to account for this exercise.

Also, please note the difference between 5A and 5E. 5E is an optional element to provide strategic input and advisory role on potential future country/site selection.

5B. Online Registration Platform and onsite registration delivery: **REQUIRED**

The RFP response to include a plan for an online and onsite registration delivery service. Please refer to the detailed registration specification for the response (**Annexure F**).

Please include a response for 2027, 2028 and 2029 based on a registration system for 4,000 delegates, with the 2027 WCLH being held in the Bali International Convention Centre, Nusa Dua, Bali, Indonesia: <https://baliconvention.com/>, and 2028 and 2029 venue to be determined, but similar delivery parameters.

5C. 2027 WCLH Delivery: **REQUIRED**

Please include a detailed description and costing for the items numbered **5C i-xiv** below. For the purposes of the RFP response, please consider that the 2027 WCLH will be held in the Bali International Convention Centre, Nusa Dua, Bali, Indonesia: <https://baliconvention.com/>.

For the purposes of this section of the RFP, please base your costing on a conference delivery for 4,000 delegates onsite. The conference will be held over 4 days, from Tuesday - Friday, in the second or third week of November.

Please ensure that all sections of the RFP response are addressed in the technical response, in the order listed below and that the financial quotation is aligned with the section headings, **5C i-xiv**, as itemised below and follows the format in Annexure C.

5C i) Venue Planning 2027: REQUIRED

The RFP response to include a plan and an estimated cost for venue scoping and the deliverable of full set of visuals on the venue (video, photos)

- Detailed drawings of the venue with suggested usage of all venue areas to include:
 - Registration area and cloakroom space
 - Exhibitor area
 - Sessionrooms X10 (9 core programme, 1 Community Connect) ; Plenary room x1
 - Side meeting rooms space x5
 - Community Connect Space
 - Networking areas and food and beverage areas
 - Volunteer space (300 volunteers), Speaker Centre
 - Operational team offices for conference delivery team
 - Executive Office, Union Board Office
 - Specialist on-site services spaces- see specifics below

5C ii) Registration Area set up and infrastructure: REQUIRED

The RFP response to include a functional registration area with all necessary infrastructure in place, for the registration team to be able to deliver registration during the event.

The RFP response to include staffing plan for registration for 5 days of the event, including pre-conference day, with a decreasing amount of support needed as the conference progresses.

5C iii) Scenic, staging and room set up for the session rooms: REQUIRED.

For the purposes of the RFP, consider 10 session rooms, each with a capacity of 300 and one plenary room (capacity 1200)

These rooms are used to deliver the abstract sessions, the oral abstracts and the symposia, the daily plenary and satellite sessions.

The RFP response and quotation is to include

- Stage set up-carpets, seating, tables, prompt screens
- Davos style seating and staging for plenary session
- Front of House (FOH) Coverage for all
- iPads for all session rooms for Q&A

5C iv) Exhibition: REQUIRED

To provide the design, infrastructure build and management of the Conference Exhibition space.

For the purposes of this request, this is limited to 40 exhibition units of various sizes in shell scheme format. The proposed size distribution:

- 10 units – 2m x 2m
- 18 units – 3m x 3m
- 7 units – 6m x 3m
- 3 units – 6m x 6m
- 2 units – 9m x 6m

The RFP response will include the provision, installation and removal of the basic wall structures, lighting and a power outlet as standard per booth. The quotation will include a basic furniture package of table and 2 chairs per booth.

There should also be a listing of additional items, fully costed to include graphics and furniture packages which exhibitors can order to complete their booth “look and feel”.

There should be the inclusion of an online store shopfront, developed by the provider, which allows all exhibitors to order the graphics packages and order the furniture and any extra AV materials for their specific booth

In addition, the RFP response quotation must include all costs required for:

- The design and layout of the exhibition floor to fit the venue space
- The management of the area on-site during the build, open days and the de-rig days including removal of all elements and ethical wastes management
- The production and distribution of an exhibitors’ manual of operations, 12 weeks in advance of event with a nominated person available for pre-calls with exhibitors
- Online store of all goods and services for exhibitors to purchase upgrade packages, including graphics, power and furniture, 12 weeks in advance of the event
- Full process for management of any custom build booth spaces to ensure integration in overall exhibition area
- Print proofing services

The RFP response must also include:

- All costs associated with ensuring that the exhibition and exhibitors’ operations meet all local and national safe working requirements.
- A system for ensuring and documenting that all exhibitors have the correct type and level of insurance(s) in force (e.g. Health & Safety paperwork, Risk and Methods documentation (RAM)).
- Staffing and systems to deliver an onsite help desk during the build stage and all open days of the event.
- An online help desk service for exhibitors to provide a response to their questions and information requests, with a turnaround time of 24 hours.

5C v) Audio, Visual and Lighting: REQUIRED

The RFP response to include detail and costing to provide, install, remove and manage all the audio, visual and lighting requirements for ten presentation session rooms and one plenary session room that will be operating simultaneously

It is assumed, for the purpose of the quotation, that each room has a capacity for min 300 delegates and there are no infrastructure elements other than power available in the room. The normal operating hours for each room are from 08:00 to 20:00 over four days.

Lighting should allow for a minimum even stage wash and lectern focus.

Minimum requirements are for the procurement, installation, operation and removal of a screen(s) of a suitable size and quality for medical based presentations (fine text) and projection facilities to enable presentations from the (3rd party) presentation management system to be displayed with the presenter operating the presentation via a laptop.

A VLAN internet drop will be required for each room to connect to the laptop (laptop supplied by the presentation management supplier). Most presentations consist of PowerPoint type presentation.

A sound system and provision of microphones to enable questions to be asked from the floor and responded to by the presenter(s).

The RFP response quotation should include provision for on-site technical support in each room during operating hours and account for any needed overnight changes.

5C vi) E-poster area design and set up: REQUIRED

The RFP response to include a proposed set up for the e-poster area, including the necessary audio, visual and lighting for area.

The response to include appropriate technical support for delegates during e-poster sessions.

The e-poster design and set up should include:

- Freestanding unit for screen mounting to display 9 e-Poster screens;
- Appropriate fit out for e-poster display
- 55" Touchscreens X 9 screens
- 750 headsets (over-ear, not in-ear), with 9 x channels of audio
- Wired internet in area to allow for Internet connectivity and channel selection.

5C vii) Community Connect area - design and set up: REQUIRED

Community Connect (CC) is where affected community and civil society representatives come together to share experiences and develop solutions on issues surrounding lung health. The CC space includes one open space for events and sessions; one main session room; a networking space; art installation space.

The RFP response to include:

- Furniture for communal seating and networking in the Community Connect area
- Scenic, Dressing, Signage and Branding and set up of stage area for core area within the space to include staging, carpeted, ramp to stage
- Audio, visual and lighting requirements for the area
- Art Wall space for installations/exhibitions within the area
- Exhibition area in Community Connect to include
 - 8 booths of 2x2 metre shell scheme build, each with carpet, electrical, structure and lighting and reception desk and 2x chairs per stand

5C viii) Side room space set up: REQUIRED

The RFP response to include the set-up of 5 side meeting rooms in boardroom style for 20 people

The room specification to include as standard

- 1x 55"screen with sound capacity
- Capacity to connect laptop to screen in room
- Wifi enabled in rooms

5C ix) Networking areas: REQUIRED

The RFP response to include a suggested plan for networking areas for delegates within the venue. These areas are used for unofficial meetings and hang out space.

The RFP response to include items that enhance the delegate experience

- Furniture: furnishing of the key networking areas to allow for delegate meetings and food and beverage areas within the venue
- Charging stations for delegates

5C x) Onsite branding and signage all areas: REQUIRED

The RFP response to include a plan for overall venue signage and branding to ensure delegate flow, clarity and visibility/branding across all areas of the venue, both internal and external.

The RFP response to also include

- Two wall structures: a Welcome wall with branding and a wall to display Union Christmas Seals awards, both walls to be of 5 m(L) x 4 m (H)
- 10 digital totems/LED screens to be placed around the venue, and used for sponsored content

5C xi) Content and Broadcast: REQUIRED

The RFP response to detail the equipment and support services to Content Capture the presentations, including presenter graphics, given in 10 sessions rooms and one plenary

room of the entire programme, and enable this content to be collated, manipulated and then live streamed to registered delegates both at the Conference and in virtual locations around the world.

Content must be made within 24 hours, as video on demand and collated to be made available as free-to-view during and after the conference for all registered delegates.

The content delivery network must be robust for worldwide availability, including China, and integrate seamlessly with The Union's existing conference app for delegate viewing.

5C xii) Specialist Services: REQUIRED

The RFP response to include:

- The production of an Event Safety Management Plan, a Public Safety plan and on-site safety provision, including staff, for the safe delivery of the Conference of approximately 4000 delegates
- Production of a Security plan and on-site security provision, including staff, for the safe delivery of the Conference of approximately 4000 delegates
- Production of a Medical plan and on-site medical provision, including staff, for the safe delivery of the Conference of approximately 4000 delegates
- A staffing plan for cloakroom and cleaning staffing for all event days

5C xiii) Delivery Production team: REQUIRED

The RFP response to include detail and costing on:

- Production team for the event delivery- offsite planning, scoping and design team to include project management of the event and listing of key personnel for entire project
- Onsite event production team to include onsite delivery team and descriptive of integration plan for core delivery team, and annual onsite team
- Photography and Video: Include costs for 1 videographer and 1 photographer for the event duration, who will take direction from the Union team.
- Resource to manage venue, hotel contracts and hotel room bookings within hotel allocation on behalf of The Union
- Resource to manage full food & beverage planning for entire event; including menu development, dietary requirements and food safety compliance for crew, client and delegates.

- Resource to create and oversee an online booking service for menu selection and ordering of F&B for conference clients (exhibitors, side meeting hosts, etc)
- Travel and food allowance/per diem costs for project team to deliver event
- Accommodation: Please note, there is no need to add costing for this as the project team will be accommodated within The Union allocation at the venue.

5C xiv) Technical infrastructure of Venue: REQUIRED

The RFP response to consider and include, based on venue capacity

- Internet and Wi-Fi provision for all delegates
- Power and constancy of electricity supply for all services
- Interface capacity with Union existing providers for app delivery; speaker services; registration services
- Translation options and suggested use of AI

5D: Conference Delivery 2028 and 2029: REQUIRED

The RFP response is to provide descriptive text and indicative budget for conference management services for the 2028 and 2029 conferences based on the scope outlined in this RFP and inclusive of the core delivery elements defined in section **5Ci-xiv** above for the 2027 WCLH.

As venues for the 2028 and 2029 conferences are yet to be finalised and will be chosen in collaboration with the selected service provider, the financial proposal submitted will be based on reasonable planning assumptions and will be used for evaluation purposes only and will not constitute a binding commitment by either party.

Upon confirmation of the conference venues and any specific requirements for those years, the selected service provider will be requested to submit a detailed budget which will be negotiated and agreed upon before final approval.

Please use the following assumptions for your estimates:

- For 2028, the venue will be in a high burden TB country, in the African region.
- For 2029, the venue may be in a low burden TB country in WHO Europe Region.

5E. Strategic input and advisory role on potential future site selection: OPTIONAL.

In the RFP response, please describe your organisation's capacity and experience to engage with national stakeholders in the relevant geographies (Annexure A), with a view to building relationships in the delivery site and securing funding for cost-contribution to the WCLH delivery. Please also advise on your organisation's capacity to collaborate with The Union on building additional revenue streams within the conference delivery model. Please also detail any information on the potential to engage relevant exhibitors and/or commercial sponsors.

Please illustrate your response with examples of prior work and how you would recommend specific countries and potential venues for WCLH. If your organisation has the capacity to deliver this component, or you will partner with another Service Provider (see section 3.5), please include indicative costs in the financial proposal to account for this exercise.

CONSIDERATIONS

The RFP response must include the delivery of all elements listed above. If any third-party contractors are to be used, this must be declared and detailed information to be provided as to how these third parties will be evaluated in terms of:

- The quality of their service/s
- The on-site management to ensure fault free delivery
- Ensuring on time delivery within a fixed budget
- Include the mechanism for underwriting of third-party contracts in terms of responsibility and financials

CONDITIONS

The successful request will be decided with consideration of the following key factors:

- Design creativity and quality
- Past experience and portfolio
- Compliance with deadlines
- Price competitiveness

Respondents will need to provide 2 Nominated Customer References The Union can contact for recommendations as part of the selection process.

6. ELIGIBILITY CRITERIA

On successful completion of eligibility criteria, the service provider will be considered for technical and financial evaluation. List of documents mentioned will be considered for assessment of eligibility criteria.

The service provider will be assessed on the basis of following: -

Sl. No.	Eligibility Criteria	Documents to be submitted with Technical Proposal
1	Bidder is a legally registered entity	Provide a copy of the statutes/registration of the legal entity
2	No conflicts of interest in accordance with clause 4.	Signed disclosure to be submitted

3	Not declared bankruptcy, not involved in bankruptcy or receivership proceedings, and there is no judgment or pending legal action against the vendor that could impair its operations in the foreseeable future.	Signed undertaking to be provided
4	Previous Experience Minimum 5 years of relevant experience.	<p>Please list only previous similar assignments successfully completed in the last 3 years. List only those assignments for which the Bidder was legally contracted or sub-contracted by the Client as a company or was one of the Consortium/JV partners. Assignments completed by the Bidder's individual experts working privately or through other firms cannot be claimed as the relevant experience of the Bidder, or that of the Bidder's partners or subconsultants, but can be claimed by the Experts themselves in their CVs.</p> <p>The Bidder should be prepared to substantiate the claimed experience by presenting copies of relevant documents and references if so requested by The Union</p>
5	<p>Financial Standing Minimum average annual turnover of USD 7million for the last 3 years.</p> <p>(For JV/Consortium/Association, all Parties cumulatively should meet requirement).</p>	Statement of Financial Accounts for last 3 years
6	Bidder must follow format specifications for bid delivery for both technical and financial proposals	Should the bidder not deliver submission documents in the exact format requested, they will be automatically excluded from the bid analysis even though then have technically qualified.

7. PROPOSAL SUBMISSION:

A. Proposals through email are invited from the reputed agency for the aforesaid purpose. The proposal should include the **"Technical" and "Financial"** details.

B. The interested bidder must submit their proposals in two separate emails and should clearly state in the subject line - **"Technical Proposal – Hiring of Agency for multi-year management of elements of the Union World Conference on Lung Health (WCLH) 2027–2029"** and **"Financial Proposal–Hiring of Agency for multi-year management of elements of the Union World Conference on Lung Health (WCLH) 2027–2029"** with all relevant documents as listed in Annexures A, B & C to Procurement.union@theunion.org by **10th July 2026**.

C. The "**Technical proposal**" to be prepared in accordance with documentation as detailed in **Annexure–B and Technical Evaluation Criteria** as indicated in Section 8 of this RFP. The Technical Proposal should not contain any cost information whatsoever.

D. The Detailed **Financial Proposal** shall be in accordance with instructions in **Annexure-** to this RFP.

E. "**Financial Proposal**" shall remain password-protected, and such password shall be obtained by procurement committee appointed by The Union after the Technical Qualification of the Proposal submitted by the bidder.

F. Proposal validity period will be for **180 days** from the date of submission of proposal.

G. You may send your queries to Procurement.union@theunion.org latest **29th June 2026**. After this date, no queries/ questions will be entertained.

H. In case of any change/clarification, a corrigendum will be uploaded latest by **6th July 2026 on the Union's website**. Please download the same from the source.

8. EVALUATION CRITERIA:

8.1 Technical Evaluation – Scoring criteria

Sr. No.	Evaluation Criteria	Maximum Scoring
A)	Bidder's qualification, capacity and expertise	20
1	Brief description of the organisation, including the year and country of incorporation, and types of activities undertaken.	
2	General organisational capability which is likely to affect implementation: management structure, financial stability and project financing capacity, project management controls, extent to which any work would be subcontracted (if so, provide details).	
3	Relevance of specialised knowledge and experience on similar engagements done in the region/country	
4	Quality assurance procedures and risk mitigation measures as demonstrated by supporting documents.	
5	Organisation's commitment to sustainability.	
B)	Proposed Methodology, Approach and Implementation Plan	40
1	A detailed description of the approach and methodology for how the Bidder will achieve the Terms of Reference of the project, keeping in mind the appropriateness to local conditions and project environment. Details how the different service elements shall be organised, controlled and delivered. The format of the technical proposal document is to clearly follow the different sections as numbered in the RFP, and ensure sufficient level of detail is provided.	
3	Explain whether any work would be subcontracted, to whom, how much percentage of the work, the rationale for such, and the roles of the proposed sub-contractors and how everyone will function as a team.	
4	Implementation plan including a Gantt Chart or Project Schedule indicating the detailed sequence of activities that will be undertaken and their corresponding timing.	

C)	Management Structure and Key Personnel	10
1	Describe the overall management approach toward strategic planning and implementing the project. Include an organisation chart for the management of the project describing the relationship of key positions and designations.	
2	Provide a spreadsheet to show the activities of all personnel and the time allocated for his/her involvement along with CVs for key personnel that will support the Implementation. CVs should demonstrate qualifications in areas relevant to the Scope of Services.	
D)	Presentation and Interview The presentation will be of 30 minutes duration, followed by a 30 minute discussion and time for questions and answers. It will focus on clarification of any questions arising from the technical proposal shared with the review team.	30
	TOTAL SCORE	100
E)	Strategic input and advisory role on potential future site selection (Additional Bonus Points) <ul style="list-style-type: none"> • 10 = Exceptional optional offering with clear added value. • 6 = Meets optional requirement adequately. • 1 = Limited value. • 0 = Not offered 	10

A. Presentation -As a part of Evaluation of proposals submitted by the applicants, The Union may seek further information or a presentation from the organisations for evaluation purposes. The Union may call for such information/presentation at a short notice.

B. The bidder must obtain a minimum **score of 60 for Technical** Qualification of the Proposal submitted by them.

C. The procurement committee appointed by The Union shall review and evaluate the Technical Proposals based on their responsiveness to the **Scope of Work** and **Annexure** to the RFP applying the evaluation criteria, sub-criteria, and the scoring mechanism specified in the above clauses. A Proposal shall be rendered non-responsive at the technical evaluation stage if it fails to achieve the minimum technical score stated herein above.

8.2 Financial Evaluation

The Financial Proposals of only those Bidders who achieve the minimum technical score will be opened by the committee appointed by The Union, after obtaining a password from the respective bidder. The Financial Proposal evaluation shall be carried out in reference to **Annexure-C**. The Financial Proposals corresponding to Technical Proposals that were rendered non-responsive shall remain unopened.

The Financial proposal must follow the format shared in the RFP publication precisely, and be prepared in USD.

A. The Financial Score shall be calculated through the following formula

Financial Score = (Lowest Priced Offer / Price of the Offer Being Reviewed) x 100

B. The proposal will be evaluated on **Quality Cum Cost Based Selection**. Technical Scores obtained shall carry a weight of 70%, whereas the Financial Score shall carry 30% weightage.

C. The Agencies securing the highest combined evaluation score (Top 3) will be invited for negotiations.

9. IMPORTANT DATES & TIMES (Table A)

Particulars	Date & Time
Date of floating Request for Proposals	17 th June 2026
Last date for question submission	29 th June 2026
Corrigendum, if any	6 th July 2026
Last date and time for Submission of Proposals	10 th July 11:55PM (CET) This is an absolute deadline, proposals received after this date will be disqualified.
Presentation & Technical Evaluation	Within 2 weeks from the date of submission
Financial Evaluation	Second week of August 2026
Signing of Contract	Second week of September 2026

10. DURATION

A. The agreement will be for an initial period of **3 years**. The bidder shall be subject to performance evaluation at the end of each year.

B. Extension of the agreement will be made based on annual budget approval and workplan

C. In case of any changes made during the assignment, these changes will be made with mutual agreement specifying the deviations and justifications

11. PENALTY CLAUSE:

Please note, in case of delay, The Union may levy a penalty appropriate to the deliverable.

Successful supplier will subject to Contractual Terms and Conditions of The Union – Annexure E

2027: BICC, Bali, Indonesia (subject to confirmation)

2028: Region = South & in a High Burden TB Country

2029: Region = WHO Europe Region & (potentially) in a Low Burden TB Country

There are nine criteria which The Union uses to assess the suitability of the conference location; each criterium is assessed on a general level and in the context of the Union World Conference on Lung Health community through the lens of suitability of location to the WCLH community; travel connectivity, level of TB Burden; national stability and civil rights and national support and engagement.

1. **Financial Viability and level of national stakeholder support:** The country level support for the conference (Ministry of Health and other key government and civil society stakeholders) is crucial and involves several elements
 - i. Financial contribution to the event- which is to be agreed ahead of the selection. This contribution cannot be in-kind and must contribute to the running of the conference.
 - ii. General visibility and engagement with the national stakeholders to promote the event and the messaging around it
 - iii. Advisory to consular missions of the host country of the conference existence to ensure visa officers are aware in dealing with visa requests at national level
2. **Openness:** How welcoming/open is the country for conference delegates on a government and public level? Considerations to include visa requirements and challenge to access for global delegates, especially those travelling from LMICs.
 - i. **Henley Openness Index:** How welcoming the country is for the event and guests on a government and public level.
3. **TB Burden and Lung Disease Burden at national level:** high burden vs low burden and aligned with The Union Location Recommendation Document, and its rotational strategy
4. **Human Rights:** How is the country perceived in relation to Human Rights across all main areas for example LBGTQ communities, female equality?
 - i. **Human Right Watch / Human Freedom Index:** The country rating on all human right matters.
5. **Global Peace Index:** General level of safety and stability of the country.
6. **Connectivity:** An overview of airport connectivity, transportation and ease of access to the venue from arrival hubs within the selected city

7. **Delegate Infrastructure:** An overview of flight, hotel, taxi/uber, and food prices in the selected cities to ensure there are accessibly priced options for delegates across all aspects. We need to have
 - i. range of hotel room within access to venue are different price points.
 - ii. Local transport infrastructure vs taxi options from airport to venue
 - iii. Food pricing and offers within venue and close by

8. **Production Infrastructure:** The standard of technical, scenic, exhibition options and internet capacity in the locations to be able to deliver the specification for delivery. It should be clearly articulated what infrastructure is included in venue core pricing, and what needs to be added on when recommending venues for consideration.

9. **Geographical Location Factors – Environment, Diseases:** Air quality, traffic challenges, endemic diseases, risk of natural disaster

DETAILED TECHNICAL PROPOSAL OF BIDDER

Proposals should include the following information:

1. A brief profile of the Bidder/Applicant (Organisation), with the details of the head of the organisation and team/ facilitators who will be involved in the assignment (1 page)
2. Proposed Methodology, Approach and Implementation Plan, timelines (up to 4 pages)
3. Technical description of each of the areas outlined in section 5A-D of the RFP document, **following the format of the different headings**. (up to 8 pages)
4. Proposed Methodology, Approach and Implementation Plan for the optional strategic approach, outlined in section 5E (up to 2 pages)
5. Details as per the Technical Evaluation criteria indicated at Section 8 of the RFP document. (up to 2 pages)
6. Provide a minimum of two (2) trade references that the Bidder have partnered with on similar interventions as mentioned in the RFP including names of persons, who may be contacted, position of person, address and phone number. (1 page)
7. Letter of interest (LOI)/Cover letter on letter head signed by authorised signatory (1 page)
8. Additional information (if any) - no more than 5 pages

DETAILED FINANCIAL PROPOSAL OF BIDDER

The Bidder is required to prepare the Financial Proposal following the below format and submit it as indicated in the clause 7 of the RFP. Any Financial information provided in the Technical Proposal shall lead to Bidder’s disqualification. The Financial Proposal should align with the requirements in the Terms of Reference and the Bidder’s Technical Proposal. The financial proposals should include the following:

- (i) Name and address of the Organisation/Institution:
- (ii) Cancelled cheque detailing organisation’s bank account (Non FCRA bank account), account number, bank name, IFSC Code etc.
- (iii) Taxes and other applicable charges to be indicated and clearly outlined in the financial proposal

Summary of Overall Costs

Details	COST (USD)
1. Venue search for 2028 and 2029 WCLH inclusive of scoping exercise	
2. Online Registration Platform and onsite registration delivery	
3. 2027 WCLH Conference Delivery in BICC, Bali, Indonesia	
4. 2028 Conference Delivery-Indicative	
5. 2029 Conference Delivery- Indicative	
6. Strategic Input and Advisory role on potential future sites	
7. Any other costs	
Total Cost of Financial Proposal	

Breakdown of Price per Deliverable- each deliverable area as outlined in the RFP section 5 is to be costed as per the format provided here. Bids returned in a format other than this will be considered ineligible.

Deliverable/Activity	Time (Person/Days)	Professional Fees	Other cost	Total Costs
5A. Venue search for the 2028 and 2029				

WCLH and venue scoping exercise				
5B i). Online Registration Platform				
5B ii). Onsite registration delivery				
5B iii)Registration delivery staffing/team differentiated for online and onsite				
5C 2027 WCLH Delivery				
(i)Venue Scoping				
(ii) Registration Area set up and infrastructure				
(iii) Scenic, staging and room set up for the session rooms				
(iv) Exhibition				
(v) Audio, Visual and Lighting				
(vi) E-poster area design and set up				
(vii) Community Connect area-design and set up				
(viii) Side room space set up				
(ix) Networking areas				
(x) Onsite branding and signage all areas				
(xi) Content and Broadcast				
(xii) Specialist Services				
(xiii) Delivery Production team				
(xiv) Technical infrastructure of Venue				
5D i) 2028 Conference				

Delivery- indicative				
5D ii) 2029 Conference Delivery- indicative				
5E. Strategic input and advisory role on potential future site selection- OPTIONAL				
Any other costs				

Annexure D

Respondents must provide the following general disclosures:

If they are or have been the subject of any proceedings or other arrangements relating to bankruptcy, insolvency or the financial standing of the Respondent including but not limited to the appointment of any officer such as a receiver in relation to the Respondent personal or business matters or an arrangement with creditors or of any other similar proceedings.

Yes

No

If they have been convicted of, or are the subject of any proceedings, relating to:

Criminal offence or other offence, a serious offence involving the activities of a criminal organisation or found by any regulator or professional body to have committed professional misconduct.

Yes

No

Corruption including the offer or receipt of any inducement of any kind in relation to obtaining any contract, with The Union or any other contracting body or authority

Yes

No

Failure to fulfil any obligations in any jurisdiction relating to the payment of taxes

Yes

No

They do not intend to use equipment, services, or systems that use covered telecommunications equipment or services as a substantial or essential component of any system, or as critical technology as part of any system.

Yes

No

If they have any business relationship with or knowingly received payment or other support from any tobacco product manufacturer or wholesaler (the "Tobacco Industry"), or any parent, affiliate, subsidiary, organisation, or foundation with majority support from the Tobacco Industry, or any person, interest group, advocacy organisation, or other business or organisation (other than a law firm, advertising agency, or accounting firm) that represents the interests of the Tobacco Industry.

Yes

No

TERMS AND CONDITIONS OF CONTRACT

1. CONFIDENTIALITY

- 1.1 The Contractor shall treat as confidential, during as well as after the performance of any work under this Agreement, any information, including any personal information defined by The Union, to which the Contractor becomes privy as a result of acting under the Agreement (the “**Confidential Information**”). For more certainty, the Contractor shall not disclose any such Confidential Information to any other person or party which is not participating in the Agreement in a form that could reasonably be expected to identify the person, including individuals, to whom such information relates. However, the Consultant may disclose the Confidential Information as required by law, a court or any governmental or regulatory authority.
- 1.2 Where the work to be performed under the Agreement involves access by the Contractor to confidential, classified or protected documents of The Union, the Contractor shall comply with all applicable security procedures and requirements of The Union, keep the Confidential Information secure and not disclose it. Any inquiries as to what information is confidential or what procedures should be applied when handling Confidential Information should be addressed to the Global Human Resources and Finance Departments of The Union.
- 1.3 Information which is or will be in the public domain, is lawfully in the other Party’s possession prior to disclosure and/or has been made available to a Party on a non-confidential basis, is not covered by this clause.
- 1.4 At the end of the contractual relations and at The Union's request, the Contractor must return any document containing confidential information entrusted to it and keep no copy of it.
- 1.5 This provision is valid throughout the duration of the Agreement and after the Agreement reaches its term, and for whatever reasons, for the duration of twelve (12) months.

2. DATA PROTECTION

- 2.1 Where processing of personal data is to be carried out, the Contractor guarantees to implement in advance appropriate technical and organisational measures in such a manner that processing meets the requirements of the European General Data Protection Regulation (EU Regulation 2016/679), and ensure the protection of the rights of the data subject as stipulated in Article 28 of the regulation.
- 2.2 Furthermore, the Contractor shall not engage any sub-processor without the prior specific written authorisation of The Union.
- 2.3 The Contractor must delete or return all personal data to The Union as requested at the end of the contract.

3. INTELLECTUAL PROPERTY

- 3.1 Nothing in this Agreement shall be construed as implying the transfer of ownership of The Union intellectual property to the Contractor or any of its collaborators or subcontractors.
- 3.2 The Union expressly reserves and retains any rights that are not expressly granted to the Contractor under this Agreement.
- 3.3 Nothing herein shall impose any obligation on The Union to make use of any of the rights set forth herein.
- 3.4 Upon completion of the related payments provided herein, all material created for purposes of the Agreement or provided to The Union as part of the Services hereinafter “**the Contract Material**”, shall be the property of The Union.

4. WARRANTIES AND REPRESENTATIONS

The Contractor warrants and represents that:

- 4.1 It has full right, power, legal capacity and authority to enter into this Agreement and to carry out all of its terms and conditions and the signatory is a duly authorised representative with full powers to sign this Agreement on its behalf.
- 4.2 It will ensure all aspects of the work to be performed pursuant to this Agreement will conform to The Union’s standards and meet all deadlines specified in the Agreement.
- 4.3 The Contractor warrants that any and all written work submitted under this Agreement are not and have never been published in paper, or any other format with any organisation that may still own proprietary rights to the work.
- 4.4 The Contractor warrants that this work is not currently in the public domain. If any part of this work has been copyrighted, an original letter of permission from the copyright holder to use the work shall be submitted to The Union.

5. NO EXCLUSIVITY

Nothing in this Agreement shall be construed to establish an exclusivity relationship between The Union and the Contractor. The Union shall be free to select other contractors to conduct work that is within the expertise of the Contractor. The Contractor also retains the ability to conduct work on behalf of other Parties subject to the limitations set out in Clause 19.

6. LIABILITY AND INDEMNIFICATION

- 6.1 The Union, its officers, employees and agents, shall not be liable for any injury to the person or for loss or damages to the property of the Contractor or of anyone else, occasioned by, or in any way attributable to the Contractor under this Agreement unless such injury, loss or damage is caused by the negligence of an officer, employee or agent of The Union acting within the scope of his employment.
- 6.2 Nothing in the Agreement limits any liability which cannot legally be limited, including liability for fraud, fraudulent misrepresentation, death or personal injury.

6.3 Subject to Clause 9.2, The Union's total liability to the Contractor shall not exceed twice the amount mentioned in Clause 3.1 and the following types of loss are wholly excluded: (i) loss of profits; (ii) loss of sales or business; (iii) loss of agreements or contracts; (iv) loss of anticipated savings; (v) loss of use or corruption of software, data or information; (vi) loss of or damage to goodwill; and (vii) indirect or consequential loss.

6.4 The Parties will mutually defend and forever hold each other and their officers, employees and agents harmless against and from any and all third-party claims, lawsuits, judgments and expenses (including, without limitation, reasonable legal fees) arising out of any breach by the other party of any provision of this Agreement or any misrepresentation made by the other party and its officers, employees or agents. This provision shall survive the termination of the Agreement.

7. DEFAULT AND TERMINATION

7.1 TERMINATION FOR CONVENIENCE

7.1.1 This Agreement may be terminated, in whole or in part, by either Party at any time upon thirty (30) days prior written notice of termination to the other Party.

7.2 TERMINATION FOR BREACH

7.2.1 In the event any Party hereunder shall materially breach any of the terms and conditions contained in this Agreement, the other Party may immediately terminate this Agreement, at its option and without prejudice to any of its legal or equitable rights, effective seven (7) days following formal written notice from the non-defaulting Party, via registered mail with acknowledgement or receipt, if said non-performance has not been cured within such period.

7.2.2 Either Party may terminate the Agreement with immediate effect by giving written notice to the other Party via registered mail with acknowledgement or receipt, in case of breach of the following provisions: Clause 4 (Confidentiality), Clause 5, (Data Protection), Clause 6 (Intellectual Property), Clause 12 (Conflict of interest) or Clause 19 (Affiliation with Tobacco Industry), or in case the Contractor engages in any illegal activity (fraud, corruption, etc.).

7.3 TERMINATION IN THE EVENT OF THE OPENING OF COLLECTIVE PROCEEDINGS

To the extent permissible by the applicable mandatory laws, in the event any Party shall become insolvent or shall suspend its operations or shall file a voluntary petition or answer admitting to the jurisdiction of a court as to the material allegations of insolvency, or shall make an assignment for the benefit of creditors, then the other Party may thereafter immediately terminate this Agreement by giving written notice of termination to such Party or its receiver.

7.4 GENERAL PROVISION ON TERMINATION

7.4.1 Termination may occur at any time, whether Service are in progress or not.

7.4.2 If this Agreement is terminated by The Union pursuant to any of the paragraphs of Clause 10, the Contractor is entitled to reimbursement for those monetary amounts duly expended or obligations duly incurred prior to the termination of the Agreement in relation to

performance of the Services in accordance with Clause 2 provided that they are intimated to The Union during the thirty (30) days following the date of termination. This provision only applies where the Contractor has used best endeavours to mitigate the loss in relation to any such expenses.

7.4.3 Upon termination of this Agreement, The Union shall cease to have any obligation to make any payment to the Contractor in respect of the costs incurred by the Contractor after the date of termination, and, if applicable, the amount of any excess cost paid to the Contractor shall be recognised as being a debt due to The Union.

7.4.4 After the end of the Agreement for any reason, the Contractor undertakes not to use or refer to The Union, its trademarks, name and services, and in general to no longer introduce itself as The Union service provider. The Contractor undertakes to return to The Union all documents, leaflets, files and other materials which may have been delivered to it in the context of the Agreement or which it may have created for the purposes hereof.

8. NO AGENCY OR JOINT VENTURE

Nothing in this Agreement shall be deemed to create an agency relationship or joint venture between the Parties. Each party shall be responsible for all taxes, benefits, withholding, worker's compensation, and health insurance, medical evacuation costs beyond those covered by the travel insurance, and unemployment insurance and similar requirements of their own employees and neither party's employees shall be deemed agents or employees of the other party.

9. CONFLICT OF INTEREST

The Contractor undertakes to take all necessary precautions to avoid conflict of interests in accordance with The Union Conflict of Interest Policy. The Contractor agrees to comply with the policy by signing the Conflict of Interest Disclosure Form and shall inform The Union without delay of any situation constituting or likely to lead to any such conflict during the period of this Agreement.

10. SUCCESSORS AND ASSIGNS

The Agreement shall inure to the benefit of and be binding upon the Parties hereto and their lawful heirs, executors, administrators, successors and assigns.

11. ASSIGNMENT

Neither Party may assign, transfer or dispose of any way its rights and obligations under the Agreement without the prior written consent of the other Party, such agreement not to be unreasonably withheld, except that either Party is authorised to assign, transfer or dispose all or part of their rights and obligations under the Agreement to an affiliated company of its group, subject to prior information of the other Party.

12. ENTIRE AGREEMENT

The Agreement constitutes the entire accord between the Parties with respect to the subject matter of the scope of work and supersedes all previous negotiations, communications and other

Agreements relating to it unless they are incorporated by reference in the Agreement. The Parties hereby waive any claim which may arise from their relations prior to the Agreement.

13. NOTICES AND COMMUNICATION

13.1 Where in the Agreement any notice, request, direction, or other communication is required to be given or made by either Party, it shall be in writing and will be effective if delivered in person, sent by registered mail or by e-mail addressed to the Party for whom it is intended at the address mentioned in the Agreement. Any notice, request, direction or other communication shall be deemed to have been given if by registered mail, when the postal receipt is acknowledged by the other Party? and, by e-mail, when transmitted. The address of either Party may be changed by notice in the manner set out in this provision.

13.2 All notices and communications concerning this Agreement shall be addressed to the respective contact people as follows:

For The Union:

Name:

Address: International Union Against Tuberculosis and Lung Disease 2
rue Jean Lantier, 75001 Paris, France

For the Contractor:

Name:

Address:

14. AMENDMENT, MODIFICATION, WAIVER

This Agreement may only be amended, modified or supplemented by an agreement in writing signed by the Parties. No waiver by any Party of any of the provisions hereof shall be effective unless set forth in writing and signed by the Party so waiving. No waiver by any Party shall operate or be construed as a waiver in respect of any failure, breach or default not expressly identified by such written waiver, whether of a similar or different character, and whether occurring before or after such waiver. No failure to exercise, or delay in exercising, any right, remedy, power or privilege arising from this Agreement shall operate or be construed as a waiver thereof, nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.

15. FORCE MAJEURE, FORTUITOUS EVENT AND *FAIT DU PRINCE*

15.1 If any party hereto is prevented, hindered or delayed from performing its obligations under the Agreement as a result of a force majeure within the meaning of Article 1218 of the French Civil Code and of the case law of the French courts, such prevention or delay shall not be considered as a breach of the Agreement and that Party shall be relieved from its obligations for the duration of such force majeure, provided however that there is a direct relation between such prevention or delay and the force majeure.

15.2 The Party claiming to be affected by a force majeure shall notify the other Party no later than ten (10) days after the occurrence of force majeure and shall use all reasonable endeavours to mitigate the effects caused by force majeure as well as implement a work

around solution. This written notification shall indicate the day on which the force majeure occurred and the likely effects of the force majeure on its ability to perform its obligation under this Agreement.

15.3 The Party claiming to be affected by a force majeure should also, as soon as possible and in any case not later than ten (10) days after the end of the event force majeure, notify the other Party that the force majeure has ended and resume performance of its obligation under this Agreement.

15.4 In the event of force majeure, the Parties shall do their utmost to remedy the situation as quickly as possible. In the event that the proper execution of the work according to the conditions stipulated in the Agreement is hindered or prevented due to force majeure beyond thirty (30) days, either Party without having to pay indemnity to the other shall be entitled to terminate the Agreement, with effect as from receipt by the other party of the appropriate written notice of termination sent by registered mail with acknowledgment of receipt.

15.5 The Parties will also, without compensation, be relieved of their obligations by the occurrence of events constituting fortuitous events (“cas fortuit”) or “fait du prince” within the meaning of French law and French case law.

16. AFFILIATION WITH TOBACCO INDUSTRY

16.1 The Contractor does not have any business relationship with or knowingly received payment or other support from any tobacco product manufacturer or wholesaler (the “**Tobacco Industry**”), or any parent, affiliate, subsidiary, organisation, or foundation with majority support from the Tobacco Industry, or any person, interest group, advocacy organisation, or other business or organisation (other than a law firm, advertising agency, or accounting firm) that represents the interests of the Tobacco Industry (collectively, “**Tobacco Affiliates**”).

16.2 The Contractor currently does not accept and shall not accept financial or other support from the Tobacco Industry or Tobacco Affiliates until at least one year after the end of this Agreement. Failure to comply with this clause may constitute grounds for termination of this Agreement and The Union shall have the right to demand and receive a return of all funds under this Agreement, plus interest, as liquidated damages, other provisions of this Agreement notwithstanding.

17. DISPUTE RESOLUTION

17.1 This Agreement is an understanding amongst the Parties hereto and shall bind the Parties to the fulfilment of the terms and conditions contained herein. In the event of any differences or disputes arising out of the interpretation or application of the provisions of this Agreement, the Parties shall immediately consult each other with a view to expeditiously resolve such differences or disputes in a spirit of mutual understanding and cooperation. Such amicable settlement shall be done within (15) days of the first written communication of the dispute between the Parties.

17.2 In the event the Parties fail to reach a settlement, any dispute concerning the validity, interpretation, performance, non-performance or termination of the Agreement or otherwise related to the Agreement shall be submitted to the Commercial Court of Paris.

18. APPLICABLE LAW

This Agreement shall be governed by and construed in accordance with the laws of France.

IN WITNESS WHEREOF, the Parties have executed this Agreement:

For The Union:

For the Contractor:

Name
Title

Name
Title

Date: _____

Date: _____

REGISTRATION SPECIFICATIONS: ONLINE PLATFORM AND ONSITE DELIVERY

1. Proposal Scope

The Union is seeking an online and onsite event registration and management solution and partner for the 2027 Conference for 4000 delegates, and for similar offering in 2028 and 2029. This will cover all aspects of an 'online' registration platform and the delivery and management of the full 'on site' registration fulfilment service and high quality delegate experience.

This system should allow users to create both individual and group event bookings, which incorporates a range of registration fees, social event bookings, workshops and enable delegates to become a member of The Union.

To create a bespoke On Line Gateway (OLG) and provide support and to operate the system, while The Union remains responsible for content, operational decisions and the overall delegate experience for the Union World Conference on Lung Health. This includes but is not limited to paying for their registration, providing supportive documentation where necessary, offering added opportunities such as Membership of The Union or paid for events at the time of the Conference.

In addition, to ensure that the online system is a simple and effective method of communication with existing and prospective delegates.

System Overview:

The OLG is the primary point of contact for all aspects of delegate sales and ticketing. The system must incorporate both Individual and Group booking processes and be able to manage payments in both STRIPE, the Union's online payment system, and assist in tracking bank transfers to the Union's bank account.

A secondary purpose is to provide a platform for communication with the delegate base and fulfil any additional needs relating to documentation that may be required to facilitate attendance at the Conference.

The OLG also provides the foundation for all On Site Registration fulfilment operations.

The online registration system needs to be ready to go live at the beginning of May of the annual conference timeline. The conference delivery is scheduled for the second or third week of November annually. The onsite registration deliverables are also to be included in the quotation.

All transactions are conducted in Euros

2. Delivery requirements

ONLINE PLATFORM

The proposed service should include full management of the following areas:

- Provision of an online event registration system for individual participants, groups and exhibitors, including full setup, form design and production linking to the conference website
- Dedicated and experienced registration manager, who will be a focal contact person with The Union registration coordinator throughout the project process

The OLG must provide the following 'front office' functions:

- I. Creation and management of an individual booking record for a delegate
- II. Creation and management of a group booking record, through a delegate group co-ordinator
- III. Operation and management of a registration pricing structure based on a mix of three criteria at any one time:
 - a. Level of Country income as defined by the World Bank or status (nurse or student). The Union will provide and validate the country classifications.
 - b. Date of Booking
 - c. Membership or Non-Membership of The Union
- IV. Collection of data and provision of a supporting letter of invitation to the conference
- V. Provision of receipt for all STRIPE payments
- VI. Assist in the issuing of fiscal invoice distribution (when/if mandated)
- VII. Issue attendance certificates for delegates at end of conference and provision of bulk email capacity for sharing emails with registered delegates
- VIII. Facilitate a delegate enquires function with a response time of no longer than 48 hours in most cases
- IX. Facilitation of communication function, for platform related issues, with delegates
- X. Integrate within the platform a system for the management of free of charge 'sponsored' delegates – e.g scholars, guests, staff and committees' members and volunteers

The OLG must provide the following 'back office' functions:

- I. Access for and integration within the platform for The Union's financial systems to enable a full income reconciliation process. The Union remains responsible for validating payments and managing bank transfers.
- II. Assist in the tracking of the refund process, The Union remains responsible for refund decisions.
- III. Provision for detailed monitoring
- IV. Access for the generation of detailed information on a weekly basis
- V. API integration with external systems when requested will be specified and subject to a separate quotation. The agreement includes the provision and set up of one (1) read-only integration with a single identified third-party system.
- VI. Provide for the importing of list (via an Excel template) and for the management of defined group registrations
- VII. Reporting of all events' attendee lists, including statistical, demographic and financial reporting, as required, on the schedule agreed with The Union

ONSITE DELIVERY

- Development of a comprehensive plan for the management and delivery of the 'on-site' registration fulfilment service

- Working with The Union Registration lead, create and deliver delegate badge and lanyard requirements to a standard agreed and specified by The Union team
- Provide a detailed post event report noting possible improvements and suggested developments for future events
- Flight and reimbursement cost for onsite registration delivery team (excluding local registration hosts)

3. System Requirements

1. Online forms

We require a registration form customised to the needs of the Conference and in accordance to the best practice recommended by the Service Partner, including relevant data capture fields and booking options such as tiered registration fees, workshop bookings and social events.

The supplier needs to work closely with The Union's Conference Team:

- To devise the most effective user journey for the numerous pathways that somebody might need for their registration. It is important that the system can be tailored to the specific needs of the registration process.
- To produce a correctly branded product with a coherent look and feel, and correct use of the Union's house style.
- To ensure a seamless connection with the Conference website.
- To ensure that the online forms should be easy and intuitive for all delegates, responsive on mobile devices and browsers including, but not limited to, Edge, Firefox, Chrome and Safari.
- To deliver a high-quality user experience.

2. Automated elements

A personalised, automated confirmation letter should be sent to each delegate upon completion of the booking process and/or payment.

A system-generated login and password can also be included, should the participant wish to make any changes to their registration.

Post Conference, there is a need to provide certificates, when requested, to prove general attendance and to delegates who have worked as volunteers as a thank you.

3. Delegate Communication

Communication with participants to be managed directly from the online system. This should be done via a dedicated registration email and include an option for both mass mailing and individual communication with delegates.

The registration support team on the Service Partner side shall manage communication, including:

- Post registration changes and re-confirmation
- Payment queries
- General event queries from participants based on the conference guidelines
- Mass emailing of joining instructions or any other mass email campaign required by the conference Secretariat (payment reminders, registration reminders, key deadlines notifications etc.)

4. Financial management

Delegate payments and refunds shall be processed and managed via the proposed online payment gateway (Stripe).

5. Union account integration

Working closely with the Registration Manager and the Union's HQ Accounts team to ensure that all Union accounts processes and requirements are integrated and met through carefully devised 'back office' systems.

6. Administration, reporting and event management

The system shall include a full package of administration tools (i.e. managing records by various statuses, categories, sorting / filtering data, extract data with new entries identified etc.), and should produce a variety of reports.

Of particular relevance for the accounting and reporting systems is that, once the periodic report is produced, no additional entries on the previous period may be allowed (e.g. once the period from May 18 and May 25 is concluded, no additional bookings can be made between those dates).

The system also must allow a data extraction within a date range (between XX and YY dates).

The Conference Team must also be able to add an unlimited number of system users, with specific user permissions, to manage and administer the registrations if required. We will need full admin rights for at least one key member of The Union team.

7. Technical requirements and GDPR

There are a number of technical requirements including compliance with standards, data integrity and security, and hosting. For more details on technical requirements, please see the appendix at the end of this document.

8. Data governance

The Union requires an authentication process against its user database. This can be performed via an API or a synchronisation or a direct access to the database.

The Union requires to have each user recorded in its user database. This can be performed via an API or a synchronisation or a direct access to the database.

The Union requires to have each user session activity /abstract in its user database. This can be performed via an API or a synchronisation or a direct access to the database.

The Union requires a full access to the back office in order to access in real time all data values.

9. GDPR

Where processing of personal data is to be carried out, the Service Provider must guarantee to implement appropriate technical and organisational measures to ensure that they meet the requirements of the European General Data Protection Regulation (EU Regulation 2016/670) and ensure the protection of the rights of the data subject as stipulated in Article 28 of the regulations.

Furthermore, the Contractor shall not engage any sub-processor without the prior specific written authorisation of The Union.

The Contractor must delete or return all personal data to The Union as requested at the end of the contract.

The Union must also agree to any privacy policy and marketing permissions that users are asked to sign. Where possible, users should have the option to sign up to marketing from The Union. The language and technical specifications of this should be agreed with The Union Conference team.

10. Database Integration:

The proposed system must have seamless synchronisation with The Union's internal systems, including Single Sign-On (SSO) capabilities

11. Onsite System

A special database and the interface (front end and back end) to manage onsite registration should be provided for fast check in and onsite badge printing.

This onsite data base/interface shall be fully integrated with the registration system as well as provide unlimited number of individual logins for conference staff/volunteers operating onsite.

12. Designing and printing badges and tickets

The system should be able to lay out and pre-print all badges including barcodes or QR codes, and all personalised event materials such as tickets to any conference events. The design of these materials must be completed and signed off by The Union's communications team.

13. Onsite Capacity to include

- **Print-on-Demand Badges:** Instant printing of full-colour, double-sided badges. Designs must be differentiated by attendee type and of high quality, as specified and reviewed by the Union team. The system should be able to print on-demand badges and tickets and include the badge printing equipment and supplies. Mock up samples to be shared prior to the event and for all the event categories for final approval.

- Each participant shall receive an automated email confirmation that contains a barcode or QR code. Upon arrival to the event registration, the participant shall present the barcode to be scanned in order to receive their badge and any other printed materials.
- Self-Scan Check-In Kiosks: Provision of QR-code-based scanning stations for a contactless and rapid arrival.
- Materials Distribution: Coordination of lanyards and conference bags.
- Technical Help Desks: Dedicated stations for troubleshooting, name corrections, and on-site registrations.
- Hardware & International Logistics: Provision of all necessary hardware and management of freight, including ATA Carnets and customs clearance for equipment entering Brazil.
- Badge screening/scanning capacity: attendees tracking through the Event through scanners or other tracking equipment and badge scanner option for exhibitor usage

14. Staffing and Training

- **Staff Coordination:** Management of registration personnel (local hosts) and local multi-lingual volunteers.
- **Training:** Conduct a mandatory on-site training session prior to the conference opening, covering platform usage, venue orientation, and delegate flow management.
- **Uniform Standards:** All staff must adhere to the professional dress code as shared by The Union in advance of the event

Possibility of auditing

The Union reserves the right to mandate an audit of any kind regarding this invitation to tender. This audit may be carried out either by The Union employee or by entities mandated by The Union to do so.

The Union will inform the Provider beforehand of this audit with a minimum notice of five working days. The Provider shall assist in carrying out such audits.

The technical solution must above all cover a broad spectrum of defined functional and organisational needs. It must also respect the following prerequisites:

Version upgrade management

The production of a new version of the software must be done in the most transparent way possible. In particular, the technical modifications of the site (for example corrections of anomalies) must integrate without jeopardising the integrity of the site's content or functions.

The Provider will describe precisely the process followed during an upgrade of the site.

In particular, they will explain how changes made to the production version (new content, changes to existing content, etc.) will be included in the new version and will specify, if need be, how long the site will be offline.

Quality of service requirements

The provider must detail the technical architecture of the solution, but The Union reserves the right to choose a technical architecture.

Availability

Availability	Level of availability of the target on a monthly basis.
24/24; 7 days a week Hourly range: 24h - 24h	99%

Although use of the software is expected to be relatively constant over the year, peaks can be observed in response to current events.

For example, around a specific application deadline we might expect to have an increased average attendance by a factor of over 6.

Knowing that backups of applications (database and file system) are performed daily, the Provider will suggest backup solutions to provide the minimum durations of data loss:

- Any incident, except in the case of a major disaster: loss of data < one hour.
- Any major disaster: loss of data <= one working day.

Response time

As part of its commitments to service quality, the Service Provider is in charge of setting up a monitoring system guaranteeing the prevention of performance degradation.

The architecture suggested must be able to absorb the increase in load resulting from the progressive increase in the number of connected Internet users expected.

The Service Provider will therefore detail in the most precise way its commitments in terms of response time for a "normal" use with a standard number of connected Internet users.

The technical environment will consist of servers allowing testing before the new evolutions go online, according to a three-tier organisation:

Environment	Description
Development Environment	Managed by the Provider This environment should be accessible in a secure manner by The Union (e.g. pre-VA tests) It will be possible to access some third party services for testing (Pure test player)
Qualification Environment	Managed by the hosting provider Used for deliveries for validation and production preparation. Enables testing of services when needed
Production Environment	Managed by the hosting provider

Data integrity and security

The Provider will be responsible for the security of the data managed by the web site in case of attacks from the network or the exploitation of security breaches.

The Provider will be responsible for defining, designing and validating all procedures for backing up, archiving and restoring data.

The Provider will also be a consultant for the implementation of procedures preventing the access of the web site from robots (detection, limitation of access ...)

These procedures will be designed to meet the availability requirements.

Responsive design

The Service Provider will specify how the completion of the entire web site that it proposes meets the requirements of Responsive Design to facilitate use of the site from different devices (desktop, tablets, mobile and other emergent devices).

The Provider shall specify in particular its commitments in support of these terminals. In particular it will specify the availability of its solution on the platforms currently in production, and in particular on the most popular smartphones and tablets.

Workstation requirements

Technical Requirements

Delegates need to log in to the system using a username and password as well as Union SSO. The registration platform also needs to communicate with the Union Membership API to validate their membership and allow members to receive the membership price rate.

Screen Resolution

The website should be optimised for a minimum desktop resolution of **1280 × 768 pixels**. The site must follow **Responsive Web Design** principles, ensuring proper display across mobile, tablet, desktop, and large monitor screens.

Responsive Design

The website should follow a **mobile-first approach**, allowing the interface to adapt to different screen sizes and orientations.

Supported device widths include:

Mobile devices: **320px and above**

Tablets: **768px and above**

Desktop screens: **1280px and above**

Browser compatibility

The site must be fully functional and tested on the latest stable versions and the immediately preceding major versions of the following widely used browsers:

- The website must support the latest stable versions of the following browsers:
- Windows Internet Explorer: **11.0 and higher**
- Mozilla Firefox: **43.0 and higher**
- Google Chrome: **47.0 and higher**
- Apple Safari: **5.1 and higher**

Applicable Standards

Web Standards

The website must comply with modern web development standards, including **HTML5, CSS3, and modern JavaScript**.

Accessibility

The website should comply with **W3C WCAG 2.0 Level AA accessibility guidelines**, including keyboard navigation, proper colour contrast, and screen reader compatibility.

Hosting

The server infrastructure should be provided and managed by the service provider, and it must be hosted within Europe to ensure full compliance with GDPR requirements. The vendor must also ensure proper load balancing and scalability to handle peak traffic during critical periods.

Reversibility

In the event of termination of the contract between the successful provider and The Union, for any reason whatsoever, the Provider must commit, under the following conditions, to ensure the reversibility of the web site in order to allow The Union to have it taken over by a third party.

At the end of this contract, the Provider provides assistance to The Union (or an operator mandated by The Union) to ensure a transition to a new support.

During the reversibility period:

- The Provider will carry out the activities assigned to it as part of the transition with the teams that will take over the Service and will operationally train the new teams on the functionalities and characteristics of the web site;
- The service shall continue to be provided under the terms and conditions set out in this Framework Agreement;
- The Provider shall not in any way modify or reduce its services and obligations;
- The Provider must commit to cooperate loyally with the third party who will take over the Service.

From the start of the project, the owner initiates a reversibility plan.

Dated: 6 July 2026

This is with reference to the queries received from prospective bidders for the bid having reference: The Union/ /HQ/2026/003 Dated: 17 June 2026 for **a multi-year agreement to manage elements of the World Conference on Lung Health 2027–2029. Please find below the clarifications in Red: -**

REGISTRATION

1. Are we expected to provide a detailed quote to respond to all elements of the specification for this.

Although The Union provided a detailed specification for registration in Annexure F, we do not wish bidders to focus unduly on the level of detail presented. The Union requests that bidders provide a technical and financial proposal for the delivery on an online and onsite registration system, as requested in 5B. The format for the financial proposal is listed in Annexure C and for the technical proposal in Annexure B.

The Union will provide onsite volunteers Not specified in RFP but please include costs for local registration hosts to work as per the following schedule

- Day before conference opens: 6 hosts
- Day 1: 6 hosts
- Day 2: 4 hosts
- Day 3: 3 hosts
- Day 4: 2 hosts

There is an error in that Brazil is referenced in Annexure F and this is to be ignored (it was a carryover from an old specification).

2. Should the financial proposal include costs, such as kiosks, counters, and related equipment? - Please include any costs necessary to deliver onsite registration services, in so far as possible without venue specific detail being available for 2028 and 2029 iterations
3. Can The Union provide prior-year attendance data, including onsite attendees, virtual attendees, countries represented, exhibitor count, sponsor count, registration categories, and peak registration/check-in periods? - For the purposes of the RFP response, please work on the figure of 4,000 delegates on site and 40 exhibitors Peak registration period is the day before the conference and first day of conference. The country representation is global, with delegates coming from all world regions. In 2025, there were 112 different countries represented on site.
4. For online registration, does The Union have a preferred registration platform or incumbent provider, or should bidders propose their own solution? - Bidders should propose their own solution. Please note that bidders may partner with a registration provider, should they not have the capacity in-house.
5. Can The Union provide technical documentation for the required SSO, membership API, user database authentication, and any required integrations? - We cannot provide the technical documentation at the bid stage. These will be shared during discussions

with successful bidders. For the purposes of the response, be aware that The Union has complete documentation and a fully functional API that is currently being used for the conference registration system and mobile app. It is a separate application connected to the central database and the membership portal.

6. The registration specification notes that all transactions are conducted in Euros, while the financial proposal must be submitted in USD. Should payment processing fees, currency conversion, chargebacks, bank fees, and foreign exchange risk be included in the bidder's cost proposal? - **Please provide your quotation in USD as requested in the RFP . The reference on page 30 is for the registration platform bookings, which are handled exclusively in EUROS. No registration income is taken in USD and there is no need to manage exchange rate risk for registration income**
7. Will The Union's Stripe account be used for all registration transactions, or is the selected provider expected to provide the payment gateway? -**The Union's stripe account will be used for all registration transactions**
8. Can The Union clarify whether bank transfer tracking is manual support only, or whether automated integration with The Union's financial systems is expected?- **For the purposes of the RFP response, please consider it is manual tracking. Please indicate if automatic integration may be feasible if systems/expectations were to evolve to require this.**
9. For onsite registration, can The Union confirm the expected number of check-in stations, self-scan kiosks, help desk stations, badge printers, and onsite registration staff?
For the purposes of the RFP response, please consider a minimum of:
 - **4 staffed check in stations**
 - **6 self scan kiosks**
 - **1 help desk station**
 - **5 badge printers**
 - **3 on site registration staff,**
10. Will The Union provide local hosts and volunteers for onsite registration, or should the selected provider source and manage all local registration staff?
The Union will provide onsite volunteers
Not specified in RFP but please include costs for local registration hosts to work as per the following schedule
 - **Day before conference opens: 6 hosts**
 - **Day 1: 6 hosts**
 - **Day 2: 4 hosts**
 - **Day 3: 3 hosts**
 - **Day 4: 2 hosts**
11. The registration specification references hardware and customs clearance for equipment entering Brazil. Can The Union confirm whether this is a carryover reference from a prior event, or whether bidders should account for Brazil-related logistics in any year of this RFP? - **Apologies, that was a typo from an older document.**
12. Can The Union provide examples of badge types, attendee categories, lanyard requirements, and conference bag/material distribution requirements from prior WCLH

events? - Badge type: firm card of approx 100x135mm- but open to suggestion by bidders

Lanyard requirements are open to suggestion by bidders

Attendee categories for badge delivery, for the purposes of the RFP, please consider 12 categories

SCOPE

1. To confirm, the RFP is looking for a PCO to manage the following areas?
 - Destination and venue sourcing for 2028 and 2029 **Yes**
 - Online and onsite registration (including registration software) **Yes**
 - Onsite staffing- for the delivery elements included in the RFP **Yes**
 - Onsite logistics, including venue setup, AV, F&B coordination, signage, and venue coordination etc.. **Yes**
 - Exhibitor Management- **Yes**
 - Hotel Management (delegates & or The Union staff)- **for Union allocation only (250 rooms max), NOT for delegate**
2. Can you also confirm whether The Union team will retain responsibility for the following areas?
 - General pre-conference administration, committee management, and overall timeline management
 - Speaker and programme management
 - Abstract management
 - Marketing
 - Website management
 - Sponsorship and exhibit sales
 - Sponsorship fulfilment
 - Financial and budget management

Yes, we confirm that The Union team will retain responsibility for the areas outlined below
3. As the RFP is limited to the organisation of elements of the Union World Conference on Lung Health 2027–2029, particularly technical and operational venue elements and registration management, I would be interested understand the operational governance model and reporting lines and understand if congress management and supervision of different parties would be executed by your staff team at the headquarters office in Paris, and if we would be in touch directly with any local or general organising committee(s) - **The Union would oversee the management of the entire event, and be the direct contact with local and scientific organising committees.**
4. Could you please confirm whether the scope excludes the following areas, or whether any level of support is expected:
 - Scientific programme support (e.g., abstract management, speaker coordination)
 - Marketing, communications, website, or graphic design
 - Event technology beyond registration and streaming (e.g., mobile applications)

The scope includes the areas listed in the RFP. The areas listed above are not included.

5. Could you clarify the extent of sponsorship and exhibition sales support required?
 - Is this included within the scope for 2027 and/or the future editions (2028–2029)?
 - Or is the PCO expected to support delivery only once sales are secured?
The required baseline exhibitor build is included within the scope for 2027 and for 2028-2029
6. For specialist services, should bidders include the cost of security, medical, cleaning, cloakroom, and safety staffing, or only planning and coordination of those services?
Yes, it is specified in the RPP 5C xii) . The cost for security, medical, cleaning, cloakroom and safety staff should be included as well as the planning and coordination of these services
7. Are there existing Event Safety Management Plan, Public Safety Plan, Security Plan, Medical Plan, or crisis management templates that The Union expects the selected provider to use? **-No**
8. Can The Union clarify insurance requirements, including general liability, professional liability, employer liability, event cancellation, cyber/data protection, and any venue-specific coverage requirements? **-Not at this point**

HOTEL & ACCOMODATION

1. For hotel room bookings within The Union allocation, will the selected provider be managing rooming lists only, or also negotiating, contracting, reconciling, and financially guaranteeing hotel blocks? - **The provider will be negotiating, contracting, reconciling, and financially guaranteeing hotel blocks which will constitute The Union allocation.**
2. For food and beverage planning, should bidders include only planning and coordination fees, or also all delegate, client, exhibitor, side meeting, and crew F&B costs? **-To respond to point 5C xiii) the bidder should include the fees for planning and coordinating all the F&B provision with the venue, on behalf of The Union.**
This includes provision of an ordering interface for clients who wish to reserve F&B for side meetings, or other events during the conference, within the rooms held; exhibitors who may order (if permissible as per venue rules to have F&B at booths)
3. Can The Union clarify who will hold the master accounts for venue, hotel, F&B, internet, electrical, and other direct venue charges - **The Union will hold the master accounts.**
We expect the delivery partner to negotiate terms and attrition clauses on our behalf; manage the room blocks, and food and beverage services and tallies daily; act as the interlocuter for the venue coordinator, while The Union retains final signature on the contract
4. The RFP notes there is no need to include costing for project team accommodation because the project team will be accommodated within The Union allocation at the venue. Can The Union confirm whether bidders should exclude hotel room costs but include travel, per diem, and local transportation?
Correct. Bidders should exclude hotel room costs but include travel, per diem, and local transportation

COMMERCIAL & FINANCIAL LOGISTICS

1. Currency: Page 3 states all quotes must be in USD, but page 30 says all transactions are conducted in Euros. Which currency should we use for our official financial proposal submission, and how would you like us to handle exchange rate risks for the registration income? **Please provide your quotation in USD as requested in the RFP .The reference on page 30 is for the registration platform bookings, which are handled exclusively in EUROS. No registration income is taken in USD and there is no need to manage exchange rate risk for registration income**
2. Fee Adjustments: If the finalized destinations for 2028 or 2029 present severe local inflation or incredibly complex regional tax laws, will we be allowed to adjust our professional management fees accordingly when those budgets are negotiated? **We would aim to avoid countries with complex regional tax laws or severe local inflation and such considerations should be part of your thinking for future conference locations.**
3. Can The Union provide the latest BICC Bali floorplans, technical specifications, venue inclusions, loading and rigging information, internet capacity, and any exclusive-supplier requirements for the 2027 costing exercise? - **Please base your estimate on publicly available data for the purposes of the costing exercise.**
4. Stripe Merchant Account Ownership & Reconciliation: Annexure F, Section 1 (Page 30) states that payments will be processed via The Union's Stripe system, while Section 2.1 (Page 30) tasks the PCO with providing receipts and assisting in income reconciliation. Could you clarify if the selected PCO will be given restricted API/dashboard access to The Union's existing Stripe account for real-time financial tracking, or will the PCO be expected to set up a separate sub-account/connected account structure - **The PCO will be expected to set up a separate sub-account/connected account structure**
5. Financial Liability on Hotel Blocks: Section 5C xiii (Page 9) notes that the PCO will manage venue/hotel contracts and allocations on behalf of The Union. Could you confirm that The Union remains the sole legal and financial signatory on these contracts, and that the PCO will not carry underwriting or attrition liabilities for these room blocks? - **Confirmed**
6. Could you confirm your preferred financial model for this engagement (e.g., fixed fees, variable per-delegate pricing, hybrid structure)? *.This will allow us to propose a commercial model that aligns with your expectations while ensuring transparency and scalability.* **For the purposes of the bid response we wish to have a fixed fee estimation, with information on how additional items would be billed.**
7. Are there any budget parameters or target cost ranges The Union can share to help bidders submit a realistic and cost-effective proposal? - **No, there are no target cost ranges.**
Please base your estimate on publicly available data for the purposes of the costing exercise, and on reasonable planning assumptions for delivery of the elements defined in the RFP
8. For 2028 and 2029 indicative conference delivery budgets, should bidders price based on the same 2027 scope and 4,000-delegate assumption, with final pricing to be revised once venues are selected? -**Yes**

9. Since 2028 and 2029 venues are not yet confirmed, how will The Union evaluate the financial proposal for those years against other bidders? -Bidders have been requested to provide descriptive text and indicative budget for conference management services for the 2028 and 2029 conferences based on the scope outlined in this RFP and inclusive of the core delivery elements defined in section 5Ci-xiv above for the 2027 WCLH.
This will form the basis of the evaluation against other bidders
10. Can The Union confirm whether taxes, permits, work permits, customs, import duties, freight, carnets, local labor requirements, and currency-related costs should be shown as separate line items where they cannot be fully confirmed at this stage? -Yes, please include as separate line items in the financial proposal and have reference text in the technical proposal
11. Can The Union clarify whether bidder travel, per diem, local transportation, freight, and onsite production expenses should be included in each relevant deliverable line item or shown separately? -Please include in section 5C xiii) Delivery Production team as outlined in the RFP unless specific to registration, in which case it can be included in the registration technical description and the costs in the relevant section of the Financial proposal format outlined in Annexure C

TECHNOLOGY, DATABASE, & IT INFRASTRUCTURE GAPS

1. Existing systems and integrations
Please confirm the existing providers and technical requirements for the conference app, abstract and speaker systems, presentation management, and registration-related integrations.- The Union does not wish to provide requirements nor existing providers for these components. For the purposes of your response please note any caveats that are related to integration, and their potential impact.
2. Legacy Browser Compatibility: Annexure F, Section 3.8 (Page 37) requires the registration platform to support Windows Internet Explorer 11.0, alongside older versions of Mozilla Firefox (43.0+) and Google Chrome (47.0+). Given that IE11 is deprecated and poses significant security and GDPR compliance challenges for modern payment environments, is strict compatibility with IE11 a mandatory requirement? -No, we understand that updates may be required with technology evolution. Please suggest relevant alternates in your response
3. Database & API Integration Ownership: Annexure F, Section 8 (Page 33) outlines extensive authentication, synchronization, and session/abstract tracking requirements against The Union's internal user database via API or direct access. Does The Union currently have a fully documented REST API available for the selected PCO to connect to, or is the PCO expected to build these integration points from scratch? -This is specific to registration. Yes, we do
4. Business Splitting vs. System Architecture: Section 3.4 (Page 2) states that The Union reserves the right to split the business among multiple agencies. Given that the registration platform (Annexure F) requires a highly integrated end-to-end infrastructure linking the front office, back office, and onsite badge printing systems, how does The Union envision managing data integrity if the registration scope is split

across different vendors? - Registration delivery is to be considered as a single delivery system. It is not to be split across different vendors. The "split" refers to the fact that certain PCOs may need to partner with other agencies to allow for delivery of certain elements listed in the RFP, and that this is permissible. Registration is one such example.

5. Can The Union confirm whether all 10 session rooms and the plenary room are expected to operate simultaneously for the full 08:00-20:00 daily schedule? - Yes
5. Can The Union provide a draft or prior-year program schedule showing plenary sessions, abstract sessions, symposia, satellite sessions, Community Connect programming, side meetings, poster sessions, breaks, and receptions?
Please refer to 2025 Detailed Programme for reference – pdf attached
Please refer to 2025 and 2024 online programme schedule referenced in the rfp
 - <https://unionconf2025.abstractserver.com/programme/#/programme/1/vertical>

<https://unionconf2024.abstractserver.com/programme/#/programme/1/horizontal>
6. For the 10 session rooms and plenary room, should bidders assume presentation support only, or should each room also include camera capture of presenters, audience Q&A, and room ambience? -It should include all items listed in the RFP, which include content capture and audiovisual set up, as well as stage set up.
7. What level of camera coverage is expected for the plenary room and for each session room? -Please make a suggestion of the minimum spec for camera coverage based on the expected audience size in the plenary room.
8. For content capture, is The Union expecting full video recording of each session, audio plus slides, or another format? The Union is expecting recording of each session audio and the slides presented, so that anyone who is not in room can review the session as delivered in the room
9. Should all 10 session rooms and the plenary room be live streamed, or are some rooms only required for capture and video-on-demand? -All 10 session rooms and plenary room should be live-streamed for the purposes of the RFP response.
10. Can The Union provide more detail on the required content delivery network, including any known requirements for access in China? -The Union expect bidders to suggest a response based on the information shared in the RFP
11. What conference app or platform is currently used by The Union, and what integration will be required for livestreaming and video-on-demand access?
For the purposes of the RFP, bidders may suggest a suitable platform for livestreaming and video-on demand access which has the capacity to integrate with a customised programme planner.
12. How long should video-on-demand content remain available after the conference? -It should be made available until end of March of the year following the conference.
13. Are closed captioning, transcription, translation, or simultaneous interpretation required for any sessions? If so, how many languages should bidders include? -These items are not requested in the RFP. Bidders may include optional suggestions for these items for consideration
14. The RFP references translation options and suggested use of AI. Can The Union clarify whether AI translation is required, optional, or simply open for recommendation? -It is open for recommendation.

15. Can The Union confirm the required presentation management system? Will this be provided by The Union, by a third party, or by the selected provider? -No, we cannot confirm the presentation management system. It is not included in the scope of this RFP. It is delivered currently by a third party
16. For the VLAN internet drop required in each session room, can The Union provide minimum bandwidth, security, and network configuration requirements? -Not at this time. Bidders may suggest minimum requirements based on delegate numbers.
17. Should delegate Wi-Fi and internet be included by the bidder as part of the technical infrastructure scope, or will this be contracted directly by The Union or through the venue? -To be included by the bidder as part of the technical response. Specific need will be subject to the standard of each venue.
18. For the plenary room, can The Union clarify the desired scenic, staging, screen, lighting, and seating expectations beyond the Davos-style setup referenced in the RFP? -The scenic and staging expectation is for a staging set up scaled appropriately for a 1200 capacity room with proportional screen (s); lectern and davos seating for 8 people; Lighting should allow for a minimum even stage wash and lectern focus
Minimum requirements are for the procurement, installation, operation and removal of a screen(s) of a suitable size and quality for medical based presentations (fine text) and projection facilities to enable presentations from the (3rd party) presentation management system to be displayed with the presenter operating the presentation via a laptop. Seating for the room is in theatre style x1200
19. Are there brand guidelines, prior event design examples, signage standards, or environmental branding guidelines that can be shared with bidders? - Not at this time.
20. For the 10 digital totems/LED screens, should bidders include only the hardware and placement, or also content design, content management, scheduling, and sponsor content playback? -Bidders to include the hardware, placement, content management, scheduling and playback. Content design will be provided.
21. For the e-poster area, can The Union confirm the expected number of posters, presentation schedule, attendee flow expectations, and whether the e-poster software/platform is provided by The Union or by the selected provider?
For the RFP response, consider a total of 63 eposters
Eposter schedule can be consulted in 2025 programme to give indicative schedule:
<https://unionconf2025.abstractserver.com/programme/#/programme/4/vertical>
The e-poster system is currently provided by our abstract system provider.
22. For the Community Connect area, can The Union provide examples, photos, layouts, or program information from prior years to help bidders understand the desired atmosphere, programming style, and design expectations?
Please refer to 2024 and 2025 programmes online to have an idea:
<https://unionconf2025.abstractserver.com/programme/#/programme/4/vertical>
<https://unionconf2024.abstractserver.com/programme/#/programme/1/horizontal>
23. For the exhibition, will The Union manage exhibitor and sponsor sales, or is the selected provider expected to support sales, revenue generation, or exhibitor outreach? - The Union will manage exhibitor and sponsor sales
24. Can The Union provide the current or expected sponsorship and exhibitor prospectus for WCLH?- Yes- the 2026 sponsorship brochure is shared as a pdf

25. Should revenue from exhibitor upgrade packages, graphics, furniture, power, and AV orders through the online shopfront be collected by the selected provider or by The Union? -By the selected provider
26. Can The Union clarify whether the online exhibitor shopfront must integrate with The Union systems, or whether a standalone exhibitor ordering portal is acceptable? -A standalone exhibitor ordering portal is acceptable
27. For custom booth management, will The Union establish booth design rules and approval standards, or should the selected provider develop those standards? -The selected provider must respect the maximum footprint size and dimensions for booth design. The selected provider is expected to make suggested standards based based on the specific rules and regulations of each venue
28. Are exhibitors required to provide insurance, health and safety paperwork, risk assessments, and method statements directly to the selected provider for review and approval?
Yes

OPERATIONAL & HUMAN RESOURCES SCOPE

1. Local Staffing Financial Responsibility: Section 5C ii (Page 5), Section 5C xii (Page 9), and Annexure F (Page 34) reference the deployment and coordination of local registration hosts and volunteers. Is the PCO expected to directly contract and pay for the local hostesses/temporary staff within its financial proposal, or will these local personnel be sourced and funded directly via a Local Host Committee? -The PCO is expected to directly contract and pay for the local hostesses/temporary staff that are specified within the RFP within its financial proposal
2. Volunteer Scale: Section 5C i (Page 5) notes a dedicated space for 300 volunteers. Could you clarify the general operational scope of these 300 volunteers, and the level of management and training expected from the PCO delivery team? -The volunteers assist with the delivery of the conference. The management of the volunteers lies with The Union team. The delivery partner would be expected to participate in initial training on pre conference day to brief them on the venue layout and operating specifics only.

VENUE STRATEGY (2028-2029)

1. Can you please confirm that we are to include a cost for destination and venue sourcing/scoping for 2028 and 2029, but are not required to submit along with specific venues or their confirmed quotations as part of this proposal? - Correct. Please include a cost for destination and venue sourcing/scoping for 2028 and 2029, but bidders are not required to submit specific venues or their confirmed quotations as part of this proposal
2. For the venue-search and scoping exercise, please confirm the expected number of countries, cities and venues to be assessed; whether physical site inspections are required; and whether bidder pricing should include travel for Union representatives. - A desk based scoping on at least 3 countries in the region, with an expected proposal of top 1 country, and your recommendation for top 1-2 venues (if certain countries have

- more than one potential venue)- having taken into consideration The Union criteria for venue specification.
Physical site inspection required to top ranking country site to scope venues
Please include travel for 2 Union team members to accompany the visit
3. For the indicative 2028 and 2029 budgets, should bidders assume the same 4,000-delegate, four-day, ten-session-room and one-plenary-room model specified for WCLH 2027? – YES
 4. For venue sourcing for the 2028–2029 editions, could you please clarify:
 - Any preferred or pre-identified destinations or regions- refer to The Union criteria (see Annexure A) and geographical focus areas (Annexure A),
 - The key decision-making criteria (e.g., cost optimisation, accessibility, geographic rotation, strategic priorities) - refer to The Union criteria (see Annexure A) and geographical focus areas (Annexure A),
 - The approval and governance process for venue selection: The Union Conference department will make a recommendation to The Union Board, decide based on the results of the venue search proposal as delivered by the PCO and as described in section 5A, and which must align with the criteria in Annexure A
 5. Can The Union confirm the anticipated dates for the 2027 WCLH in Bali? - The RFP indicates the anticipated dates for the conference will be from Tuesday through Friday in the second or third week of November 2027.
 6. Has the Bali International Convention Centre been fully contracted for 2027, or is the venue still subject to final confirmation? - Venue still subject to confirmation
 7. Can The Union provide the anticipated build, rehearsal, show, and load-out/strike schedule for the 2027 conference at BICC? - Anticipated build will be Saturday-Sunday ahead of event (Monday too in non registration area) . Derig and clearance will be Friday evening through Saturday/Sunday after the event
 8. Can The Union provide CAD files, scaled floor plans, room capacities, ceiling heights, rigging points, power specifications, internet specifications, loading dock information, and venue rules for BICC? - Not at this point
 9. For 2028 and 2029 venue search and scoping, how many countries, cities, and venues should bidders assume will be evaluated? - A desk based scoping on at least 3 countries in the region, with an expected proposal of top 1 country, and your recommendation for top 1-2 venues (if certain countries have more than one potential venue)- having taken into consideration The Union criteria for venue specification.
Physical site inspection required to top ranking country site to scope venues
 10. Should bidders include international travel for site visits related to 2028 and 2029 venue selection? If so, how many site visits and how many team members should be assumed? - Bidders to propose their suggested team size for venue scoping.
One visit is suggested for physical inspection of recommended location ahead of selection
Please include 2 Union team members in this visit
 11. Can The Union clarify the expected timeline for selecting the 2028 and 2029 host cities and venues?
2028 to be selected not later than Q1 2027
2029 be selected no later than Q1 2028

12. For the optional strategic input and advisory role, does The Union expect the provider to actively engage Ministries of Health, government stakeholders, local convention bureaus, sponsors, and commercial partners, or only advise The Union on strategy? - **The Union expects advice on strategy and potential engagement with commercial partners and sponsorship avenues within a country**
13. The Brazil Reference: Page 34 mentions managing customs clearance and ATA Carnets for equipment entering Brazil. Since the rotational plan lists Bali, Africa, and Europe, is Brazil actually under consideration for 2028/2029, or was that just a leftover typo from a previous document? - **Please ignore, this was a typo from an older document.**
14. Streaming in China: Page 8 notes the live stream needs to work seamlessly in China. Does The Union already hold an ICP license or domestic hosting solution there that we can tap into, or are we expected to source a workaround independently? - **The Union does not hold an ICP currently. You are expected to propose a suitable workaround**
15. Baseline Assumptions for 2028 and 2029: For the indicative budgets requested in Section 5D (Page 10), should bidders assume a baseline venue footprint, capacity, and cost structure identical to the Bali (BICC) parameters outlined for 2027? -**Yes**

THIRD PARTIES

1. For the detailed delivery items listed under 5C i–xiv, can you please clarify whether The Union is looking for the PCO to obtain and include specific supplier quotations at this stage from AV, show services, the venue, and other relevant suppliers? Or are you looking for a quote to manage these areas and engage in an RFP process with suppliers after the contract is awarded? - **We expect your response to include costs to manage these areas and also to deliver each of the areas listed under 5C i–xiv**
2. should third-party supplier costs be shown as detailed per-line estimates or estimated per-category costs? -**Please include costs per category**
3. If specific supplier pricing is required at this stage, can you please provide the current proposal/agreement with the Bali convention centre? This would help us better understand the space allocation, limitations, inclusions within the venue cost, move-in/move-out details, and any venue-specific requirements or exclusivities. - **No such details can be provided at this time, and the venue is to be taken as indicative for the purposes of the quotation.**
4. Are there any venue-mandated, or The Union preferred suppliers that bidders must use or price against
Not for the purposes of the RFP
5. Can The Union confirm whether it intends to appoint one lead contractor for all mandatory components, or whether individual workstreams may be awarded separately to multiple providers? - **The Union wishes to appoint one lead contractor for all mandatory components. A lead may submit a proposal in collaboration with a partner agency for a specific component.**
6. Please confirm whether The Union expects the selected provider to contract and financially underwrite major third-party suppliers, or whether The Union will contract directly with approved suppliers and the provider will manage procurement,

coordination, and delivery on The Union's behalf - **The Union expects the selected provider to contract and financially underwrite major third-party suppliers. If there is a financial cost to this, please explain this in your proposal.**

7. The RFP mentions providing a mechanism for underwriting third-party contracts financially and operationally. If The Union introduces or mandates a specific local vendor (like a venue-exclusive AV, rigging, or catering team), will we still be expected to underwrite them, or does this rule only apply to suppliers we source independently? - **This mechanism only applies to suppliers sourced via the lead contractor**
8. Are there any required or exclusive vendors at BICC for AV, rigging, electrical, internet, security, cleaning, registration infrastructure, freight, booth construction, or other event services? - **For the purposes of the RFP, please consider there are not.**

PROJECT GOVERNANCE

1. We have a commercial relationship with a tobacco corporation, the sole purpose of which is the production and management of an online scientific journal on the harmful effects of smoking, accessible only to medical professionals. This contract expires on 31 December 2026, and the turnover generated by it is insignificant in comparison with our total turnover. In view of the above, is this commercial relationship prohibited under RFP? - **We would be unable to partner with an organisation that has any relationship with the tobacco industry at any level.**
2. If we make a proper disclosure about our relationship with the tobacco corporation, as required by RFP, what impact does our disclosure have in relation to the prohibition? are we safe and exempt from having to comply with the prohibition? - **See response to 1.**
3. With regard to the restriction on organisations affiliated with the tobacco industry, could you please clarify whether this requirement is assessed at a global organisational level or at the level of the specific legal entity/office delivering the contract? - **See response to 1.**
4. As a global agency operating multiple, independent offices across multiple markets, this clarification will help us ensure an accurate representation of compliance within the context of the proposed delivery team. **See response to 1.**
5. Could you outline The Union's team structure and operating model for WCLH delivery, including key roles, responsibilities, and internal stakeholder groups?
No. The details of the Conference dept structure and roles etc would be discussed at a later point after technical submission.
6. Additionally, could you detail the governance framework, including:
 - Decision-making authority and approval processes
 - Steering committees or advisory groups
 - Expected timelines for key approvals and escalation pathways
 - *This will support us in designing an effective governance approach that aligns with your internal structure and enables efficient collaboration.*
 - What does The Union consider to be the primary risks for the 2027 Congress, particularly related to hosting the event in Bali?**Bidders are welcome to share any risks they concern of relevance as part of their technical proposal**

MISCELLANEOUS

1. Given the level of detail required, an opportunity for a brief call would be much appreciated to help ensure our response is both accurate and submitted in a timely manner - **We are unable to hold calls with bidders.**
2. We would like to be re-confirm that certain elements of conference planning are not required as part of the requirements particularly as it relates to the scientific programme or stakeholder management; being the handling of (local) organising and scientific committee, abstract management, speaker management, exhibitor management, accommodation management, social events management (if any) - **Correct. Respond only to the items listed in the RFP. For exhibition and accommodation management the requirements for which a response is expected is specified in the RFP.**
3. Is there any flexibility regarding the submission date, should additional time be required for the preparation of a comprehensive proposal? - **The date is not subject to change**
4. ESG, SUSTAINABILITY & DEI
 - i. Are there specific ESG, sustainability, or diversity, equity and inclusion (DEI) requirements that should be incorporated into delivery?
 - ii. If so, how will these elements be evaluated or weighted within the proposal assessment and ongoing performance?**No, there are no specified SG, sustainability, or diversity, equity and inclusion (DEI) requirements that should be incorporated into delivery. However, as indicated in the technical evaluation, the bidder's approach to commitment to sustainability is to be outlined in the technical proposal.**
5. Can The Union provide the 2025 Conference Programme PDF referenced in the RFP, along with any available prior-year run of show, room matrix, or conference schedule? - **Yes, shared.**
6. The RFP notes there is no need to include costing for project team accommodation because the project team will be accommodated within The Union allocation at the venue. Can The Union confirm whether bidders should exclude hotel room costs but include travel, per diem, and local transportation?
Correct. Bidders should exclude hotel room costs but include travel, per diem, and local transportation

RFP FORMAT & SUBMISSION

1. Would it be possible to provide the response templates (financial tables and required formats) in Word or Excel format to support accurate and efficient completion? - **The exact format required is specified in Annexure B and C. Please follow that format in Word and excel for the bid submission**
2. Can The Union confirm whether bidders are required to register in any procurement system or vendor database prior to submitting questions or a proposal, or whether email submission to Procurement.union@theunion.org is sufficient? - **only email is required to Procurement.union@theunion.org**

3. Can The Union confirm whether a bidder may submit as a lead agency with named partners and/or subcontractors, as long as each entity's role and legal status are clearly described in the proposal? -Yes
4. For joint proposals or subcontracted proposals, should each participating legal entity provide registration documents, financial statements, disclosures, references, and CVs, or only the lead bidder? - Our focus is on the lead bidder, but consortia partners or subcontractors would also be subject to our terms. These elements would need to be demonstrated prior to contracts being agreed.
5. For the minimum average annual turnover requirement of USD 7 million, can this be met cumulatively by a consortium or joint proposal team? Yes, this can be met cumulatively.
6. Can The Union clarify whether contract exceptions or requested modifications to Annexure E may be submitted with the proposal? - YES
7. Can The Union confirm whether the presentation/interview will be held virtually or in person? - VIRTUALLY
8. Can The Union confirm who from The Union will participate in the presentation/interview and whether the focus will be technical approach, financial proposal, team structure, or all of the above? The Bid Evaluation team will consist of a cross section of Union Senior leadership team. The focus will be all of the above (without discussion on the Financial proposal).
9. Are bidders permitted to include optional value-added recommendations or alternative approaches in addition to the required scope, as long as the required financial format is still followed?- Yes, bidders may make recommendations and alternative approaches in addition to the required scope as long as the requested elements are responded to clearly in both the technical proposal and the financial proposal format



The Union

**WORLD
CONFERENCE
ON LUNG HEALTH
2026** RIO DE JANEIRO
NOV 17-20

SPONSORSHIP
OPPORTUNITIES

For more information, contact us:
partners@theunion.org

worldlunghealth.org

Sponsorship & Exhibition Opportunities

Thank you for your interest in supporting the world's largest lung health conference. This prospectus outlines our standard exhibition and sponsorship packages, plus a range of additional branding opportunities.

About the Conference

The Union World Conference on Lung Health brings together researchers, clinicians, implementers, advocates, community partners and policymakers to advance action on tuberculosis and lung health worldwide.

Taking place at Windsor Convention & Expo Center, Rio de Janeiro, Brazil.

Standard sponsorship packages

Category	Feature	INNOVATE	ADVANCE	PROGRESS	PROGRESS PLUS	CURE	IMPACT
Overview	Eligibility	Turnover < €1M	Booths cannot be combined				
	Quantity Available	4	24	8	2	1	3
Investment	Early bird (before 1 May 2026)	€5,840	€17,530	€40,900	€46,745	€76,000	€85,000
	Standard rate	€7,300	€20,500	€45,000	€54,000	€88,000	€95,000
Exhibition and core benefits	Booth space	2m x 2m	3m x 3m	6m x 3m	6m x 6m	9m x 6m	Private room
	Shell scheme	Included	Included	Space only	Space only	Space only	Space only
	Booth daily cleaning	Yes	Yes	Yes	Yes	Yes	Yes
	Badge scanner licences	2	2	4	4	5	6
	Complimentary conference passes	2	4	6	10	11	12
Digital and visibility benefits	Programme app: Logo and profile listing	Yes	Yes	Yes	Yes	Yes	Yes
	Programme app: Banner ad	No	No	Yes	Yes	Yes	Yes
	Programme app: Splash ad	No	No	No	Yes	Yes	Yes
	Digital totems (slides)	1	2	3	4	4	4
	Pre-conference email inclusion	Name + link	Logo + link	Non-exclusive	Non-exclusive	Dedicated	Dedicated
	Conference website recognition	Name	Sponsor tile	Sponsor tile	Sponsor tile	Sponsor tile	Sponsor tile
	Plenary placeholder slide	Name	Small logo	Medium logo	Medium logo	Large logo (secondary placement)	Large logo (secondary placement)
Social media recognition	1	1	2	2	3	3	

Additional rate information

- The INNOVATE rate is available for companies/organisations with an annual operational budget of less than €1 million.
- For ADVANCE, an NGO rate is available for organisations with an annual operational budget of less than €20 million. Please contact Alison to discuss details.

Exhibition delivery

- Sponsors will work directly with our appointed Exhibition Contractor to ensure smooth installation and dismantling. Costings for additional items including furniture, graphics and AV/IT requirements are available upon request.

Shell scheme stands include

- Aluminium structure (wall positions detailed on the floorplan)
- Lighting
- Electrical outlet (1 x 500W outlet for stands of 9m² or less; 2 outlets for stands of 12m² or more)
- Carpet
- Waste bin
- Fascia board displaying the exhibitor's name
- Daily cleaning

Other Sponsorship Items

In addition to the standard sponsorship packages, the following exclusive and non-exclusive opportunities are available. Please contact Alison about these or any other promotional activities you would like us to consider.

EXCLUSIVE ITEMS

Opportunity	Description	Investment
Exclusive email blast	Dedicated email to Conference audience announcing sponsor	€5,500
Wireless Wi-Fi Internet	Branded Wi-Fi login landing page and on-screen logo placement throughout the venue.	€19,000

NON-EXCLUSIVE OPPORTUNITIES

Opportunity	Description	Investment
TBScience sponsor	Recognition on TBScience listings, 2 delegate passes, website listing and email inclusion.	€5,500
Youth4LungHealth sponsor	Recognition on Youth4LungHealth listings, 2 delegate passes, website listing and email inclusion.	€5,500

SCHOLARSHIP SUPPORT

Opportunity	Description	Investment
Speaker scholarships	Support speakers from low and lower-middle income countries to ensure inclusive representation for researchers, public health workers, affected communities and survivors. Note: Sponsors are not involved in the selection process of scholarship awardees	€3,800 per person

Brand and promotional guidelines

- Use of The Union and conference logos is subject to review and approval.
- All promotional materials must be relevant, educational in nature and approved prior to distribution.
- The Union does not provide direct access to delegate data or email lists.
- Certain sponsorship items may be restricted in accordance with applicable compliance regulations.

Satellite Sessions

Submissions for the Union Conference have now launched. Satellite sessions submitted by 27 May 2026 will receive notification by 3 June 2026. If there are slots remaining, there will be a second round of satellite session submissions between 28 May and 03 August 2026. Notifications for the second round will be sent by 11 August 2026. More details on the application and review process can be found on the [website](#) – [key dates](#) are listed [here](#)

SATELLITES		Price	NGO*
Morning	Up to 60 minutes	€ 13,250.00	€ 8,400.00
Afternoon	Up to 90 minutes	€ 37,100.00	
Evening	Up to 90 minutes	€ 21,200.00	€ 16,800.00

A Satellite Session is either an educational or an industry organised activity that is supported by individuals, non-profit groups, organisations or commercial entities. Satellite sessions are up to 90 minutes long and are normally scheduled outside the core programme.

[Review Criteria](#)

[Submission Guidelines](#)

[Key dates](#)

[Submit a Satellite Session](#)

List of Tracks

Your session must be submitted under one of the official tracks of the conference, found here: [list of tracks](#).

Selection Review System

The Scientific Programme Committee of the Conference bases their programme selection decisions according to a pre-defined review system.

Satellite session sponsors receive the following benefits

1. Listing in the official conference programme app and on conference website
2. Dedicated pre conference email sent to delegates ahead of the event (grouped not individual)

Prime (lunchtime and evening) session sponsors receive the following additional benefits

3. 1 dedicated pre conference email promotion
4. 2 push notifications on app

IMPORTANT NOTE:

Chairs and speakers are required to register to attend the conference, including for sessions they will be contributing to.

* NGO rates are available for morning and evening sessions for not for profit organisations with an annual operational budget of less than €20million.

Tuesday, 18. November 2025

Opening Session

09:00 - 10:00

Main

OS01 - Opening Session

Welcome	09:00 - 09:08
Cassandra Kelly-Cirino (Switzerland)	
Opening remarks	09:08 - 09:13
Hans Henri P Kluge (Denmark)	
Keynote speech	09:13 - 09:33
John Green (United States)	
Remarks	09:33 - 09:43
Guy Marks (Sydney, Australia)	
The Union Medal	09:43 - 09:48
Community voices	09:48 - 09:55
Olya Klymenko (Kyiv, Ukraine)	
Lucas Pucarato (Brazil)	

Break

10:00 - 10:15

Main

Break/Networking

Community Connect

10:00 - 17:00

CCART

CCA001 - 'Hospitality': Selected Works (Preview) Exhibition by artist and TB survivor Paulina Siniatkina

Paulina Siniatkina (Netherlands)

Workshops

10:10 - 13:10

R5

WS04 - UPSKILL TB: Strengthening of drug-resistant TB management through implementation of global open online training

Hansel Andita Kristiandi (Indonesia)

Maria Diachenko (Ukraine)

Sandeep Juneja (New York, United States)

Erlina Burhan (Jakarta, Indonesia)

Welcome remarks	10:10 - 10:17
Erlina Burhan (Jakarta, Indonesia)	
Sandeep Juneja (New York, United States)	
The process: UPSKILL TB development and objectives	10:17 - 10:32
Erlina Burhan (Jakarta, Indonesia)	
Q&A	10:32 - 10:37
Inside UPSKILL TB: Content, learning features, and evaluation	10:37 - 11:00
Eghar Anugrapaksi (Indonesia)	
Q&A	11:00 - 11:10
Lessons learned and scaling up UPSKILL TB globally	11:10 - 11:28
Maria Diachenko (Ukraine)	
Q&A	11:28 - 11:38

Interactive Hands-on UPSKILL TB Trial

Frizka Widyana Widjanarko (Indonesia) Hansel Andita Kristiandi (Indonesia)	11:38 - 12:43
Feedback from participants Hansel Andita Kristiandi (Indonesia) Frizka Widyana Widjanarko (Indonesia)	12:43 - 13:03
Wrap-up and closing remarks Erlina Burhan (Jakarta, Indonesia) Sandeep Juneja (New York, United States)	13:03 - 13:10

Post-Graduate Courses
10:10 - 18:00

R6

PGC02 - TB MAC: An introduction to TB modelling

Finn McQuaid (London, United Kingdom)
Kristian Godfrey (United Kingdom)
Sandip Mandal (New Delhi, India)
Katherine C. Horton (London, United Kingdom)

Introduction to the day	10:10 - 10:20
Lecture 1: An introduction to TB modelling Richard White (London, United Kingdom)	10:20 - 11:00
Practical 1: Setting up a model of M. tuberculosis Lara Goscé (London, United Kingdom) Alvaro Schwalb (London, United Kingdom) Martin Harker (United Kingdom) Katherine C. Horton (London, United Kingdom) Mphatso D. Phiri (Blantyre, Malawi) Finn McQuaid (London, United Kingdom) Rebecca A. Clark (London, United Kingdom) Chaelin Kim (United Kingdom)	11:00 - 12:40
Paper Discussion 1: How to critically review a modelling paper Rebecca A. Clark (London, United Kingdom)	12:40 - 13:10
Lunch Break	13:10 - 15:00
Paper Discussion 2: How to critically review a modelling paper Rebecca A. Clark (London, United Kingdom)	15:00 - 15:30
Lecture 2a&b: TB modelling - Interventions and cost effectiveness Sandip Mandal (New Delhi, India) Nicolas Menzies (United States)	15:30 - 16:30
Practical 2: Modelling the impact and cost-effectiveness of TB interventions Martin Harker (United Kingdom) Nicolas Menzies (United States) Alvaro Schwalb (London, United Kingdom) Katherine C. Horton (London, United Kingdom) Mphatso D. Phiri (Blantyre, Malawi) Finn McQuaid (London, United Kingdom) Rebecca A. Clark (London, United Kingdom) Chaelin Kim (United Kingdom)	16:30 - 17:50
Summary of the day and TB MAC Katherine C. Horton (London, United Kingdom)	17:50 - 18:00

Post-Graduate Courses

10:10 - 13:10

R7

PGC04 - Updates on the latest recommendations on TB from the World Health Organization

Linh Nguyen (Switzerland)

Fuad Mirzayev (Geneva, Switzerland)

Norbert Ndjeka (South Africa)

Patricia Hall-Eidson (Switzerland)

Introduction

10:10 - 10:15

Norbert Ndjeka (South Africa)

Patricia Hall-Eidson (Switzerland)

Updated WHO recommendations and guidance on drug-resistant TB treatment

10:15 - 10:35

Fuad Mirzayev (Geneva, Switzerland)

Updated WHO recommendations and guidance on nutritional support for people with TB or at risk of TB and their household contacts

10:35 - 10:55

Kerri Viney (Geneva, Switzerland)

Updated WHO guidance on TB preventive treatment, screening and asymptomatic TB

10:55 - 11:15

Dennis Falzon (Geneva, Switzerland)

Updated WHO recommendations and guidance on TB diagnostics

11:15 - 11:35

Patricia Hall-Eidson (Switzerland)

Perspectives of the National TB Programme and civil society in South Africa on the development, dissemination, adoption and uptake of WHO TB recommendations and guidance

11:35 - 12:05

Ingrid Schoeman (Pretoria, South Africa)

Norbert Ndjeka (South Africa)

Panel discussion: technical assistance to support countries on the uptake, dissemination and implementation of the WHO guidance

12:05 - 12:50

Norbert Ndjeka (South Africa)

Patricia Hall-Eidson (Switzerland)

Grania Brigden (Switzerland)

Kobto Koura (Paris, France)

Agnes Gebhard (Netherlands)

Askar Yedilbayev (Denmark)

Mariam Toure (Switzerland)

Post-Graduate Courses

10:10 - 18:00

WS-PGC

PGC03 - Social protection programmes for people affected by TB: From planning to monitoring and evaluation

Delia Boccia (London, United Kingdom)

Farai Mavhunga (Switzerland)

Social protection and TB: An introduction

10:10 - 10:10

Farai Mavhunga (Switzerland)

Planning social protection for people affected by TB

10:10 - 10:10

Delia Boccia (London, United Kingdom)

Designing inclusive and responsive social protection programmes for people affected by TB

10:10 - 10:10

Priya Shete (United States)

Rachel Forse (Ho Chi Minh City, Vietnam)

Achieving universal social protection coverage: A monitoring and evaluation framework

10:10 - 10:10

Debora Pedrazzoli (Switzerland)

Models of multisectoral collaborations between TB and the social protection sector and tips to build an investment case	10:10 - 10:10
Salla Atkins (Tampere, Finland)	
Practicals on social protection and TB	10:10 - 10:10
Jillian Kadota (United States)	

Post-Graduate Courses

10:10 - 13:10

WS-PGC

PGC05 - TBData4Action in half a day: Using routine data for quality improvement of TB management

Riitta Dlodlo (Bulawayo, Zimbabwe)

Einar Heldal (Norway)

Olumuyiwa Adesina Owolabi (Gambia)

Sithabiso Dube (Harare, Zimbabwe)

Introduction	10:10 - 10:20
Riitta Dlodlo (Bulawayo, Zimbabwe)	
Einar Heldal (Norway)	
Olumuyiwa Adesina Owolabi (Gambia)	
Sithabiso Dube (Harare, Zimbabwe)	

TBData4Action: Charting the path to quality improvement in TB prevention and care	10:20 - 10:35
Stephen John (Yola, Nigeria)	

Q&A	10:35 - 10:40
----------------	---------------

Why and how to integrate TB data into site support and performance review meetings	10:40 - 10:50
Kobto Koura (Paris, France)	

Q&A	10:50 - 10:55
----------------	---------------

How to tabulate and analyse data at facility level with exercises	10:55 - 11:15
Jane Carter (United States)	

Q&A	11:15 - 11:20
----------------	---------------

How to tabulate and analyse data at district and other subnational levels	11:20 - 11:45
Riitta Dlodlo (Bulawayo, Zimbabwe)	

Q&A	11:45 - 11:50
----------------	---------------

Exercise - group work (40min) and plenary (20min)	11:50 - 12:50
--	---------------

TBData4Action in Togo: Results of how using data can strengthen TB management in a West African country	12:50 - 13:00
Mohammed Fall Dogo (Lomé, Togo)	

Q&A	13:00 - 13:05
----------------	---------------

Wrap - up and closing remarks	13:05 - 13:10
--------------------------------------	---------------

Workshops

10:10 - 18:00

WS-PGC

WS02 - Implementing effective active TB drug safety monitoring and management (aDSM) on the introduction and scale up of novel shorter regimens

Mansa Mbenga (Netherlands)

Agnes Gebhard (Netherlands)

Introduction	10:10 - 10:15
Mansa Mbenga (Netherlands)	

Agnes Gebhard (Netherlands) Cherise Scott (Switzerland)	
Principle of implementing effective aDSM	10:15 - 10:35
Dennis Falzon (Geneva, Switzerland)	
Quiz	10:35 - 10:50
Self-assessment and planning, and challenges implementing aDSM	10:50 - 11:10
Mansa Mbenga (Netherlands)	
Q&A	11:10 - 11:20
First practical session: Status and challenges	11:20 - 12:00
Country Experiences	12:00 - 12:00
Country experience - Nigeria	12:00 - 12:25
Adesigbin Clement Olufemi (Abuja, Nigeria)	
Country experience - Belarus	12:25 - 12:50
Natalia Yatskevich (Belarus)	
Country experience - Philippines	12:50 - 13:15
Maria Imelda Quelapio (Philippines)	
Q&A	13:15 - 13:40
Agnes Gebhard (Netherlands) Cherise Scott (Switzerland)	
Lunch Break	13:40 - 15:00
Country experience - Mozambique	15:00 - 15:25
Gisela Sendela (Mozambique)	
Country experience - Ukraine - Drug-safety monitoring on DR-TB in Ukraine	15:25 - 15:50
Olesia Medvedieva (Ukraine)	
Q&A Panel with country lead	15:50 - 16:10
Second practical session: Solutions and plans	16:10 - 17:00
Panel discussion / feedback from groups	17:00 - 17:50
Wrap up and closing remarks	17:50 - 18:00
Agnes Gebhard (Netherlands) Cherise Scott (Switzerland)	

Plenary Sessions

10:15 - 11:15

Main

PL01 - Can we end TB in Europe?

Daria Podlekareva (Copenhagen, Denmark)

Giovanni Battista Migliori (Tradate, Italy)

Introduction

10:15 - 10:20

Unpacking the TB epidemic in Europe: Data-driven action

10:20 - 10:35

Senia Rosales-Klintz (Sweden)

Syndemic of TB, HIV, and Hepatitis: Integrated person-centred care

10:35 - 10:50

Jens D Lundgren (Denmark)

	Scaling up TB prevention: Addressing M. tuberculosis infection in hard-to-reach populations	10:50 - 11:05
	Raquel Duarte (Porto, Portugal)	
	Panel discussion with Q&A	11:05 - 11:15
<i>Break</i>		
11:15 - 11:30		Main
Break/Networking		
<i>Special Sessions</i>		
11:30 - 13:00		Main
	SPS01 - From exclusion to inclusion: Building consensus on integrating pregnant and lactating women in TB drug and vaccine research	
	Kerri Viney (Geneva, Switzerland)	
	Amita Gupta (Baltimore, United States)	
	Introduction: TB Pregnancy Consensus project	11:30 - 11:35
	Kerri Viney (Geneva, Switzerland)	
	Double trouble: One pregnant woman's battle with TB to save two lives	11:35 - 11:45
	Ani Herna Sari (Indonesia)	
	Unpacking Ani's experience: Lessons at the crossroads of complexity and care	11:45 - 11:55
	Jyoti Mathad (New York, United States)	
	Overview of the TB and pregnancy consensus process	11:55 - 12:10
	Sabine Verkuijl (Geneva, Switzerland)	
	Panel presentation: Preclinical, clinical, surveillance, vaccine	12:10 - 12:30
	Christina Lancioni (United States)	
	Jennifer Hughes (Cape Town, South Africa)	
	Lee Fairlie (South Africa)	
	Moorine Penninah Sekadde (Kampala, Uganda)	
	Advocacy	12:30 - 12:40
	Oxana Rucsineanu (Moldova)	
	Panel discussion with the Q&A from the audience	12:40 - 12:50
<i>Late Breaker Oral Abstract Sessions</i>		
11:30 - 13:00		TBS
	LB01 - RIT/JATA Student Late Breaker Session on Lung Health	
	Katharina Kranzer (United Kingdom)	
	Akihiro Ohkado (Tokyo, Japan)	
In	Introduction	11:30 - 11:32
LB01-1300-18	Management of people with positive TB infection tests: Thinking in 4 dimensions	11:32 - 11:38
	Mayara Lisboa Bastos (Winnipeg, Canada)	
LB01-1301-18	Improving M. tuberculosis DNA detection from urine and non-sputum sample using the QuickConc method: Preliminary results from a spike-in experiment	11:38 - 11:44
	Mayu Hikone (Nairobi, Kenya)	
LB01-1302-18	Potent inhibition of wild-type and fluoroquinolone-resistant M.avium DNA gyrase by sitafloxacin and DC159a	11:44 - 11:50
	Sasini Jayaweera (Sapporo, Japan)	

LB01-1303-18	Finding TB post-treatment in India: Cost-effectiveness of phone compared to home-based screening Shreeya Wasunkar (Seoul, Korea, Republic of)	11:50 - 11:56
LB01-1304-18	Diagnostic and predictive accuracy of a 3-gene <i>M. tuberculosis</i> Host Response Cartridge in household contacts - Updated results from the multi-centre prospective ERASE-TB study Anna-Lisa Behnke (Munich, Germany)	11:56 - 12:02
LB01-1305-18	Impact of sequencing and analysis artefacts on the performance of the WHO mutation catalogue for genotypic drug susceptibility testing of <i>M. tuberculosis</i> Noud Hermans (The Hague, Netherlands)	12:02 - 12:08
LB01-1306-18	Estimating the global financial burden of TB: Updated forecasts and funding scenarios, including a PEPFAR withdrawal scenario analysis Nompumelelo Mzizi (Houston, United States)	12:08 - 12:14
LB01-1307-18	Assessing the economic viability of introducing new shorter TB drug regimens in Ethiopia Endalkachew Fekadu (Addis ababa, Ethiopia)	12:14 - 12:20
LB01-1308-18	TB and cytomegalovirus co-pathogenicity amongst adults with cryptococcal meningitis: A prospective cohort study Jayne Ellis (London, United Kingdom)	12:20 - 12:26
LB01-1309-18	Pre-existing isoniazid resistance selects for acquired rifampicin-resistant TB: A combined prospective cohort and case-control study in Ho Chi Minh City, Viet Nam Ruan Spies (Ho Chi Minh City, Vietnam)	12:26 - 12:32
LB01-1310-18	Causal links between gut microbiota and the risk of TB and type 2 diabetes: A Mendelian randomisation meta-analysis Arohi Chauhan (Delhi, India)	12:32 - 12:38
LB01-1311-18	Linezolid-associated adverse events and outcomes in the treatment of multidrug/rifampicin-resistant TB: A systematic review and meta-analysis of randomised controlled trials Mita Restinia (Tainan, Taiwan)	12:38 - 12:44
LB01-1312-18	Impact beyond the lungs: Evidence of muscle power deficits and functional impairment in severe pulmonary TB Angus De Wilton (Harare, Zimbabwe)	12:44 - 12:50
	Q&A	12:50 - 13:00

Symposia

11:30 - 13:00

R1

SY01-110-01 - The Lancet Global Health Commission on medical oxygen security

Rebecca Nantanda (Kampala, Uganda)

Carina King (Stockholm, Sweden)

Introduction

11:30 - 11:35

The Lancet Global Health Commission on Medical Oxygen Security: Findings and recommendations

11:35 - 11:50

Carina King (Stockholm, Sweden)

The vital role of pulse oximetry as the gateway to safe, effective, and appropriate medical oxygen services

11:50 - 12:05

Eric McCollum (Baltimore, United States)

Long-term oxygen therapy for people with chronic needs: Addressing a neglected and rapidly growing population

12:05 - 12:20

	Neelima Navuluri (Durham, United States)	
	Oxygen for essential emergency and critical care, including during pandemics and other health emergencies	12:20 - 12:35
	Tim Baker (Dar es Salaam, Tanzania)	
	Closing pulse oximetry and medical oxygen access gaps across Africa: What will it take?	12:35 - 12:50
	Rebecca Nantanda (Kampala, Uganda)	
	Q&A	12:50 - 13:00
<i>Oral Abstract Sessions</i>		
11:30 - 13:00		R2
OA01 - Forgotten lungs: Emerging from the shadow of TB, silicosis, and NTM		
Ajoy Kumar Verma (New Delhi, India)		
Daniela Cirillo (Milan, Italy)		
	Introduction	11:30 - 11:35
OA01-100-18	Comprehensive epidemiological analysis of silicosis (J62) and concurrent tuberculosis (J65) in Brazil, 2006-2024	11:35 - 11:42
	Fernanda Dockhorn (Brasília, Brazil)	
OA01-101-18	Global patterns and trends in mesothelioma incidence in 185 countries: A population-based study	11:42 - 11:49
	Leiwen Fu (Beijing, China)	
OA01-102-18	Respiratory symptoms in mineworkers with silicosis in Rwandan	11:49 - 11:56
	Hagenimana Pacifique (Kigali, Rwanda)	
OA01-103-18	Detecting radiological signs suggestive of silicosis in chest radiographs using artificial intelligence: A pilot retrospective cross-sectional study	11:56 - 12:03
	Justy Antony Chiramal (Atlanta, United States)	
OA01-104-18	Epithelial-macrophage interactions in cystic fibrosis are responsible for accelerated <i>Mycobacterium abscessus</i> growth	12:03 - 12:10
	Ashlea T. Lorenz (Sydney, Australia)	
OA01-105-18	Antibiotic prescriptions - A risk factor for nontuberculous mycobacterial disease?	12:10 - 12:17
	Andreas Arnholdt Pedersen (Odense, Denmark)	
OA01-106-18	GeneXpert-negative samples with <i>rpoB</i> amplicons reveal High NTM prevalence: A diagnostic opportunity	12:17 - 12:24
	Mohammad Khaja Mafij Uddin (Dhaka, Bangladesh)	
OA01-107-18	Speciation, antimicrobial resistance and virulence factors of clinical isolates of NTM from a tertiary care hospital in South India	12:24 - 12:31
	Noyal Mariya Joseph (Puducherry, India)	
OA01-108-18	Baseline EQ-5D-5L improves prediction of treatment discontinuation in NTM pulmonary disease: Analysis from a nationwide cohort study	12:31 - 12:38
	Youbeen Shim (Seoul, Korea, Republic of)	
OA01-109-18	Phage-derived endolysins as anti-microbial agents against multidrug-resistant <i>Mycobacterium abscessus</i> clinical isolates	12:38 - 12:45
	Hyejin Kim (Cheongju, Korea, Republic of)	
	Q&A	12:45 - 13:00

Oral Abstract Sessions

11:30 - 13:00

R3

OA02 - Life after TB

Giovanni Battista Migliori (Tradate, Italy)

Celso Khosa (Maputo, Mozambique)

	Introduction	11:30 - 11:35
OA02-119-18	Interplay between biological and social vulnerability, and poor TB treatment outcome in Brazil: A nationwide study of disease registry data Beatriz Barreto-Duarte (Salvador, Brazil)	11:35 - 11:42
OA02-110-18	Quantifying lifetime mortality burden following active TB: A matched cohort study in Taiwan Hsien-Ho Lin (Taipei, Taiwan)	11:42 - 11:49
OA02-111-18	Tuberculosis Recurrence and Associated Factors: A 12-Year Retrospective Cohort Study in Brazil Evelyn Lepka de Lima (Baltimore, United States)	11:49 - 11:56
OA02-112-18	Long-term mortality causes of TB in Korea: A population-based matched cohort study Dawoon Jeong (Seoul, Korea, Republic of)	11:56 - 12:03
OA02-113-18	Restrictive lung disease and abnormal diffusing capacity are more frequent than airflow obstruction in Ugandans post-TB Katerina Byanova (San Francisco, United States)	12:03 - 12:10
OA02-114-18	Looking beyond active disease: Burden and characteristics of post-TB lung disease among TB household contacts in Southern Africa Akanksha Mimi Malhotra (Liverpool, Zimbabwe)	12:10 - 12:17
OA02-115-18	Cured yet struggling: The lingering impact of TB on mind and life Diksha Walia (Chandigarh, India)	12:17 - 12:24
OA02-116-18	Beyond the cure: The link between food insecurity and disability in recent TB survivors in Uganda Juliet Sekandi (Athens, United States)	12:24 - 12:31
OA02-117-18	Multimorbidity and the risk of post-TB lung functional impairment: A systematic review and meta-analysis Katherine Hill (St Andrews, United Kingdom)	12:31 - 12:38
OA02-118-18	Prevalence and predictors of post-TB lung disease among people living with HIV in Pune, India Haridas Prasad (India)	12:38 - 12:45
	Q&A	12:45 - 13:00

Symposia

11:30 - 13:00

R4

SY02-120-02 - Expanding access to molecular testing for TB: Evidence, scope, and impact of specimen pooling strategies

Jacob Creswell (Geneva, Switzerland)

Mohammed Yassin (Geneva, Switzerland)

	Introduction	11:30 - 11:35
	Increasing access to rapid molecular detection of TB with pooled testing of specimens from multiple individuals in Cameroon Valerie Flore Donkeng Donfack (Yaounde, Cameroon)	11:35 - 11:50
	Evaluating the feasibility and acceptability of pooled testing for TB screening: A qualitative study across seven high-burden, low- and	11:50 - 12:05

middle-income countries

Vibol Iem (Liverpool, United Kingdom)

Testing more for less: evidence on pooling specimens for molecular testing at healthcare facilities and by active case finding in communities across seven high-burden countries 12:05 - 12:20

Tushar Garg (Geneva, Switzerland)

Mass testing, smarter strategies: The case for sputum pooling for TB prevention and care among vulnerable populations 12:20 - 12:35

Beatriz Barreto-Duarte (Salvador, Brazil)

Post-TBM neurological sequelae: Outcomes and challenges 12:35 - 12:50

Q&A 12:50 - 13:00

Community Connect Sessions

11:30 - 12:15

CC

CCS001 - Community-driven TB stigma reduction initiatives in high- burden TB settings: Lessons learned

Ingrid Schoeman (Pretoria, South Africa)

Viorel Soltan (Switzerland)

Introduction 11:30 - 11:32

Community-driven TB stigma reduction initiatives in high- burden TB settings: Lessons learned 11:32 - 11:39

Blessina Kumar (New Delhi, India)

How TB stigma acts as a barrier to both accessing and providing services 11:39 - 11:46

Sok Chamreun Choub (Phnom Penh, Cambodia)

Multi-sectoral TB champion engagement to reduce TB stigma in Khayelitsha, South Africa 11:46 - 11:53

Phumeza Tisile (Cape Town, South Africa)

The power of tradition: Harnessing indigenous leadership and communication to reduce TB stigma 11:53 - 12:00

Ifeanyi Okekearu (Abuja, Nigeria)

Question and answers 12:00 - 12:15

Community Connect Sessions

11:30 - 13:15

CCC

CCWS005 - Community campaign development — Funding TB communities

James Malar (Genève, Switzerland)

Aman Shukla (India)

Welcome and opening remarks 11:30 - 11:40

Aman Shukla (India)

Lucica Ditiu (Switzerland)

Context: Challenge facility for civil society (CFCS) 11:40 - 11:55

Olya Klymenko (Kyiv, Ukraine)

The basics of communication and advocacy campaigns 11:55 - 12:15

James Malar (Genève, Switzerland)

Introducing the communications toolkit 12:15 - 12:30

Olya Klymenko (Kyiv, Ukraine)

Aman Shukla (India)

Hands-on media creation with workshop breakouts: Make your own short visual campaign 12:30 - 12:45

	Rhea Lobo (Australia) Robyn Waite (Ottawa, Canada)	
	Showcase and feedback	12:45 - 13:05
	Lucica Ditiu (Switzerland)	
	Closing and next steps	13:05 - 13:15
	James Malar (Genève, Switzerland) Kinz Ul Eman (Islamabad, Pakistan)	
<i>Community Connect Sessions</i>		
12:30 - 13:15		CC
CCS002 - Catalysing community power: Driving demand and accountability in drug-resistant TB care		
Akshaya Patil (India) James Malar (Genève, Switzerland) Eden Mendoza-Hisey (Philippines)		
	Introduction	12:30 - 12:35
	Survivor-led peer networks driving adherence and strengthening treatment pathways for drug-resistant TB	12:35 - 12:40
	Anupama Srinivasan (Chennai, India)	
	Click to cure: Digital campaigns creating demand and awareness, including youth-led initiatives that increase TB treatment literacy, tackle stigma, and mobilise communities for access	12:40 - 12:45
	Kinz Ul Eman (Islamabad, Pakistan)	
	Travelling community schools for TB: Local hubs for awareness and monitoring that engage trusted spaces to educate, support, and collect community feedback on drug-resistant TB treatment	12:45 - 12:50
	Melecio Mayta (Peru)	
	Data by the people: Community monitoring for equitable drug-resistant TB access using community scorecards and local data to track rollout progress and influence policy decisions	12:50 - 12:55
	Khaled Bin Yousuf (Bangladesh)	
	Radio jingles and talk shows: Community media driving demand and accountability using local communication channels to raise awareness, generate demand and monitor BPAL access	12:55 - 13:00
	Theresa Laraba Jatau (Nigeria)	
	Question and answers	13:00 - 13:15
<i>Break</i>		
13:00 - 15:00		Main
Break/Networking		
<i>TBScience E-Poster Sessions</i>		
13:00 - 14:35		
TBS-EP-01 - TBScience Moderated E-Posters I		
Florian Marx (Germany)		
TBS-EP05	Distinct immune profiles in tobacco and biomass smoke-induced COPD: A comparative study across two populations	13:00 - 13:05
	Catherine Rush (Townsville, Australia)	
TBS-EP08	LyseTB - Comparative analysis of lysis devices for molecular testing of tuberculosis	13:05 - 13:10
	Sonal Jain (Heidelberg, Germany)	
TBS-EP11	Growth phase-specific DNA methylation bias manifesting as	13:10 - 13:15

	intercellular mosaic methylation in <i>Mycobacterium tuberculosis</i> clinical isolates	
	Faramarz Valafar (San Diego, United States)	
TBS-EP17	Spontaneous control of early <i>Mycobacterium tuberculosis</i> infection in children exposed to <i>M. tuberculosis</i> without standard treatment	13:15 - 13:20
	Alia Razid (Münich, Germany)	
TBS-EP20	The Treatment Recommender: An AI-powered decision aid for a stratified precision medicine approach to rifampicin resistant tuberculosis treatment	13:20 - 13:25
	Annelies Van Rie (Antwerp, Belgium)	
TBS-EP23	Interred mechanisms of resistance and host immune evasion revealed through network-connectivity analysis of <i>M. tuberculosis</i> complex graph pangenome	13:25 - 13:30
	Monica Espinoza (Hannover, United States)	
TBS-EP29	<i>In vitro</i> characterization of GSK2556286 activity in combination with bedaquiline and pretomanid against <i>M. tuberculosis</i>	13:30 - 13:35
	Jordana Galizia (Zaragoza, Spain)	
TBS-EP32	Machine learning model for community-based tuberculosis screening: A proof-of-principle study	13:35 - 13:40
	Alexandra Zimmer (Heidelberg, Germany)	
TBS-EP35	Quantitative IFNγ Responses from QuantiFERON-TB Gold Plus Predict Progression to Active Tuberculosis in Global High-Burden Settings	13:40 - 13:45
	Justine Sunshine (Cambridge, United States)	
TBS-EP38	Sputum metabolites correlated with lung function during and after TB treatment	13:45 - 13:50
	Joshua Chandler (Atlanta, United States)	
TBS-EP41	Longitudinal immune cell profiling reveals distinct immunophenotypes associated with treatment response in pulmonary tuberculosis	13:50 - 13:55
	Johanna Eggeling (Borstel, Germany)	
TBS-EP44	Whole genome sequencing-guided patient management - A pragmatic clinical trial of a precision medicine strategy to shorten treatment for rifampicin-resistant tuberculosis	13:55 - 14:00
	Annelies Van Rie (Antwerp, Belgium)	
TBS-EP46	Q&A	14:00 - 14:30

Satellite Sessions

13:15 - 14:45

R1

SS01 - Real-world strategies: Leveraging diagnostics across all levels of care to Find missing TB cases

Sergio Carmona (Switzerland)

Violet Chihota (South Africa)

Introduction	13:15 - 13:20
WHO Perspective	13:20 - 13:30
Patricia Hall-Eidson (Switzerland)	
National Programme Perspective	13:30 - 13:40
Shaheed Vally Omar (Johannesburg, South Africa)	
Panel discussion	13:40 - 14:35
Suvanand Sahu (Switzerland)	
Maike Scharp (United States)	
Draurio Barreira (Brazil)	

Patricia Hall-Eidson (Switzerland)
Shaheed Vally Omar (Johannesburg, South Africa)

Closing remarks 14:35 - 14:45

E-Posters

13:15 - 14:15

B1A

EP01 - Next-gen technology for TB: Bridging the gaps in surveillance, diagnosis, and treatment

Hervé Gando (Bangui, Central African Republic)

EP01-706-18 **Prescription to notification: Digitizing drug sales in Uttar Pradesh** 13:15 - 13:20
Bharatesh Karunakar Shetty (Lucknow, India)

EP01-700-18 **The use of technological innovation (MATS App) to improve TB case finding in PPM intervention: The Katsina State experience** 13:20 - 13:25
Abishai Galadima (Katsina, Nigeria)

EP01-701-18 **Leveraging health information systems to diagnose health system performance: Insights from the Global Fund PPM grant using CommTB in Katsina, Nigeria** 13:25 - 13:30
Patrick Batur (Katsina, Nigeria)

EP01-702-18 **IVRS-based cough tracking for early TB diagnosis among individuals purchasing cough syrups from local practitioners** 13:30 - 13:35
Debadutta Parija (Delhi, India)

EP01-703-18 **Helping household TB contacts navigate the contact tracing cascade using a WhatsApp chatbot under South Africa's universal testing policy: Findings from Shesha** 13:35 - 13:40
Don Mudzengi (Johannesburg, South Africa)

EP01-704-18 **Innovative connectivity solution enhanced enrolment and management in Nigeria of people with drug-resistant TB and HIV in Nigeria** 13:40 - 13:45

EP01-705-18 **Reducing diagnostic delays through a radiology information system in Kirovohradska oblast, Ukraine** 13:45 - 13:50
Gunta Dravniece (Kyiv, Ukraine)

EP01-707-18 **Portable digital X-ray (PDX) screening as a catalyst for early multi-drug resistant TB detection among contacts in high-burden settings: A cross-sectional study from Katsina, Nigeria** 13:50 - 13:55
Innocent Tidisha Lawrence (Katsina, Nigeria)

EP01-708-18 **Designing a digital clinical decision support system to strengthen implementation of treatment decision algorithms for childhood TB in Zambia and Mozambique** 13:55 - 14:00
Celso Khosa (Maputo, Mozambique)

EP01-709-18 **Improving TB treatment outcomes through an interactive voice-based mobile health tool: Evaluation of the Call for Life tool in Karamoja, Uganda** 14:00 - 14:05
Tadeo Nsubuga (Kampala, Uganda)

Q&A 14:05 - 14:15

E-Posters

13:15 - 14:15

B1B

EP02 - Diagnostic networks in TB: Optimisation through innovation

Harald Hoffmann (Gauting, Germany)

EP02-710-18 **A catalytic approach to strengthening laboratory systems through innovative solutions in technical assistance, training and capacity building: Case study of the Uganda Supranational Reference** 13:15 - 13:20

	Laboratory	
	Hasfah Ssentamu Nakato (Kampala, Uganda)	
EP02-711-18	Moving from microscopy to nucleic acid amplification test: Leveraging diagnostic network optimisation to address challenges and strengthen TB testing in Jalandhar, India Prabhjeet Kaur Samra (New Delhi, India)	13:20 - 13:25
EP02-712-18	Early lessons of - TB diagnostic network optimisation- to accelerate TB diagnosis in India Archana Beri (Delhi, India)	13:25 - 13:30
EP02-713-18	Optimising TB diagnostics: Evaluating the screening capacity and cost benefits of sputum pooling in PHC Masaka, Nasarawa State, Nigeria Gracious Adalci Bahuyak (Nasarawa, Nigeria)	13:30 - 13:35
EP02-715-18	Enhancing molecular testing for TB detection through diagnostic network optimisation: Implementation insight from the 100 days TB Campaign in Uttar Pradesh, India Udit Mohan (Lucknow, India)	13:35 - 13:40
EP02-716-18	Impact of diagnostic network optimisation on TB diagnostic capacity and detection in high-burden setting: A comparative study from Delhi, India Lakshmi Aravindakshan (Delhi, India)	13:40 - 13:45
EP02-717-18	A pilot study on external quality assessment using dried tube spot samples on the Truenat platform in Nigeria: Results and lessons learnt Rita Akpakpan (Abuja, Nigeria)	13:45 - 13:50
EP02-718-18	Optimal utilisation of NAAT devices by strengthening population accessibility between NAAT labs and peripheral health centers in Maharashtra, India Himanshu Vashistha (Pune, India)	13:50 - 13:55
EP02-714-18	Diagnostic network optimisation: Increasing access and utilisation of molecular WHO recommended rapid diagnostics (mWRD) for TB Elimination in Uttar Pradesh, India Bharatesh Karunakar Shetty (Lucknow, India)	13:55 - 14:00
	Q&A	14:00 - 14:15
	<i>E-Posters</i>	
	13:15 - 14:15	B1C
	EP03 - Childhood TB: Prevention and treatment for drug-susceptible and resistant TB James Seddon (Cape Town, South Africa)	
EP03-719-18	Optimising child-friendly TB prevention regimens: Qualitative insights from Ethiopian interest-holders Christiaan Mulder (The Hague, Netherlands)	13:15 - 13:20
EP03-720-18	Effectiveness of strengthening frontline workers in enhancing TPT uptake among child contacts Adetokunbo Okungbure (Lagos, Nigeria)	13:20 - 13:25
EP03-721-18	Closing the gaps in TB preventive therapy for under-6 child contacts in Enugu State, Nigeria: A 4-year review Joy Ikebudu (Enugu, Nigeria)	13:25 - 13:30
EP03-722-18	Paediatric drug-resistant TB prevention in resource-limited settings: Mozambique's experience with levofloxacin prophylaxis Criménia Mbate Mutemba (Maputo, Mozambique)	13:30 - 13:35

EP03-724-18	Revolutionising childhood TB treatment: Programmatic implementation and rollout of the four-month shorter treatment regimen for drug-susceptible childhood TB in Zambia Alan Kachuka (Lusaka, Zambia)	13:35 - 13:40
EP03-725-18	Urine biomarker assessment of adherence to TB treatment in children enrolled in a prospective cohort study in a high-burden setting Lilian Njagi (Nairobi, Kenya)	13:40 - 13:45
EP03-726-18	Integrating paediatric drug-resistant TB into primary care: Mozambique's decentralisation strategy and its impact on detection Criménia Mbate Mutemba (Maputo, Mozambique)	13:45 - 13:50
EP03-727-18	Trends in the management and outcome of paediatric multi-drug-resistant TB in Namibia from 2013 to 2023: A review of national registry data Ingrid Burkhardt (Bern, Switzerland)	13:50 - 13:55
EP03-728-18	Pharmacokinetics and safety of clofazimine in children with rifampicin-resistant TB with novel dosing schedule Milena Boczar (Uppsala, Sweden)	13:55 - 14:00
	Q&A	14:00 - 14:15
<i>E-Posters</i>		
13:15 - 14:15		B1D
EP04 - Strengthening laboratory systems for TB management		
Nazir Ismail (Johannesburg, South Africa)		
EP04-729-18	Operational challenges in TB laboratory networks: An analysis of delays in specimen processing and result reporting Julius Ogwu (Abuja, Nigeria)	13:15 - 13:20
EP04-730-18	Strengthening TB diagnosis: Integrating new molecular platforms into South Africa's National TB Programme Anura David (Johannesburg, South Africa)	13:20 - 13:25
EP04-731-18	Bridging turnaround time gaps in TB treatment initiation: Assessing the impact of Phygital training in corporate laboratory settings in India Vikas Kurne (Noida, Delhi-NCR, India)	13:25 - 13:30
EP04-732-18	Strengthening laboratory services for drug resistance testing of bedaquiline Jyoti Kayesth (New Delhi, India)	13:30 - 13:35
EP04-733-18	Diagnostic accuracy of SOS-Xpert Ultra on frozen stool samples for TB detection in rural Angola: Preliminary findings Patricia Comella-del-Barrio (Badalona, Spain)	13:35 - 13:40
EP04-734-18	Diagnostic performance of the FluoroType MTBDR assay for rifampicin and isoniazid resistance in routine laboratory setting Kabelo Kaapu (Polokwane, South Africa)	13:40 - 13:45
EP04-735-18	Deeplex Myc-TB-based single-nucleotide polymorphism(SNP) analysis of genetic diversity for <i>M. tuberculosis</i> strains in Eswatini Mangaliso Ziyane (Mbabane, Eswatini)	13:45 - 13:50
EP04-736-18	Added value of Truenat as a first intention test for the detection of <i>M. tuberculosis</i> in the Democratic Republic of Congo Muriel Aloni (Kinshasa, Congo (Democratic Republic))	13:50 - 13:55
EP04-737-18	Operational performance of GeneXpert for TB diagnosis in West	13:55 - 14:00

	Java province, Indonesia: A public health evaluation Bony Wiem Lestari (Bandung, Indonesia)	
EP04-738-18	Blazing the trail of TB diagnosis in Nigeria: A journey that made sense Nkiru Nwokoye (Abuja, Nigeria)	14:00 - 14:05
	Q&A	14:05 - 14:15
<i>E-Posters</i>		
13:15 - 14:15		B1E
	EP05 - Childhood TB: Diagnosis and case-finding Bryan Vonasek (East Lansing, United States) Olivier Marcy (Bordeaux, France)	
EP05-739-18	Increase in TB diagnosis among children after implementing new WHO treatment decision algorithms in 5 sub-Saharan African countries Emily Briskin (Paris, France)	13:15 - 13:20
EP05-740-18	Enhancing detection and enrollment of childhood TB through integrated community and facility-based approaches in high-burden settings: Lessons from two TB high-burden states in Northern Nigeria Gift Maren (Jos, Nigeria)	13:20 - 13:25
EP05-741-18	Diagnostic accuracy of new treatment decision algorithms for TB in children: A multi-country diagnostic study Helena Huerga (Brussels, Belgium)	13:25 - 13:30
EP05-742-18	Interpreting Xpert MTB/RIF Ultra trace-positive results in children: Experience from a large referral hospital Hendrik Simon Schaaf (Cape Town, South Africa)	13:30 - 13:35
EP05-743-18	Impact of implementation of the molecular WHO-recommended rapid diagnostic test on bacteriological confirmation of pulmonary TB in children less than 15 years: A Peruvian cohort Marco Tovar (La MolinaPeru, Peru)	13:35 - 13:40
EP05-744-18	TB in teens: Risk factors for diagnostic delay and age-specific associations with disease severity Justin Wyda (Providence, United States)	13:40 - 13:45
EP05-745-18	Incorporating paediatric TB surge in polio zero-dose community activities: Learnings from Kaduna State Victor George (Kaduna, Nigeria)	13:45 - 13:50
EP05-746-18	Assessment of paediatric TB prevalence among Bacillus Calmette-Guerin vaccinated paediatric age group in Delta State Nigeria Eziashi Emmanuel Ajumuka (Abuja, Nigeria)	13:50 - 13:55
EP05-747-18	Predictors of paediatric TB disease in a pastoralist community, Turkana County, Kenya: A case-control study James Marcomic (Nairobi, Kenya)	13:55 - 14:00
EP05-748-18	Performance of the Fujifilm SILVAMP TB LAM II (FujiLAM II) assay in diagnosing childhood TB Sosina Ayalew (Addis Ababa, Ethiopia)	14:00 - 14:05
	Q&A	14:05 - 14:15

E-Posters

13:15 - 14:15

B1F

EP06 - Pregnancy: M. tuberculosis infection, TB diagnosis and treatment

Chishala Chabala (Lusaka, Zambia)

EP06-749-18 **Effect of gestational diabetes on interferon-gamma responses among pregnant women in India: Results of the PraGaTHi study** 13:15 - 13:20
Priyanka Raichur (Pune, India)

EP06-750-18 **A multicentre, hospital-based survey of TB after in vitro fertilisation in China** 13:20 - 13:25
Xuhui Liu (Shanghai, China)

EP06-751-18 **Integrated TB screening in pregnant women during ANC: A study on early detection, TB treatment and pregnancy outcomes from rural India** 13:25 - 13:30
Kajal Taluja (Samastipur, India)

EP06-752-18 **Improving TB detection among pregnant women through community-based integrated TB/HIV screening in Southeast Nigeria: Early implementation results** 13:30 - 13:35
Jude Ilozumba (Abuja, Nigeria)

EP06-753-18 **The effectiveness of integrating prevention of mother-to-child transmission (PMTCT) and TB screening services in Abia State, Nigeria** 13:35 - 13:40
Violet Iyonu Ogbe (FCT Abuja, Nigeria)

EP06-754-18 **Traditional birth attendants: Key allies in the fight against TB in hard-to-reach areas in Oyo State, Nigeria** 13:40 - 13:45
Olayinka Adedayo (Ibadan, Nigeria)

EP06-755-18 **Assessing blood-based TB transcriptomic gene signatures in pregnant women with bacteriologically confirmed and non-confirmed TB** 13:45 - 13:50
Paulo Ranaivomanana (Antananarivo, Madagascar)

EP06-756-18 **TB treatment outcomes and safety among pregnant women and their infants** 13:50 - 13:55
Lelia Chaisson (San Francisco, United States)

EP06-757-18 **Rifampicin-resistant TB in pregnant and breastfeeding women: A review of national guidelines across high-burden countries** 13:55 - 14:00
Natalia Hernandez-Morfin (Baltimore, United States)

EP06-758-18 **Pharmacokinetics and safety of clofazimine in women treated for rifampicin-resistant TB during pregnancy and the postpartum period** 14:00 - 14:05
Jennifer Hughes (Cape Town, South Africa)

Q&A

14:05 - 14:15

E-Posters

13:15 - 14:15

B1G

EP07 - Measuring what matters: Prevalance, adherence and the human dimensions of TB care

Prashant Kulkarni (Pune, India)

EP07-759-18 **Prevalence and trend of tuberculosis cases in tribal-dominated districts in India: A time series analysis** 13:15 - 13:20
Nirmalya Mukherjee (Kolkata, India)

EP07-760-18 **Demographic and immunological patterns in tuberculosis infection: Insights from a hospital cohort of over 14,000 QFT-tested patients** 13:20 - 13:25
Patricia Comella-del-Barrio (Badalona, Spain)

EP07-761-18	Sex stratified tuberculosis prevalence in low- and middle-income countries: Systematic review and meta-analysis Nicole Swartwood (Boston, United States)	13:25 - 13:30
EP07-762-18	Tuberculosis in prisons in Eastern Europe and Central Asia: A scoping review of prevention, diagnosis, and treatment interventions Samyra R. Cox (Baltimore, United States)	13:30 - 13:35
EP07-763-18	Delays in uptake of global guidance for treatment of drug-susceptible tuberculosis case of Perú Jimmy Galarza (Houston, United States)	13:35 - 13:40
EP07-764-18	Integrated service delivery for tuberculosis: Assessing people-centeredness, sustainability, and effectiveness in wave 10 TB REACH interventions Julia Alonso (Amsterdam, Netherlands)	13:40 - 13:45
EP07-765-18	Temporal complexity in non-adherence to anti-tuberculosis treatment, a prospective cohort study in Tanzania Helen Ruth Stagg (London, United Kingdom)	13:45 - 13:50
EP07-766-18	A comparison of adherence to tuberculosis treatment measured using self-report and urine testing amongst people with drug susceptible pulmonary tuberculosis (DSTB) in Johannesburg, South Africa Fadzai Munedzimwe (Johannesburg, South Africa)	13:50 - 13:55
EP07-767-18	A theory-driven evaluation of the acceptability of a complex DRTB/HIV adherence intervention in South Africa Boitumelo Seepamore (Durban, South Africa)	13:55 - 14:00
EP07-768-18	Digital DOTS's expansion for TB care in Brazilian municipalities: An operational analysis André Luiz Teixeira Vinci (Ribeirão Preto, Brazil)	14:00 - 14:05
	Q&A	14:05 - 14:15
<i>E-Posters</i>		
13:15 - 14:15		B1H
EP08 - TB treatment risks uncovered: Tackling adverse drug events and drug interactions		
Ralf Otto-Knapp (Berlin, Germany)		
EP08-769-18	Drug-drug interactions between antiretroviral and anti-TB therapy in adults and children: A systematic review of pharmacokinetic and clinical outcomes Gestina Aliska (Padang, Indonesia)	13:15 - 13:20
EP08-770-18	Real-world challenges of 4-month rifapentine-moxifloxacin TB regimen: High hyperbilirubinemia in Thailand Thanyanuch Sanchat (Muang District, Thailand)	13:20 - 13:25
EP08-771-18	The efficacy and safety of varying doses of linezolid in people with rifampicin-resistant TB Yilin Zhang (Shanghai, China)	13:25 - 13:30
EP08-772-18	NAT2 genotypes and clinical characteristics associated with liver injury in people with TB treated with first-line anti-TB therapy Inthira Simapichet (Chiangrai, Thailand)	13:30 - 13:35
EP08-773-18	Active TB drug safety of novel drug-resistant regimens: Challenges and solutions in a decentralised setting Irene Flores (City of San Fernando, Philippines)	13:35 - 13:40
EP08-774-18	Adverse events in the treatment of rifampicin-resistant TB:	13:40 - 13:45

	Findings of comprehensive active drug-safety monitoring and management	
	Rebecca Chou-Jui Lin (Taoyuan, Taiwan)	
EP08-775-18	Cycloserine-induced neuropsychiatric toxicity in multidrug-resistant TB: Association with peak plasma concentration Ren Zheng (Hangzhou, China)	13:45 - 13:50
EP08-776-18	Incidence and severity of QTc prolongation associated with QT-prolonging drugs in rifampicin-resistant TB: Preliminary findings from a prospective cohort in China Yilin Zhang (Shanghai, China)	13:50 - 13:55
EP08-777-18	Impact of the high-dose rifapentine regimens for drug-susceptible TB on peripheral blood neutrophils: A noteworthy treatment-related adverse event Yang Li (Shanghai, China)	13:55 - 14:00
EP08-778-18	Five-year experience with anti-TB drug desensitisation in Singapore Estee Soh (Singapore, Singapore)	14:00 - 14:05
	Q&A	14:05 - 14:15
<i>E-Posters</i>		
13:15 - 14:15		B11
EP09 - Training & education to end TB		
Mohammed Fall Dogo (Lomé, Togo)		
EP09-779-18	Building resilience: Capacity building for front-line workers to provide integrated symptomatic TB and HIV testing services for pregnant women at informal settings in Nigeria Williams Mayah (Abuja, Nigeria)	13:15 - 13:20
EP09-780-18	Enhancing TB knowledge among Alaramma (informal school teachers) in Kano State: Output assessment Jane Adizue (Federal Capital Territory, Nigeria)	13:20 - 13:25
EP09-781-18	Integrating gender-related knowledge into the national medical training curriculum and healthcare workplace practices Lesia Tonkonoh (Kyiv, Ukraine)	13:25 - 13:30
EP09-782-18	Assessing the effect of a community-driven, gender-responsive TB initiative on TB-related knowledge and stigma: A controlled before-and-after interventional study in peri-urban communities, Nigeria Chidiebube Aneke (Karu, Nigeria)	13:30 - 13:35
EP09-783-18	Overcoming language barriers and stigma in communication on TB: Using artificial intelligence (AI) for person-centred TB information for people from migrant populations Job van Rest (The Hague, Netherlands)	13:35 - 13:40
EP09-784-18	Strengthening capacity for TB services: Effectiveness analysis of training methods, a comparative study Sinthia Tarin (Dhaka, Bangladesh)	13:40 - 13:45
EP09-785-18	Digitally-enabled youth engagement model to support HCWs to improve TB presentation to care in underserved urban slums of India: The Take Charge Against TB program Deepak Balasubramanian (New Delhi, India)	13:45 - 13:50
EP09-786-18	Results from "Empowering frontline healthcare workers through holistic upskilling intervention on 3C's for underserved urban poor communities of India": The Take Charge against TB programme Deepak Balasubramanian (New Delhi, India)	13:50 - 13:55

EP09-787-18	Effective capacity building for TB prevention and care: A modernised training approach for programme managers in India Rakesh PS (New Delhi, India)	13:55 - 14:00
EP09-788-18	TB training through Camparience (camping and experience) learning method: Engaging 20 young leaders across 18 regions in Indonesia in 2024 Iman Maha Putra Zein (Jakarta Selatan, Indonesia)	14:00 - 14:05
EP09-789-18	Bridging gaps in TB/HIV research: Empowering Eswatini's future scholars Kwatekai Lockhart (Houston, United States)	14:05 - 14:10
	Q&A	14:10 - 14:15
<i>Community Connect</i> 13:15 - 14:00		CCC
CCAP001 - 2025 Stop TB Partnership Community Award Presentation Lucica Ditiu (Switzerland)		
<i>Side Meetings</i> 13:30 - 14:30		TBS
Africa Region		
<i>Side Meetings</i> 13:30 - 14:30		R8
Smoke Free TB and Tobacco Control Section		
<i>TBScience Unmoderated E-Posters</i> 14:15 - 19:00		
TBS-EP-TUE - TBScience Unmoderated E-Posters		
TBS-EP362	Toward entropy-based precision monitoring of tuberculosis: A systematic review of immune dysregulation as a predictive framework for treatment innovation Satiti Palupi Purwanto (Hat Yai, Thailand)	14:15 - 14:15
TBS-EP365	Machine learning models reveal predictive signatures of therapy outcome in Phase 3 TB trials Daniel Garger (Munich, Germany)	14:15 - 14:15
TBS-EP368	The use of unmanned aerial vehicles (UAV) on delivering biological samples for tuberculosis and COVID-19 diagnosis: A scoping review Olga Maira Machado Rodrigues (Brasilia, Brazil)	14:15 - 14:15
TBS-EP371	Evaluation of an oral bedaquiline regimen for treating multidrug-resistant TB in China: A randomized trial Jingtao Gao (Beijing, China)	14:15 - 14:15
TBS-EP374	Treatment outcomes and risk factors among tuberculosis patients infected with <i>Mycobacterium tuberculosis</i> Beijing lineage in Ukraine (2020-2023) Dmytro Butov (Kharkiv, Ukraine)	14:15 - 14:15
TBS-EP377	Addressing tobacco industry tactics in university campuses and its impact on tobacco cases in Iraq Thamer Alhilfi (Baghdad, Iraq)	14:15 - 14:15
TBS-EP380	Breath-based pathogen detection technologies for diagnosing respiratory infections: A scoping review Sonal Jain (Heidelberg, Germany)	14:15 - 14:15

TBS-EP383	Leveraging artificial intelligence driven mobile X-ray screening on TB detection in high-risk brick Kiln communities of Punjab, Pakistan Qasim Mehmood (Lahore, Pakistan)	14:15 - 14:15
TBS-EP386	Drug resistance detection from swab samples - A proof of principle pilot study using Molbio Truenat MTB-RIF-Dx and MTB-INH assays Seda Yerlikaya (Heidelberg, Germany)	14:15 - 14:15
TBS-EP389	AI-powered TB screening revolution: Impact of CAD4TB and DELFT portable X-ray machines in Punjab, Pakistan Bilal Ahmed (Lahore, Pakistan)	14:15 - 14:15
TBS-EP395	Preventive practices of pulmonary tuberculosis in Chitwan districts Kamal Kalakheti (Ilam, Nepal)	14:15 - 14:15
TBS-EP398	Genetic pattern of the ST 61 cluster of the Cameroon family among Mycobacterium tuberculosis complex strains collected during the CANTAM I project in Cameroon Alix Kevine G. T. Tchoupe (Yaoundé, Cameroon)	14:15 - 14:15
TBS-EP401	SHIFTING paradigms in DR-TB management: Real-world outcomes of injectable Kanamycin vs. Bedaquiline all-oral regimens using Ni-Kshay surveillance data Zuha Jabeen Shaikh (Mumbai, India)	14:15 - 14:15
TBS-EP404	Analysis of the incidence of tuberculosis lung injury and related factors of lung function after cure of pulmonary tuberculosis: A prospective observational study Wenli Cao (Beijing, China)	14:15 - 14:15
TBS-EP410	Human reader vs CAD4TB: Enhancing TB case detection through AI-supported mobile screening in Cambodia Monyrath Chry (Phnom Penh, Cambodia)	14:15 - 14:15
TBS-EP413	Tuberculosis recurrence prediction: A machine learning approach Olga Zofia Wieromiejczyk (Copenhagen, Denmark)	14:15 - 14:15
TBS-EP416	Bridging the knowledge gap: KAP assessment on tuberculosis among undergraduate health professional students in Baghdad with a focus on tobacco smoke and curriculum adequacy Thamer Alhilfi (Baghdad, Iraq)	14:15 - 14:15
TBS-EP419	Development and evaluation of hydrogel loaded with human amniotic membrane in wound healing Faheem Jan (Islamabad, Pakistan)	14:15 - 14:15
TBS-EP425	Impact of discordant isoniazid and rifampicin susceptibility results between the Anyplex™ II MTB/MDR assay and the BACTEC MGIT 960 system on treatment decisions Kanphai Wongjarit (Bangkok, Thailand)	14:15 - 14:15
TBS-EP428	The role of physiotherapy in demystifying pulmonary tuberculosis in Uganda Sheillah T. Nakisanze (Masaka, Uganda)	14:15 - 14:15
TBS-EP431	Clinical performance of the CAD4TB AI system for pulmonary tuberculosis detection among young adults in Mongolia: A diagnostic screening study Yanjindulam Purevsuren (Ulaanbaatar, Mongolia)	14:15 - 14:15
TBS-EP434	Addressing access to treatment and diagnostic barriers in TB treatment through the Market and Patent Intelligence Study: A focus on intellectual property barrier Duke Otieno (Nairobi, Kenya)	14:15 - 14:15

TBS-EP440	Shortened treatment regimens for drug resistant (DR)-TB patients in Azerbaijan: First results Irada Akhundova (Baku, Azerbaijan)	14:15 - 14:15
TBS-EP443	Concomitant subclinical pulmonary tuberculosis in patients with extra-pulmonary tuberculosis Tejaswini Gude (New Delhi, India)	14:15 - 14:15
TBS-EP446	Evaluation of the second-generation Fujifilm SILVAMP TB-LAM assay for TB diagnosis in Nigerian adults Nadiia Tytarenko (Badalona, Spain)	14:15 - 14:15
TBS-EP449	Novel mutations in genes associated with bedaquiline and linezolid resistance in drug-naïve <i>Mycobacterium tuberculosis</i> isolates Chikanshi Sharma (Delhi, India)	14:15 - 14:15
TBS-EP452	Measuring cellular responses against respiratory pathogens can help to guide prophylaxis in immunocompromised patients Irene Latorre (Badalona, Spain)	14:15 - 14:15
TBS-EP455	Radiological features of pulmonary nontuberculous mycobacterial disease depending on the species of the pathogen Anastasiya Gaida (Moscow, Russian Federation)	14:15 - 14:15
TBS-EP458	Estimating the effect of implementing novel diagnostics in adults and children on pediatric TB indicators in KwaZulu-Natal, South Africa Mark Fajans (Seattle, United States)	14:15 - 14:15
TBS-EP461	The iron-vitamin D axis in tuberculosis: Hepcidin modulation as a target for precision host-directed therapy Satiti Palupi Purwanto (Hat Yai, Thailand)	14:15 - 14:15
TBS-EP464	Research on patients with NTM lung disease accompanied by anxiety or depression and related risk factors Xiang Shi (Shang Hai, China)	14:15 - 14:15
TBS-EP467	Reasons for refusal of TB preventive treatment uptake by eligible contacts of TB patients in high TB burden settings Sobia Faisal (Islamabad, Pakistan)	14:15 - 14:15
TBS-EP470	Isolation of non-tuberculous mycobacteria (NTM) from household water of patients with NTM pulmonary disease Wei Sha (Shang Hai, China)	14:15 - 14:15
TBS-EP479	Adherence to isoniazid preventive therapy and its associated factors among HIV patients receiving treatment in five districts in Ghana Mavis Pearl Kwabla (Hohoe, Ghana)	14:15 - 14:15
TBS-EP482	Prospective prediction of TBAJ-876-PaL phase 2 clinical outcomes in NC-009 trial via a multi-model framework Eunsol Yang (San Francisco, United States)	14:15 - 14:15
TBS-EP485	Implementation of TPT with shorter regimens: Experience from Bangladesh Rifat Jahan Khan (Dhaka, Bangladesh)	14:15 - 14:15
TBS-EP488	Empowering National TB Control Program through artificial intelligence-enhanced portable X-ray deployment in Bangladesh Rifat Jahan Khan (Dhaka, Bangladesh)	14:15 - 14:15
TBS-EP491	Lineage identification and mutation profile of <i>Mycobacterium tuberculosis</i>: A study from National Reference Laboratory, India Raj Narayan Yadav (New Delhi, India)	14:15 - 14:15

TBS-EP493	Oral rinse outperforms facemask capture for non-sputum diagnosis of pulmonary TB Simon C Mendelsohn (Cape Town, South Africa)	14:15 - 14:15
TBS-EP503	Trends in tuberculosis detection using GeneXpert in a rural Ghanaian district: A six-year retrospective analysis (2019-2024) Eyram Hanu (Hohoe, Ghana)	14:15 - 14:15
TBS-EP506	Fate of TB treatment among the patients who remained bacteriologically positive after two months of anti-TB drugs Sobia Faisal (Islamabad, Pakistan)	14:15 - 14:15
TBS-EP509	Physiotherapy management in tuberculosis patients with co-existing HIV infection: Challenges in immunocompromised care Elizabeth Nakanwagi (Kampala, Uganda)	14:15 - 14:15
TBS-EP512	Can simple blood tests predict heart disease in patients with pulmonary tuberculosis? - The TB-HEART Study Marcello Scopazzini (London, United Kingdom)	14:15 - 14:15
TBS-EP515	Threat beyond TB: Rising menace of NTM infections and the urgent need for accurate diagnosis Jyotirmayee Turuk (Bhubaneswar, India)	14:15 - 14:15
TBS-EP518	Genomic insights into <i>Mycobacterium tuberculosis</i> lineages and antimicrobial resistance profiles in three Canadian provinces Reema Singh (Saskatoon, Saskatchewan, Canada)	14:15 - 14:15
TBS-EP521	Transcriptomic profiles from animal hosts following infection with <i>Mycobacterium bovis</i>: A systematic review Liliana C. M. Salvador (Tucson, United States)	14:15 - 14:15
TBS-EP524	Assessment of awareness and knowledge of butchers on bovine tuberculosis in the Volta region of Ghana Iddrisu Saliu (Hohoe, Ghana)	14:15 - 14:15
TBS-EP527	Effectiveness of BPaL/BPaLM in central area of Taiwan Yi-Wen Huang (Changhua, Taiwan)	14:15 - 14:15
TBS-EP530	Ibuprofen and acetylsalicylic acid as adjunctive to anti-tuberculosis treatment: Phase II clinical trial Cris Vilaplana (Badalona, Spain)	14:15 - 14:15
TBS-EP533	Pathobionts and antimicrobial resistance in symptomatic people with and without tuberculosis Suventha Moodley (Cape Town, South Africa)	14:15 - 14:15
TBS-EP536	Validation of a DNA methylation signature of active tuberculosis in the buccal mucosa using methylation-specific PCR Isabelle Öhrnberg (Linköping, Sweden)	14:15 - 14:15
TBS-EP539	The Tuberculosis Knowledge and Analytics Platform: TB Nexus Analytics Nibedita Rath (Bangalore, India)	14:15 - 14:15
TBS-EP562	Effect of combined inspiratory and expiratory muscle training in pulmonary rehabilitation of active and post tuberculosis Sheillah T. Nakisanze (Masaka, Uganda)	14:15 - 14:15
TBS-EP565	Establishment of a model for early warning of onset in population exposed to <i>Mycobacterium tuberculosis</i> Jingli Du (Beijing, China)	14:15 - 14:15
TBS-EP568	Nutritional status of tuberculosis patients and its associated factors in four districts in Ghana Mavis Pearl Kwabla (Hohoe, Ghana)	14:15 - 14:15

TBS-EP571	Maternal and infant outcomes in acute hematogenous disseminated pulmonary tuberculosis during pregnancy Huiru An (Beijing, China)	14:15 - 14:15
TBS-EP577	Development of a loop-mediated Isothermal amplification (LAMP) assay for the detection of pepQ gene in Mycobacterium tuberculosis Joannah Marie Bislumbre (Manila, Philippines)	14:15 - 14:15
TBS-EP580	Factors that impact the expansion of coverage for preventive treatment of TB in the Kyrgyz Republic Dinara Madybaeva (Bishkek, Kyrgyzstan)	14:15 - 14:15
TBS-EP583	Clinical features of pulmonary tuberculosis and nanostructural characteristics of multidrug-resistant Mycobacterium tuberculosis strains Natalia Yatskevich (Belarus)	14:15 - 14:15
TBS-EP586	Long term impact of pulmonary TB on health-related functioning and well-being in four African countries Kamban Hirasen (Johannesburg, South Africa)	14:15 - 14:15
TBS-EP589	Enrichment of <i>M. tuberculosis</i> in patient sputa using a limiting dilution assay Dale Liebenberg (Johannesburg, South Africa)	14:15 - 14:15
TBS-EP592	Bridging diagnostic gaps of drug-resistant pulmonary tuberculosis with clinical diagnosis in a low-and middle-income state, Southwest, Nigeria: A secondary data analysis Emmanuel Irek (Ekiti, Nigeria)	14:15 - 14:15
TBS-EP595	Diagnostic potential of hematological counts and ratios in pediatric tuberculosis: A five-year retrospective study Simona Mäsiarová (Martin, Slovakia)	14:15 - 14:15
TBS-EP598	Polystyrene particles alter mycobacterial lipidic cell wall composition Iris Romero-Andrada (Badalona, Spain)	14:15 - 14:15
TBS-EP601	Population pharmacokinetics of isoniazid in TB patients: Accounting for age, sex, weight, diabetes, and HIV Felipe Ridolfi (United States)	14:15 - 14:15
TBS-EP603	Single-cell transcriptomic profiling identifies immune signatures in latent Mycobacterium tuberculosis infection and active tuberculosis Jie Tian (Shanghai, China)	14:15 - 14:15
TBS-EP606	Latent tuberculosis infection retains cytotoxic molecule expression and functionality lost during active disease Carlos Peña Bates (CDMX, Mexico)	14:15 - 14:15
TBS-EP609	Harnessing AI for rapid, consistent, and efficient scientific writing: Large language models for TB trial protocol generation Brian Hiroshi Aldana (San Francisco, United States)	14:15 - 14:15
TBS-EP614	Predictive modeling of tuberculosis prevalence among medical workers in the Vynnytsia Region, Ukraine: Insights from 2007-2029 Artemii Bogomolov (Vynnytsya, Ukraine)	14:15 - 14:15
TBS-EP616	Knowledge of tuberculosis prevention and control among public service vehicle operators in the South Rift Valley, Kenya Cheruiyot Sambu (Eldoret, Kenya)	14:15 - 14:15
TBS-EP618	Is transmission the primary route to bedaquiline resistance? A context specific framework for transmission threshold estimation	14:15 - 14:15

	Abel Kjaersgaard (London, United Kingdom)	
TBS-EP620	Utility of antibody responses in the diagnosis of tuberculosis in rural Papua New Guinea Catherine Rush (Townsville, Australia)	14:15 - 14:15
TBS-EP622	Evaluation of the consistency between phenotypic MIC and genomic mutations in the detection of Bedaquiline and Clofazimine cross-resistance in <i>Mycobacterium tuberculosis</i> isolates from the Philippines Shiomi Yoshida (Kiyose, Tokyo, Japan)	14:15 - 14:15
TBS-EP624	Gastrointestinal parasites and their association with TB immune responses in Rural Papua New Guinea Jeffrey Warner (Townsville, Australia)	14:15 - 14:15
TBS-EP626	Accelerating tuberculosis prevention: Assessing novel TB preventive treatments in a preclinical infection model Andréanne Lupien (Montreal, Canada)	14:15 - 14:15
TBS-EP628	The computer-aided detection software using chest X-ray images in TB screening may have the potential to identify early TB patients in China Wei Liu (China)	14:15 - 14:15
TBS-EP630	Comparing LAM to other sputum-based biomarkers in NC-009 trial Juliano Timm (New York, United States)	14:15 - 14:15
TBS-EP632	Low complexity-manual nucleic acid amplification tests for detection of pulmonary tuberculosis in adolescents and adults with presumptive tuberculosis: A systematic-review and meta-analysis of diagnostic accuracy Adhin Bhaskar (Chennai, India)	14:15 - 14:15
TBS-EP634	Impact of TB preventive therapy at grassroots level in community setting in Pune, India Govinda Narke (Pune, India)	14:15 - 14:15
TBS-EP636	Innovative AI tool for TB diagnosis based on metabolomic detection in urine Jose Dominguez (Barcelona, Spain)	14:15 - 14:15
TBS-EP638	Comparison of different chemicals as an alternative sputum liquefaction reagent to N-acetyl-L-cysteine with Sodium Hydroxide (NALC-NaOH) Jo Mary Lei Majaducon (Manila, Philippines)	14:15 - 14:15
TBS-EP647	Enhancing lung health through physiotherapy for overall well-being Elizabeth Nakanwagi (Kampala, Uganda)	14:15 - 14:15
TBS-EP653	Tissue-specific immune phenotyping reveals divergent responses to BCG vaccination and <i>Mycobacterium tuberculosis</i> challenge Irene Latorre (Badalona, Spain)	14:15 - 14:15
TBS-EP656	Risk of human tuberculosis associated with exposure to livestock in rural Ballabgarh, Haryana: A Case-Control Study Rakesh Kumar (New Delhi, India)	14:15 - 14:15
TBS-EP665	Detection of first-line and second-line Drug-Resistance mediating mutations in <i>Mycobacterium tuberculosis</i> with DNA extracted with different extraction methods directly from sputum using Next-Generation Sequencing Vera Allerheiligen (Nehren, Germany)	14:15 - 14:15
TBS-EP668	Frequency and co-resistance of bedaquiline, clofazimine, delamanid, and pretomanid in MDR-TB isolates at a North Indian	14:15 - 14:15

	reference laboratory Rashmi Ratnam (Lucknow, India)	
TBS-EP674	Breaking resource barriers: Development of portable AIMLAM for active TB diagnosis in the HIV- population Xiang Yang (Guangzhou, China)	14:15 - 14:15
TBS-EP677	Exhaled breath condensate: A new window on aerobiology of <i>Mycobacterium tuberculosis</i> Benjamin Patterson (Cape Town, South Africa)	14:15 - 14:15
TBS-EP680	Assessment of a simplified and portable IGRA-TB platform based on fluorescence immunoassay for the diagnosis of <i>Mycobacterium tuberculosis</i> Infection Jose Dominguez (Barcelona, Spain)	14:15 - 14:15
TBS-EP683	Diagnostic Utility of Fluorescein Diacetate (FDA) Staining for Rapid Tuberculosis Detection: A Comparative Study Against Automated Liquid Culture Rashmi Ratnam (Lucknow, India)	14:15 - 14:15
TBS-EP689	Prevalence and risk factors of anti-tuberculosis drug-induced hepatitis based on liver function tests among TB patients at Hargeisa TB Hospital, Somaliland Mohamed Abdi Hergeye (Hargeisa, Somalia)	14:15 - 14:15
TBS-EP695	Post TB morbidity - What is the optimal management of TB IRIS? Proposal for a clinical trial Kasha Singh (Melbourne, Australia)	14:15 - 14:15
TBS-EP698	Preliminary diagnostic performance of novel LAM antibodies in CSF of HIV negative Vietnamese children with TB meningitis: A SURE substudy Julie Huynh (Ho Chi Minh City, Vietnam)	14:15 - 14:15
TBS-EP701	Investigating the impact of inoculum size on EUCAST methodology for MIC <i>Mycobacterium tuberculosis</i> determinations Deborah Recchia (Pavia, Italy)	14:15 - 14:15
TBS-EP704	Targeting the tryptophan synthase TrpAB to fight <i>Mycobacterium tuberculosis</i> Giovanni Stelitano (Pavia, Italy)	14:15 - 14:15
TBS-EP710	Achieving 100% participant retention in an active tuberculosis cohort Zainab Baig (Durban, South Africa)	14:15 - 14:15
TBS-EP713	Pre-extensively drug-resistant extrapulmonary tuberculosis: A growing threat Manu Singh (Lucknow, India)	14:15 - 14:15
TBS-EP716	Pharmacogenetic insights for tuberculosis treatment using Namibian human genetic diversity Lorraine Boois (Windhoek, Namibia)	14:15 - 14:15
TBS-EP722	Integrated genomic and host-based assessment of a persistent extensively drug resistant <i>M. tuberculosis</i> Beijing strain during therapy Mandira Varma-Basil (Delhi, India)	14:15 - 14:15
TBS-EP725	Optimization of community-based tuberculosis screening informed by Bayesian Latent Class modelling Aquiles R. Henriquez-Trujillo (Antwerp, Belgium)	14:15 - 14:15
TBS-EP734	Neutrophil-to-lymphocyte-ratio and neutrophil-to-monocyte-plus-lymphocyte-ratio in the blood of adolescents with pulmonary	14:15 - 14:15

	tuberculosis	
	Larissa Gorbach (Minsk, Belarus)	
TBS-EP737	Using artificial intelligence for parameterization of mechanistic epidemiological models in tuberculosis control Nishant Chavan (New Delhi, India)	14:15 - 14:15
TBS-EP740	Chronotherapy for tuberculosis: A conceptual framework to harness host circadian rhythms and destabilize mycobacterium tuberculosis physiology Satiti Palupi Purwanto (Hat Yai, Thailand)	14:15 - 14:15
TBS-EP743	Neutrophil, lymphocyte and monocyte ratios in children with active and latent tuberculosis Larissa Gorbach (Minsk, Belarus)	14:15 - 14:15
TBS-EP746	Platelet-to-lymphocyte-ratio in children and adolescents with pulmonary tuberculosis and latent tuberculosis Larissa Gorbach (Minsk, Belarus)	14:15 - 14:15
TBS-EP755	Computer aided diagnostics for TB diagnosis: Overcoming challenges and leveraging opportunities in LMICs Arnold Kennedy Tumuhairwe (Kampala, Uganda)	14:15 - 14:15
TBS-EP761	Alteration in micromineral levels, cluster of differentiation 4+ and gamma glutamyl transferase in subjects on anti-tuberculosis chemotherapy at Infectious Disease Hospital Calabar, Nigeria Raymond Eworo (Calabar, Nigeria)	14:15 - 14:15
TBS-EP767	Targeting TB granulomas to develop HDTs Mohlopheni Jackson Marakalala (Cape Town, South Africa)	14:15 - 14:15
TBS-EP773	Genotypes of <i>Mycobacterium tuberculosis</i> complex isolated from GeneXpert negative PTB patients: Whole genome sequence based comparative study Alem Alemayehu (Addis Ababa, Ethiopia)	14:15 - 14:15
TBS-EP779	Systemic immune inflammation index and systemic inflammation response index in children with pulmonary tuberculosis and latent tuberculosis Larissa Gorbach (Minsk, Belarus)	14:15 - 14:15
TBS-EP782	The impact of information technology on the epidemiological profile of tuberculosis in the socio-economic zones of the Republic of Sakha Aleksey Kazakov (Moscow, Russian Federation)	14:15 - 14:15
TBS-EP785	Modern capabilities of neural network models in the analysis of chest X-rays: A systematic review Aleksey Kazakov (Moscow, Russian Federation)	14:15 - 14:15
TBS-EP788	Characteristics of non-specific microflora in patients with pulmonary tuberculosis Anastasiya Gaida (Moscow, Russian Federation)	14:15 - 14:15

TBScience Sessions
14:40 - 16:15

TBS

TBS01 - Decoding TB pathology at the microscopic level: Linking animal models and human TB disease

Henry Mwandumba (United Kingdom)
Al Leslie (South Africa)

TBS01-01	Welcome to TBScience Willem Hanekom (South Africa) Henry Mwandumba (United Kingdom) Al Leslie (South Africa)	14:40 - 14:45
----------	--	---------------

TBS01-05	High-endothelial venules represent a vaccine-inducible backdoor for homing of T cells in <i>Mycobacterium tuberculosis</i> lung lesions Nafsika Panagiotopoulou (Denmark)	14:45 - 15:00
TBS01-10	Revisiting human postmortem tissue studies: New perspectives on TB immunopathology and latent TB infection Adrie Steyn (South Africa)	15:00 - 15:15
TBS01-15	Microscopic pioneers in TB pathology Ben Gern (United States)	15:15 - 15:30
TBS01-20	Lymph nodes in tuberculosis: guardians of immunity or sanctuaries for <i>M. tuberculosis</i>? Virginie Rozot (Cape Town, South Africa)	15:30 - 15:45
TBS01-25	Q&A	15:45 - 16:15

Spotlight Sessions
15:00 - 18:30

Main

SL01 - WHO Global End TB Symposium

Opening session: No time to slow down: Breaking through barriers to end TB Hannah Monica Dias (Switzerland)	15:00 - 16:00
Welcome and global overview: Delivering end TB commitments in a challenging landscape Tereza Kasaeva (Switzerland)	16:00 - 16:00
Civil society perspectives on accelerating the TB response in a challenging landscape Yassen Tcholakov (Montreal, Canada)	16:00 - 16:00
The road forward: Strategic priorities for transforming the global TB response Nimalan Arinaminpathy (Geneva, Switzerland)	16:00 - 16:00
Interactive Q&A	16:00 - 16:00
High Level Panel: New realities, bold responses: Ending TB in a changing world	16:00 - 17:15
The transformative and multisectoral role of Parliamentarians in safeguarding and elevating the TB agenda in times of crisis Nick Herbert (United Kingdom)	17:15 - 17:15
Importance of innovative and sustainable financing mechanisms to ramp up the End TB response in a challenging landscape Yogan Pillay (South Africa)	17:15 - 17:15
Harnessing innovation and research to accelerate China's journey toward ending TB Zhao Yanlin (China)	17:15 - 17:15
India's bold campaign to reach all people with TB: A game-changer for TB detection and care Urvashi Singh (New Delhi, India)	17:15 - 17:15
South Africa at the forefront: Powering the End TB response through innovation and the G20 agenda Norbert Ndjeka (South Africa)	17:15 - 17:15
Interactive Q&A	17:15 - 17:15

	Research spotlight: Transformative advances in TB science and innovation	17:15 - 18:15
	Matteo Zignol (Switzerland)	
	New perspectives on TB screening and preventive therapy	18:15 - 18:15
	Gavin Churchyard (Isando, South Africa)	
	Multi-disease testing in the context of patient-centered care	18:15 - 18:15
	Claudia Denking (Heidelberg, Germany)	
	Shorter, safer, better -- what will the future of TB treatment bring?	18:15 - 18:15
	Hanif Esmail (London, United Kingdom)	
	Interactive Q&A	18:15 - 18:15
	Closing session	18:15 - 18:30
	Resilience in adversity: Impacted community's call to reinforce investment and fast-track the global TB response	18:30 - 18:30
	Ashna Ashesh (Patna, India)	
	Closing remarks	18:30 - 18:30
	Tereza Kasaeva (Switzerland)	
	<i>Short Oral Abstract Sessions</i>	
	15:00 - 16:30	R1
	SOA01 - Maternal, child, and adolescent TB care: Prevention, diagnosis and treatment	
	Karen Du Preez (Cape Town, South Africa)	
	Toyin Togun (London, United Kingdom)	
	Introduction	15:00 - 15:03
SOA01-500-18	Integrating traditional birth attendants into TB disease finding: A culturally sensitive approach	15:03 - 15:10
	Hauwa Usman Garba (Kaduna, Nigeria)	
SOA01-501-18	Leveraging traditional birth attendants to integrate TB/HIV screening into maternal care in unconventional settings: Experience from Katsina State, Nigeria	15:10 - 15:17
	Hamza Tilde (Kano, Nigeria)	
SOA01-502-18	Facility-based screening for TB in pregnant and post-partum women in Papua New Guinea	15:17 - 15:24
	Walley Ambano (Port Moresby, Papua New Guinea)	
SOA01-503-18	Leveraging AI-powered predictive mapping to improve TB/HIV case identification among pregnant women in Nigeria	15:24 - 15:31
	Temitope Adetiba (Abuja, Nigeria)	
SOA01-504-18	Preferences identified by key stakeholders for novel TB treatment regimens for pregnant and breastfeeding women in two high-burden TB settings	15:31 - 15:38
	Yael Hirsch-Moverman (New York, United States)	
SOA01-505-18	Clinical mentoring to support the use of treatment decision algorithms for child TB diagnosis within a programmatic pilot in Mozambique and Zambia	15:38 - 15:45
	Emilie Desselas (Montpellier, France)	
SOA01-506-18	Clinical predictors for radiological severe pulmonary TB in children: An individual participant data-analysis	15:45 - 15:52
	Akshita Gupta (München, Germany)	
SOA01-507-18	Closing the gap in paediatric TB detection: Innovative approaches to improve case finding among children in Nigeria	15:52 - 15:59

	Bethel Nwaogu (Abuja, Nigeria)	
SOA01-508-18	TB screening in the traditional initiation schools in the Leribe district of Lesotho Llang Maama (Maseru, Lesotho)	15:59 - 16:06
SOA01-509-18	Community generated content to mitigate stigma: Telangana's youth led solution Suresh Bollepogu (Hyderabad, India)	16:06 - 16:13
SOA01-510-18	Differences in social networks of children and youth with and without incident TB infection in rural Uganda Elijah Kakande (Kampala, Uganda)	16:13 - 16:20
	Q&A	16:20 - 16:30
<i>Symposia</i>		
15:00 - 16:30		R2
SY03-130-03 - The urgent need for pragmatic clinical trials for new TB regimens: Considerations for design and conduct		
Christian Lienhardt (France)		
Gavin Churchyard (Isando, South Africa)		
	Introduction	15:00 - 15:05
	Pragmatic trials and streamlined trials: What are they and why do we need them in TB? Samuel Schumacher (Geneva, Switzerland)	15:05 - 15:20
	Maximising both internal *and* external validity: Practical design considerations for pragmatic TB trials Patrick Phillips (San Francisco, United States)	15:20 - 15:35
	A pragmatic trial of high-dose rifampicin in India Gopalan Narendran (Chennai, India)	15:35 - 15:50
	The 4MOR trial: Evaluating HPMZ in a pragmatic cluster-randomised trial Sean Wasserman (London, United Kingdom)	15:50 - 16:05
	Panel discussion on pragmatic TB trials: Charting the way forward Panel Discussion (Mixed, Switzerland)	16:05 - 16:20
	Q&A	16:20 - 16:30
<i>Oral Abstract Sessions</i>		
15:00 - 16:30		R3
OA03 - Innovations in assessing TB transmission across different settings		
Edward Nardell (Brookline, MA 02446, United States)		
Nicky McCreesh (London, United Kingdom)		
	Introduction	15:00 - 15:05
OA03-120-18	Use of genomic and spatiotemporal correlation for enhanced TB prevention and care in New South Wales, Australia Xiaome Zhang (Sydney, Australia)	15:05 - 15:12
OA03-121-18	Ungrouped whole genome sequencing isolates: What can it tell us? Deborah HL Ng (Singapore, Singapore)	15:12 - 15:19
OA03-122-18	Tuberculosis transmission among older adults in Southern Taiwan Hsien-Ho Lin (Taipei, Taiwan)	15:19 - 15:26
OA03-123-18	CAD score of chest radiograph vs. cough as determinants of	15:26 - 15:33

	household <i>M. tuberculosis</i> transmission risk among people with sputum-positive TB Palwasha Yousafzai Khan (London, United Kingdom)	
OA03-124-18	Household transmission of TB from people with smear-negative Edmund Shen (Boston, United States)	15:33 - 15:40
OA03-125-18	Smoked drug use drives TB transmission dynamics in a rural community in the Western Cape, South Africa Samantha Malatesta (Boston, United States)	15:40 - 15:47
OA03-126-18	<i>M. tuberculosis</i> transmission dynamics in congregate settings: A genomic epidemiology study Katharine Walter (Salt Lake City, United States)	15:47 - 15:54
OA03-127-18	Using whole genome sequencing and other metadata to estimate factors associated with TB transmission in Lima, Peru Anne Shapiro (Boston, United States)	15:54 - 16:01
OA03-128-18	Comparative transmissibility of bacteriologically confirmed vs. clinically diagnosed pulmonary TB in a school setting: Implications for contact screening strategies Yanfei Ren (Shanghai, China)	16:01 - 16:08
OA03-129-18	Pairwise analyses of transmission among individuals with isoniazid-resistant and pan-susceptible TB using genomic and spatial data Hao-Hsuan Olivia Lin (Taipei, Taiwan)	16:08 - 16:15
	Q&A	16:15 - 16:30
 <i>Oral Abstract Sessions</i>		
	15:00 - 16:30	R4
	OA04 - TB and co-morbidities Ole Kirk (Copenhagen, Denmark) Limakatso Lebina (Durban, South Africa)	
	Introduction	15:00 - 15:03
OA04-130-18	TB multimorbidity and its impact on mortality amongst adults in South Africa: A prospective cohort study nested in a trial Greta Wood (Liverpool, United Kingdom)	15:03 - 15:10
OA04-131-18	Community-based, peer-led psychosocial support was associated with reduced TB stigma and depression among adults with TB in Indonesia: A prospective interventional cohort study Ahmad Fuady (Jakarta, Indonesia)	15:10 - 15:17
OA04-132-18	Association of <i>Helicobacter pylori</i> co-infection with TB disease severity: A cross-sectional study Joseph Baruch Baluku (Kampala, Uganda)	15:17 - 15:24
OA04-133-18	Nasal host gene expression in adults with pulmonary TB and HIV in Uganda Nisreen Khambati (Oxford, United Kingdom)	15:24 - 15:31
OA04-134-18	COVID-19 severity and risk of TB disease development within one year follow-up: A nationwide cohort study in Chile Salvador Vargas-García (Santiago, Chile)	15:31 - 15:38
OA04-135-18	Biomarkers for diabetes mellitus (DM) and inflammation in people diagnosed with pulmonary TB (PTB) Firdaus Nabeemeeah (Johannesburg, South Africa)	15:38 - 15:45
OA04-136-18	The impact of HIV on the phenotype and function of <i>M. tuberculosis</i>-infected human alveolar macrophages	15:45 - 15:52

	Cheusisime Kajanga (Blantyre, Malawi)	
OA04-137-18	Impact of glycemetic control on multidrug-resistant TB treatment outcomes Radhika P. Tampi (Boston, United States)	15:52 - 15:59
OA04-138-18	Demonstrating integrated mental health screening during treatment of people-centred drug-susceptible TB (DSTB) service in Myanmar Aye Pyei Sone Phoo (Yangon, Myanmar)	15:59 - 16:06
OA04-139-18	Disability is a risk factor for 1-year mortality after TB diagnosis in Korea Jinsoo Min (Seoul, Korea, Republic of)	16:06 - 16:13
OA04-140-18	CD4 counts in HIV-negative participants in the RATIONS trial: The effects of gender and disease status Anurag Bhargava (Mangaluru, India)	16:13 - 16:20
	Q&A	16:20 - 16:30
 <i>Workshops</i>		
15:00 - 18:00		R5
	WS03 - "No-one ever asked us before!" Building trust and collaborative action through participatory visual methods in TB research	
	Beate Ringwald (Uganda) Beate Ringwald (Uganda) Mary Mpakibi (Uganda)	
	Welcome	15:00 - 15:20
	Mary Mpakibi (Uganda) Beate Ringwald (Uganda)	
	Sharing my journey from disease to recovery: A TB survivor's reflections on the 'rivers of life' method	15:20 - 15:38
	Zakaria Derow Abdullahi (Kenya)	
	Visual storytelling for collective solution seeking: Photovoice method with young people in Malawi	15:38 - 15:55
	Rebecca Karimu Mtambo (Malawi)	
	Q&A	15:55 - 16:00
	Engaging community members as partners in TB implementation research: The DESTINE study in Nigeria	16:00 - 16:18
	Chukwuebuka Ugwu (Nigeria)	
	Evaluating implementation process with healthcare workers using visual methods: The IGNITE study in Uganda	16:18 - 16:35
	Jasper Nidoi (Kampala, Uganda)	
	Q&A	16:35 - 16:40
	Break	16:40 - 16:50
	Interactive session: Participatory visual methods: A deep dive	16:50 - 17:45
	Rhoda Pola (Nairobi, Kenya)	
	Feedback	17:45 - 17:55
	Wrap - up and closing remark	17:55 - 18:00
	Beate Ringwald (Uganda) Mary Mpakibi (Uganda)	

Workshops

15:00 - 18:00

R7

WS06 - Critical path for introducing and scaling new diagnostics in high-burden countries

Madhukar Pai (Montreal, Canada)

Puneet Dewan (Seattle, United States)

Patricia Hall-Eidson (Switzerland)

Mikashmi Kohli (Geneva, Switzerland)

Introduction to the session

15:00 - 15:05

Puneet Dewan (Seattle, United States)

Madhukar Pai (Montreal, Canada)

Patricia Hall-Eidson (Switzerland)

Critical path for introduction of new diagnostics in the Africa region

15:05 - 15:30

Marguerite Massinga Loembé (Gabon)

Critical path for introduction of new diagnostics in Indonesia

15:30 - 15:45

Ari Probandari (Indonesia)

Critical path for introduction of new diagnostics in Pakistan

15:45 - 16:00

Sadia Shakoor (Pakistan)

Critical path for introduction of new diagnostics in Bangladesh

16:00 - 16:15

Shahidul Islam (Bangladesh)

Break

16:15 - 16:35

Critical path for introduction of new diagnostics in India

16:35 - 17:00

Mikashmi Kohli (Geneva, Switzerland)

Summary of cross-country synthesis and recommendations for streamlining and shortening the critical path

17:00 - 17:30

Mikashmi Kohli (Geneva, Switzerland)

Patricia Hall-Eidson (Switzerland)

Marguerite Massinga Loembé (Gabon)

Discussions and Q&A

17:30 - 17:50

Closing remarks

17:50 - 18:00

Patricia Hall-Eidson (Switzerland)

Puneet Dewan (Seattle, United States)

Madhukar Pai (Montreal, Canada)

Post-Graduate Courses

15:00 - 18:00

R8

PGC01 - Shifting perspectives: Novel shorter regimens for a TB-free world

Medea Gegia (Geneva, Switzerland)

Linh Nguyen (Switzerland)

Fuad Mirzayev (Geneva, Switzerland)

Ignacio Monedero-Recuero (Vilanova i la Geltrú, Spain)

Welcome

15:00 - 15:05

Linh Nguyen (Switzerland)

Fuad Mirzayev (Geneva, Switzerland)

Ignacio Monedero-Recuero (Vilanova i la Geltrú, Spain)

The evolution of drug-resistant TB treatment: Advancing to novel shorter regimens

15:05 - 15:25

Chen-Yuan Chiang (France)

Optimising regimen selection: Criteria, composition, and eligibility of affected person

15:25 - 15:45

Fuad Mirzayev (Geneva, Switzerland)

Q&A	15:45 - 15:55
Treatment monitoring and adverse events management in shorter drug-resistant TB regimens Ignacio Monedero-Recuero (Vilanova i la Geltrú, Spain)	15:55 - 16:15
Q&A	16:15 - 16:20
Break	16:20 - 16:30
Interactive session: key considerations for novel drug-resistant TB treatments: Outcome assessment and regimen modification Gisele Badoum (Ouagadougou, Burkina Faso)	16:30 - 16:50
Scaling up novel shorter regimens: Lessons learned and future directions Animesh Sinha (United Kingdom)	16:50 - 17:10
Q&A	17:10 - 17:15
Panel Discussions	17:15 - 17:45
Wrap-up and closing remarks Fuad Mirzayev (Geneva, Switzerland) Ignacio Monedero-Recuero (Vilanova i la Geltrú, Spain)	17:45 - 18:00
<i>Workshops</i> 15:00 - 18:00	WS-PGC
WS05 - Navigating the complexity of TB: A digital clinical decision support system for optimised care pathways Akshaya Patil (India) Sandeep Juneja (New York, United States)	
Welcome Sandeep Juneja (New York, United States)	15:00 - 15:05
Need for Clinical Decision Support Systems in DR-TB Management Akshaya Patil (India)	15:05 - 15:10
Transforming DR-TB Care with Clinical Decision Support Systems (CDSS): ManageTB Development journey and vision Amitesh Gupta (India)	15:10 - 15:20
Idea to design: How ManageTB Maps 200 million Treatment Permutations for DR-TB Care Harsh Shah (India)	15:20 - 15:35
Leveraging National TB Digital Infrastructure to Enable Next-Generation Decision Support: Synergies between EDRWeb and clinical decision support systems like Manage TB Norbert Ndjeka (South Africa)	15:35 - 15:45
Scalability: Using DSS tools to support broader implementation of short treatment regimens in other countries (Ukraine perspective) Nataliia Lytvynenko (Ukraine)	15:45 - 15:55
Panel Session Rupak Singla (India) Nataliia Lytvynenko (Ukraine) Norbert Ndjeka (South Africa) Sandeep Juneja (New York, United States)	15:55 - 16:15
Break	16:15 - 16:25
Reimagining DR-TB Clinical Decisions: Live Demonstration of	16:25 - 17:25

ManageTB for Smarter, Safer Patient Care

Rupak Singla (India)

Feedback session with Q/A

Rupak Singla (India)

17:25 - 17:45

Wrap - up and closing remarks

Sandeep Juneja (New York, United States)

17:45 - 18:00

Community Connect Sessions

15:00 - 15:45

CC

CCS003 - Lives on hold: The impact of the TB funding crisis from global to grassroots

Atul Shendge (Sonipat, India)

Blessina Kumar (New Delhi, India)

Introduction

15:00 - 15:02

Funding gaps and their grassroots impact in India

Vikas Panibatla (Hyderabad, India)

15:02 - 15:09

What we lose when TB programmes lose funding

Robyn Waite (Ottawa, Canada)

15:09 - 15:16

Survivor's view: Political neglect, community leadership and the cost of donor dependence

Stephen Anguva (Nairobi, Kenya)

15:16 - 15:23

Bridging the gaps: Global solidarity and the role of the Challenge Facility for Civil Society

Viorel Soltan (Switzerland)

15:23 - 15:30

Question and answers

15:30 - 15:45

Community Connect Sessions

15:00 - 16:30

CCC

CCWS004 - Nourish to flourish: Youth-led strategies for integrating nutrition and social protection in TB responses

James Malar (Genève, Switzerland)

Aman Shukla (India)

Opening remarks & brochure introduction

Lucica Ditiu (Switzerland)

15:00 - 15:00

Scientific framing: TB-nutrition nexus and the strategic imperative for integration

Suvanand Sahu (Switzerland)

15:00 - 15:00

Youth voices & resource dissemination: Advocacy toolkit and action plan

Aman Shukla (India)

15:00 - 15:00

Country spotlight India: Leveraging Ni-Kshay Poshan Yojana for TB-affected families.

Aman Shukla (India)

15:00 - 15:00

Country spotlight Moldova: Transitioning nutrition support from Global Fund to national funding

15:00 - 15:00

Country spotlight Nigeria: Using malnutrition indicators for early TB detection in nomadic regions.

15:00 - 15:00

Country spotlight Brazil: Using Bolsa Família's conditional cash transfers to reduce TB incidence

15:00 - 15:00

	Interactive question and answer	15:00 - 15:00
	James Malar (Genève, Switzerland)	
	Closing and call to action	15:00 - 15:00
<i>Community Connect</i>		
15:00 - 17:00		CCART
	CCAT001 - Art therapy, a healing process playing with colors -- Tuberculosis and nutrition.	
	Mohammad Rofiqul (Royal) Islam (Bangladesh)	
	Introduction about art therapy	15:00 - 15:10
	Mohammad Rofiqul (Royal) Islam (Bangladesh)	
	Art therapy	15:10 - 17:00
	Mohammad Rofiqul (Royal) Islam (Bangladesh)	
<i>Community Connect Sessions</i>		
16:00 - 16:45		CC
	CCS004 - Community pharmacists as enablers of equitable TB care and referral in India	
	Apoorva Murali (India)	
	Vijayashree Yellapa (India)	
	Introduction	16:00 - 16:03
	Community-led innovative tools and technologies in TB programmes	16:03 - 16:12
	Sanjay Mattoo (New Delhi, India)	
	Prachi Shukla (India)	
	Miranda Brouwer (Haren, Netherlands)	
	Community-led innovative tools and technologies in TB programmes	16:12 - 16:21
	Sudeshwar Kumar Singh (India)	
	Question and answers	16:21 - 16:36
<i>TBScience Sessions</i>		
16:25 - 18:00		TBS
	TBS02 - Mixed oral abstract presentations I	
	Elisa Nemes (South Africa)	
	TBS02-01 Session introduction	16:25 - 16:27
	TBS02-05 Clinical and transcriptomic risk factors for post-tuberculosis lung disease (PTLD) phenotypes in Kenyan adults	16:27 - 16:34
	Jerry S. Zifodya (New Orleans, United States)	
	TBS02-10 Integrative proteogenomics illuminates molecular drivers of <i>M. tuberculosis</i> virulence	16:34 - 16:41
	Matthys Gerhardus Potgieter (Cape Town, South Africa)	
	TBS02-15 Impact of diabetes on macrophage and <i>Mycobacterium tuberculosis</i> interaction: Insights from dual RNA-seq	16:41 - 16:48
	Julia Brake (Nijmegen, Netherlands)	
	TBS02-20 Proteins associated with neutrophil degranulation result in lung damage in symptomatic TB patients	16:48 - 16:55
	Marshlin Delon Naicker (Durban, South Africa)	
	TBS02-25 Studying the Influence of host Iron genotypes, iron supplementation and iron chelators on <i>Mycobacterium tuberculosis</i> complex infections in vitro	16:55 - 17:02

	Naffie Top (Banjul, Gambia)	
TBS02-30	Unmasking hidden diversity: Direct sputum sequencing reveals extensive mixed-lineage TB infections missed by culture in a high-burden setting Brendon C. Mann (Cape Town, South Africa)	17:02 - 17:09
TBS02-35	Latent <i>Mycobacterium tuberculosis</i> infection is associated with increased inflammatory cytokines with dysregulation of antigen presentation pathways and innate immunity in diabetic individuals Zahra Hasan (Karachi, Pakistan)	17:09 - 17:16
TBS02-40	An imaging-based artificial intelligence (AI) system for diagnosing recurrent pulmonary tuberculosis Prem Thilak Palani (New Delhi, India)	17:16 - 17:23
TBS02-45	Expanding TB screening and triage through standardised sweep ultrasound and AI: Findings from a pilot study in Zambia Elze Swinkels (Eindhoven, Netherlands)	17:23 - 17:30
TBS02-50	Q&A	17:30 - 18:00
	<i>Break</i> 16:30 - 16:45	R3
	Break/Networking	
	<i>Short Oral Abstract Sessions</i> 16:45 - 18:15	R1
	SOA02 - Eyes on the Unseen: Leveraging data, tech, and community in finding the missing people with TB Pranay Sinha (Boston, United States) Sonia Menon (Brussels, Belgium)	
	Introduction	16:45 - 16:50
SOA02-511-18	Reaching the undiagnosed: The contribution of active TB case finding campaign in Zambia Mary Mulobe Mwanabeti (Lusaka, Zambia)	16:50 - 16:56
SOA02-512-18	Reaching the unreached: India's 100-Day Drive to find every missing person with TB Mrigen Deka (New Delhi, India)	16:56 - 17:02
SOA02-513-18	Reaching the unreached: Leveraging community volunteers and colour cards to enhance finding people with TB and adherence in Ethiopia's pastoralist areas Zemedu Trife (Addis Ababa, Ethiopia)	17:02 - 17:08
SOA02-514-18	Community involvement in finding people with active TB in Indonesia: Two heads are better than one Betty Nababan (South Jakarta, Indonesia)	17:08 - 17:14
SOA02-515-18	Strengthening active case finding for TB advocacy in Chinese media: A practice-driven case study of communication interventions Xiuli Wang (Beijing, China)	17:14 - 17:20
SOA02-516-18	Systematic community TB screening using digital X-ray and live data monitoring to improve finding TB in rural Lesotho Afom Tesfalem Andom (Maseru, Lesotho)	17:20 - 17:26
SOA02-517-18	Leveraging a mass religious gathering for intensified TB case finding: Insights from the Maha Kumbh Mela, Prayagraj, India Vinod Kumar VG (New Delhi, India)	17:26 - 17:32

SOA02-518-18	Hidden no more: Community-led TB detection among street families in Kenya Sharon Kitui (Nairobi, Kenya)	17:32 - 17:38
SOA02-519-18	Screening and finding active TB among individuals undergoing Methadone treatment at Ngara Methadone Clinic in Nairobi County, Kenya Elizabeth Mueni (Nairobi, Kenya)	17:38 - 17:44
SOA02-520-18	Sensitivity and specificity of symptom-based screening among household contacts of people with TB in high-burden TB countries Jennifer Nagudi (Johannesburg, South Africa)	17:44 - 17:50
SOA02-521-18	Impact of using the 10-symptom complex for TB screening on programme indicators during the 100-day Intensified TB Case Finding campaign in Chandigarh, India Suman Singh (Chandigarh, India)	17:50 - 17:56
SOA02-522-18	Enhancing TB detection: A comparative study of AI-identified vs. routine data-derived hotspots in Pakistan Amna Mahfooz (Islamabad, Pakistan)	17:56 - 18:02
	Q&A	18:02 - 18:15
 <i>Oral Abstract Sessions</i>		
	16:45 - 18:15	R2
	OA05 - It takes a village: Improving prevention and detection of TB among children Sylvia LaCourse (Seattle, United States) Denise Banze (Maputo, Mozambique)	
	Introduction	16:45 - 16:50
OA05-141-18	Global, regional, and national burden of TB among children aged 0-14 years from 1990 to 2021: Results from the Global Burden of Disease Study 2021 Jian Du (Beijing, China)	16:50 - 16:57
OA05-142-18	Accuracy of Xpert MTB/RIF Ultra vs. liquid culture in induced sputum samples from children in a multicentric Brazilian study Renato Stein (Porto Alegre, Brazil)	16:57 - 17:04
OA05-143-18	Impact of the simple one step stool sample processing technique: The wellness on wheels truck experience in Ganjuwa Nutrition clinic, Bauchi State, Nigeria Adamu Abdullahi (Kano, Nigeria)	17:04 - 17:11
OA05-144-18	End-user perspectives on pediatric TB diagnostic processes in Uganda and Peru: A qualitative study Franziska Held (Maastricht, Netherlands)	17:11 - 17:18
OA05-145-18	Scaling impact: Enhancing childhood TB detection through monthly testing initiatives in Cross River State Amina Kewa (Abuja, Nigeria)	17:18 - 17:25
OA05-146-18	Comparison of the National TB and Leprosy Program and World Health Organization criteria for pulmonary TB severity classification among children in Uganda Peter Wambi (Kampala, Uganda)	17:25 - 17:32
OA05-147-18	Accelerating childhood TB detection in Bangladesh: BRAC experience from effective implementation strategies Nawrin Kabir (Dhaka, Bangladesh)	17:32 - 17:39
OA05-148-18	Safety, completion rate and rifapentine plasma concentration in Chinese children with 1HP for TB infection	17:39 - 17:46

Peize Zhang (Shenzhen, China)

Q&A

17:46 - 18:01

Symposia

16:45 - 18:15

R3

SY04-140-04 - Innovative financing for TB programmes: Maximising resources in line with ambitious targets

Lucica Ditiu (Switzerland)

Yogan Pillay (South Africa)

Introduction

16:45 - 16:50

The Global Fund perspective on sustaining financing for TB elimination at the country level

16:50 - 17:05

Eliud Wandwalo (Geneva, Switzerland)

The role of multilateral development banks in financing for TB elimination at the country level

17:05 - 17:20

Pandu Harimurti (Indonesia)

The potential role of debt-for-health transactions in financing for TB elimination at the country level

17:20 - 17:35

Raphael Hurley (South Africa)

The role of private and corporate philanthropy and investments in financing for TB elimination at the country level

17:35 - 17:50

Egbe Dawodu (Lagos, Nigeria)

Lessons from Indonesia's experience with mobilisation of domestic resources for TB

17:50 - 18:05

Lucia Rizka Andalusia (Indonesia)

Q&A

18:05 - 18:15

Symposia

16:45 - 18:15

R4

SY05-150-05 - Drug-drug interactions in TB management: What every clinician should know

David Burger (Nijmegen, Netherlands)

Introduction

16:45 - 16:50

INSTI-based cART + HRZE for people with TB/HIV infection: New data changing policy

16:50 - 17:07

Kelly Dooley (Nashville, United States)

QTc-interval prolongation in people on bedaquiline and other TB drugs: A perfect storm or a tempest in a teacup?

17:07 - 17:24

Ignacio Monedero-Recuero (Vilanova i la Geltrú, Spain)

TB and diabetes mellitus: Drug-drug interactions in two colliding epidemics

17:24 - 17:41

Ruslami Rovina (Bandung, Indonesia)

Depression and TB: Double trouble?

17:41 - 17:58

Rob Aarnoutse (Nijmegen, Netherlands)

Q&A

17:58 - 18:15

Community Connect Sessions

16:45 - 17:45

CCC

CCWS006 - Creating safe spaces for sharing TB experiences and getting lives back on track

Ingrid Schoeman (Pretoria, South Africa)

Atul Shendge (Sonipat, India)

Panel Discussion: Creating safe spaces for sharing TB experiences and getting lives back on track

16:45 - 16:45

Blessina Kumar (New Delhi, India)

Vikas Panibatla (Hyderabad, India)

Phumeza Tisile (Cape Town, South Africa)

Stephen Anguva (Nairobi, Kenya)

Break

18:30 - 18:55

Main

Break/Networking

Opening Session

18:30 - 20:00

Welcome Gathering

Wednesday, 19. November 2025

Satellite Sessions

08:00 - 09:00

R1

SS02 - Management of Drug-Resistant Tuberculosis

Francesca Conradie (Johannesburg, South Africa)

Introduction

08:00 - 08:02

Global prevalence of drug-resistant tuberculosis

08:02 - 08:12

Erlina Burhan (Jakarta, Indonesia)

Key considerations for selecting regimens for patients with drug-resistant tuberculosis

08:12 - 08:27

Francesca Conradie (Johannesburg, South Africa)

Real-World Experiences with Newer DRTB Regimen Usage

08:27 - 08:42

Nataliia Lytvynenko (Ukraine)

Q&A

08:42 - 08:55

Closing remarks

08:55 - 09:00

Satellite Sessions

08:00 - 09:00

R2

SS03 - Transforming TB detection through tongue swab-based molecular testing

Claudia Denkinger (Heidelberg, Germany)

Madhukar Pai (Montreal, Canada)

Introduction

08:00 - 08:02

Sputum scarcity and quality in different populations

08:02 - 08:12

Mary Gaeddert (Germany)

Qualitative work around sampling preferences and acceptability

08:12 - 08:22

Andrew Kerkhoff (San Francisco, United States)

Diagnostic yield of tongue swab- compared to sputum-based molecular testing for tuberculosis in four high-burden countries

08:22 - 08:32

Adithya Cattamanchi (United States)

Pulmonary Tuberculosis Detection with the Pluslife MiniDock MTB Test and Molbio Truenat Ultima Using Tongue and Sputum Swabs

08:32 - 08:42

Seda Yerlikaya (Heidelberg, Germany)

Cost and cost-effectiveness of tongue swab-based molecular testing for tuberculosis in the Philippines, Uganda, Vietnam, and Zambia

08:42 - 08:52

Florian Marx (Germany)

Q&A

08:52 - 09:00

Meet the Expert Sessions

08:00 - 09:00

R3

MTE-01 - Linkage to care in TB: Closing the gaps between diagnosis and treatment

Zahedul Islam (Kyiv, Ukraine)

Live introduction

08:00 - 08:05

Linkage to care in TB: Closing the gaps between diagnosis and treatment

08:05 - 08:20

Evgenia Geliukh (Kyiv, Ukraine)

	Discussion and Q&A	08:20 - 09:00
<i>Meet the Expert Sessions</i>		
08:00 - 09:00		R4
MTE-02 - Pooled resources, maximum impact: Can sputum pooling revolutionise TB testing?		
Grania Brigden (Switzerland)		
	Live introduction	08:00 - 08:05
	Pooled resources, maximum impact: Can sputum pooling revolutionise TB testing?	08:05 - 08:20
Valerie Flore Donkeng Donfack (Yaounde, Cameroon)		
	Discussion and Q&A	08:20 - 09:00
<i>Meet the Expert Sessions</i>		
08:00 - 09:00		R5
MTE-03 - Importance of smoking cessation in improving TB treatment outcomes		
Akihiro Ohkado (Tokyo, Japan)		
	Live introduction	08:00 - 08:05
	Importance of smoking cessation in improving TB treatment outcomes	08:05 - 08:20
Tara Singh Bam (Singapore, Singapore)		
	Discussion and Q&A	08:20 - 09:00
<i>Community Connect Sessions</i>		
08:00 - 08:45		CC
CCS006 - Understanding the principles, building blocks and priority investment areas to realise stronger and sustainable community systems to end TB: Launching a new Stop TB Partnership Community Support Package		
James Malar (Genève, Switzerland)		
James Malar (Genève, Switzerland)		
Ramya Ananthakrishnan (Chennai, India)		
	Introduction	08:00 - 08:02
	The historical development of TB CSS	08:02 - 08:09
Sok Chamreun Choub (Phnom Penh, Cambodia)		
	Principles and building blocks for TB CSS	08:09 - 08:16
Kinz Ul Eman (Islamabad, Pakistan)		
	Examples of effective TB CSS investments and interventions	08:16 - 08:23
Deborah Ikeh (Abuja, Nigeria)		
	Launching the TB CSS community support package	08:23 - 08:30
James Malar (Genève, Switzerland)		
	Question and answers	08:30 - 08:45
<i>TBScience Unmoderated E-Posters</i>		
08:00 - 19:00		
TBS-EP-WED - TBScience 2025 Unmoderated E-Posters		
TBS-EP362	Toward entropy-based precision monitoring of tuberculosis: A systematic review of immune dysregulation as a predictive framework for treatment innovation	08:00 - 08:00
Satiti Palupi Purwanto (Hat Yai, Thailand)		

TBS-EP365	Machine learning models reveal predictive signatures of therapy outcome in Phase 3 TB trials Daniel Garger (Munich, Germany)	08:00 - 08:00
TBS-EP368	The use of unmanned aerial vehicles (UAV) on delivering biological samples for tuberculosis and COVID-19 diagnosis: A scoping review Olga Maira Machado Rodrigues (Brasilia, Brazil)	08:00 - 08:00
TBS-EP371	Evaluation of an oral bedaquiline regimen for treating multidrug-resistant TB in China: A randomized trial Jingtao Gao (Beijing, China)	08:00 - 08:00
TBS-EP374	Treatment outcomes and risk factors among tuberculosis patients infected with <i>Mycobacterium tuberculosis</i> Beijing lineage in Ukraine (2020-2023) Dmytro Butov (Kharkiv, Ukraine)	08:00 - 08:00
TBS-EP377	Addressing tobacco industry tactics in university campuses and its impact on tobacco cases in Iraq Thamer Alhilfi (Baghdad, Iraq)	08:00 - 08:00
TBS-EP380	Breath-based pathogen detection technologies for diagnosing respiratory infections: A scoping review Sonal Jain (Heidelberg, Germany)	08:00 - 08:00
TBS-EP383	Leveraging artificial intelligence driven mobile X-ray screening on TB detection in high-risk brick Kiln communities of Punjab, Pakistan Qasim Mehmood (Lahore, Pakistan)	08:00 - 08:00
TBS-EP386	Drug resistance detection from swab samples - A proof of principle pilot study using Molbio Truenat MTB-RIF-Dx and MTB-INH assays Seda Yerlikaya (Heidelberg, Germany)	08:00 - 08:00
TBS-EP389	AI-powered TB screening revolution: Impact of CAD4TB and DELFT portable X-ray machines in Punjab, Pakistan Bilal Ahmed (Lahore, Pakistan)	08:00 - 08:00
TBS-EP395	Preventive practices of pulmonary tuberculosis in Chitwan districts Kamal Kalakheti (Ilam, Nepal)	08:00 - 08:00
TBS-EP398	Genetic pattern of the ST 61 cluster of the Cameroon family among <i>Mycobacterium tuberculosis</i> complex strains collected during the CANTAM I project in Cameroon Alix Kevine G. T. Tchoupe (Yaoundé, Cameroon)	08:00 - 08:00
TBS-EP401	SHIFTING paradigms in DR-TB management: Real-world outcomes of injectable Kanamycin vs. Bedaquiline all-oral regimens using Ni-Kshay surveillance data Zuha Jabeen Shaikh (Mumbai, India)	08:00 - 08:00
TBS-EP404	Analysis of the incidence of tuberculosis lung injury and related factors of lung function after cure of pulmonary tuberculosis: A prospective observational study Wenli Cao (Beijing, China)	08:00 - 08:00
TBS-EP410	Human reader vs CAD4TB: Enhancing TB case detection through AI-supported mobile screening in Cambodia Monyrath Chry (Phnom Penh, Cambodia)	08:00 - 08:00
TBS-EP413	Tuberculosis recurrence prediction: A machine learning approach Olga Zofia Wieromiejczyk (Copenhagen, Denmark)	08:00 - 08:00
TBS-EP416	Bridging the knowledge gap: KAP assessment on tuberculosis among undergraduate health professional students in Baghdad with a focus on tobacco smoke and curriculum adequacy	08:00 - 08:00

	Thamer Alhilfi (Baghdad, Iraq)	
TBS-EP419	Development and evaluation of hydrogel loaded with human amniotic membrane in wound healing Faheem Jan (Islamabad, Pakistan)	08:00 - 08:00
TBS-EP425	Impact of discordant isoniazid and rifampicin susceptibility results between the Anyplex™ II MTB/MDR assay and the BACTEC MGIT 960 system on treatment decisions Kanphai Wongjarit (Bangkok, Thailand)	08:00 - 08:00
TBS-EP428	The role of physiotherapy in demystifying pulmonary tuberculosis in Uganda Sheillah T. Nakisanze (Masaka, Uganda)	08:00 - 08:00
TBS-EP431	Clinical performance of the CAD4TB AI system for pulmonary tuberculosis detection among young adults in Mongolia: A diagnostic screening study Yanjindulam Purevsuren (Ulaanbaatar, Mongolia)	08:00 - 08:00
TBS-EP434	Addressing access to treatment and diagnostic barriers in TB treatment through the Market and Patent Intelligence Study: A focus on intellectual property barrier Duke Otieno (Nairobi, Kenya)	08:00 - 08:00
TBS-EP440	Shortened treatment regimens for drug resistant (DR)-TB patients in Azerbaijan: First results Irada Akhundova (Baku, Azerbaijan)	08:00 - 08:00
TBS-EP443	Concomitant subclinical pulmonary tuberculosis in patients with extra-pulmonary tuberculosis Tejaswini Gude (New Delhi, India)	08:00 - 08:00
TBS-EP446	Evaluation of the second-generation Fujifilm SILVAMP TB-LAM assay for TB diagnosis in Nigerian adults Nadiia Tytarenko (Badalona, Spain)	08:00 - 08:00
TBS-EP449	Novel mutations in genes associated with bedaquiline and linezolid resistance in drug- naive <i>Mycobacterium tuberculosis</i> isolates Chikanshi Sharma (Delhi, India)	08:00 - 08:00
TBS-EP452	Measuring cellular responses against respiratory pathogens can help to guide prophylaxis in immunocompromised patients Irene Latorre (Badalona, Spain)	08:00 - 08:00
TBS-EP455	Radiological features of pulmonary nontuberculous mycobacterial disease depending on the species of the pathogen Anastasiya Gaida (Moscow, Russian Federation)	08:00 - 08:00
TBS-EP458	Estimating the effect of implementing novel diagnostics in adults and children on pediatric TB indicators in KwaZulu-Natal, South Africa Mark Fajans (Seattle, United States)	08:00 - 08:00
TBS-EP461	The iron-vitamin D axis in tuberculosis: Hepcidin modulation as a target for precision host-directed therapy Satiti Palupi Purwanto (Hat Yai, Thailand)	08:00 - 08:00
TBS-EP464	Research on patients with NTM lung disease accompanied by anxiety or depression and related risk factors Xiang Shi (Shang Hai, China)	08:00 - 08:00
TBS-EP467	Reasons for refusal of TB preventive treatment uptake by eligible contacts of TB patients in high TB burden settings Sobia Faisal (Islamabad, Pakistan)	08:00 - 08:00

TBS-EP470	Isolation of non-tuberculous mycobacteria (NTM) from household water of patients with NTM pulmonary disease Wei Sha (Shang Hai, China)	08:00 - 08:00
TBS-EP479	Adherence to isoniazid preventive therapy and its associated factors among HIV patients receiving treatment in five districts in Ghana Mavis Pearl Kwabla (Hohoe, Ghana)	08:00 - 08:00
TBS-EP482	Prospective prediction of TBAJ-876-PaL phase 2 clinical outcomes in NC-009 trial via a multi-model framework Eunsol Yang (San Francisco, United States)	08:00 - 08:00
TBS-EP485	Implementation of TPT with shorter regimens: Experience from Bangladesh Rifat Jahan Khan (Dhaka, Bangladesh)	08:00 - 08:00
TBS-EP488	Empowering National TB Control Program through artificial intelligence-enhanced portable X-ray deployment in Bangladesh Rifat Jahan Khan (Dhaka, Bangladesh)	08:00 - 08:00
TBS-EP491	Lineage identification and mutation profile of <i>Mycobacterium tuberculosis</i>: A study from National Reference Laboratory, India Raj Narayan Yadav (New Delhi, India)	08:00 - 08:00
TBS-EP493	Oral rinse outperforms facemask capture for non-sputum diagnosis of pulmonary TB Simon C Mendelsohn (Cape Town, South Africa)	08:00 - 08:00
TBS-EP503	Trends in tuberculosis detection using GeneXpert in a rural Ghanaian district: A six-year retrospective analysis (2019-2024) Eyram Hanu (Hohoe, Ghana)	08:00 - 08:00
TBS-EP506	Fate of TB treatment among the patients who remained bacteriologically positive after two months of anti-TB drugs Sobia Faisal (Islamabad, Pakistan)	08:00 - 08:00
TBS-EP509	Physiotherapy management in tuberculosis patients with co-existing HIV infection: Challenges in immunocompromised care Elizabeth Nakanwagi (Kampala, Uganda)	08:00 - 08:00
TBS-EP512	Can simple blood tests predict heart disease in patients with pulmonary tuberculosis? - The TB-HEART Study Marcello Scopazzini (London, United Kingdom)	08:00 - 08:00
TBS-EP515	Threat beyond TB: Rising menace of NTM infections and the urgent need for accurate diagnosis Jyotirmayee Turuk (Bhubaneswar, India)	08:00 - 08:00
TBS-EP518	Genomic insights into <i>Mycobacterium tuberculosis</i> lineages and antimicrobial resistance profiles in three Canadian provinces Reema Singh (Saskatoon, Saskatchewan, Canada)	08:00 - 08:00
TBS-EP521	Transcriptomic profiles from animal hosts following infection with <i>Mycobacterium bovis</i>: A systematic review Liliana C. M. Salvador (Tucson, United States)	08:00 - 08:00
TBS-EP524	Assessment of awareness and knowledge of butchers on bovine tuberculosis in the Volta region of Ghana Iddrisu Saliu (Hohoe, Ghana)	08:00 - 08:00
TBS-EP527	Effectiveness of BPaL/BPaLM in central area of Taiwan Yi-Wen Huang (Changhua, Taiwan)	08:00 - 08:00
TBS-EP530	Ibuprofen and acetylsalicylic acid as adjunctive to anti-tuberculosis treatment: Phase II clinical trial	08:00 - 08:00

	Cris Vilaplana (Badalona, Spain)	
TBS-EP533	Pathobionts and antimicrobial resistance in symptomatic people with and without tuberculosis Suventha Moodley (Cape Town, South Africa)	08:00 - 08:00
TBS-EP536	Validation of a DNA methylation signature of active tuberculosis in the buccal mucosa using methylation-specific PCR Isabelle Öhrnberg (Linköping, Sweden)	08:00 - 08:00
TBS-EP539	The Tuberculosis Knowledge and Analytics Platform: TB Nexus Analytics Nibedita Rath (Bangalore, India)	08:00 - 08:00
TBS-EP562	Effect of combined inspiratory and expiratory muscle training in pulmonary rehabilitation of active and post tuberculosis Sheillah T. Nakisanze (Masaka, Uganda)	08:00 - 08:00
TBS-EP565	Establishment of a model for early warning of onset in population exposed to <i>Mycobacterium tuberculosis</i> Jingli Du (Beijing, China)	08:00 - 08:00
TBS-EP568	Nutritional status of tuberculosis patients and its associated factors in four districts in Ghana Mavis Pearl Kwabla (Hohoe, Ghana)	08:00 - 08:00
TBS-EP571	Maternal and infant outcomes in acute hematogenous disseminated pulmonary tuberculosis during pregnancy Huiru An (Beijing, China)	08:00 - 08:00
TBS-EP577	Development of a loop-mediated Isothermal amplification (LAMP) assay for the detection of pepQ gene in <i>Mycobacterium tuberculosis</i> Joannah Marie Bislumbre (Manila, Philippines)	08:00 - 08:00
TBS-EP580	Factors that impact the expansion of coverage for preventive treatment of TB in the Kyrgyz Republic Dinara Madybaeva (Bishkek, Kyrgyzstan)	08:00 - 08:00
TBS-EP583	Clinical features of pulmonary tuberculosis and nanostructural characteristics of multidrug-resistant <i>Mycobacterium tuberculosis</i> strains Natalia Yatskevich (Belarus)	08:00 - 08:00
TBS-EP586	Long term impact of pulmonary TB on health-related functioning and well-being in four African countries Kamban Hirasen (Johannesburg, South Africa)	08:00 - 08:00
TBS-EP589	Enrichment of <i>M. tuberculosis</i> in patient sputa using a limiting dilution assay Dale Liebenberg (Johannesburg, South Africa)	08:00 - 08:00
TBS-EP592	Bridging diagnostic gaps of drug-resistant pulmonary tuberculosis with clinical diagnosis in a low-and middle-income state, Southwest, Nigeria: A secondary data analysis Emmanuel Irek (Ekiti, Nigeria)	08:00 - 08:00
TBS-EP595	Diagnostic potential of hematological counts and ratios in pediatric tuberculosis: A five-year retrospective study Simona Mäsiarová (Martin, Slovakia)	08:00 - 08:00
TBS-EP598	Polystyrene particles alter mycobacterial lipidic cell wall composition Iris Romero-Andrada (Badalona, Spain)	08:00 - 08:00
TBS-EP601	Population pharmacokinetics of isoniazid in TB patients:	08:00 - 08:00

Accounting for age, sex, weight, diabetes, and HIV		
	Felipe Ridolfi (United States)	
TBS-EP603	Single-cell transcriptomic profiling identifies immune signatures in latent <i>Mycobacterium tuberculosis</i> infection and active tuberculosis Jie Tian (Shanghai, China)	08:00 - 08:00
TBS-EP606	Latent tuberculosis infection retains cytotoxic molecule expression and functionality lost during active disease Carlos Peña Bates (CDMX, Mexico)	08:00 - 08:00
TBS-EP609	Harnessing AI for rapid, consistent, and efficient scientific writing: Large language models for TB trial protocol generation Brian Hiroshi Aldana (San Francisco, United States)	08:00 - 08:00
TBS-EP614	Predictive modeling of tuberculosis prevalence among medical workers in the Vinnitsya Region, Ukraine: Insights from 2007-2029 Artemii Bogomolov (Vinnitsya, Ukraine)	08:00 - 08:00
TBS-EP616	Knowledge of tuberculosis prevention and control among public service vehicle operators in the South Rift Valley, Kenya Cheruiyot Sambu (Eldoret, Kenya)	08:00 - 08:00
TBS-EP618	Is transmission the primary route to bedaquiline resistance? A context specific framework for transmission threshold estimation Abel Kjaersgaard (London, United Kingdom)	08:00 - 08:00
TBS-EP620	Utility of antibody responses in the diagnosis of tuberculosis in rural Papua New Guinea Catherine Rush (Townsville, Australia)	08:00 - 08:00
TBS-EP622	Evaluation of the consistency between phenotypic MIC and genomic mutations in the detection of Bedaquiline and Clofazimine cross-resistance in <i>Mycobacterium tuberculosis</i> isolates from the Philippines Shiomi Yoshida (Kiyose, Tokyo, Japan)	08:00 - 08:00
TBS-EP624	Gastrointestinal parasites and their association with TB immune responses in Rural Papua New Guinea Jeffrey Warner (Townsville, Australia)	08:00 - 08:00
TBS-EP626	Accelerating tuberculosis prevention: Assessing novel TB preventive treatments in a preclinical infection model Andréanne Lupien (Montreal, Canada)	08:00 - 08:00
TBS-EP628	The computer-aided detection software using chest X-ray images in TB screening may have the potential to identify early TB patients in China Wei Liu (China)	08:00 - 08:00
TBS-EP630	Comparing LAM to other sputum-based biomarkers in NC-009 trial Juliano Timm (New York, United States)	08:00 - 08:00
TBS-EP632	Low complexity-manual nucleic acid amplification tests for detection of pulmonary tuberculosis in adolescents and adults with presumptive tuberculosis: A systematic-review and meta-analysis of diagnostic accuracy Adhin Bhaskar (Chennai, India)	08:00 - 08:00
TBS-EP634	Impact of TB preventive therapy at grassroots level in community setting in Pune, India Govinda Narke (Pune, India)	08:00 - 08:00
TBS-EP636	Innovative AI tool for TB diagnosis based on metabolomic detection in urine	08:00 - 08:00

	Jose Dominguez (Barcelona, Spain)	
TBS-EP638	Comparison of different chemicals as an alternative sputum liquefaction reagent to N-acetyl-L-cysteine with Sodium Hydroxide (NALC-NaOH) Jo Mary Lei Majaducon (Manila, Philippines)	08:00 - 08:00
TBS-EP647	Enhancing lung health through physiotherapy for overall well-being Elizabeth Nakanwagi (Kampala, Uganda)	08:00 - 08:00
TBS-EP653	Tissue-specific immune phenotyping reveals divergent responses to BCG vaccination and <i>Mycobacterium tuberculosis</i> challenge Irene Latorre (Badalona, Spain)	08:00 - 08:00
TBS-EP656	Risk of human tuberculosis associated with exposure to livestock in rural Ballabgarh, Haryana: A Case-Control Study Rakesh Kumar (New Delhi, India)	08:00 - 08:00
TBS-EP665	Detection of first-line and second-line Drug-Resistance mediating mutations in <i>Mycobacterium tuberculosis</i> with DNA extracted with different extraction methods directly from sputum using Next-Generation Sequencing Vera Allerheiligen (Nehren, Germany)	08:00 - 08:00
TBS-EP668	Frequency and co-resistance of bedaquiline, clofazimine, delamanid, and pretomanid in MDR-TB isolates at a North Indian reference laboratory Rashmi Ratnam (Lucknow, India)	08:00 - 08:00
TBS-EP674	Breaking resource barriers: Development of portable AIMLAM for active TB diagnosis in the HIV- population Xiang Yang (Guangzhou, China)	08:00 - 08:00
TBS-EP677	Exhaled breath condensate: A new window on aerobiology of <i>Mycobacterium tuberculosis</i> Benjamin Patterson (Cape Town, South Africa)	08:00 - 08:00
TBS-EP680	Assessment of a simplified and portable IGRA-TB platform based on fluorescence immunoassay for the diagnosis of <i>Mycobacterium tuberculosis</i> Infection Jose Dominguez (Barcelona, Spain)	08:00 - 08:00
TBS-EP683	Diagnostic Utility of Fluorescein Diacetate (FDA) Staining for Rapid Tuberculosis Detection: A Comparative Study Against Automated Liquid Culture Rashmi Ratnam (Lucknow, India)	08:00 - 08:00
TBS-EP689	Prevalence and risk factors of anti-tuberculosis drug-induced hepatitis based on liver function tests among TB patients at Hargeisa TB Hospital, Somaliland Mohamed Abdi Hergeye (Hargeisa, Somalia)	08:00 - 08:00
TBS-EP695	Post TB morbidity - What is the optimal management of TB IRIS? Proposal for a clinical trial Kasha Singh (Melbourne, Australia)	08:00 - 08:00
TBS-EP698	Preliminary diagnostic performance of novel LAM antibodies in CSF of HIV negative Vietnamese children with TB meningitis: A SURE substudy Julie Huynh (Ho Chi Minh City, Vietnam)	08:00 - 08:00
TBS-EP701	Investigating the impact of inoculum size on EUCAST methodology for MIC <i>Mycobacterium tuberculosis</i> determinations Deborah Recchia (Pavia, Italy)	08:00 - 08:00
TBS-EP704	Targeting the tryptophan synthase TrpAB to fight <i>Mycobacterium</i>	08:00 - 08:00

	tuberculosis	
	Giovanni Stelitano (Pavia, Italy)	
TBS-EP710	Achieving 100% participant retention in an active tuberculosis cohort Zainab Baig (Durban, South Africa)	08:00 - 08:00
TBS-EP713	Pre-extensively drug-resistant extrapulmonary tuberculosis: A growing threat Manu Singh (Lucknow, India)	08:00 - 08:00
TBS-EP716	Pharmacogenetic insights for tuberculosis treatment using Namibian human genetic diversity Lorraine Boois (Windhoek, Namibia)	08:00 - 08:00
TBS-EP722	Integrated genomic and host-based assessment of a persistent extensively drug resistant <i>M. tuberculosis</i> Beijing strain during therapy Mandira Varma-Basil (Delhi, India)	08:00 - 08:00
TBS-EP725	Optimization of community-based tuberculosis screening informed by Bayesian Latent Class modelling Aquiles R. Henriquez-Trujillo (Antwerp, Belgium)	08:00 - 08:00
TBS-EP734	Neutrophil-to-lymphocyte-ratio and neutrophil-to-monocyte-plus-lymphocyte-ratio in the blood of adolescents with pulmonary tuberculosis Larissa Gorbach (Minsk, Belarus)	08:00 - 08:00
TBS-EP737	Using artificial intelligence for parameterization of mechanistic epidemiologic models in tuberculosis control Nishant Chavan (New Delhi, India)	08:00 - 08:00
TBS-EP740	Chronotherapy for tuberculosis: A conceptual framework to harness host circadian rhythms and destabilize mycobacterium tuberculosis physiology Satiti Palupi Purwanto (Hat Yai, Thailand)	08:00 - 08:00
TBS-EP743	Neutrophil, lymphocyte and monocyte ratios in children with active and latent tuberculosis Larissa Gorbach (Minsk, Belarus)	08:00 - 08:00
TBS-EP746	Platelet-to-lymphocyte-ratio in children and adolescents with pulmonary tuberculosis and latent tuberculosis Larissa Gorbach (Minsk, Belarus)	08:00 - 08:00
TBS-EP755	Computer aided diagnostics for TB diagnosis: Overcoming challenges and leveraging opportunities in LMICs Arnold Kennedy Tumuhairwe (Kampala, Uganda)	08:00 - 08:00
TBS-EP761	Alteration in micromineral levels, cluster of differentiation 4+ and gamma glutamyl transferase in subjects on anti-tuberculosis chemotherapy at Infectious Disease Hospital Calabar, Nigeria Raymond Eworo (Calabar, Nigeria)	08:00 - 08:00
TBS-EP767	Targeting TB granulomas to develop HDTs Mohlopheni Jackson Marakalala (Cape Town, South Africa)	08:00 - 08:00
TBS-EP773	Genotypes of <i>Mycobacterium tuberculosis</i> complex isolated from GeneXpert negative PTB patients: Whole genome sequence based comparative study Alem Alemayehu (Addis Ababa, Ethiopia)	08:00 - 08:00
TBS-EP779	Systemic immune inflammation index and systemic inflammation response index in children with pulmonary tuberculosis and latent tuberculosis	08:00 - 08:00

	Larissa Gorbach (Minsk, Belarus)	
TBS-EP782	The impact of information technology on the epidemiological profile of tuberculosis in the socio-economic zones of the Republic of Sakha Aleksey Kazakov (Moscow, Russian Federation)	08:00 - 08:00
TBS-EP785	Modern capabilities of neural network models in the analysis of chest X-rays: A systematic review Aleksey Kazakov (Moscow, Russian Federation)	08:00 - 08:00
TBS-EP788	Characteristics of non-specific microflora in patients with pulmonary tuberculosis Anastasiya Gaida (Moscow, Russian Federation)	08:00 - 08:00
<i>Break</i>		
09:00 - 09:15		Main
Break/Networking		
<i>Community Connect Sessions</i>		
09:00 - 09:45		CC
CCS007 - "There'll be dragons": Untangling stigma and discrimination		
Kathy Fiekert (United Kingdom)		
Kathy Fiekert (United Kingdom)		
Paulina Siniatkina (Netherlands)		
	Introduction	09:00 - 09:05
	Untangling stigma and discrimination Kathy Fiekert (United Kingdom)	09:05 - 09:10
	Art against TB: How to end the TaBoo Paulina Siniatkina (Netherlands)	09:10 - 09:15
	Turning the tide: From provider perpetuated stigma to respectful shared decision making Jennifer Furin (boston, United States)	09:15 - 09:20
	What gender is stigma? Recognising the gendered dimension of TB Ángela León Cáceres (Ecuador)	09:20 - 09:25
	How do we know we have won? How do we define success? Bianca Conçalves Tasca (Netherlands)	09:25 - 09:30
	Question and answers	09:30 - 09:45
<i>Community Connect Sessions</i>		
09:00 - 11:00		CCC
CCWS008 - Systems at Risk: A Multisectoral Simulation on Climate Adaptation, Crisis Response and Resilient Health Care		
Kinz Ul Eman (Islamabad, Pakistan)		
Usman Rasool Lodhi (Islamabad, Pakistan)		
	Opening Remarks Kinz Ul Eman (Islamabad, Pakistan)	09:00 - 09:05
	Insights and setting the scene James Malar (Genève, Switzerland)	09:05 - 09:10
	Sprint 1: Climate Shock Simulation James Malar (Genève, Switzerland) Stephen John (Yola, Nigeria) Ramya Ananthakrishnan (Chennai, India)	09:10 - 09:40

Madhava Sai Sivapuram (India) Priyanka Aiyer (Delhi, India) Ghulam Nabi Kazi (Pakistan) Sabira Tahseen (Islamabad, Pakistan) Tilal Asif (Pakistan)	
Sprint 2: Innovation Hack	09:40 - 10:10
James Malar (Genève, Switzerland) Stephen John (Yola, Nigeria) Ramya Ananthakrishnan (Chennai, India) Madhava Sai Sivapuram (India) Priyanka Aiyer (Delhi, India) Ghulam Nabi Kazi (Pakistan) Sabira Tahseen (Islamabad, Pakistan) Tilal Asif (Pakistan)	
Rapid-Fire Pitches	10:10 - 10:40
Workshop synthesis	10:40 - 10:50
Kinz Ul Eman (Islamabad, Pakistan)	
Solidarity Closing	10:50 - 11:00
James Malar (Genève, Switzerland)	

Community Connect

09:00 - 17:00

CCART

CCAE002 - 'Hospitality': Selected Works (Preview) Exhibition by artist and TB survivor Paulina Siniatkina

Paulina Siniatkina (Netherlands)

TBScience E-Poster Sessions

09:05 - 10:45

TBS-EP-02 - TBScience Moderated E-posters II

Simon C Mendelsohn (Cape Town, South Africa)

TBS-EP47	Design optimization for a global phase 3 trial of the M72/AS01_{E-4} Mycobacterium tuberculosis (Mtb) vaccine Amy Cinar (Cambridge, MA, United States)	09:05 - 09:10
TBS-EP50	What is the potential impact of vaccinating younger (9-14 year old) adolescents with new TB vaccines? Rebecca A. Clark (London, United Kingdom)	09:10 - 09:15
TBS-EP53	Immunometabolic profiling of Mycobacterium tuberculosis infected human lung tissue Barry Truebody (Durban, South Africa)	09:15 - 09:20
TBS-EP56	Investigation into the peripheral localization, morphology and host/pathogen interaction of MDSCs during stages human tuberculosis lymph nodes granuloma evolution Sefiyat Odunola Adebisi (Cape Town, South Africa)	09:20 - 09:25
TBS-EP59	Improving collaboration through access: A scoping review of TB clinical trial repositories Mairi McClean (Germany)	09:25 - 09:30
TBS-EP62	Phosphatidylcholine alterations correlate with natural and M. tuberculosis-specific antibody responses in a primate model Sofia Santiago Torres (New Orleans, United States)	09:30 - 09:35
TBS-EP65	Baseline Sputum Gene Expression and Its Association with Pulmonary Fibrosis and Post-TB Lung Function Hyejeong Hong (Philadelphia, United States)	09:35 - 09:40
TBS-EP68	Use of tuberculosis molecular bacterial load assay in sputum	09:40 - 09:45

	samples to characterize tuberculosis treatment response over 12 weeks	
	Thanakorn Vongjarudech (Nijmegen, Netherlands)	
TBS-EP71	<i>Mycobacterium tuberculosis</i> curli pili reduces oxygen consumption rate of THP-1 macrophages during early infection	09:45 - 09:50
	Shinese Ashokcoomar (Durban, South Africa)	
TBS-EP74	Non-sputum biomarkers for on-treatment prediction of TB disease recurrence	09:50 - 09:55
	Mairi McClean (Germany)	
TBS-EP77	On the replacement of smear microscopy: Decontamination has a negative impact on GeneXpert Ultra	09:55 - 10:00
	Daniel Augustinsson (Linköping, Sweden)	
TBS-EP80	Persistent immune alterations following TB treatment: Longitudinal profiling and possible association with microbiota	10:00 - 10:05
	Loide Shipingana (Cape Town, South Africa)	
TBS-EP83	Blood RNA biomarkers to predict treatment failure or relapse after truncated treatment of pulmonary tuberculosis	10:05 - 10:10
	Rishi Gupta (London, United Kingdom)	
TBS-EP86	Proposing a framework for human dose prediction of anti-tuberculosis drug candidates	10:10 - 10:15
	Anu Patel (San Francisco, United States)	
TBS-EP89	Evaluating the association between baseline neutrophil counts and pulmonary tuberculosis outcomes: Baseline and post-treatment lung function and high-resolution CT findings	10:15 - 10:20
	Yejin Kang (Philadelphia, United States)	
TBS-EP90	Q&A	10:20 - 10:45

Special Sessions

09:15 - 10:45

Main

SPS02 - A 360° dialogue on ending TB: Ambition, evidence, and equity

Kobto Koura (Paris, France)

Sadia Shakoor (Pakistan)

Introduction	09:15 - 09:20
Perspective of person affected with TB	09:20 - 09:30
Olya Klymenko (Kyiv, Ukraine)	
Can we actually end TB?	09:30 - 09:40
David Dowdy (Baltimore, United States)	
Active case finding strategies	09:40 - 09:50
Mikaela Coleman (Munich, Germany)	
New diagnostics and treatments	09:50 - 10:00
Scott Heysell (United States)	
The role of vaccines	10:00 - 10:10
Keren Middelkoop (South Africa)	
Social determinants and equity	10:10 - 10:20
Pranay Sinha (Boston, United States)	
Panel discussion with Q&A	10:20 - 10:40
Wrap up	10:40 - 10:45

Symposia

09:15 - 10:45

TBS

SY06-160-06 - Progress towards a PAN-TB regimen: Insights from the PAN-TB collaboration's XBQS phase 2b/c Trial

David Holtzman (Cambridge, United States)
Morounfolu Olugbosi (Sandton, South Africa)

	Introduction	09:15 - 09:20
	When things don't PAN out: Results from the PAN-TB randomised controlled, treatment-shortening clinical trial	09:20 - 09:35
	Rod Dawson (Mowbray, South Africa)	
	Use and impact of whole genome sequencing to determine outcomes in the PAN-TB trial	09:35 - 09:50
	Kelly W. Stinson (Atlanta, United States)	
	Implementing a person-centered approach to TB care in the PAN-TB trial via a holistic treatment support model including video-supported treatment	09:50 - 10:05
	Maria Tarcela S. Gler (Silang, Cavite, Philippines)	
	In pursuit of non-culture-based TB treatment response biomarkers: Results from novel biomarker assays in the PAN-TB trial	10:05 - 10:20
	Nicole Frahm (Cambridge, United States)	
	Protecting participants and preserving endpoints in treatment-shortening trials: Experience implementing a stop-treatment-and-watch framework in the PAN-TB trial	10:20 - 10:35
	Suzanne Staples (Durban, South Africa)	
	Q&A	10:35 - 10:45

Oral Abstract Sessions

09:15 - 10:45

R1

OA08 - Preventing TB by addressing the gap

Joan-Pau Millet (Barcelona, 08022, Spain)
Mathias Gröschel (Berlin, Germany)

	Introduction	09:15 - 09:20
OA08-171-19	Risk of immunological sensitisation to <i>M. tuberculosis</i> and progression to incident TB disease in a high-burden setting	09:20 - 09:27
	Humphrey Mulenga (Cape Town, South Africa)	
OA08-172-19	Predictive performance of the ESAT6-CFP10 skin test for incident TB: A prospective cohort study	09:27 - 09:34
	Jianming Wang (Nanjing, China)	
OA08-173-19	Differences in conversion and reversion rates of interferon gamma release assay in the elderly under different tuberculosis epidemic settings: A prospective quantitative study	09:34 - 09:41
	Wei Wang (Hangzhou, China)	
OA08-174-19	Effect of community-based vs. clinic-based delivery of TB preventive therapy on completion of TB preventive therapy in South Africa: Outcomes from a randomised controlled trial (ThiPhiSA)	09:41 - 09:48
	Adrienne E. Shapiro (Seattle, United States)	
OA08-175-19	Bridging diagnostic needs in TB elimination: Evidence from a novel TB skin test SIILTBCY using <i>M. Tuberculosis</i> specific antigens	09:48 - 09:55
	Teunie Westera (Bilthoven, Netherlands)	
OA08-176-19	Clinical safety of levofloxacin for contacts of multidrug-resistant TB: Insights from the VQUIN trial	09:55 - 10:02

	Alvin Kuo Jing Teo (Sydney, Australia)	
OA08-177-19	Adherence to weekly 3HP for TB prevention among TB contacts in Uganda: A cross-sectional study Alex Kityamuwesi (Kampala, Uganda)	10:02 - 10:09
OA08-178-19	Implementing intervention strategy framework to enhance TB preventive treatment in Mansa District of Punjab, India Prabhjeet Kaur Samra (New Delhi, India)	10:09 - 10:16
	Q&A	10:16 - 10:31
<i>Symposia</i>		
	09:15 - 10:45	R2
	SY07-170-07 - Aligning priorities: Integrating TB and maternal health for better outcomes Chidimma Okoye (Abak, Nigeria) Beatrice Wangari Kirubi (Geneva, Switzerland)	
	Introduction	09:15 - 09:20
	TB and pregnancy; what we don't know and need to know Helen Cox (Melbourne, Australia)	09:20 - 09:37
	Integrating Tuberculosis Care into Maternal and Newborn Health Services in Papua New Guinea Anca Vasiliu (Houston, United States)	09:37 - 09:54
	Connecting Care: Home Visits & Screenings, Transforming TB & Pregnancy in India Kajal Taluja (Samastipur, India)	09:54 - 10:11
	Addressing the challenge of Tuberculosis among clients seeking maternal and reproductive health services in Afghanistan Ghulam Qader Qader (Kabul, Afghanistan)	10:11 - 10:28
	Q&A	10:28 - 10:45
<i>Oral Abstract Sessions</i>		
	09:15 - 10:45	R3
	OA06 - Genotypic and phenotypic resistance testing for TB Claudio Köser (Cambridge, United Kingdom) Rumina Hasan (Karachi, Pakistan)	
	Introduction	09:15 - 09:20
OA06-149-19	Phenotypic and genotypic resistance to key TB drugs in M. tuberculosis isolates from endTB-Q participants Elisa Ardizzoni (Antwerp, Belgium)	09:20 - 09:27
OA06-150-19	Comprehensive analysis of mutations associated with rifampicin and isoniazid-resistant TB in a high-burden setting Juliana Maira Watanabe Pinhata (São Paulo, Brazil)	09:27 - 09:34
OA06-151-19	FreezeTB: A fast, reliable, economical tool to zap endemic TB using nanopore targeted next generation sequencing Tara Ness (Houston, United States)	09:34 - 09:41
OA06-152-19	One-day TB diagnosis and resistance mapping with BD MAX MDR-TB and ONT AmPORE assays Andrey Golubov (Gauting, Germany)	09:41 - 09:48
OA06-153-19	Targeted next-generation sequencing - A promising approach in the diagnosis of M. tuberculosis and drug resistance Li Shi (Changsha, Hunan, China)	09:48 - 09:55

OA06-154-19	AI-enhanced detection of rifampicin or multidrug resistance in TB using MALDI-TOF lipid spectra: A novel approach to DST Minji Kang (Osong, Korea, Republic of)	09:55 - 10:02
OA06-155-19	Diagnostic performance of Sanity 2.0 to detect resistance to rifampicin, isoniazid and fluoroquinolones among people with TB Zhen Feng (Shanghai, China)	10:02 - 10:09
OA06-156-19	Improved internal quality control enhances accuracy of drug susceptibility testing in Eastern Europe and Central Asia Uladzimir Antonenka (Gauting, Germany)	10:09 - 10:16
OA06-157-19	Phenotypic drug susceptibility testing and genotypic characterisation of Bedaquiline resistance among drug-resistant <i>M. tuberculosis</i> isolates Joy Sarojini Michael (Vellore, India)	10:16 - 10:23
OA06-158-19	Determining the complete drug resistance pattern within a single day using a composite platform of BD-MAX™ MDR-TB and AmPORE TB with clinical samples Harald Hoffmann (Gauting, Germany)	10:23 - 10:23
OA06-159-19	Evaluation of the BD MAX™ and COBAS® platforms for the detection of <i>M. tuberculosis</i> and resistance to rifampicin and isoniazid in Peru Zully Puyen Guerra (Chorrillos, Peru)	10:23 - 10:30
	Q&A	10:30 - 10:45
<i>Short Oral Abstract Sessions</i>		
09:15 - 10:45		R4
SOA04 - Innovative programmatic approaches to eliminate TB		
Yana Terleieva (Kyiv, Ukraine) Manisha Yapa (Westmead, NSW, Australia)		
	Introduction	09:15 - 09:20
SOA04-534-19	Enhancement of village midwife contribution to increase coverage of TB preventive treatment (TPT) in 3 selected districts in Sumatera Utara Province, Indonesia Elvi Solita Siahaan (Medan, Indonesia)	09:20 - 09:26
SOA04-535-19	The positive impact of using riders for health in TB specimen transportation compared to health workers in Ogun State Fadeyi Muse (Ibadan, Nigeria)	09:26 - 09:32
SOA04-536-19	Overview of cross-border TB management in West and Central Africa Christ Kevin Houessinon (Cotonou, Benin)	09:32 - 09:38
SOA04-537-19	Evaluation of a low-cost digital courier monitoring system using Kobo Collect, R, and Shiny to strengthen specimen referral performance in Zambia Jonathan Mpundu Chama (Lusaka, Zambia)	09:38 - 09:44
SOA04-538-19	QR code efficiency: Transforming specimen management in laboratories Vishal Abhishek Laxmalla (Noida, India)	09:44 - 09:50
SOA04-539-19	Following TB testing: Safe disposal of molecular testing waste in Kenya John Gituma (Nairobi, Kenya)	09:50 - 09:56
SOA04-540-19	Enhancing sample transportation under National TB Elimination Programme through a cost-effective multisectoral accountability	09:56 - 10:02

	model	
	Aparna Mohan (Thiruvananthapuram, India)	
SOA04-541-19	Leveraging digital technologies to reduce service downtime and improve turnaround time of results from GeneXpert testing facilities in Southwest Nigeria	10:02 - 10:08
	Jamiu Olabamiji (Lagos state, Nigeria)	
SOA04-542-19	A comparative analysis of novel latent TB infection screening tests to drive economic gains in TB Preventive Therapy (TPT) programme in Zambia	10:08 - 10:14
	Lawrence Mwenge (Lusaka, Zambia)	
SOA04-543-19	Assessing the acceptance and effectiveness of a digital adherence technology for TB preventive treatment in Bangladesh	10:14 - 10:20
	Pushpita Samina (Ontario, Canada)	
SOA04-544-19	Estimating healthcare worker time for TB preventive treatment activities in high-burden TB-HIV countries in sub-Saharan Africa	10:20 - 10:26
	Suvesh Shrestha (Ottawa, Canada)	
SOA04-545-19	Acceptability of home-based TB prevention services by community health workers in the CHIP-TB trial	10:26 - 10:32
	Alanna Bergman (Charlottesville, United States)	
	Q&A	10:32 - 10:45
 <i>Short Oral Abstract Sessions</i>		
	09:15 - 10:45	R5
	SOA05 - Surveillance in the digital age	
	Hsien-Ho Lin (Taipei, Taiwan)	
	Justin Denholm (Melbourne, Australia)	
	Introduction	09:15 - 09:18
SOA05-546-19	The impact of early warning outbreak recognition system (EWORS) on improving finding TB in Katsina, Nigeria	09:18 - 09:24
	Innocent Tidisha Lawrence (Katsina, Nigeria)	
SOA05-547-19	Geospatial analysis and optimisation of TB diagnostic network coverage in Zambia	09:24 - 09:30
	Judith Mzyece (Lusaka, Zambia)	
SOA05-548-19	Leveraging AI for targeted TB/HIV prevention and care: Insights from the EPCON pilot in Katsina State, Nigeria	09:30 - 09:36
	Abishai Galadima (Katsina, Nigeria)	
SOA05-549-19	Next-gen TB analytics in Nigeria: AI-enhanced DHIS2 integration for smarter predictions and reporting (EPCON AI in Focus)	09:36 - 09:42
	Busayo Shokunbi (Lagos, Nigeria)	
SOA05-550-19	Impact of scaling-up an automated monitoring system, TB-Watch, on programmatic performance for TB elimination in Uttar Pradesh, India	09:42 - 09:48
	Shiv Joshi (New Delhi, India)	
SOA05-551-19	Digital transformation in TB communities: Enhancing health system responsiveness using Power BI in Telangana, India	09:48 - 09:54
	Sneha Shukla (Hyderabad, India)	
SOA05-552-19	Integrating socioeconomic determinants with monitoring TB communities: A data linkage approach to addressing TB burden and poverty in Indonesia	09:54 - 10:00
	Ferdiana Yunita (Jakarta, Indonesia)	

SOA05-553-19	Integrating genomics and digital innovation for tuberculosis surveillance in Nigeria Opeyemi Alayande (Ibadan, Nigeria)	10:00 - 10:06
SOA05-554-19	Connectivity technology monitors and reduces high test error rates reported among drug resistance TB testing in Nigeria	10:06 - 10:12
SOA05-555-19	Leveraging artificial intelligence predictive maintenance models for timely GeneXpert module replacement in TB diagnostics Tumwine Julius (Kampala, Uganda)	10:12 - 10:18
SOA05-556-19	Development of a novel digital lung auscultation annotation platform for improving artificial intelligence-powered lung sound classification algorithms: Auscultation Lab Sunaina Kapoor (Baltimore, United States)	10:18 - 10:24
SOA05-557-19	Innovative use of mobile digital chest-Xray equipped with artificial intelligence (AI) to improve TB diagnosis among PLHIV at primary health centres (PHCs) in Lagos, Nigeria Obioha Udunze (Lagos, Nigeria)	10:24 - 10:30
	Q&A	10:30 - 10:43
 <i>Oral Abstract Sessions</i>		
	09:15 - 10:45	R6
	OA07 - Diagnosing and treating drug-resistant TB Lorenzo Guglielmetti (Verona, Italy) Yousra Kherabi (PARIS, France)	
	Introduction	09:15 - 09:18
OA07-160-19	Whole genome sequencing for new and repurposed anti-TB drugs among people with drug-resistant TB in the Philippines Dessa Jean Casalme (Dasmariñas, Philippines)	09:18 - 09:25
OA07-161-19	Targeted Nanopore sequencing for early detection of heteroresistance in <i>M. tuberculosis</i> Aishwarya Babu (Manipal, India)	09:25 - 09:32
OA07-162-19	Assessing the performance of culture-free next generation sequencing for drug-resistant TB detection Ilaria Iannucci (Milan, Italy)	09:32 - 09:39
OA07-163-19	Multicentre study on the <i>M. tuberculosis</i> H37Rv reference strain using a new EUCAST-AMST reference protocol developed for MIC-determination of bedaquiline, clofazimine, delamanid and pretomanid Jim Werngren (Stockholm, Sweden)	09:39 - 09:46
OA07-164-19	Baseline and acquired resistance-associated <i>M. tuberculosis</i> variants in BPaL-based regimens Anna Bateson (London, United Kingdom)	09:46 - 09:53
OA07-165-19	Association between pre-diagnostic fluoroquinolone exposure and acquired fluoroquinolone resistance in <i>M. tuberculosis</i> in Shanghai, China: An EHR-based case-control study using whole-genome sequencing Li Danni (Shanghai, China)	09:53 - 10:00
OA07-166-19	Baseline resistance to new and repurposed anti-TB drugs in the endTB-Q clinical trial Praharsinie Rupasinghe (Antwerp, Belgium)	10:00 - 10:07
OA07-167-19	Baseline and emergent phenotypic pretomanid resistance in RR/MDR-TB patients in KwaZulu-Natal: Findings from the ADAP-	10:07 - 10:14

	TIV trial	
	Max O'Donnell (New York, United States)	
OA07-168-19	Bedaquiline, pretomanid, and linezolid resistance among rifampicin-resistant <i>M. tuberculosis</i> strains in South Africa Shaheed Vally Omar (Johannesburg, South Africa)	10:14 - 10:21
OA07-169-19	When treatment options narrow: Management of bedaquiline-resistant TB in Uzbekistan Matthew J. Saunders (London, United Kingdom)	10:21 - 10:28
OA07-170-19	Safety and efficacy of an adaptive injectable-containing regimen for rifampicin-resistant-TB: Results from the SHOORT trial in Niger Mahamadou Bassirou Souleymane (Niamey, Niger)	10:28 - 10:35
	Q&A	10:35 - 10:45
<i>Symposia</i>		
09:15 - 10:45		R7
	SY08-180-08 - Crossing borders: Addressing TB in migrant and refugee populations Tereza Kasaeva (Switzerland)	
	Introduction	09:15 - 09:20
	Innovative solutions for the elimination of TB among migrants and refugees Kerri Viney (Geneva, Switzerland)	09:20 - 09:35
	TB and drug-resistant TB in migrants and conflict-displaced populations: The experience of the MSF-TB project in Poland, responding to the Ukrainian crisis Joanna Ladamirska (Den Haag, Netherlands)	09:35 - 09:50
	Addressing cross-border TB burden: IOM experience in regular migration pathways Alexander Klosovski (Geneva, Switzerland)	09:50 - 10:05
	From Risk to Resilience: Collective Action to End TB in Humanitarian Settings Allen Gidraf Kahindo Maina (Switzerland)	10:05 - 10:20
	The Need for Rights-Based Responses on TB in Migrant and Refugee Populations Tenzin Kunor (United States)	10:20 - 10:35
	Q&A	10:35 - 10:45
<i>Short Oral Abstract Sessions</i>		
09:15 - 10:45		R8
	SOA06 - Window of opportunity: Integrated service delivery for co-morbidities Alena Skrahina (Berlin, Germany) Evgenia Geliukh (Kyiv, Ukraine)	
	Introduction	09:15 - 09:20
SOA06-558-19	Impact on patient wait times at Yala Sub-County Hospital through the integration of comprehensive care centres and TB clinics into mainstream outpatient health services Felix Oloo (Siaya, Kenya)	09:20 - 09:26
SOA06-559-19	Comorbidities, determinants and disability management in TB treatment: An observational cohort study under routine programme conditions in YiChang, China	09:26 - 09:32

	Zhu Jin (YiChang, China)	
SOA06-561-19	Enhancing TB detection in Ethiopia: Results from the Oromia TB Catch-Up Campaign Bizuneh Alemu Fetenesa (Addis Ababa, Ethiopia)	09:32 - 09:38
SOA06-562-19	Integrated service delivery for TB and non-communicable disease detection using a primary health care approach in Cambodia Sokun Chay (Phnom Penh, Cambodia)	09:38 - 09:44
SOA06-563-19	Mental health interventions in TB care: A systematic scoping review in the SAARC region Namrata Rana (Hamilton, Canada)	09:44 - 09:50
SOA06-564-19	Depression as a comorbid factor in people with TB attending the rural Government TB Hospital in Tamil Nadu, India Delfin Lovelina Francis (Chennai, India)	09:50 - 09:56
SOA06-565-19	Developing a pilot clinical and programmatic handbook on integrated service delivery of TB, community-acquired pneumonia, asthma and COPD in Nigeria Ngozi Murphy-Okpala (Enugu, Nigeria)	09:56 - 10:02
SOA06-566-19	Primary care visits: Are they a window for timely TB screening in migrants to British Columbia, Canada? Kamila Romanowski (Montreal, Canada)	10:02 - 10:08
SOA06-567-19	Innovative models for TB/HIV integrated service delivery in Osun State Oladayo Peter (Ibadan, Nigeria)	10:08 - 10:14
SOA06-568-19	Localising public-private mix: Advancing TB service integration through district government engagement in Indonesia Nurliyanti Nurliyanti (Jakarta Selatan, Indonesia)	10:14 - 10:20
SOA06-569-19	Pharmacy engagement through hub and spoke model for finding the missing people with TB: An experience from four major cities of Nepal Bijay Maharjan (Kathmandu City, Nepal)	10:20 - 10:26
	Q&A	10:26 - 10:39
 <i>Community Connect Sessions</i>		
	10:00 - 11:00	CC
CCS008 - Trust, tools and TB: Community-led solutions for local challenges		
Apoorva Murali (India) Prachi Shukla (India)		
	Introduction	10:00 - 10:02
	Trust, tools and TB: Community-led solutions for local challenges Ramya Ananthakrishnan (Chennai, India) Mohan Harnalli Lakkappa (India) Aparna Chaudhary (New Delhi, India) Miranda Brouwer (Haren, Netherlands)	10:02 - 10:30
	Question and answers	10:30 - 10:45
 <i>Break</i>		
	10:45 - 11:00	Main
Break/Networking		

Plenary Sessions

11:00 - 12:00

Main

PL02 - Diagnostic and antibiotic stewardship

Rumina Hasan (Karachi, Pakistan)

Nazir Ismail (Johannesburg, South Africa)

Introduction

11:00 - 11:05

Genotypic and phenotypic drug susceptibility testing methods for MTBC

11:05 - 11:20

Claudio Köser (Cambridge, United Kingdom)

TB drug regimen design and optimal dosing

11:20 - 11:35

Rada Savic (San Francisco, United States)

Towards clinical breakpoints for NTMs

11:35 - 11:50

Thomas Schön (Kalmar, Sweden)

Panel discussion with Q&A

11:50 - 12:00

Break

12:00 - 14:10

Main

Break/Networking

TBScience E-Poster Sessions

12:00 - 13:00

TBS-EP-03 - TBScience Moderated E-posters III

Cecilia Lindestam Arlehamn (Copenhagen, Denmark)

TBS-EP92

Features of lesions on PET-CT predict progression from subclinical TB to symptomatic TB disease, but interferon gamma release assays do not

12:00 - 12:05

Stephanus Malherbe (Cape Town, South Africa)

TBS-EP95

The expansion of an immune-evasive Mycobacterium tuberculosis subclade of lineage 2 in Lima, Peru

12:05 - 12:10

Chuan-Chin Huang (Boston, United States)

TBS-EP101

Improving the efficiency of drug resistant tuberculosis treatment trials: A time-to-event alternative marker for bacteriological response and adaptive minimization for randomization

12:10 - 12:15

Annelies Van Rie (Antwerp, Belgium)

TBS-EP104

Assessment of effect of weight on pyrazinamide pharmacokinetics in support of flat dosing in adults with TB

12:15 - 12:20

Sejung Hwang (San Francisco, United States)

TBS-EP107

Impact of nutritional support on transcriptomics of persons with latent tuberculosis infection: Why does nutritional support prevent TB?

12:20 - 12:25

Evan Johnson (Newark, United States)

TBS-EP110

Bioanalytical strategies to support the development of novel anti-TB drug regimens

12:25 - 12:30

Enaksha Wickremsinhe (Cambridge, United States)

TBS-EP113

Genotypic-phenotypic discordance and emerging drug resistance in rifampicin-resistant extrapulmonary tuberculosis

12:30 - 12:35

Manu Singh (Lucknow, India)

TBS-EP116

Urine LAM quantification using ultrasensitive single-molecule counting technology: A novel approach for improved tuberculosis diagnosis and treatment monitoring

12:35 - 12:40

Steven Tan (Sunnyvale, United States)

TBS-EP119	Development of a CRISPR-Cas13a based SNP assay for detection of bedaquiline resistance in <i>Mycobacterium tuberculosis</i> Michael Kim J. R. Mendoza (Manila, Philippines)	12:40 - 12:45
TBS-EP26	Single-cell RNA sequencing of cerebrospinal fluid in HIV-associated tuberculous meningitis James R Barnacle (London, United Kingdom)	12:45 - 12:50
TBS-EP27	Q&A	12:50 - 13:00
<i>E-Posters</i>		
12:05 - 13:05		B1A
EP10 - Enhanced TB detection: Integrating digital radiography with other tools Morten Ruhwald (Copenhagen, Denmark)		
EP10-790-19	A decade of impact: How the South African TB Think Tank transforms evidence to policy and programming Mthokozisi Dube (Johannesburg, South Africa)	12:05 - 12:10
EP10-792-19	Comparative study of computer aided detection CXR AI threshold scores across TB diagnostic platforms in North Central Nigeria David Atuwu (Auta Balefi, Nigeria)	12:10 - 12:15
EP10-793-19	Chest X-ray AI scores guide pooled testing to increase access to rapid molecular testing for TB in communities in Cameroon Ngha Ndze Mbuh (Bamenda, Cameroon)	12:15 - 12:20
EP10-794-19	AI-assisted chest radiograph analysis for TB screening in mobile diagnostic units: Experience from a High TB-burden country, India Asha Frederick (Chennai, India)	12:20 - 12:25
EP10-795-19	Impact of mobile TB clinics with digital X-ray, CAD4TB, and Xpert MTB/RIF/Ultra on same-day TB diagnosis and treatment initiation: Insights from Uganda Alex Mulindwa (Kampala, Uganda)	12:25 - 12:30
EP10-796-19	Pairing artificial intelligence (AI) with WHO-recommended rapid molecular diagnostics (mWRDs) in community settings: Targeted screening and early diagnosis for improved tuberculosis (TB) notification Shalom Balogun (Abuja, Nigeria)	12:30 - 12:35
EP10-797-19	Monthly portable digital X-ray screening to combat tuberculosis burden in New Katsina Prison: A scalable model for prisons Suleiman Bello (Katsina, Nigeria)	12:35 - 12:40
EP10-798-19	Evaluating diagnostic yield of a numeric CAD score to triage mWRD negative patients for repeat mWRD testing in a rural Indian ACF programme Bornali Datta (New Delhi, India)	12:40 - 12:45
	Q&A	12:45 - 13:05
<i>E-Posters</i>		
12:05 - 13:05		B1B
EP11 - From mines to clinics, securing lung health in high-risk occupations Janika Hauser (London, United Kingdom)		
EP11-799-19	From awareness to action: Workplace initiative for TB screening and care Hellen Auma (Kampala, Uganda)	12:05 - 12:10
EP11-800-19	Epidemiology and statistical analysis of occupational health risks: Implications for workplace safety and worker well-being	12:10 - 12:15

	Isaac Sarkodie (Novi Sad, Serbia)	
EP11-801-19	TB among healthcare workers in Zambia: A trend analysis 2018-2022 Jonathan M CHAMA (Lusaka, Zambia)	12:15 - 12:20
EP11-803-19	Impactful collaborations: Multi-sector engagement and accountability for TB free workplace in a mining predominant district of Karnataka, India Hamsaveni G (New Delhi, India)	12:20 - 12:25
EP11-804-19	Artisanal and small-scale miners' perceptions on targeted TB and occupational health screening programme in Zimbabwe Akanksha Mimi Malhotra (Liverpool, Zimbabwe)	12:25 - 12:30
EP11-805-19	Effectiveness of TB treatment in individuals exposed to silica or with silicosis: A systematic review Rodney Ehrlich (Cape Town, South Africa)	12:30 - 12:35
EP11-806-19	Reaching behind bars: Mobile TB van initiative for central region district prison TB eradication in Malawi Peter Chimalizeni (Lilongwe, Malawi)	12:35 - 12:40
EP11-808-19	Radiation protection and safety of end users of the portable digital X-ray (PDX) machines for TB screening in Nigeria: Experience of KNCV Nigeria Eze Chukwu (Abuja, Nigeria)	12:40 - 12:45
	Q&A	12:45 - 13:05
<i>E-Posters</i>		
	12:05 - 13:05	B1C
EP12 - Leveraging AI across the TB care cascade: From hotspot detection to treatment success		
Yacine Mar Diop (Dakar, Senegal)		
EP12-809-19	Leveraging eCBSS data for geospatial mapping of TB hotspots and optimising the integrated TB case finding (CAST+) intervention in Eastern Uganda Louis Ocen (Kampala, Uganda)	12:05 - 12:10
EP12-810-19	AI-powered vulnerability mapping for TB as a guiding tool for active case-finding activities Aparna Chaudhary (New Delhi, India)	12:10 - 12:15
EP12-811-19	Effectiveness of systematic screening of TB amongst key vulnerable populations using AI-enabled X-ray machines in Lagos State, Nigeria Adebayo Opeyemi (Abuja, Nigeria)	12:15 - 12:20
EP12-812-19	Leveraging AI to enhance TB detection among asymptomatic individuals: A comparative analysis from community screening in Ladakh, India Praveen Kumar Yadav (New Delhi, India)	12:20 - 12:25
EP12-813-19	Using artificial intelligence software to improve TB screening efficiency: Comparison between intensified case finding in public facilities and the wow interventions in Kano State, Nigeria Joshua Jacob (Bauch, Nigeria)	12:25 - 12:30
EP12-814-19	Impactful use of handheld X-ray device for reaching the unreached population of tribal district Nandurbar in Maharashtra, India Aniruddha Kadu (New Delhi, India)	12:30 - 12:35
EP12-815-19	Bridging diagnostic gaps in rural Nigeria: The role of AI-supported PDX-CAD in TB detection	12:35 - 12:40

	Eziashi Emmanuel Ajumuka (Abuja, Nigeria)	
EP12-816-19	Evaluating diagnostic accuracy and cost-effectiveness of AI-based CAD (QURE) for TB screening in Guinea Aoubacar Sidiki Magassouba (Conakry, Guinea)	12:40 - 12:45
EP12-817-19	Using AI to improve reported treatment adherence under the National TB Elimination Programme (NTEP) in India Aparna Chaudhary (New Delhi, India)	12:45 - 12:50
EP12-818-19	Outcomes of TB screening of immigrants using AI-enabled digital X-rays at the Lagos-Abidjan corridor Amavie Oboku (Lagos, Nigeria)	12:50 - 12:55
	Q&A	12:55 - 13:05
<i>E-Posters</i>		
12:05 - 13:05		B1D
EP13 - Electrifying TB: Using digital tools across the care cascade		
Guy Stallworthy (United States)		
EP13-819-19	Implementation of the TB electronic monitoring system in Uganda Mabel Nakawooya (Kampala, Uganda)	12:05 - 12:10
EP13-820-19	Enhancing TB prevention and care in Maharashtra: Insights from Expand ELEVATE project through automated data analysis Deepak Balasubramanian (New Delhi, India)	12:10 - 12:15
EP13-821-19	Improving DHIS2 TB data quality across regions in Uganda Mabel Nakawooya (Kampala, Uganda)	12:15 - 12:20
EP13-822-19	Digitising TB care: Advancing person-centred approaches through T-bu Lite in Nakuru County, Kenya Gregory Onyango (Nairobi, Kenya)	12:20 - 12:25
EP13-823-19	Integrated genomic and epidemiological surveillance of TB in Germany, 2020-2024: Results from three cities Teresa Domaszewska (Berlin, Germany)	12:25 - 12:30
EP13-824-19	Advancing TB monitoring: Digitalisation of Nepal's National Tuberculosis Programme Naveen Prakash Shah (Thimi, Bhaktapur, Nepal)	12:30 - 12:35
EP13-826-19	Enhancing timely monitoring and follow-up of drug-resistant TB: Implementing a digital laboratory information system in Uganda Joel Kabugo (Kampala, Uganda)	12:35 - 12:40
EP13-827-19	Multi-country consortium data systems - setup, challenges, and solutions: A case study of the Start4All initiative Olusegun Michael Akinwande (Liverpool, United Kingdom)	12:40 - 12:45
EP13-828-19	Optimising electronic medical records to strengthen TB/HIV service delivery: A multi-phase redesign and evaluation of impact in Southern Nigeria Emeka Ezieke (Uyo, Nigeria)	12:45 - 12:50
	Q&A	12:50 - 13:05
<i>E-Posters</i>		
12:05 - 13:05		B1E
EP14 - Enhancing TB diagnosis and case finding among children		
Norbert Heinrich (Munich, Germany)		
EP14-829-19	Enhancing childhood TB detection in Bangladesh: The role of	12:05 - 12:10

	government hospitals and strategic screening initiatives F. M. Monirul Haque (Dhaka, Bangladesh)	
EP14-830-19	Leveraging community-based models and private sector engagement to improve paediatric TB detection in Sokoto State, Nigeria Saminu Msheliza (Abuja, Nigeria)	12:10 - 12:15
EP14-831-19	Advancing TB detection in children with stool test: KNCV Nigeria experience Nkiru Nwokoye (Abuja, Nigeria)	12:15 - 12:20
EP14-832-19	Exploring role of CXR CAD for paediatric TB detection: A retrospective evaluation of CXR CAD performance in children and adolescents in Myanmar Thet Maung (Yangon, Myanmar)	12:20 - 12:25
EP14-833-19	Treatment decision algorithms to detect paediatric pulmonary TB in unstable settings: Experience in South Sudan Lazro Fidelle Nyikayo (Malakal, South Sudan)	12:25 - 12:30
EP14-834-19	Traditional birth attendants are major contributors to finding childhood TB: Comparative analysis of childhood TB case-finding across TB LON 3 interventions in Oyo State Anderson Ricketts (Ibadan, Nigeria)	12:30 - 12:35
EP14-835-19	Overcoming barriers to childhood TB detection: Scaling up childhood TB case detection through integrated facility and community-based interventions in Niger State, Nigeria Dauda Samuel Hananiya (Minna, Nigeria)	12:35 - 12:40
EP14-836-19	Innovative approach to finding missing child TB cases in Nigeria: An account of the national child TB testing week Obioma Chijioke-Akaniro (Abuja, Nigeria)	12:40 - 12:45
EP14-837-19	Assessing CAD performance in detecting TB in paediatric chest radiographs Zhi Zhen Qin (Geneva, Switzerland)	12:45 - 12:50
EP14-838-19	The current landscape of artificial intelligence-assisted chest radiography for paediatric TB: A scoping review Irina Aulianisa (Seoul, Korea, Republic of)	12:50 - 12:55
	Q&A	12:55 - 13:05
 <i>E-Posters</i>		
	12:05 - 13:05	B1F
	EP15 - Prevent to end: Catalysing implementation of TB preventive treatment Harald Hoffmann (Gauting, Germany)	
EP15-839-19	India's experience of programmatic implementation of TPT for contacts of people with drug-resistant Radha Taralekar (New Delhi, India)	12:05 - 12:10
EP15-840-19	Opportunities for optimising routine delivery of TB preventive treatment for people living with HIV in high-burden TB settings Lucy Chimoyi (Johannesburg, South Africa)	12:10 - 12:15
EP15-841-19	TPT refusal rates and barriers among people who are HIV-negative TB contacts aged 5 years and above Lilungwe Mutti (Lusaka, Zambia)	12:15 - 12:20
EP15-842-19	Scaling up TB preventive treatment: Expanding coverage to all age groups, including people without HIV Md. Toufiq Rahman (Geneva, Switzerland)	12:20 - 12:25

EP15-843-19	Safety and hepatotoxicity profile of 3HP for TB preventive therapy among people living with HIV in Uganda Allan Kengo (Kampala, Uganda)	12:25 - 12:30
EP15-844-19	Improving systematic TPT prescription using QuantiFERON®-TB Gold test results in Ukraine Gunta Dravniece (Kyiv, Ukraine)	12:30 - 12:35
EP15-846-19	Attrition among people with TB from contact screening until TB preventive therapy initiation: Programmatic challenges and bottlenecks in high-burden TB settings Sobia Faisal (Islamabad, Pakistan)	12:35 - 12:40
EP15-847-19	Identifying missed opportunities in tuberculosis preventive treatment care cascade: Analysis of programme data from Maharashtra, India Anuj Mundra (Wardha, India)	12:40 - 12:45
	Q&A	12:45 - 13:05
<i>E-Posters</i>		
12:05 - 13:05		B1G
EP16 - Finding the missing people with TB: Lessons learned from and across Nigeria		
Mustapha Gidado (Den Haag, Netherlands)		
EP16-848-19	Unintended gains: How childhood TB awareness campaigns boosted adult TB case finding P Alu (Lagos, Nigeria)	12:05 - 12:10
EP16-849-19	Optimizing tuberculosis (TB) screening services using innovative strategies: Insights from TB LON 1&2 project implementation in Bauchi State, Nigeria Habusafwan Ibrahim (Bauchi, Nigeria)	12:10 - 12:15
EP16-850-19	Optimizing TB active case finding in Nigeria: Comparative analysis of screening models across four States Murna Yashim-Ankut (Abuja, Nigeria)	12:15 - 12:20
EP16-851-19	Revolutionizing tuberculosis case finding in rural Nigeria: Unleashing the power of digital innovation and community engagement Chimezie Dimkpa (Bauchi, Nigeria)	12:20 - 12:25
EP16-852-19	Community-driven approach to improve tuberculosis case detection: Experience from AMAC'A', Federal Capital Territory, Nigeria Obioma Ekwueme (Abuja, Nigeria)	12:25 - 12:30
EP16-853-19	Boosting tuberculosis case finding in Nasarawa state, Nigeria through strong partnerships with community-based organizations and community stakeholders Chijioke Osakwe (Mararaba, Nigeria)	12:30 - 12:35
EP16-854-19	Early experiences from the large-scale deployment of portable digital X-rays for active TB screening in Nigeria Micheal Sheshi (Abuja, Nigeria)	12:35 - 12:40
EP16-855-19	Experiences with chest X-ray mobile vans and artificial intelligence software in TB screening and diagnosis at hard-to-reach areas in Lagos Nigeria Taiwo Osatuyi (Lagos, Nigeria)	12:40 - 12:45
EP16-856-19	Sustained impact of active community case finding on tuberculosis detection and notification trends in Benue State, Nigeria: A 13-year comparative analysis (2010-2023)	12:45 - 12:50

	Oluchukwu Odume (Makurdi, Nigeria)	
EP16-857-19	Eliminating missed diagnoses: Expanding TB/HIV testing for pregnant women in high-burden communities in Katsina State, Nigeria Patrick Batur (Katsina, Nigeria)	12:50 - 12:55
EP16-858-19	One goal, many paths: Transforming TB case finding through multi-sector approaches in Nigeria Olugbenga Daniel (Ikeja, Nigeria)	12:55 - 13:00
	Q&A	13:00 - 13:05
<i>E-Posters</i>		
12:05 - 13:05		B1H
EP17 - Improving diagnostic yield for TB: Methods and innovations		
Frederick Quinn (Athens, United States)		
EP17-859-19	High diagnostic yield of sputum and non-sputum tuberculosis tests in an emergency centre in Cape Town, South Africa Ananja van der Westhuizen (Cape Town, South Africa)	12:05 - 12:10
EP17-860-19	Analyzing the effect of demographic factors on Xpert positivity and cycle threshold values in tuberculosis testing Timan Taryuta Eliya (Karu, Nigeria)	12:10 - 12:15
EP17-861-19	Who, what, and how much: Sputum scarcity amongst people requiring tuberculosis testing across multiple countries Welile Nwamba (Cape Town, South Africa)	12:15 - 12:20
EP17-862-19	Enhancing tuberculosis microscopy diagnosis and external quality assurance using telepathology in Kenya: A case of Meru County James Magiri (Nairobi, Kenya)	12:20 - 12:25
EP17-863-19	Incremental yield of the addition of tongue swab to sputum molecular testing for tuberculosis in South African adult primary healthcare clinic attendees Rebecca Berhanu (Johannesburg, South Africa)	12:25 - 12:30
EP17-864-19	Use of TB-LAMP assay for active case finding of pulmonary tuberculosis in Nepal Bijay Maharjan (Kathmandu City, Nepal)	12:30 - 12:35
EP17-865-19	Evaluating optimal functionality of the GeneXpert machine as a point-of-care diagnostic tool for tuberculosis in Nigeria: Lessons from KNCV, Cepheid Authorized Service Provider Christopher Ehimanre (Abuja, Nigeria)	12:35 - 12:40
EP17-866-19	Evaluating the cost-effectiveness of integrating TB LAMP and GeneXpert for tuberculosis diagnosis in Kaduna State, Nigeria Chinenye Igwetu (Federal Capital Territory, Nigeria)	12:40 - 12:45
EP17-867-19	A prospective multicentre diagnostic accuracy study of the Truenat MTB Plus/COVID-19 assay for simultaneous detection of TB and COVID-19 Adam Penn-Nicholson (Geneva, Switzerland)	12:45 - 12:50
EP17-868-19	Improving performance and efficiency through digital platforms: The Accelerated Implementation Methodology (AIM 250) experience in Kano State, Nigeria Abdulmutalib Bello (Kano, Nigeria)	12:50 - 12:55
	Q&A	12:55 - 13:05

E-Posters

12:05 - 13:05

B11

EP18 - PLHIV - the continuum of TB care (prevention, diagnosis, treatment and post-treatment)

Sean Wasserman (London, United Kingdom)

Jayne Ellis (London, United Kingdom)

EP18-869-19	Universal TB testing with simultaneous TPT prescribing among people living with HIV in South Africa Neil Martinson (Soweto, South Africa)	12:05 - 12:10
EP18-870-19	Effect of secondary tuberculosis preventive therapy on posttreatment outcomes of people with HIV in Uganda Shafic Makumbi (Kampala, Uganda)	12:10 - 12:15
EP18-871-19	Kynurenine-to-tryptophan ratio is a suitable blood-based screening tool for active tuberculosis in pregnant women living with HIV Clement Gascua Adu-Gyamfi (Johannesburg, South Africa)	12:15 - 12:20
EP18-872-19	Diagnostic accuracy of point-of-care ultrasound for tuberculosis disease among inpatients with HIV: A prospective cohort study in Ghana Johanna Åhsberg (Odense, Denmark)	12:20 - 12:25
EP18-873-19	People living with HIV have increased plasmacytoid dendritic cells and systemic inflammation if they have history of pulmonary TB Kathryn Dupnik (New York, United States)	12:25 - 12:30
EP18-874-19	Implementing data linkage to qualify trends of unfavorable TB-HIV outcomes in Brazil (2013-2023) Luiza Harada (Brasília, Brazil)	12:30 - 12:35
EP18-875-19	Integrating self-care into TB-HIV management: Addressing mental health challenges for persons infected with TB-HIV co-morbidities in Kano State, Nigeria Jane Adizue (Federal Capital Territory, Nigeria)	12:35 - 12:40
EP18-876-19	Predictors of post tuberculosis treatment mortality among people living with HIV: An observational cohort study, Andhra Pradesh, India, 2024 Ramesh Allam (Delhi, India)	12:40 - 12:45
	Q&A	12:45 - 13:05

Satellite Sessions

12:15 - 13:45

R1

SS04 - Long-Acting TB Regimens and the Future of Treatment

Debra Flood (United States)

Norbert Ndjeka (South Africa)

	Welcome and introduction	12:15 - 12:20
	Unlocking the Promise: How long-acting regimens could transform the path to TB elimination Fuad Mirzayev (Geneva, Switzerland)	12:20 - 12:30
	Community first: Communicating the value of long-acting TB treatments Uvistra Naidoo (Austria)	12:30 - 12:40
	Toward transformative TB treatment: Scientific frontiers—and challenges—for LAIs Rajneesh Taneja (United States)	12:40 - 12:50
	Bridging experience: Shaping clinical development pathways for long-acting TB regimens	12:50 - 13:00

	Cissy Kityo Mutuluuza (Uganda)	
	Financing the future: Building the case for investment in long-acting TB solutions	13:00 - 13:10
	Grania Brigden (Switzerland)	
	Panel Discussion on Advancing LAIs for TB Treatment	13:10 - 13:30
	Q&A	13:30 - 13:40
	Closing remarks and reflections	13:40 - 13:45
<i>Side Meetings</i>		
12:30 - 13:30		R2
	TB infection control working group	
<i>Side Meetings</i>		
12:30 - 13:30		R3
	Europe Region	
<i>Side Meetings</i>		
12:30 - 13:30		R4
	North America Region	
<i>Side Meetings</i>		
12:30 - 13:30		R5
	South East Asia Region	
<i>Side Meetings</i>		
12:30 - 13:30		R6
	Middle East Region	
<i>Side Meetings</i>		
12:30 - 13:30		R7
	Maternal and child TB working group	
<i>Side Meetings</i>		
12:30 - 13:30		R8
	Asia Pacific Region	
<i>TBScience E-Poster Sessions</i>		
13:05 - 14:05		
	TBS-EP-04 - TBScience Moderated E-posters IV	
	Annelies Van Rie (Antwerp, Belgium)	
TBS-EP122	Breaking the TB Cycle: AI-driven mobile X-ray screening with CAD4TB enhances early detection in high-risk coal mining communities of Punjab, Pakistan	13:05 - 13:10
	Qasim Mehmood (Lahore, Pakistan)	
TBS-EP125	Treatment of chronic pulmonary cavitary aspergillosis using an endobronchial valve and local antifungal therapy	13:10 - 13:15
	Anastasiya Gaida (Moscow, Russian Federation)	
TBS-EP128	Diagnostic accuracy of a novel high-sensitivity urine LAM assay	13:15 - 13:20
	Alfred Andama (Kampala, Uganda)	

TBS-EP131	Host and pathogen diversity influence the efficacy of tyrosine kinase inhibitor-based host-directed therapies in tuberculosis Leopold D. Tientcheu (Banjul, Gambia)	13:20 - 13:25
TBS-EP134	Nitroimidazole resistance amongst people with tuberculosis: A meta-analysis of prevalence and genotypic-phenotypic concordance Camus Nimmo (London, United Kingdom)	13:25 - 13:30
TBS-EP137	Diagnostic performance of a new near-point-of-care assay to detect TB from tongue and sputum swabs Cyrille Mbuli (Bamenda, Cameroon)	13:30 - 13:35
TBS-EP140	A multi-arm multi-stage trial design using desirability of outcome ranking and stratified medicine for MDR-TB Vera Hsu (San Francisco, United States)	13:35 - 13:40
TBS-EP143	Machine learning of plasma multi-omics data distinguishes pulmonary tuberculosis from other respiratory infections Zaynab Mousavian (Atlanta, GA, United States)	13:40 - 13:45
TBS-EP146	Field Deployment of a TB-Mobile Diagnostic System (TB-MDS) for Latent Tuberculosis Infection (LTBI) detection in Resource-limited Setting Xiang Yang (Guangzhou, China)	13:45 - 13:50
TBS-EP149	Comparing early outcomes of BPaL-L and 9-month regimens for drug-resistant tuberculosis in South Africa Yulene Kock (Pretoria, South Africa)	13:50 - 13:55
TBS-EP150	Q&A	13:55 - 14:05

E-Posters

13:10 - 14:10

B1A

EP19 - Adult lung - burden and care of lung conditions

Simon Tiberi (London, United Kingdom)

Jeremiah Chakaya (Nairobi, Kenya)

EP19-878-19	Clinico-radiological spectrum of respiratory post-acute COVID-19 in adults in Lusaka, Zambia: A cross-sectional study Lobina Kajimanga (Lusaka, Zambia)	13:10 - 13:15
EP19-879-19	Determinants of COVID-19 mortality and temporal trends according to the health regions of São Paulo, Brazil Ricardo Alexandre Arcencio (Ribeirão Preto, Brazil)	13:15 - 13:20
EP19-880-19	Influence of pneumopathy on the survival of people with COVID-19 in Brazil (2021-2024) Ricardo Alexandre Arcêncio (Ribeirão Preto, Brazil)	13:20 - 13:25
EP19-881-19	What is it if it's not TB? Infections causing a similar clinical picture and their morbidity and mortality Stefan Fabian Weber (Heidelberg, Germany)	13:25 - 13:30
EP19-882-19	Prevalence and clinical implications of <i>Aspergillus</i> infection in a Peruvian TB cohort Alicia E. Madden (Boston, United States)	13:30 - 13:35
EP19-883-19	Adopting an integrated approach to lung health: A case study in Murang'a County, Kenya Lucy Irungu (Nairobi, Kenya)	13:35 - 13:40
EP19-884-19	Metabolic disorders and clinical outcomes in AECOPD: A multi-centre cohort study Jiaqi Pu (Chengdu, China)	13:40 - 13:45

EP19-885-19	Strengthening chronic respiratory diseases detection through a targeted Moonlight Outreach in Muthurwa, Nairobi, Kenya Sharon Olwande (Nairobi, Kenya)	13:45 - 13:50
EP19-886-19	Assessing integrated lung health services in selected primary healthcare facilities (PHC) in North-Central Nigeria: Findings from a 2023-2024 pre-implementation baseline survey Kenneth Ojobor (Minna, Nigeria)	13:50 - 13:55
EP19-887-19	Factors associated with increased mortality among people with lung cancer in Tanzania and Uganda Grace Isaac Soka (Dar Es Salaam, Tanzania)	13:55 - 14:00
EP19-888-19	Detection to neglect: Gaps in care for non-TB lung conditions revealed by integrated chest X-ray screening in underserved communities in Nigeria James Ngbede Ekwu (Karu, Nigeria, Nigeria)	14:00 - 14:05
	Q&A	14:05 - 14:10
<i>E-Posters</i>		
13:10 - 14:10		B1B
EP20 - Messaging that matters: Effective communication for TB elimination Priyanka Aiyer (Delhi, India)		
EP20-889-19	Could content creation be the hope of TB diagnosis? Insights from KNCV Nigeria's Wellness on Keke initiative Kelvin Anadi (Abuja, Nigeria)	13:10 - 13:15
EP20-890-19	360-degree communication campaign to mobilize communities to undergo early testing for Tuberculosis in India Ashish Bhardwaj (New Delhi, India)	13:15 - 13:20
EP20-891-19	Bridging the TB knowledge gap: The impact of media in Himachal Pradesh, India Sunil Savita (Shimla, India)	13:20 - 13:25
EP20-892-19	Organizing site visits for journalists to provide firsthand, experiential insight into TB program interventions Srikanth Ravishanker (New Delhi, India)	13:25 - 13:30
EP20-893-19	From silence to strength: A 100-day tuberculosis-awareness drive utilizing community radio, newspapers, and television broadcasts under IMPACT-India in Chandigarh Union Territory (UT) and Punjab, India Ramesh Dasari (Hyderabad, India)	13:30 - 13:35
EP20-894-19	Smartphone and social media use among people living with tuberculosis: A key for less resource intensive IEC Abhay Kadam (Pune, India)	13:35 - 13:40
EP20-895-19	Tuberculosis education and communication in the digital era: Mixed-methodology study to assess perspectives of healthcare professionals and other stakeholders Aniruddha Kadu (New Delhi, India)	13:40 - 13:45
EP20-896-19	Barriers and facilitators of tuberculosis treatment among Cameroon refugees in Nigeria: A mixed-methods study Suraj Abdulkarim (Gombe, Nigeria)	13:45 - 13:50
EP20-897-19	Effect of community awareness, screening, diagnosis, and treatment campaigns on TB care in Uganda Ronald Mulebeke (Kampala, Uganda)	13:50 - 13:55
EP20-898-19	Enhancing TB treatment: Developing and evaluating Spanish-	13:55 - 14:00

	language LLM chatbots for real-time support, accuracy, and empathy	
	Sarah Iribarren (Seattle, United States)	
	Q&A	14:00 - 14:10
<i>E-Posters</i>		
13:10 - 14:10		B1C
	EP21 - TB contact screening across the age spectrum	
	Maryline Bonnet (Montpellier, France)	
EP21-899-19	Active tuberculosis in household contacts of central Ethiopia: Whole genome sequencing based genomic diversity, transmission dynamics and drug resistance pattern analysis	13:10 - 13:15
	Getachew Abegaz (Addis Ababa, Ethiopia)	
EP21-900-19	Application of RNA sequencing in school tuberculosis outbreak response: A nested case-control study in Shanghai, China	13:15 - 13:20
	Xiao Xiao (Shanghai, China)	
EP21-901-19	Reasons for non-enrollment of household contacts in a multinational MDR-TB preventive treatment clinical trial	13:20 - 13:25
	Savita Kanade (Pune, India)	
EP21-902-19	Perceptions of universal TB testing among persons with TB and household contacts in Lesotho, South Africa and Tanzania	13:25 - 13:30
	Manthomeng Matete (Maseru, Lesotho)	
EP21-903-19	Resilient TB contact tracing amid crisis: Evaluating household-based screening during the COVID-19 pandemic	13:30 - 13:35
	Amanda Brumwell (Seattle, United States)	
EP21-904-19	Scoring the silent threat: Age-specific risk models for pediatric TB contacts	13:35 - 13:40
	Meredith Brooks (Boston, United States)	
EP21-905-19	Chest X-ray operational barriers in school-based pulmonary tuberculosis screening in China: A cross-sectional study	13:40 - 13:45
	Bo Wu (Chongqing, China)	
EP21-906-19	Evaluating the impact of clinical contact tracing on tuberculosis case finding and preventive treatment in Lagos State, Nigeria: A pilot study	13:45 - 13:50
	P Alu (Lagos, Nigeria)	
EP21-907-19	Strain discordance among household index-secondary patient pairs with tuberculosis disease	13:50 - 13:55
	Martha Chipinduro (Harare, Zimbabwe)	
	Q&A	13:55 - 14:05
<i>E-Posters</i>		
13:10 - 14:10		B1D
	EP22 - The challenge of extrapulmonary TB	
	Sven Hoffner (Stockholm, Sweden)	
EP22-908-19	Clinical profile and outcomes of children with tuberculous meningitis at Kenyatta National Hospital: A six-year retrospective study	13:10 - 13:15
	Joy Masinde (Nairobi, Kenya)	
EP22-909-19	Long-term survival and prognostic determinants of tuberculous meningitis in a high-migration metropolis: A decade-long bidirectional cohort study	13:15 - 13:20

	Liang Fu (Shenzhen, China)	
EP22-910-19	GeneXpert (Xpert MTB/RIF) testing of extrapulmonary samples in Nepal: A five-year trends analysis from the National Tuberculosis Program Naveen Prakash Shah (Thimi, Bhaktapur, Nepal)	13:20 - 13:25
EP22-911-19	Extrapulmonary tuberculosis in the Netherlands (1993-2022): Localization patterns and treatment outcomes Frouke Procee (Amsterdam, Netherlands)	13:25 - 13:30
EP22-912-19	Beyond the lungs: Extrapulmonary tuberculosis as a risk for TB deaths in faith based health facilities in Kampala, Uganda (2020-2023) Louis Ocen (Kampala, Uganda)	13:30 - 13:35
EP22-914-19	Tuberculosis-related sepsis is associated with increased in-hospital mortality across Universal Vital Assessment mortality risk score groups in adults in Mbarara, Uganda Megan Null (Charlottesville, Uganda)	13:35 - 13:40
EP22-915-19	Lung versus genital symptoms: Which better predicts female genital tuberculosis? Dzerlina Syanaiscara Rahari (Hat Yai, Thailand)	13:40 - 13:45
EP22-916-19	Prevalence and associated factors of active tuberculosis among IGRA-negative population Cheng Li Bei (ChangSha, China)	13:45 - 13:50
	Q&A	13:50 - 14:10
<i>E-Posters</i>		
13:10 - 14:10		B1E
EP23 - Unravelling Progress: The fallout of donor funding and accountability		
Blessina Kumar (New Delhi, India)		
EP23-917-19	Impact of USAID funding suspension on TB case detection in Cambodia: A critical setback Sok Chamreun Choub (Phnom Penh, Cambodia)	13:10 - 13:15
EP23-918-19	Enhancing performance management and accountability in TB program implementation: The AIM 250 experience Ruth Ogbonna (Lafia, Nigeria)	13:15 - 13:20
EP23-919-19	Leveraging the Multi-Sectoral Accountability Framework to accelerate TB elimination in Uganda: Political commitment, policy integration, and cross-sector collaboration Nelson Modi (Kampala, Uganda)	13:20 - 13:25
EP23-920-19	Development of a multistakeholder accountability framework for tuberculosis control: A case study from Liberia Fakhra Ikhlaq (Birmingham, United Kingdom)	13:25 - 13:30
EP23-921-19	Volatile funding in fight to tuberculosis: Dilemma in LMICs - Bangladesh context Md Ferdous Wahid (Dhaka, Bangladesh)	13:30 - 13:35
EP23-922-19	Health financing - The two-year planning cycle, simplified planning formats and conditionality-based incentives in India's TB program. Innovation from India Vigneshwaran Somasundaram (New Delhi, India)	13:35 - 13:40
EP23-923-19	Rethinking the TB funding landscape in Pakistan: From donor dependency to domestic leadership Shifa Salman Habib (Karachi, Pakistan)	13:40 - 13:45

EP23-924-19	TB funding in Nigeria: The politics of resource allocation, donor dependence, and accountability challenges Victor Abel (Abuja, Nigeria)	13:45 - 13:50
	Q&A	13:50 - 14:00
<i>E-Posters</i>		
13:10 - 14:10		B1F
EP24 - Frontiers in immunology and biomarkers - infection, disease risk and treatment monitoring		
Kathrin Held (Munich, Germany)		
EP24-925-19	Impact of maternal helminth infection and MTB exposure on neonatal IgE, maternal and neonatal IgG immune profiles Meaza Zewde (Addis Ababa, Ethiopia)	13:10 - 13:15
EP24-926-19	Regulation of TIM-3 expression in macrophages by IκBζ during Mycobacterium tuberculosis infection: Mechanisms and functional implications Yayan Niu (Suzhou, China)	13:15 - 13:20
EP24-927-19	Biomarkers for Asymptomatic TB Diagnostosis Mahlatse Maseeme (Durban, South Africa)	13:20 - 13:25
EP24-928-19	Lens-free shadow imaging technology-based quantification of T cell activation for latent tuberculosis diagnosis Yuyeon Jang (Sejong, Korea, Republic of)	13:25 - 13:30
EP24-929-19	Evaluation of absolute monocyte to lymphocyte ratio in peripheral blood as an index of tuberculosis in Lusaka, Zambia Kondwelani John Mateyo (Lusaka, Zambia)	13:30 - 13:35
EP24-930-19	A novel blood-based 3-gene signature score for treatment monitoring in rifampicin-resistant tuberculosis: Preliminary results Yilin Zhang (Shanghai, China)	13:35 - 13:40
EP24-931-19	The value of platelet albumin ratio in monitoring treatment response and predicting time to culture conversion in patients with tuberculosis: A multicenter prospective study Yang Li (Shanghai, China)	13:40 - 13:45
EP24-932-19	The value of SAT-TB in monitoring the early therapeutic efficacy of MDR/RR tuberculosis Yuanyuan Chen (Hangzhou, China)	13:45 - 13:50
EP24-933-19	Multiparameter flow cytometry and machine learning identify a predictive blood-based immune signature for tuberculosis diagnosis and treatment monitoring Johanna Eggeling (Borstel, Germany)	13:50 - 13:55
EP24-934-19	Influence of single nucleotide polymorphism of IL-10 (rs.1800896, -1082 A/G) On the risk of tuberculosis and drug resistance in Kaduna State, Nigeria Innocent Tidisha Lawrence (Katsina, Nigeria)	13:55 - 14:00
	Q&A	14:00 - 14:05
<i>E-Posters</i>		
13:10 - 14:10		B1G
EP25 - Community wide systematic screening: Programmatic considerations		
Monde Muyoyeta (Lusaka, Zambia)		
EP25-935-19	21st century challenges in scaling communityTB active case finding: Abnormal X-ray and negative mWRD? Bornali Datta (New Delhi, India)	13:10 - 13:15

EP25-936-19	Bacterial and host determinants of cough aerosol culture-positivity in minimally symptomatic or asymptomatic patients with tuberculosis diagnosed during community-based active case finding Shameem Jaumdally (Cape Town, South Africa)	13:15 - 13:20
EP25-937-19	Repeated community-wide screening for tuberculosis: Impact on burden Geofrey Amanya (Kampala, Uganda)	13:20 - 13:25
EP25-938-19	Optimizing digital chest X-ray for TB screening: A process evaluation across South Africa Farzana Sathar (Johannesburg, South Africa)	13:25 - 13:30
EP25-939-19	Scaling TB elimination: High-yield community screening and detection strategies from South Africa's ACCELERATE program Priashni Subrayen (Durban, South Africa)	13:30 - 13:35
EP25-940-19	Strengthening health systems: The role of community health workers (CHWs) in improving access to TB and HIV services in Kano State, Nigeria Husna Baffa (Kano, Nigeria)	13:35 - 13:40
EP25-941-19	Detecting missed tuberculosis cases at health facilities in Ethiopia Using WRD test Kassahun Damete (Addis Ababa, Ethiopia)	13:40 - 13:45
EP25-942-19	Fostering sustainable facility-based active TB screening through human resource for health strengthening: TB LON project experience in three southern states of Nigeria Chijioko Oke (Awka, Nigeria)	13:45 - 13:50
EP25-943-19	Interim findings from community-wide screening to treat TB disease and infection in a high prevalence MDR-TB setting in Papua New Guinea Tafireyi Marukutira (Daru, Papua New Guinea)	13:50 - 13:55
EP25-944-19	A retrospective analysis of screening activities from 2019 to 2023 in Pakistan: What more needs to be done! Amna Mahfooz (Islamabad, Pakistan)	13:55 - 14:00
	Q&A	14:00 - 14:10
<i>E-Posters</i>		
	13:10 - 14:10	B1H
EP26 - Finding the missing millions: A focus on key populations		
Helen Ayles (Lusaka, Zambia)		
EP26-946-19	An experience from Pakistan under a multi-country TB grant; TB and MDR-TB interventions among Afghan refugees, returnees, and mobile populations in Afghanistan, Iran, and Pakistan Mahboob Ul Haq (Islamabad, Pakistan)	13:10 - 13:15
EP26-947-19	A strategic active case finding approach to maximize coverage among working men population, Madurai, Tamil Nadu-India Asha Frederick (Chennai, India)	13:15 - 13:20
EP26-948-19	Enhancing tuberculosis detection in elderly general population using Rapid qPCR tongue swabs for active case finding during routine physical examinations in low burden city Yang Li (Shanghai, China)	13:20 - 13:25
EP26-949-19	Active tuberculosis screening and case finding within informal drinking establishments and drug abuse dens in Githurai, Nairobi County, Kenya Elizabeth Mueni (Nairobi, Kenya)	13:25 - 13:30

EP26-950-19	Yield of targeted universal TB testing strategy among people living with HIV in Zimbabwe Blessing Mushangwe (Harare, Zimbabwe)	13:30 - 13:35
EP26-951-19	Point-of-care C-reactive protein testing for tuberculosis screening among people living with HIV: A feasibility study in Uganda Viola Kasone (Kampala, Uganda)	13:35 - 13:40
EP26-952-19	Field performance evaluation of the point of care afinion C-reactive protein for TB screening in people living with HIV in Uganda Proscovia Namuwenge (Kampala, Uganda)	13:40 - 13:45
EP26-953-19	Peak tuberculosis transmission at 24 weeks post-exposure with BCG-driven risk reduction in household contacts Fengling Mi (Beijing, China)	13:45 - 13:50
EP26-954-19	Acceptability of education materials for training and collection of tongue swabs for tuberculosis screening in migrant settings: A qualitative study Renee Codsi (Seattle, United States)	13:50 - 13:55
	Q&A	13:55 - 14:10
<i>E-Posters</i>		
13:10 - 14:10		B11
EP27 - Cracking the code on TB surveillance		
Palwasha Yousafzai Khan (London, United Kingdom) Delia Boccia (London, United Kingdom)		
EP27-955-19	Long-term sub-national trends in tuberculosis case notification in Kiribati Jeremy Hill (Sydney, Australia)	13:10 - 13:15
EP27-956-19	Digitization of tuberculosis data through a quality improvement approach: Electronic case-based TB surveillance system at 155 health facilities in Uganda Diana Cherotin (Mbale, Uganda)	13:15 - 13:20
EP27-957-19	Addressing the missing millions: A digital health and community-led approach to TB detection in India Selva Raj (Virudhunagar, India)	13:20 - 13:25
EP27-958-19	Healthcare-related factors associated with the rate of missing tuberculosis cases: A subregional ecological analysis in Indonesia Muhammad Prasetio Wardoyo (Jakarta Timur, Indonesia)	13:25 - 13:30
EP27-959-19	Characteristics of TB cases and clustering of TB risk factors: An analysis in the ERASE-TB study Edson Tawanda Marambire (Harare, Zimbabwe)	13:30 - 13:35
EP27-960-19	Long-term transmission dynamics and phylogeography of <i>Mycobacterium tuberculosis</i> in an emerging city in China: A population-based phylodynamic analysis Xi Zhu (Shenzhen, China)	13:35 - 13:40
EP27-961-19	Refining TB molecular surveillance in Taiwan: A cohort study addressing MIRU-VNTR variations with WGS validation Sheng-Yu Huang (Taoyuan, Taiwan)	13:40 - 13:45
EP27-962-19	Distribution of <i>Mycobacterium tuberculosis</i> lineages and clades by drug profile in Ethiopia: Systematic review and meta-analysis Muluwork Getahun (Addis Abba, Ethiopia)	13:45 - 13:50
EP27-963-19	Leveraging the AIM250 ODK Vantage Solution for enhanced performance monitoring and data-driven decision-making in TB	13:50 - 13:55

	and HIV grant implementation by KNCV Nigeria Mercy Chukwu (Abuja, Nigeria)	
EP27-964-19	Transitioning to a paperless system for tuberculosis data management: Evaluating the eTB Manager in Sherpur District, Bangladesh F. M. Monirul Haque (Dhaka, Bangladesh)	13:55 - 14:00
	Q&A	14:00 - 14:10
<i>Community Connect</i>		
13:15 - 14:00		CCC
	CCBS002 - Book signing with Author of THE BLACK ANGELS -- Maria Smilios	
	Introduction and moderators impression of the book Petra Heitkamp (Ottawa, Canada)	13:15 - 13:20
	Live reading from the book Maria Smilios (Asheville, United States)	13:20 - 13:30
	Question and answer with the author Petra Heitkamp (Ottawa, Canada)	13:30 - 13:40
	Book signing & meet and greet with Maria Smilios Maria Smilios (Asheville, United States)	13:40 - 14:00
<i>Spotlight Sessions</i>		
14:10 - 15:40		Main
	SL02 - The cost of retreat: Modelling the impact of donor funding cuts on TB in low- and middle-income countries Nimalan Arinaminpathy (Geneva, Switzerland) Obioma Chijioko-Akaniro (Abuja, Nigeria)	
	Introduction	14:10 - 14:15
	Potential epidemiological and economic impacts of reductions in international donor funding to national TB programmes across 79 countries Katherine C. Horton (London, United Kingdom)	14:15 - 14:30
	Navigating the funding gap: The impact of international donor cuts on Nigeria's TB programme and mitigation strategies amidst fiscal constraints Obioma Chijioko-Akaniro (Abuja, Nigeria)	14:30 - 14:42
	A deadly equation: The global toll of US TB funding cuts Sandip Mandal (New Delhi, India)	14:42 - 14:57
	Country Reality: Impact of USG/USAID funding cuts on TB in Bangladesh Rupali Sisir Banu (Dhaka, Bangladesh)	14:57 - 15:09
	Additional implications of funding cuts: Paediatric TB and TB in high-income countries Nicolas Menzies (United States)	15:09 - 15:24
	Panel discussion	15:24 - 15:40

TBScience Sessions

14:10 - 15:10

TBS

TBS03 - Accelerating prediction of treatment response in drug/regimen evaluation: The key role of biomarkers

Norbert Heinrich (Munich, Germany)

Christian Lienhardt (France)

TBS03-05	Session introduction	14:10 - 14:15
TBS03-10	Evaluating 'pathogen health' rather than 'pathogen burden': Induction of bacterial physiologic injury and adaption Nick Walter (United States)	14:15 - 14:25
TBS03-15	Host-based biomarkers: key results from the PREDICT TB study Stephanus Malherbe (Cape Town, South Africa)	14:25 - 14:35
TBS03-20	Host-based biomarkers: blood transcriptomic signatures (TB22; TB27) Maja Reimann (Borstel, Germany)	14:35 - 14:45
TBS03-25	Early gene expression responses to individual drugs as predictors of efficacy and effects on transmission Ruvandhi Nathavitharana (United States)	14:45 - 14:55
TBS03-30	Q&A	14:55 - 15:10

Symposia

14:10 - 15:40

R1

SY09-190-09 - How to improve trials and development, and ensure uptake, of innovations to prevent, diagnose, and treat TB

Ani Herna Sari (Indonesia)

Anneke C. Hesseling (Cape Town, South Africa)

	Introduction	14:10 - 14:15
	Person-centred outcomes in clinical trials of TB treatment and preventive therapy Oxana Rucsineanu (Moldova)	14:15 - 14:30
	When are uncontrolled trials in TB scientifically and ethically justified: Borrowing wisdom from early AIDS clinical trials Carole Mitnick (Boston, United States)	14:30 - 14:45
	Toward earlier inclusion of pregnant and breastfeeding women in TB treatment trials Sabine Verkuijl (Geneva, Switzerland)	14:45 - 15:00
	Continuity of care among TB treatment trial participants whose study treatment is discontinued Maria Tarcela S. Gler (Silang, Cavite, Philippines)	15:00 - 15:15
	Best practices for paediatric investigational plans in TB drug/regimen development Pauline Howell (Johannesburg, South Africa)	15:15 - 15:30
	Q&A	15:30 - 15:40

Short Oral Abstract Sessions

14:10 - 15:40

R2

SOA07 - Managing drug-resistant TB in the 21st century: Data, diagnostics and delivery

Troels Lillebæk (Copenhagen, Denmark)

Līga Kuksa (Stopinu pag, Ropažu novads, Latvia)

In	Introduction	14:10 - 14:15
----	---------------------	---------------

SOA07-570-19	Prevalence and risk factors of drug-resistant TB in Nepal: Findings from the sixth national drug-resistance TB survey Shree Ram Tiwari (Kathmandu, Nepal)	14:15 - 14:21
SOA07-571-19	Dominance of Lineage 2 and clonal endemic transmission of TB in Bhutan Ruan Spies (Ho Chi Minh City, Vietnam)	14:21 - 14:27
SOA07-572-19	Application of targeted next-generation sequencing (tNGS) in diagnosis and drug resistance prediction of extrapulmonary TB Chang Liu (Shenyang, China)	14:27 - 14:33
SOA07-573-19	Can targeted mentorship enhance multi-drug-resistant TB detection in resource-limited settings like Malawi? A quasi-experimental evaluation Sosten Mtalika (Lilongwe, Malawi)	14:33 - 14:39
SOA07-574-19	Tackling drug-resistant TB in Punjab, Pakistan: Treatment regimens and outcomes from a cohort study Laura Sannino (Paris, France)	14:39 - 14:45
SOA07-575-19	Characteristics, risk factors, and treatment outcomes of isoniazid mono-resistant TB in Cambodia: A retrospective study using Xpert XDR technology Sok Chamreun Choub (Phnom Penh, Cambodia)	14:45 - 14:51
SOA07-576-19	Effects of pyrazinamide and/or ethambutol resistance on TB treatment outcomes determined by whole genome sequencing, South Africa, 2020 - 2025 Sinothando Dlamini (Gauteng, South Africa)	14:51 - 14:57
SOA07-577-19	Early treatment outcomes for the six-month BPaLM regimen under programmatic conditions in Ethiopia Emawayish Tesema (Addis Ababa, Ethiopia)	14:57 - 15:03
SOA07-578-19	Long-term treatment outcomes of multi-drug-resistant TB/ rifampicin-resistant TB in Latvia Sophie Charlotte Meier (Borstel, Germany)	15:03 - 15:09
SOA07-579-19	Predicting drug-resistant TB outcomes: Examining pill-taking behaviours for bedaquiline Max O'Donnell (New York City, United States)	15:09 - 15:15
SOA07-580-19	The association between adherence and treatment outcomes among people with rifampicin-resistant TB who used the electronic pillbox in South Africa Tanyaradzwa Dube (Johannesburg, South Africa)	15:15 - 15:21
SOA07-581-19	Leveraging digital adherence technology and tele-counselling to improve monitoring of drug-resistant TB in Nigeria Karen Uche (Central Business District, Nigeria)	15:21 - 15:27
	Q&A	15:27 - 15:40
<i>Oral Abstract Sessions</i>		
	14:10 - 15:40	R3
OA09 - Finding TB in key vulnerable populations		
	Christian Wejse (Aarhus N, Denmark) Raquel Duarte (Porto, Portugal)	
	Introduction	14:10 - 14:15
OA09-179-19	Optimising TB detection through diagnostic intensification: A case study from Baran, Rajasthan Raksha Gupta (New Delhi, India)	14:15 - 14:22

OA09-180-19	TB in an urban slum: Collecting community stories to improve awareness and screening of TB in the Philippines Emilie Venables (Paris, France)	14:22 - 14:29
OA09-181-19	Improving finding TB among vulnerable populations using portable digital X-ray (PDX) machine: Experience from Kano State correctional centres Samira Bashir (Kano, Nigeria)	14:29 - 14:36
OA09-182-19	From evidence to policy: Prioritising TB key and vulnerable populations (KVPs) in Tanzania for strategic investment Rabia Abeid Khaji (Kahama Municipal Council, Tanzania)	14:36 - 14:43
OA09-183-19	Invisible populations, visible impact: Reaching nomadic and hard-to-reach populations through community TB interventions in Northern Nigeria Aderonke Agbaje (Abuja, Nigeria)	14:43 - 14:50
OA09-184-19	Integrating TB screening and treatment into social protection programmes to enhance early detection and access to care Mathius Mwesige (Kampala, Uganda)	14:50 - 14:57
OA09-185-19	Associations between community venue-time and incident TB infection among children and youth in rural Uganda Carina Marquez (San Francisco, United States)	14:57 - 15:04
OA09-186-19	Paradigm of ending TB in special populations in Kano State Saidat Ibrahim (Kano, Nigeria)	15:04 - 15:11
OA09-187-19	Addressing the gap: TB preventive treatment implementation in people with silicosis in Brazil Fernanda Dockhorn (Brasília, Brazil)	15:11 - 15:18
OA09-188-19	Leveraging on nutritional clinics to improve childhood TB detection in public health facilities: Kano State experience Gideon Zephaniah (Kano, Nigeria)	15:18 - 15:25
	Q&A	15:25 - 15:40

Short Oral Abstract Sessions

14:10 - 15:40

R4

SOA03 - Refining the performance of computer-assisted TB diagnostics

Imran Pambudi (Jakarta, Indonesia)
Mustapha Gidado (Den Haag, Netherlands)

In	Introduction	14:10 - 14:13
SOA03-523-19	Man vs. machine: A comparative analysis of AI-assisted screening and community referrals for TB detection under the C-PAT project Vikas Panibatla (Hyderabad, India)	14:13 - 14:20
SOA03-524-19	Optimising TB screening using chest X-ray with computer-aided detection: Diagnostic efficiency across threshold scores to assist human reading Nichel Marquez (Pasig City, Philippines)	14:20 - 14:27
SOA03-525-19	CAD4TB's precision, threshold 45 optimises TB screening in West Nile region, Uganda Louis Ocen (Kampala, Uganda)	14:27 - 14:34
SOA03-526-19	Impact of computer-aided X-ray diagnosis to optimise Xpert-orientated community-based active case-finding for TB: An open-label, randomised controlled trial Alex John Scott (Cape Town, South Africa)	14:34 - 14:41

SOA03-527-19	Large burden of asymptomatic TB detected with chest X-ray and computer-aided detection software Catherine Hewison (Paris, France)	14:41 - 14:48
SOA03-528-19	Intensified TB case finding and GeneXpert optimisation using chest X-rays with computer-aided detection (CAD) in Kenyan hospitals Immaculate Kathure (Nairobi, Kenya)	14:48 - 14:55
SOA03-529-19	Strengthening TB detection in Uganda through mobile clinics and digital diagnostics: Lessons learned and future directions Alex Mulindwa (Kampala, Uganda)	14:55 - 15:02
SOA03-530-19	Reducing the TB detection gap with AI: Advancing health equity in remote rural communities in Nigeria Chidimma Okoye (Abak, Nigeria)	15:02 - 15:09
SOA03-532-19	Accelerating TB screening and finding TB through artificial intelligence retrofits into existing X-ray systems in Kenya Immaculate Kathure (Nairobi, Kenya)	15:09 - 15:16
SOA03-533-19	Enabling access to TB diagnosis and treatment through AI-enabled portable solutions in Ukraine Gunta Dravniece (Kyiv, Ukraine)	15:16 - 15:23
	Q&A	15:23 - 15:33

Oral Abstract Sessions

14:10 - 15:40

R5

OA10 - Just the two of us: The continuum of maternal and early childhood TB

Jyoti Mathad (New York, United States)

Olivier Marcy (Bordeaux, France)

	Introduction	14:10 - 14:15
OA10-189-19	Systematic review of TB screening and diagnostic tools for pregnant and postpartum women Samyra Cox (Baltimore, United States)	14:15 - 14:22
OA10-190-19	Maternal TB infection risk in pregnant women living with HIV Louise Pretorius (Tembisa, South Africa)	14:22 - 14:29
OA10-191-19	Cytokine profiles in pregnant women from India and South Africa stratified by presence of TB or latent TB across pregnancy stages Vandana Kulkarni (Pune, India)	14:29 - 14:36
OA10-192-19	An assessment of guideline implementation for TB screening among pregnant women living with HIV using linked population data in the Western Cape, South Africa Emma Kalk (Cape Town, South Africa)	14:36 - 14:43
OA10-193-19	Pregnant women experience delay in initiating anti-TB treatment Sue-Ann Meehan (Cape Town, South Africa)	14:43 - 14:50
OA10-194-19	Improving access to BDLLC regimens for pregnant women with rifampicin-resistant TB in South Africa Jennifer Hughes (Cape Town, South Africa)	14:50 - 14:57
OA10-195-19	Clofazimine exposure in the breastmilk of women treated for rifampicin-resistant TB Richard Court (Cape Town, South Africa)	14:57 - 15:04
OA10-196-19	Risk of TB infection in young children exposed to multidrug-resistant TB in the TB-CHAMP multi-site randomised controlled trial Susan Purchase (Cape Town, South Africa)	15:04 - 15:11

OA10-197-19	Preventing TB and deaths among children living with HIV: The efficacy of TPT among children in a programmatic setting Nunurai Ruswa (Windhoek, Namibia)	15:11 - 15:18
	Q&A	15:18 - 15:33
<i>Oral Abstract Sessions</i>		
14:10 - 15:40		
	OA11 - Life after TB: Priorities and opportunities in post-TB health and wellbeing	R6
Giovanni Battista Migliori (Tradate, Italy) Gisele Badoum (Ouagadougou, Burkina Faso)		
	Introduction	14:10 - 14:15
OA11-198-19	Previous pulmonary TB as a risk factor for lung functional impairment: A cross-sectional study in a rural area of Senegal Lucia Allavena (Milano, Italy)	14:15 - 14:22
OA11-199-19	An assessment of abnormal 6 Minute Walk Distance (6MWD) and associated factors in people with post-TB lung disease at a tertiary hospital (Zambia): Cross-sectional study Chisha Sinyangwe (Lusaka, Zambia)	14:22 - 14:29
OA11-200-19	Patterns of pulmonary impairment before and after TB treatment Michael Marll (Atlanta, United States)	14:29 - 14:36
OA11-201-19	Trajectories of lung function in people with and without HIV during and after pulmonary TB treatment Michael Marll (Atlanta, United States)	14:36 - 14:43
OA11-202-19	Silent aftermath: Cardiovascular risks in post-TB survivors Mrinalima Chopra (Chandigarh, India)	14:43 - 14:50
OA11-203-19	Breaking the silence: The power of TB survivor stories in reducing stigma and fear Uche Ekwugha (FCT, Nigeria)	14:50 - 14:57
OA11-204-19	What's special about quality of life in TB: A qualitative appraisal of generic frameworks Nancy Bedingfield (McGill, Canada)	14:57 - 15:04
OA11-205-19	Medium- and long-term post-TB sequelae burden and health-related quality of life in sub-Saharan Africa Gino Agbota (Montpellier, France)	15:04 - 15:11
OA11-206-19	Post-treatment outcomes three years after a 9-month regimen for rifampicin-resistant TB in Vietnam Thi Mai Phuong Nguyen (Hanoi, Vietnam)	15:11 - 15:18
OA11-207-19	Pulmonary rehabilitation for post-TB lung disease in Kenya: A mixed-methods study of implementation context Neelima Navuluri (Durham, United States)	15:18 - 15:25
OA11-208-19	Sustained effects of community-based pulmonary rehabilitation (PR) for adults with post-TB lung disease in Malawi Bruce Matewere (Lilongwe, Malawi)	15:25 - 15:32
	Q&A	15:32 - 15:40

Special Sessions

14:10 - 15:40

R7

SPS03 - Mental health and psychosocial support in TB care: Breaking the silence

Mohammed Yassin (Geneva, Switzerland)

Zahedul Islam (Kyiv, Ukraine)

Live Introduction

14:10 - 14:15

The overlooked epidemic: Mental health disorders among people with TB

14:15 - 14:25

Suvanand Sahu (Switzerland)

Community-based MHPSS models: Experiences from high-burden countries

14:25 - 14:35

Ahmad Fuady (Jakarta, Indonesia)

Integration of services (Including mental health) to end TB

14:35 - 14:45

Karen Jacobson (United States)

Trauma-informed care: Approaches for people with TB with histories of violence, displacement, or incarceration

14:45 - 14:55

Yana Terleieva (Kyiv, Ukraine)

Addressing TB-related stigma through community engagement and social protection

14:55 - 15:05

Erman Varella (Jakarta, Indonesia)

Panel discussion with Q&A

15:05 - 15:40

Oral Abstract Sessions

14:10 - 15:40

R8

OA12 - Navigating TB therapy: Side effects, adverse events and tolerability

Xavier Padanilam (Johannesburg, South Africa)

Introduction

14:10 - 14:15

OA12-209-19

QT interval prolongation in children taking moxifloxacin and clofazimine for rifampicin-resistant TB treatment in South Africa, India and the Philippines

14:15 - 14:22

Yuanxi Zou (Uppsala, Sweden)

OA12-210-19

Linezolid interruption and rechallenge, and their effect on clinical outcomes, in people with rifampicin-resistant TB: Appraisal of South African programmatic data from 2018 to 2022

14:22 - 14:29

Suzette Oelofse (Cape Town, South Africa)

OA12-211-19

QTcF prolongation associated with bedaquiline-delamanid-linezolid regimens containing levofloxacin or moxifloxacin: A multicentre retrospective cohort study in rifampicin-resistant TB

14:29 - 14:36

Liang Fu (Shenzhen, China)

OA12-212-19

Optimising tigecycline administration based on blood concentration monitoring in people with TB and NTM infections

14:36 - 14:43

Ren Zheng (Hangzhou, China)

OA12-213-19

Hepatotoxicity rates and risk factors within the endTB regimens approved for multidrug-resistant TB

14:43 - 14:50

Chiara Sepulcri (Genova, Italy)

OA12-214-19

Incidence and risk factors of anti-TB drug induced liver injury: A multicentre retrospective study involving 482 Chinese paediatric TB patients

14:50 - 14:57

Yiqing Zhou (Hangzhou, China)

OA12-215-19

Hepatoprotective role of N-acetylcysteine in anti-TB drug-induced

14:57 - 15:04

	hepatotoxicity: A meta-analysis of controlled clinical studies Gestina Aliska (Padang, Indonesia)	
OA12-216-19	Clofazimine pharmacokinetics in shorter treatment regimens for drug-sensitive TB Allan Kengo (Kampala, Uganda)	15:04 - 15:11
OA12-217-19	Adequacy of recommendations for adverse event management in national and international treatment guidelines for rifampicin-susceptible TB: A systematic review William Burman (Denver, United States)	15:11 - 15:18
OA12-218-19	Examining the differences and similarities of three adverse event grading systems used in TB clinical trials Sharon Nachman (Stony Brook, United States)	15:18 - 15:25
	Q&A	15:25 - 15:40
<i>Community Connect</i>		
	14:15 - 15:00	CCC
CCF001 - Films		
	Breaking barriers Melvin Chung Hsien Liang (Malaysia)	14:15 - 14:25
	Street women empowered and engaged to stop TB: Strengthening communities against TB Subrat Mohanty (India)	14:25 - 14:35
	Community innovation and engagement: Key to ending TB Phumeza Tisile (Cape Town, South Africa)	14:35 - 14:50
	Story of Hung - A Tuberculosis Fighter Anh Cao Thi Ngoc (Hanoi, Vietnam)	14:50 - 15:00
<i>Community Connect</i>		
	15:00 - 17:00	CCART
CCAT002 - Art therapy, a healing process playing with colors -- TB Treatment challenges in marginalised communities.		
Mohammad Rofiqul (Royal) Islam (Bangladesh)		
	Introduction about art therapy Mohammad Rofiqul (Royal) Islam (Bangladesh)	15:00 - 15:00
	Art therapy Mohammad Rofiqul (Royal) Islam (Bangladesh)	15:00 - 15:00
<i>Community Connect Sessions</i>		
	15:10 - 15:55	CC
CCS010 - Reaching the hardest to reach populations: Results from prioritised TB key and vulnerable population size estimations in 12 countries		
James Malar (Genève, Switzerland) Stephen John (Yola, Nigeria)		
	Introduction	15:10 - 15:12
	Developing the TB KVP SE tool James Malar (Genève, Switzerland)	15:12 - 15:19
	Results from the TB KVP size estimation in Pakistan Kinz Ul Eman (Islamabad, Pakistan)	15:19 - 15:26

	TB KVP size estimation lessons and results in Eastern European Countries	15:26 - 15:33
	Ani Herna Sari (Indonesia)	
	Analysing global trends and results from across 14 countries implementing the TB KVP size estimation toll	15:33 - 15:40
	Stephen John (Yola, Nigeria)	
	Question and answers	15:40 - 15:55
<i>TBScience Sessions</i>		
15:15 - 16:15		TBS
TBS04 - Mixed oral abstract presentations II		
Morten Ruhwald (Copenhagen, Denmark)		
TBS04-05	Session introduction	15:15 - 15:16
TBS04-10	Widespread preexisting resistance to new and repurposed anti-tuberculosis drugs through loss-of-function	15:16 - 15:23
	Derek Conkle-Gutierrez (San Diego, United States)	
TBS04-15	Safety and pharmacokinetics of bedaquiline in children aged $\geq 2 < 5$ years with MDR-TB: 24-week results from Cohort 3 of the TMC207-C211 study	15:23 - 15:30
	Munira Khan (Durban, South Africa)	
TBS04-20	Decoding the role of ATF4 in pediatric tuberculosis by single-cell transcriptomics and metabolomics	15:30 - 15:37
	Xin Yu (Suzhou, China)	
TBS04-25	A machine-learning model of sequence, biochemical, and structural features to predict bedaquiline resistance in <i>Mycobacterium tuberculosis</i>	15:37 - 15:44
	Wilma Quispe Rojas (Antwerpen, Belgium)	
TBS04-30	Evaluation of the drug resistance spectrum of <i>M. tuberculosis</i> in children from foci of multidrug-resistant tuberculosis	15:44 - 15:51
	Aleksey Kazakov (Moscow, Russian Federation)	
TBS04-35	Risk factors for unfavorable outcomes in four trials of bedaquiline and pretomanid-based regimens	15:51 - 15:58
	Sejung Hwang (San Francisco, United States)	
TBS04-40	Q&A	15:58 - 16:15
<i>Community Connect Sessions</i>		
15:15 - 16:45		CCC
CCWS002 - Mental Health and Self-Care in TB Work		
Vlada Rabinova (Ukraine)		
<i>Break</i>		
15:40 - 15:55		Main
Break/Networking		
<i>Late Breaker Oral Abstract Sessions</i>		
15:55 - 17:25		Main
LB02 - The Union/CDC Late-Breaker Session - Clinical Trial Advances in TB: HIV Co-Infection, Pediatric Meningitis, and New Drugs		
Simon Tiberi (London, United Kingdom)		
Anneke C. Hesselning (Cape Town, South Africa)		
In	Introduction	15:55 - 15:58

LB02-1313-19	Safety of rifapentine-based TB prevention in pregnant women with HIV on dolutegravir: DOLPHIN-Moms trial Sylvia LaCourse (Seattle, United States)	15:58 - 16:06
LB02-1314-19	Six-month mortality in ATLAS trial of immediate and/or high-dose anti-TB therapy for adults with HIV-related sepsis Stellah Mpagama (Siha, Tanzania)	16:06 - 16:14
LB02-1315-19	In pursuit of an improved oxazolidinone for TB: A phase 1 trial evaluating safety, tolerability, pharmacokinetics, and food effect of TBD09 (MK-7762) in healthy adults Christopher Vinnard (Cambridge, United States)	16:14 - 16:22
LB02-1316-19	Shortened intensive anti-TB treatment and aspirin for African and Asian children with TB meningitis: The 48-week results from the phase-3 factorial randomised SURE trial Diana M Gibb (London, United Kingdom)	16:22 - 16:30
LB02-1317-19	DA-7801: Cost-effective anti-TB drug with strong efficacy and low toxicity Juno Choi (Seoul, Korea, Republic of)	16:30 - 16:38
LB02-1318-19	IMPAACT 2034: Phase 1 study of the pharmacokinetics (PK), safety/tolerability and acceptability of a single dose of pretomanid in female children with rifampicin-resistant TB Ethel Weld (Baltimore, United States)	16:38 - 16:46
LB02-1319-19	An AI chest X-ray severity score is prognostic of time to culture conversion in a pulmonary TB clinical trial Erlandy Basson (Munich, Germany)	16:46 - 16:54
LB02-1320-19	Missed opportunities: High yield of universal TB testing in people and their companions in the emergency department in South Africa Rebecca Berhanu (Johannesburg, South Africa)	16:54 - 17:02
LB02-1321-19	Bedaquiline long-acting formulation: Interim results of a phase 1 pharmacokinetic and safety study for single-dose TB preventive treatment Vivian Cox (Titusville, United States)	17:02 - 17:10
	Q&A	17:10 - 17:25
 <i>Oral Abstract Sessions</i> 15:55 - 17:25		
	OA13 - Optimising community-based TB screening and finding people with TB Gisele Badoum (Ouagadougou, Burkina Faso) Julio Croda (Campo Grande, Brazil)	R1
In	Introduction	15:55 - 16:00
OA13-219-19	Who benefits from community-based active TB screening programmes? Diagnostic yields, early detection, and demographics Lauren Linde (Boston, United States)	16:00 - 16:07
OA13-220-19	Enhancing TB screening integration in Malawi: Revolutionising and enhancing uptake of community case-finding programmes Madalitso Mmanga (Lilongwe, Malawi)	16:07 - 16:14
OA13-221-19	Creative and comprehensive community engagement in community-based screening and treatment of TB infection and disease Mavis Namaibai (Daru, Papua New Guinea)	16:14 - 16:21
OA13-222-19	Engagement of local market actors to expand the reach of active case finding: Impact of TB screening at daily markets in Bauchi State, Nigeria	16:21 - 16:28

	Bakiru Nuhu (Kano, Nigeria)	
OA13-223-19	Assessing the detection efficiency of community-based active case finding interventions across 7 waves of TB REACH Mirjam I. Bakker (Amsterdam, Netherlands)	16:28 - 16:35
OA13-224-19	Point-of-care molecular diagnostics for community-based active case finding: A multicentre randomised controlled trial on TB detection and treatment initiation Tahlia Perumal (Cape Town, South Africa)	16:35 - 16:42
OA13-225-19	Mind the clinic-community gap: How concerned should we be about false positive tests in community screening? Lara Veeken (Nijmegen, Netherlands)	16:42 - 16:49
OA13-226-19	Game Changer - The role of mobile active case finding initiative in Cambodia under the USAID funded COMMIT project Sok Chamreun Choub (Phnom Penh, Cambodia)	16:49 - 16:56
OA13-227-19	Tuberculosis prevention and care in Madagascar: A mixed-method study investigating the determinants of community health workers involvement Nadine Muller (Berlin, Germany)	16:56 - 17:03
OA13-228-19	Strengthening TB policy through community-led monitoring: Multi-country evidence Olya Klymenko (Kyiv, Ukraine)	17:03 - 17:10
	Q&A	17:10 - 17:25
 <i>Oral Abstract Sessions</i>		
	15:55 - 17:25	R2
	OA14 - Predicting TB: New disease, reinfection and relapse Rishi Gupta (London, United Kingdom) Stephanus Malherbe (Cape Town, South Africa) Claire Calderwood (London, United Kingdom)	
	Introduction	15:55 - 15:58
OA14-229-19	Integrated machine learning and proteomic profiling reveal host-specific response proteins as predictive biomarkers for TB diagnosis Peng Lu (Nanjing, China)	15:58 - 16:06
OA14-231-19	Exploring nuclear magnetic resonance metabolomics in serum samples for TB diagnosis in pediatric population: A pilot study Andrea López-Suárez (Madrid, Spain)	16:06 - 16:14
OA14-232-19	Development of a four-gene host signature for paucibacillary TB diagnosis among individuals with Xpert MTB/RIF Ultra very low and trace results Kattya Lopez (Newark, United States)	16:14 - 16:22
OA14-233-19	Advancing extrapulmonary TB diagnosis and treatment monitoring with RISK6 transcriptomic biomarker Ashabul Islam (Dhaka, Bangladesh)	16:22 - 16:30
OA14-234-19	Prediction of TB by the QuantiFERON-TB Gold Plus assay in immunocompromised individuals: A prospective TBnet study Ole Skouvig Pedersen (Aarhus, Denmark)	16:30 - 16:38
OA14-235-19	Reinfection as a cause of recurrence involving drug-resistant bacilli arising from initially susceptible isolates in TB Takashi Yoshiyama (Kiyose, Japan)	16:38 - 16:46

OA14-236-19	Whole-genome sequencing provides insights into recurrent tuberculosis in Madagascar over two decades Niaina Rakotosamimanana (Antananarivo, Madagascar)	16:46 - 16:54
OA14-237-19	The impact of prior TB on risk of subsequent TB in people living in households affected by TB: Results from the ERASE-TB study Anna-Lisa Behnke (Munich, Germany)	16:54 - 17:02
OA14-238-19	Timing of asymptomatic and symptomatic TB recurrence diagnoses after successful completion of TB treatment in India Sanjay Gaikwad (Pune, India)	17:02 - 17:10
	Q&A	17:10 - 17:25
 <i>Oral Abstract Sessions</i> 15:55 - 17:25		
	OA15 - Differentiated service delivery in precarious conditions Fuad Mirzayev (Geneva, Switzerland)	R3
	Introduction	15:55 - 16:00
OA15-239-19	From silence to strength: How TB-affected communities in Kenya are accessing justice through paralegal TB champions Ishmael Maina (Nairobi, Kenya)	16:00 - 16:07
OA15-240-19	Temporal trends and spatial clusters in TB treatment interruption among homeless people in Brazil Gabriela Tavares Magnabosco (Maringá, Brazil)	16:07 - 16:14
OA15-241-19	The role of informal health care providers in TB epidemic control in Nigeria Daniel Egbule (Enugu, Nigeria)	16:14 - 16:21
OA15-242-19	Strategies employed to improve treatment outcomes amongst people with TB who use alcohol in Korogocho informal settlements, Nairobi Kenya Milcah Ombuya (Nairobi, Kenya)	16:21 - 16:28
OA15-243-19	From stigma to support: Rethinking TB care in factories and communities, a learning from India Ramesh Dasari (Hyderabad, India)	16:28 - 16:35
OA15-244-19	Lessons learnt in the TB projects for the unhoused people of Delhi, India between 2017-2025 - Experiences of Humana People to People India Jahangir Alam (Delhi, India)	16:35 - 16:42
OA15-245-19	Urban gardens: A sustainable food supplementation model for persons with TB and their families in Lusaka, Zambia Emelly Machisa (Shamva, Zimbabwe)	16:42 - 16:49
OA15-246-19	Leave no one behind in TB care: New vulnerable population group has appeared following the start of full-scale war in Ukraine Evgenia Geliukh (Kyiv, Ukraine)	16:49 - 16:56
OA15-247-19	First statewide differentiated TB care: Care cascade and death rate reduction in 2024 Hemant Deepak Shewade (Chennai, India)	16:56 - 17:03
OA15-248-19	Inuit experiences and expertise on the 21st century TB epidemic in Nunavik, Quebec, Canada: A qualitative community-based participatory study Ben Geboe (Montreal, Canada)	17:03 - 17:10
	Q&A	17:10 - 17:25

Symposia

15:55 - 17:25

R4

SY10-200-10 - Uniting voices for equitable TB care in Europe: Advancing people-centred diagnosis and treatment

Ilaria Motta (London, United Kingdom)

Senia Rosales-Klintz (Sweden)

Introduction 15:55 - 16:00

Regional landscape of TB care in the European Region 16:00 - 16:15

Askar Yedilbayev (Denmark)

From innovation to implementation: Access challenges for TB diagnostics in the European Region 16:15 - 16:30

Francesca Saluzzo (Milan, Italy)

Access to TB medicines in the European Region: Challenges and potential solutions 16:30 - 16:45

Fabienne Jouberton (Geneva, Switzerland)

Fostering availability of age-appropriate formulations for children with TB to tackle the worrying surge in paediatric TB in the EU/EEA 16:45 - 17:00

Tiziana Masini (Geneva, Switzerland)

From awareness to action: Mobilising advocacy for accessible TB medications in the European Region 17:00 - 17:15

Paul Sommerfeld (London, United Kingdom)

Q&A 17:15 - 17:25

Symposia

15:55 - 17:25

R5

SY11-210-11 - Generating evidence: A call to action for the optimal inclusion of pregnant and lactating women in TB clinical research

Kerri Viney (Geneva, Switzerland)

Yael Hirsch-Moverman (New York, United States)

Introduction 15:55 - 16:00

A pressing need: Reaching consensus on how to advance the early and optimal inclusion of pregnant and lactating women in TB clinical research 16:00 - 16:15

Sabine Verkuijl (Geneva, Switzerland)

Hot off the press: The latest estimates of TB in pregnant and lactating women 16:15 - 16:30

Pete Dodd (Sheffield, United Kingdom)

Hot stuff: Systematic review on TB and pregnancy 16:30 - 16:45

Lelia Chaisson (San Francisco, United States)

Turning up the heat: Pregnant and lactating women have been excluded from TB clinical trials for far too long 16:45 - 17:00

Sue-Ann Meehan (Cape Town, South Africa)

Invisible mothers: Closing the data gap in maternal TB monitoring 17:00 - 17:15

Tambri Housen (Canberra, Australia)

Q&A 17:15 - 17:25

Symposia

15:55 - 17:25

R6

SY12-220-12 - How can asymptomatic TB help the development and global impact of new TB vaccines?

Rhea Lobo (Australia)

Richard White (London, United Kingdom)

Introduction 15:55 - 16:00

A community perspective on why asymptomatic TB and new TB vaccines matter to global TB care and prevention 16:00 - 16:15

Blessina Kumar (New Delhi, India)

Why asymptomatic TB could accelerate TB vaccine development, and what do we know? 16:15 - 16:35

Gavin Churchyard (Isando, South Africa)

How could we fill the remaining asymptomatic TB knowledge gaps, to know if we can use aTB to accelerate vaccine trials? 16:35 - 16:50

Puneet Dewan (Seattle, United States)

New modelling results suggest that the ability of new TB vaccines to prevent asymptomatic TB may be key to their global impact 16:50 - 17:05

Rebecca A. Clark (London, United Kingdom)

What potential regulatory considerations may arise in TB vaccine clinical trials that incorporate asymptomatic TB as a study endpoint? 17:05 - 17:15

Helen Rees (South Africa)

Q&A 17:15 - 17:25

Symposia

15:55 - 17:25

R7

SY13-230-13 - Innovative TB screening and diagnosis at healthcare facilities to find the missed millions: Evidence from four high-burden TB countries

Cecily Miller (Geneva, Switzerland)

Monde Muyoyeta (Lusaka, Zambia)

Introduction 15:55 - 16:00

The Start4All Project: Enhancing TB diagnosis and linkage to care across seven high-burden countries 16:00 - 16:15

Tom Wingfield (Liverpool, United Kingdom)

Identifying optimal TB screening and diagnostic strategies at the frontline in Malawi 16:15 - 16:30

Chimwemwe Kwanjo Banda (Blantyre, Malawi)

Innovations in point-of-care TB screening and diagnosis at healthcare facilities to find the missed millions: implementation evidence from Nigeria 16:30 - 16:45

Gracious Adalci Bahuyak (Nasarawa, Nigeria)

Lessons from the field on implementation and evaluation of novel TB screening and diagnostic tests in primary healthcare facilities in Brazil 16:45 - 17:00

Victor Santos (Lagarto, Brazil)

Real-world challenges and successes of expanding novel TB screening and diagnostic tests in the health system in Kenya 17:00 - 17:15

Steven Wandiga (Kisumu, Kenya)

Q&A 17:15 - 17:25

Symposia

15:55 - 17:25

R8

SY14-240-14 - Delivering multi-drug-resistant TB services in war and complex emergencies: A joint symposium with IOM, MSF, The Union, and WHO

Medea Gegia (Geneva, Switzerland)

Anita Mesic (Amsterdam, Netherlands)

Introduction 15:55 - 16:00

Multi-drug-resistant TB in war and complex emergencies: Consequences, gaps and potential ways forward 16:00 - 16:15

Ignacio Monedero-Recuero (Vilanova i la Geltrú, Spain)

Overcoming challenges of Multi-drug-resistant TB care in the Democratic Republic of Congo: The case of North Kivu 16:15 - 16:30

Peters Luliba Mwelwa (Goma, Congo (Democratic Republic))

Maintaining multi-drug-resistant TB services for refugees of the Ukraine war: The experience of Poland 16:30 - 16:45

Joanna Ladamirska (Den Haag, Netherlands)

Against all odds: Reduction of drug-resistant TB incidence in Niger, a public health success story 16:45 - 17:00

Mahamadou Bassirou Souleymane (Niamey, Niger)

Progress and lessons learnt in management of multi-drug-resistant TB in complex emergencies in the Eastern Mediterranean Region: 2018-2024 17:00 - 17:15

Kenza Bennani (Kathmandu, Nepal)

Q&A 17:15 - 17:25

Community Connect Sessions

16:10 - 16:55

CC

CCSPS001 - The power of storytelling and how this can influence change

Phumeza Tisile (Cape Town, South Africa)

Kinz Ul Eman (Islamabad, Pakistan)

Introduction 16:10 - 16:13

TB journey of Phumeza Tisile 16:13 - 16:21

Phumeza Tisile (Cape Town, South Africa)

TB journey of Henry Reider 16:21 - 16:29

Henry Reider (Sierra Leone)

TB journey of Paran Sarimita Winarni 16:29 - 16:37

Paran Sarimita Winarni (Indonesia)

John Green's Experience 16:37 - 16:45

John Green (United States)

Question and answers 16:45 - 16:55

TBScience Sessions

16:25 - 17:30

TBS

TBS05 - Remembering the past: The emergence of resistance to new TB drugs

Daniela Cirillo (Milan, Italy)

Timothy Walker (Oxford, United Kingdom)

TBS05-05 **Session introduction** 16:25 - 16:28

TBS05-10 **Emergence of resistance to new TB drugs - the case of bedaquiline** 16:28 - 16:38

Ingrid Eshun-Wilsonova (South Africa)

TBS05-15	Transmission as a key driver of resistance to the new tuberculosis drugs Galo Goig (Switzerland)	16:38 - 16:48
TBS05-20	Bedaquiline resistance in India: a multicentric retrospective cohort study Rupak Singla (India)	16:48 - 16:58
TBS05-25	The way forward: Aligning DST development with drug development - Panel discussion Bavesh Kana (South Africa) Francesca Saluzzo (Milan, Italy) Debra Flood (United States) Eugene Sun (New York, United States)	16:58 - 17:20
TBS05-30	Q&A	17:20 - 17:30
<i>Community Connect Sessions</i>		
17:00 - 17:45		CCC
CCS024 - Art, AI-enabled X-rays and partnerships in the fight against TB		
Robyn Waite (Ottawa, Canada) Robyn Waite (Ottawa, Canada) Jacob Creswell (Geneva, Switzerland)		
	Art, advocacy and X-rays in the fight against TB Paulina Siniatkina (Netherlands)	17:00 - 17:00
	Ultra-portable X-ray systems for reaching everyone, everywhere with TB screening Michael Cairnie (United States)	17:00 - 17:00
	Using AI solutions to support clinicians in making quick and accurate TB diagnosis and treatment decisions Dara Kelleher (United Arab Emirates)	17:00 - 17:00
	Using ultra-portable chest X-ray-AI screening for TB in nomadic communities of northeast Nigeria Stephen John (Yola, Nigeria)	17:00 - 17:00
<i>Community Connect Sessions</i>		
17:10 - 17:55		CC
CCS011 - Communities first: Building responsive systems for a TB-free future		
Sophia Khumukcham (India) Urvashi Singh (New Delhi, India) Lucica Ditiu (Switzerland)		
	Introduction	17:10 - 17:15
	Jan Bhagidari in action: Leveraging community systems and local governance Nishant Kumar (New Delhi, India)	17:15 - 17:20
	Bringing TB services closer: Village-level mobilisation and private sector partnerships Tiffany Tiara Pakasi (South Jakarta, Indonesia)	17:20 - 17:25
	Strengthening community surveillance through health system reforms Dr. Nguyen Binh Hoa (Hanoi, Vietnam)	17:25 - 17:30
	Faith-based and civil society partnerships in scaling TB care Ubochioma Emperor (Nigeria)	17:30 - 17:35
	Global enablers: Investing in community systems and	17:35 - 17:40

	accountability Suvanand Sahu (Switzerland)	
	Question and answera	17:40 - 17:55
<i>Break</i> 17:25 - 17:40		Main
Break/Networking		
<i>TBScience Sessions</i> 17:40 - 19:10		TBS
TBS06 - Bold science, smarter regimens: Translational innovations from the PAN-TB Collaboration		
Debra Flood (United States) Anna Upton (United States)		
TBS06-05	Welcome and introduction from co-chairs	17:40 - 17:45
TBS06-10	Projecting the dose: Predicting human efficacy from nonclinical data Anu Patel (San Francisco, United States)	17:45 - 17:55
TBS06-15	Beyond efficacy: Ranking time-to-cure for regimens and exploring drug contributions by combining mouse model data with combination PK Sylvie Sordello (France)	17:55 - 18:15
TBS06-20	Penetrating the problem: What lesion penetration has taught us Belen P. Solans (San Francisco, Spain)	18:15 - 18:30
TBS06-25	How it all comes together: Integrating nonclinical evidence to select the next regimens Rada Savic (San Francisco, United States)	18:30 - 18:45
TBS06-30	Panel discussion/audience Q&A Anu Patel (San Francisco, United States) Sylvie Sordello (France) Belen P. Solans (San Francisco, Spain) Rada Savic (San Francisco, United States)	18:45 - 19:05
TBS06-35	Closing remarks and reflections from co-chairs	19:05 - 19:10
<i>Side Meetings</i> 17:40 - 19:10		R1
General membership meeting - All Union members invited - Meet The Union leadership including our Board of Directors, President, Executive Director, and Chief Scientific Officer		
<i>Community Connect</i> 17:40 - 18:50		R2
CCSP001 - Beyond the Statistics: A Screenplay Reading on Tuberculosis		
Handaa Enkh-Amgalan (Berlin, Germany)		
	Introduction	17:40 - 17:45
	Handaa Enkh-Amgalan (Berlin, Germany)	
	Scene 1: Screenplay Reading	17:45 - 17:50
	Panel and audience reflection	17:50 - 18:00
	Tenzin Kunor (United States) Rosianna Halse Rojas (United Kingdom) Tauhid Islam (Geneva, Switzerland)	

Scene 2: Screenplay Reading	18:00 - 18:10
Panel and Audience Reflections	18:10 - 18:20
Tenzin Kunor (United States) Rosianna Halse Rojas (United Kingdom) Tauhid Islam (Geneva, Switzerland)	
Scene 3: Screenplay Reading	18:20 - 18:25
Panel and Audience Reflections	18:25 - 18:35
Tenzin Kunor (United States) Rosianna Halse Rojas (United Kingdom) Tauhid Islam (Geneva, Switzerland)	
Panel Discussion	18:35 - 18:50
Tenzin Kunor (United States) Rosianna Halse Rojas (United Kingdom) Tauhid Islam (Geneva, Switzerland)	
<i>Side Meetings</i>	
17:40 - 18:40	R3
Drug resistant TB working group	
<i>Satellite Sessions</i>	
17:40 - 19:10	R4
SS05 - The impact of observational research: The latest science from RePORT International research consortium	
Sonali Sarkar (India) Marissa Alejandria (Philippines)	
Introduction	17:40 - 17:45
RePORT International: Collaborative Science to Eliminate Tuberculosis	17:45 - 18:00
Rajita Bhavaraju (United States)	
Beyond the person with TB: Educational disruption in the wake of TB	18:00 - 18:15
Sonali Sarkar (India)	
Immunological signatures of asymptomatic TB	18:15 - 18:30
Thomas Scriba (Cape Town, South Africa)	
Treatment of HIV-related TB: New Insights from RePORT Brazil	18:30 - 18:45
Felipe Ridolfi (United States)	
TB Recurrence and Progression to Active TB: Burden, Determinants, and Implications on TB Prevention and Care	18:45 - 19:00
John Carlo Malabad (Philippines)	
Q&A	19:00 - 19:10
<i>Satellite Sessions</i>	
17:40 - 19:10	R5
SS06 - Bridging the gap with Chinese innovation: Advancing TB detection through novel diagnostic technologies	
Liang Li (China) Yuhong Liu (China)	
Opening remarks	17:40 - 17:50
Landscape of China's TB Diagnostic Innovations: From Research to Real-World Application	17:50 - 18:00

Yu Pang (China)	
Development of rapid and highly sensitive molecular POCT diagnostic technology for tuberculosis	18:00 - 18:10
Xiang Li (Beijing, China)	
Synergistic Screening: Cost-effective Cascade Diagnosis Using Combined IGRA and Urinary Antigen Detection	18:10 - 18:20
Jianrong Lou (China)	
Updates on Ustar Three Product Platforms: PortNAT, MultNAT & EasyNAT Lab Evaluation and Clinical Trials	18:20 - 18:30
Qimin You (China)	
Empowering Decentralized TB Diagnosis: Real-World Insights from Indonesia with Pluslife Near-POCT Solutions on the Road to End TB	18:30 - 18:40
Bachti Alisjahbana (Indonesia)	
TB seq test: Targeted Nanopore Sequencing Redefines TB Diagnosis and Drug Resistance Prediction	18:40 - 18:50
Hongcang Gu (China)	
High-Throughput Solutions for Tongue-swab based TB Diagnosis and Drug Resistance Profiling	18:50 - 19:00
Long Hu (China)	
Q&A	19:00 - 19:10

Community Connect Sessions

18:10 - 19:10

CC

CCS012 - Leveraging AI and lung health innovation to reach the unreached

Usman Rasool Lodhi (Islamabad, Pakistan)

Kinz Ul Eman (Islamabad, Pakistan)

Introduction	18:10 - 18:15
Innovating for impact: TB REACH-supported integrated models of care	18:15 - 18:25
Beatrice Wangari Kirubi (Geneva, Switzerland)	
Model of care for integrated service delivery for key and vulnerable populations: A people-centred approach to lung health	18:25 - 18:35
Sabira Tahseen (Islamabad, Pakistan)	
Early findings and insights from an integrated lung health model for vulnerable populations	18:35 - 18:45
Usman Rasool Lodhi (Islamabad, Pakistan)	
Integrated TB and lung health service delivery: Lessons from Nigeria	18:45 - 18:55
Stephen John (Yola, Nigeria)	
Question and answers	18:55 - 19:10

Thursday, 20. November 2025

TBScience Sessions

08:00 - 09:00

TBS

TBS07 - AI Design of products: Drugs, vaccines, diagnostics

Kobto Koura (Paris, France)

Bachti Alisjahbana (Indonesia)

TBS07-05	Session introduction	08:00 - 08:03
TBS07-10	Drugs Joseph Sugie (United States)	08:03 - 08:18
TBS07-15	Will AI change and accelerate TB vaccine development? Isabelle Bekeredjian Ding (Germany)	08:18 - 08:33
TBS07-20	Diagnostics Morten Ruhwald (Copenhagen, Denmark)	08:33 - 08:48
TBS07-25	Q&A	08:48 - 08:58

Satellite Sessions

08:00 - 09:00

R1

SS07 - Tuberculosis treatment monitoring - Real world applications and implementation of Tuberculosis Molecular Bacterial Load Assay (TB-MBLA)

Paul Smith (United Kingdom)

Tamara Martin (United Kingdom)

	TB Diagnosis and Monitoring Evaluation (TIME): a multicentre prospective longitudinal study Tamara Martin (United Kingdom)	08:00 - 08:15
	Background to TB-MBLA, importance in clinical trials and adoption in sub-Saharan Africa Wilber Sabiiti (Glasgow, United Kingdom)	08:15 - 08:15
	Industry perspective on adoption and implementation of a diagnostic test Joseph Featherstone (United States)	08:15 - 08:15
	Use of TB-MBLA in clinical trials Kelly W. Stinson (Atlanta, United States)	08:15 - 08:15
	Panel discussion	08:15 - 08:45
	Q&A	08:45 - 09:00

Meet the Expert Sessions

08:00 - 09:00

R2

MTE-04 - Bridging the gap: Strategic integration of near-point of care NAAT tests to achieve universal TB diagnosis coverage

Grania Brigden (Switzerland)

	Live introduction	08:00 - 08:05
	Bridging the gap: Strategic integration of near-point of care NAAT tests to achieve universal TB diagnosis coverage Seda Yerlikaya (Heidelberg, Germany)	08:05 - 08:20
	Discussion Q&A	08:20 - 09:00

Meet the Expert Sessions
08:00 - 09:00 R3

MTE-05 - HIV treatment and care during and after a TB diagnosis and impact of recent funding cuts on TB and HIV prevention and care

Lucy Chimoyi (Johannesburg, South Africa)

Live introduction 08:00 - 08:05

HIV treatment and care during and after a TB diagnosis and impact of recent funding cuts on TB and HIV prevention and care 08:05 - 08:20

Christine Sekaggya-Wiltshire (Uganda)

Discussion and Q&A 08:20 - 09:00

Meet the Expert Sessions
08:00 - 09:00 R4

MTE-06 - Beyond science: Social and political challenges of One Health

Liliana C. M. Salvador (Tucson, United States)

Live introduction 08:00 - 08:05

Beyond science: Social and political challenges of One Health 08:05 - 08:20

Daniel O'Brien (United States)

Discussion and Q&A 08:20 - 09:00

Meet the Expert Sessions
08:00 - 09:00 R5

MTE-07 - The future of WHO Integrated Management of Childhood Illnesses guidelines for pneumonia

Leslie Enane (Indianapolis, United States)

Live introduction 08:00 - 08:05

The future of WHO Integrated Management of Childhood Illnesses guidelines for pneumonia 08:05 - 08:20

Eric McCollum (Baltimore, United States)

Discussion and Q&A 08:20 - 09:00

Community Connect Sessions
08:00 - 08:45 CC

CCS013 - Youth-led initiatives and using technology to drive access to better TB service and treatments

Akshaya Patil (India)

Akshaya Patil (India)

Tiemi Arakawa (Brazil)

Introduction 08:00 - 08:02

Youth-led innovations and success stories on drug-resistant TB treatment rollout 08:02 - 08:09

Aman Shukla (India)

Using community-led monitoring tools to raise awareness, generate demand, and monitor BPAL access 08:09 - 08:16

Kinz Ul Eman (Islamabad, Pakistan)

Designing scalable, sustainable and adaptable digital tools for TB-affected communities 08:16 - 08:23

Nurliyanti Nurliyanti (Jakarta Selatan, Indonesia)

From patient to advocate: Driving TB awareness and action through 08:23 - 08:30

digital platforms

Stephen Anguva (Nairobi, Kenya)

Question and answers

08:30 - 08:45

TBScience Unmoderated E-Posters

08:00 - 19:00

TBS-EP-THU - TBScience 2025 Unmoderated E-Posters

TBS-EP362	Toward entropy-based precision monitoring of tuberculosis: A systematic review of immune dysregulation as a predictive framework for treatment innovation Satiti Palupi Purwanto (Hat Yai, Thailand)	08:00 - 08:00
TBS-EP365	Machine learning models reveal predictive signatures of therapy outcome in Phase 3 TB trials Daniel Garger (Munich, Germany)	08:00 - 08:00
TBS-EP368	The use of unmanned aerial vehicles (UAV) on delivering biological samples for tuberculosis and COVID-19 diagnosis: A scoping review Olga Maira Machado Rodrigues (Brasilia, Brazil)	08:00 - 08:00
TBS-EP371	Evaluation of an oral bedaquiline regimen for treating multidrug-resistant TB in China: A randomized trial Jingtao Gao (Beijing, China)	08:00 - 08:00
TBS-EP374	Treatment outcomes and risk factors among tuberculosis patients infected with <i>Mycobacterium tuberculosis</i> Beijing lineage in Ukraine (2020-2023) Dmytro Butov (Kharkiv, Ukraine)	08:00 - 08:00
TBS-EP377	Addressing tobacco industry tactics in university campuses and its impact on tobacco cases in Iraq Thamer Alhilfi (Baghdad, Iraq)	08:00 - 08:00
TBS-EP380	Breath-based pathogen detection technologies for diagnosing respiratory infections: A scoping review Sonal Jain (Heidelberg, Germany)	08:00 - 08:00
TBS-EP383	Leveraging artificial intelligence driven mobile X-ray screening on TB detection in high-risk brick Kiln communities of Punjab, Pakistan Qasim Mehmood (Lahore, Pakistan)	08:00 - 08:00
TBS-EP386	Drug resistance detection from swab samples - A proof of principle pilot study using Molbio Truenat MTB-RIF-Dx and MTB-INH assays Seda Yerlikaya (Heidelberg, Germany)	08:00 - 08:00
TBS-EP389	AI-powered TB screening revolution: Impact of CAD4TB and DELFT portable X-ray machines in Punjab, Pakistan Bilal Ahmed (Lahore, Pakistan)	08:00 - 08:00
TBS-EP395	Preventive practices of pulmonary tuberculosis in Chitwan districts Kamal Kalakheti (Ilam, Nepal)	08:00 - 08:00
TBS-EP398	Genetic pattern of the ST 61 cluster of the Cameroon family among <i>Mycobacterium tuberculosis</i> complex strains collected during the CANTAM I project in Cameroon Alix Kevine G. T. Tchoupe (Yaoundé, Cameroon)	08:00 - 08:00
TBS-EP401	SHIFTING paradigms in DR-TB management: Real-world outcomes of injectable Kanamycin vs. Bedaquiline all-oral regimens using Ni-Kshay surveillance data Zuha Jabeen Shaikh (Mumbai, India)	08:00 - 08:00

TBS-EP404	Analysis of the incidence of tuberculosis lung injury and related factors of lung function after cure of pulmonary tuberculosis: A prospective observational study Wenli Cao (Beijing, China)	08:00 - 08:00
TBS-EP410	Human reader vs CAD4TB: Enhancing TB case detection through AI-supported mobile screening in Cambodia Monyrath Chry (Phnom Penh, Cambodia)	08:00 - 08:00
TBS-EP413	Tuberculosis recurrence prediction: A machine learning approach Olga Zofia Wieromiejczyk (Copenhagen, Denmark)	08:00 - 08:00
TBS-EP416	Bridging the knowledge gap: KAP assessment on tuberculosis among undergraduate health professional students in Baghdad with a focus on tobacco smoke and curriculum adequacy Thamer Alhilfi (Baghdad, Iraq)	08:00 - 08:00
TBS-EP419	Development and evaluation of hydrogel loaded with human amniotic membrane in wound healing Faheem Jan (Islamabad, Pakistan)	08:00 - 08:00
TBS-EP425	Impact of discordant isoniazid and rifampicin susceptibility results between the Anyplex™ II MTB/MDR assay and the BACTEC MGIT 960 system on treatment decisions Kanphai Wongjarit (Bangkok, Thailand)	08:00 - 08:00
TBS-EP428	The role of physiotherapy in demystifying pulmonary tuberculosis in Uganda Sheillah T. Nakisanze (Masaka, Uganda)	08:00 - 08:00
TBS-EP431	Clinical performance of the CAD4TB AI system for pulmonary tuberculosis detection among young adults in Mongolia: A diagnostic screening study Yanjindulam Purevsuren (Ulaanbaatar, Mongolia)	08:00 - 08:00
TBS-EP434	Addressing access to treatment and diagnostic barriers in TB treatment through the Market and Patent Intelligence Study: A focus on intellectual property barrier Duke Otieno (Nairobi, Kenya)	08:00 - 08:00
TBS-EP440	Shortened treatment regimens for drug resistant (DR)-TB patients in Azerbaijan: First results Irada Akhundova (Baku, Azerbaijan)	08:00 - 08:00
TBS-EP443	Concomitant subclinical pulmonary tuberculosis in patients with extra-pulmonary tuberculosis Tejaswini Gude (New Delhi, India)	08:00 - 08:00
TBS-EP446	Evaluation of the second-generation Fujifilm SILVAMP TB-LAM assay for TB diagnosis in Nigerian adults Nadiia Tytarenko (Badalona, Spain)	08:00 - 08:00
TBS-EP449	Novel mutations in genes associated with bedaquiline and linezolid resistance in drug- naïve <i>Mycobacterium tuberculosis</i> isolates Chikanshi Sharma (Delhi, India)	08:00 - 08:00
TBS-EP452	Measuring cellular responses against respiratory pathogens can help to guide prophylaxis in immunocompromised patients Irene Latorre (Badalona, Spain)	08:00 - 08:00
TBS-EP455	Radiological features of pulmonary nontuberculous mycobacterial disease depending on the species of the pathogen Anastasiya Gaida (Moscow, Russian Federation)	08:00 - 08:00
TBS-EP458	Estimating the effect of implementing novel diagnostics in adults and children on pediatric TB indicators in KwaZulu-Natal, South	08:00 - 08:00

Africa		
	Mark Fajans (Seattle, United States)	
TBS-EP461	The iron-vitamin D axis in tuberculosis: Hepcidin modulation as a target for precision host-directed therapy Satiti Palupi Purwanto (Hat Yai, Thailand)	08:00 - 08:00
TBS-EP464	Research on patients with NTM lung disease accompanied by anxiety or depression and related risk factors Xiang Shi (Shang Hai, China)	08:00 - 08:00
TBS-EP467	Reasons for refusal of TB preventive treatment uptake by eligible contacts of TB patients in high TB burden settings Sobia Faisal (Islamabad, Pakistan)	08:00 - 08:00
TBS-EP470	Isolation of non-tuberculous mycobacteria (NTM) from household water of patients with NTM pulmonary disease Wei Sha (Shang Hai, China)	08:00 - 08:00
TBS-EP479	Adherence to isoniazid preventive therapy and its associated factors among HIV patients receiving treatment in five districts in Ghana Mavis Pearl Kwabla (Hohoe, Ghana)	08:00 - 08:00
TBS-EP482	Prospective prediction of TBAJ-876-PaL phase 2 clinical outcomes in NC-009 trial via a multi-model framework Eunsol Yang (San Francisco, United States)	08:00 - 08:00
TBS-EP485	Implementation of TPT with shorter regimens: Experience from Bangladesh Rifat Jahan Khan (Dhaka, Bangladesh)	08:00 - 08:00
TBS-EP488	Empowering National TB Control Program through artificial intelligence-enhanced portable X-ray deployment in Bangladesh Rifat Jahan Khan (Dhaka, Bangladesh)	08:00 - 08:00
TBS-EP491	Lineage identification and mutation profile of <i>Mycobacterium tuberculosis</i>: A study from National Reference Laboratory, India Raj Narayan Yadav (New Delhi, India)	08:00 - 08:00
TBS-EP493	Oral rinse outperforms facemask capture for non-sputum diagnosis of pulmonary TB Simon C Mendelsohn (Cape Town, South Africa)	08:00 - 08:00
TBS-EP503	Trends in tuberculosis detection using GeneXpert in a rural Ghanaian district: A six-year retrospective analysis (2019-2024) Eyram Hanu (Hohoe, Ghana)	08:00 - 08:00
TBS-EP506	Fate of TB treatment among the patients who remained bacteriologically positive after two months of anti-TB drugs Sobia Faisal (Islamabad, Pakistan)	08:00 - 08:00
TBS-EP509	Physiotherapy management in tuberculosis patients with co-existing HIV infection: Challenges in immunocompromised care Elizabeth Nakanwagi (Kampala, Uganda)	08:00 - 08:00
TBS-EP512	Can simple blood tests predict heart disease in patients with pulmonary tuberculosis? - The TB-HEART Study Marcello Scopazzini (London, United Kingdom)	08:00 - 08:00
TBS-EP515	Threat beyond TB: Rising menace of NTM infections and the urgent need for accurate diagnosis Jyotirmayee Turuk (Bhubaneswar, India)	08:00 - 08:00
TBS-EP518	Genomic insights into <i>Mycobacterium tuberculosis</i> lineages and antimicrobial resistance profiles in three Canadian provinces	08:00 - 08:00

	Reema Singh (Saskatoon, Saskatchewan, Canada)	
TBS-EP521	Transcriptomic profiles from animal hosts following infection with <i>Mycobacterium bovis</i>: A systematic review Liliana C. M. Salvador (Tucson, United States)	08:00 - 08:00
TBS-EP524	Assessment of awareness and knowledge of butchers on bovine tuberculosis in the Volta region of Ghana Iddrisu Saliu (Hohoe, Ghana)	08:00 - 08:00
TBS-EP527	Effectiveness of BPaL/BPaLM in central area of Taiwan Yi-Wen Huang (Changhua, Taiwan)	08:00 - 08:00
TBS-EP530	Ibuprofen and acetylsalicylic acid as adjunctive to anti-tuberculosis treatment: Phase II clinical trial Cris Vilaplana (Badalona, Spain)	08:00 - 08:00
TBS-EP533	Pathobionts and antimicrobial resistance in symptomatic people with and without tuberculosis Suventha Moodley (Cape Town, South Africa)	08:00 - 08:00
TBS-EP536	Validation of a DNA methylation signature of active tuberculosis in the buccal mucosa using methylation-specific PCR Isabelle Öhrnberg (Linköping, Sweden)	08:00 - 08:00
TBS-EP539	The Tuberculosis Knowledge and Analytics Platform: TB Nexus Analytics Nibedita Rath (Bangalore, India)	08:00 - 08:00
TBS-EP562	Effect of combined inspiratory and expiratory muscle training in pulmonary rehabilitation of active and post tuberculosis Sheillah T. Nakisanze (Masaka, Uganda)	08:00 - 08:00
TBS-EP565	Establishment of a model for early warning of onset in population exposed to <i>Mycobacterium tuberculosis</i> Jingli Du (Beijing, China)	08:00 - 08:00
TBS-EP568	Nutritional status of tuberculosis patients and its associated factors in four districts in Ghana Mavis Pearl Kwabla (Hohoe, Ghana)	08:00 - 08:00
TBS-EP571	Maternal and infant outcomes in acute hematogenous disseminated pulmonary tuberculosis during pregnancy Huiru An (Beijing, China)	08:00 - 08:00
TBS-EP577	Development of a loop-mediated Isothermal amplification (LAMP) assay for the detection of pepQ gene in <i>Mycobacterium tuberculosis</i> Joannah Marie Bislumbre (Manila, Philippines)	08:00 - 08:00
TBS-EP580	Factors that impact the expansion of coverage for preventive treatment of TB in the Kyrgyz Republic Dinara Madybaeva (Bishkek, Kyrgyzstan)	08:00 - 08:00
TBS-EP583	Clinical features of pulmonary tuberculosis and nanostructural characteristics of multidrug-resistant <i>Mycobacterium tuberculosis</i> strains Natalia Yatskevich (Belarus)	08:00 - 08:00
TBS-EP586	Long term impact of pulmonary TB on health-related functioning and well-being in four African countries Kamban Hirasen (Johannesburg, South Africa)	08:00 - 08:00
TBS-EP589	Enrichment of <i>M. tuberculosis</i> in patient sputa using a limiting dilution assay Dale Liebenberg (Johannesburg, South Africa)	08:00 - 08:00

TBS-EP592	Bridging diagnostic gaps of drug-resistant pulmonary tuberculosis with clinical diagnosis in a low-and middle-income state, Southwest, Nigeria: A secondary data analysis Emmanuel Irek (Ekiti, Nigeria)	08:00 - 08:00
TBS-EP595	Diagnostic potential of hematological counts and ratios in pediatric tuberculosis: A five-year retrospective study Simona Mäsiarová (Martin, Slovakia)	08:00 - 08:00
TBS-EP598	Polystyrene particles alter mycobacterial lipidic cell wall composition Iris Romero-Andrada (Badalona, Spain)	08:00 - 08:00
TBS-EP601	Population pharmacokinetics of isoniazid in TB patients: Accounting for age, sex, weight, diabetes, and HIV Felipe Ridolfi (United States)	08:00 - 08:00
TBS-EP603	Single-cell transcriptomic profiling identifies immune signatures in latent Mycobacterium tuberculosis infection and active tuberculosis Jie Tian (Shanghai, China)	08:00 - 08:00
TBS-EP606	Latent tuberculosis infection retains cytotoxic molecule expression and functionality lost during active disease Carlos Peña Bates (CDMX, Mexico)	08:00 - 08:00
TBS-EP609	Harnessing AI for rapid, consistent, and efficient scientific writing: Large language models for TB trial protocol generation Brian Hiroshi Aldana (San Francisco, United States)	08:00 - 08:00
TBS-EP614	Predictive modeling of tuberculosis prevalence among medical workers in the Vinnytsia Region, Ukraine: Insights from 2007-2029 Artemii Bogomolov (Vinnytsya, Ukraine)	08:00 - 08:00
TBS-EP616	Knowledge of tuberculosis prevention and control among public service vehicle operators in the South Rift Valley, Kenya Cheruiyot Sambu (Eldoret, Kenya)	08:00 - 08:00
TBS-EP618	Is transmission the primary route to bedaquiline resistance? A context specific framework for transmission threshold estimation Abel Kjaersgaard (London, United Kingdom)	08:00 - 08:00
TBS-EP620	Utility of antibody responses in the diagnosis of tuberculosis in rural Papua New Guinea Catherine Rush (Townsville, Australia)	08:00 - 08:00
TBS-EP622	Evaluation of the consistency between phenotypic MIC and genomic mutations in the detection of Bedaquiline and Clofazimine cross-resistance in Mycobacterium tuberculosis isolates from the Philippines Shiomi Yoshida (Kiyose, Tokyo, Japan)	08:00 - 08:00
TBS-EP624	Gastrointestinal parasites and their association with TB immune responses in Rural Papua New Guinea Jeffrey Warner (Townsville, Australia)	08:00 - 08:00
TBS-EP626	Accelerating tuberculosis prevention: Assessing novel TB preventive treatments in a preclinical infection model Andréanne Lupien (Montreal, Canada)	08:00 - 08:00
TBS-EP628	The computer-aided detection software using chest X-ray images in TB screening may have the potential to identify early TB patients in China Wei Liu (China)	08:00 - 08:00
TBS-EP630	Comparing LAM to other sputum-based biomarkers in NC-009 trial	08:00 - 08:00

	Juliano Timm (New York, United States)	
TBS-EP632	Low complexity-manual nucleic acid amplification tests for detection of pulmonary tuberculosis in adolescents and adults with presumptive tuberculosis: A systematic-review and meta-analysis of diagnostic accuracy Adhin Bhaskar (Chennai, India)	08:00 - 08:00
TBS-EP634	Impact of TB preventive therapy at grassroots level in community setting in Pune, India Govinda Narke (Pune, India)	08:00 - 08:00
TBS-EP636	Innovative AI tool for TB diagnosis based on metabolomic detection in urine Jose Dominguez (Barcelona, Spain)	08:00 - 08:00
TBS-EP638	Comparison of different chemicals as an alternative sputum liquefaction reagent to N-acetyl-L-cysteine with Sodium Hydroxide (NALC-NaOH) Jo Mary Lei Majaducon (Manila, Philippines)	08:00 - 08:00
TBS-EP647	Enhancing lung health through physiotherapy for overall well-being Elizabeth Nakanwagi (Kampala, Uganda)	08:00 - 08:00
TBS-EP653	Tissue-specific immune phenotyping reveals divergent responses to BCG vaccination and <i>Mycobacterium tuberculosis</i> challenge Irene Latorre (Badalona, Spain)	08:00 - 08:00
TBS-EP656	Risk of human tuberculosis associated with exposure to livestock in rural Ballabgarh, Haryana: A Case-Control Study Rakesh Kumar (New Delhi, India)	08:00 - 08:00
TBS-EP665	Detection of first-line and second-line Drug-Resistance mediating mutations in <i>Mycobacterium tuberculosis</i> with DNA extracted with different extraction methods directly from sputum using Next-Generation Sequencing Vera Allerheiligen (Nehren, Germany)	08:00 - 08:00
TBS-EP668	Frequency and co-resistance of bedaquiline, clofazimine, delamanid, and pretomanid in MDR-TB isolates at a North Indian reference laboratory Rashmi Ratnam (Lucknow, India)	08:00 - 08:00
TBS-EP674	Breaking resource barriers: Development of portable AIMLAM for active TB diagnosis in the HIV- population Xiang Yang (Guangzhou, China)	08:00 - 08:00
TBS-EP677	Exhaled breath condensate: A new window on aerobiology of <i>Mycobacterium tuberculosis</i> Benjamin Patterson (Cape Town, South Africa)	08:00 - 08:00
TBS-EP680	Assessment of a simplified and portable IGRA-TB platform based on fluorescence immunoassay for the diagnosis of <i>Mycobacterium tuberculosis</i> Infection Jose Dominguez (Barcelona, Spain)	08:00 - 08:00
TBS-EP683	Diagnostic Utility of Fluorescein Diacetate (FDA) Staining for Rapid Tuberculosis Detection: A Comparative Study Against Automated Liquid Culture Rashmi Ratnam (Lucknow, India)	08:00 - 08:00
TBS-EP689	Prevalence and risk factors of anti-tuberculosis drug-induced hepatitis based on liver function tests among TB patients at Hargeisa TB Hospital, Somaliland Mohamed Abdi Hergeye (Hargeisa, Somalia)	08:00 - 08:00

TBS-EP695	Post TB morbidity - What is the optimal management of TB IRIS? Proposal for a clinical trial Kasha Singh (Melbourne, Australia)	08:00 - 08:00
TBS-EP698	Preliminary diagnostic performance of novel LAM antibodies in CSF of HIV negative Vietnamese children with TB meningitis: A SURE substudy Julie Huynh (Ho Chi Minh City, Vietnam)	08:00 - 08:00
TBS-EP701	Investigating the impact of inoculum size on EUCAST methodology for MIC <i>Mycobacterium tuberculosis</i> determinations Deborah Recchia (Pavia, Italy)	08:00 - 08:00
TBS-EP704	Targeting the tryptophan synthase TrpAB to fight <i>Mycobacterium tuberculosis</i> Giovanni Stelitano (Pavia, Italy)	08:00 - 08:00
TBS-EP710	Achieving 100% participant retention in an active tuberculosis cohort Zainab Baig (Durban, South Africa)	08:00 - 08:00
TBS-EP713	Pre-extensively drug-resistant extrapulmonary tuberculosis: A growing threat Manu Singh (Lucknow, India)	08:00 - 08:00
TBS-EP716	Pharmacogenetic insights for tuberculosis treatment using Namibian human genetic diversity Lorraine Boois (Windhoek, Namibia)	08:00 - 08:00
TBS-EP722	Integrated genomic and host-based assessment of a persistent extensively drug resistant <i>M. tuberculosis</i> Beijing strain during therapy Mandira Varma-Basil (Delhi, India)	08:00 - 08:00
TBS-EP725	Optimization of community-based tuberculosis screening informed by Bayesian Latent Class modelling Aquiles R. Henriquez-Trujillo (Antwerp, Belgium)	08:00 - 08:00
TBS-EP734	Neutrophil-to-lymphocyte-ratio and neutrophil-to-monocyte-plus-lymphocyte-ratio in the blood of adolescents with pulmonary tuberculosis Larissa Gorbach (Minsk, Belarus)	08:00 - 08:00
TBS-EP737	Using artificial intelligence for parameterization of mechanistic epidemiologic models in tuberculosis control Nishant Chavan (New Delhi, India)	08:00 - 08:00
TBS-EP740	Chronotherapy for tuberculosis: A conceptual framework to harness host circadian rhythms and destabilize mycobacterium tuberculosis physiology Satiti Palupi Purwanto (Hat Yai, Thailand)	08:00 - 08:00
TBS-EP743	Neutrophil, lymphocyte and monocyte ratios in children with active and latent tuberculosis Larissa Gorbach (Minsk, Belarus)	08:00 - 08:00
TBS-EP746	Platelet-to-lymphocyte-ratio in children and adolescents with pulmonary tuberculosis and latent tuberculosis Larissa Gorbach (Minsk, Belarus)	08:00 - 08:00
TBS-EP755	Computer aided diagnostics for TB diagnosis: Overcoming challenges and leveraging opportunities in LMICs Arnold Kennedy Tumuhairwe (Kampala, Uganda)	08:00 - 08:00
TBS-EP761	Alteration in micromineral levels, cluster of differentiation 4+ and gamma glutamyl transferase in subjects on anti-tuberculosis	08:00 - 08:00

	chemotherapy at Infectious Disease Hospital Calabar, Nigeria Raymond Eworo (Calabar, Nigeria)	
TBS-EP767	Targeting TB granulomas to develop HDTs Mohlopheni Jackson Marakalala (Cape Town, South Africa)	08:00 - 08:00
TBS-EP773	Genotypes of <i>Mycobacterium tuberculosis</i> complex isolated from GeneXpert negative PTB patients: Whole genome sequence based comparative study Alem Alemayehu (Addis Ababa, Ethiopia)	08:00 - 08:00
TBS-EP779	Systemic immune inflammation index and systemic inflammation response index in children with pulmonary tuberculosis and latent tuberculosis Larissa Gorbach (Minsk, Belarus)	08:00 - 08:00
TBS-EP782	The impact of information technology on the epidemiological profile of tuberculosis in the socio-economic zones of the Republic of Sakha Aleksey Kazakov (Moscow, Russian Federation)	08:00 - 08:00
TBS-EP785	Modern capabilities of neural network models in the analysis of chest X-rays: A systematic review Aleksey Kazakov (Moscow, Russian Federation)	08:00 - 08:00
TBS-EP788	Characteristics of non-specific microflora in patients with pulmonary tuberculosis Anastasiya Gaida (Moscow, Russian Federation)	08:00 - 08:00
<i>Break</i>		
09:00 - 09:15		Main
Break/Networking		
<i>Community Connect Sessions</i>		
09:00 - 09:45		CC
CCS014 - Power, policy and people: Mobilising political will and resources to end TB		
Usman Rasool Lodhi (Islamabad, Pakistan)		
Suvanand Sahu (Switzerland)		
Syed Karam Shah (Pakistan)		
	Introduction	09:00 - 09:05
	Turning advocacy into action: Securing TB financing in a shifting donor landscape Kinz Ul Eman (Islamabad, Pakistan)	09:05 - 09:10
	Provincial innovation under pressure: Sindh's sustainability reforms for TB Samreen Ashraf Qureshi (Hyderabad, Pakistan)	09:10 - 09:15
	Reimagining TB financing: Global Fund perspectives on resilience and sustainability Mohammed Yassin (Geneva, Switzerland)	09:15 - 09:20
	National Resilience in Transition: Building Fiscal Independence for a Sustainable TB Response in Pakistan Abdul Wali Khan (Pakistan)	09:20 - 09:25
	Global accountability and national action: Aligning political will with resource needs Suvanand Sahu (Switzerland)	09:25 - 09:30
	Question and answers	09:30 - 09:45

Community Connect Sessions

09:00 - 10:40

CCC

CCWS001 - From experience to impact: Community voices leading the TB response

Charity Femeyibor (Accra, Ghana)

Jerry Amoah-Larbi (Ghana)

Introduction

09:00 - 09:10

Panel discussion - From experience to impact: Community voices leading the TB response in Ghana

09:10 - 09:50

Charity Femeyibor (Accra, Ghana)

Jerry Amoah-Larbi (Ghana)

Bernard Ziem (Ghana)

Prince Gyasi (Ghana)

Moderated question and answer

09:50 - 10:10

Charity Femeyibor (Accra, Ghana)

Closing reflections

10:10 - 10:25

Wrap up

10:25 - 10:40

Community Connect

09:00 - 17:00

CCART

CCAE003 - 'Hospitality': Selected Works (Preview) Exhibition by artist and TB survivor Paulina Siniatkina

Paulina Siniatkina (Netherlands)

TBScience Sessions

09:05 - 10:00

TBS

TBS08 - Mixed oral abstract presentations III

Bruno Bezerill Andrade (Salvador, Brazil)

TBS08-05

Session introduction

09:05 - 09:07

TBS08-10

Innovating TB diagnosis: A model-based evaluation of tongue swab molecular testing across four high-burden countries

09:07 - 09:14

Florian Marx (Germany)

TBS08-15

Nutritional markers and poor weight gain during tuberculosis treatment are associated with persistent inflammation and post-tuberculosis lung disease

09:14 - 09:21

Akshay Gupte (Boston, United States)

TBS08-20

Detection of aerosolised *Mycobacterium tuberculosis* DNA from adults with presumed pulmonary tuberculosis using an electrostatic sampler in a South African primary care setting

09:21 - 09:28

Jay Achar (Stockholm, Sweden)

TBS08-25

Universal screening for asymptomatic TB among adults with household exposure to a patient with pulmonary TB

09:28 - 09:35

Simon C Mendelsohn (Cape Town, South Africa)

TBS08-30

Integration of ELISA and LAMP in a Novel urine-based assay: A visual, rapid, and non-invasive approach for diagnosing pediatric tuberculosis

09:35 - 09:42

Indu Verma (Chandigarh, India)

TBS08-35

Q&A

09:42 - 10:00

Symposia

09:15 - 10:45

Main

SY15-250-15 - The paediatric TB meningitis SURE trial: What have we learnt?

Varinder Singh (New Delhi, India)

James Seddon (Cape Town, South Africa)

Introduction

09:15 - 09:20

Overview of the SURE trial design, conduct and results

09:20 - 09:35

Suzanne Anderson (London, United Kingdom)

Low paediatric lumbar puncture rates highlight the need for sustained and effective interventions to improve diagnosis of paediatric TBM

09:35 - 09:50

Christina Zulu (Lusaka, Zambia)

Pharmacokinetics (PK) and pharmacodynamics (PD) of TB drugs in the SURE trial

09:50 - 10:05

Rob Aarnoutse (Nijmegen, Netherlands)

Neuro-imaging in the SURE trial

10:05 - 10:20

Naveen Sankhyan (Chandigarh, India)

Post-TBM neurological sequelae: outcomes and challenges

10:20 - 10:35

Julie Huynh (Ho Chi Minh City, Vietnam)

Q&A

10:35 - 10:45

Oral Abstract Sessions

09:15 - 10:45

R1

OA16 - Reaching the hard-to-reach: Increasing access and uptake

Alvin Kuo Jing Teo (Sydney, Australia)

Emma Smith (Darwin, Australia)

Introduction

09:15 - 09:20

OA16-249-20

Measuring TB stigma and its impact on accessing TB care: A study of 15 countries

09:20 - 09:27

James Malar (Genève, Switzerland)

OA16-250-20

Content strategies on TikTok to address TB stigma: A quantitative study of engagement on @TuberculosisTV

09:27 - 09:34

Muhamad Dea Firdaus (Jakarta, Indonesia)

OA16-251-20

Leveraging social media and television campaigns to raise awareness of TB during the war in Ukraine

09:34 - 09:41

Zahedul Islam (Kyiv, Ukraine)

OA16-252-20

The power of friendship: A child-centred comic to overcome TB stigma during the war in Ukraine

09:41 - 09:48

Yevheniia Kuvshynova (Kyiv, Ukraine, Ukraine)

OA16-253-20

Improving TB detection among men at community level: A case study from Malawi

09:48 - 09:55

Peter Mwamlima (Lilongwe, Malawi)

OA16-254-20

Challenges in TB screening among internally displaced persons: A case study of Benue state Nigeria

09:55 - 10:02

Stephanie Gande (Abuja, Nigeria)

OA16-255-20

Prevalence and associated factors of TB among tea estate workers in Thyolo and Mulanje districts, Malawi: A cross-sectional study

10:02 - 10:09

Benson Isake Chiwaka (Thyolo, Malawi)

OA16-256-20

Using people-centred approach to enhance finding TB in internally

10:09 - 10:16

	displaced persons (IDPs) during the war in Ukraine Evgenia Geliukh (Kyiv, Ukraine)	
OA16-257-20	Integrating TB services into mobile clinics in nomadic settings: An evaluation of the TB LON 1&2 Wellness on Wheels innovation in Bauchi State, Nigeria Chinenye Igwetu (Federal Capital Territory, Nigeria)	10:16 - 10:23
OA16-258-20	Prevalence of TB among people with substance abuse disorder: Lessons on collaboration with traditional mental health homes for TB detection in Southwest Nigeria Abiola Alege (Lagos, Nigeria)	10:23 - 10:30
	Q&A	10:30 - 10:45
<i>Special Sessions</i>		
09:15 - 10:45		R2
	SPS04 - One person, many diseases: Managing TB, HIV, HCV and social challenges in Europe Liga Kukša (Stopinū pag, Ropažu novads, Latvia) Askar Yedilbayev (Denmark)	
	Introduction	09:15 - 09:20
	Patient Pathway in a Western European Clinic Onno Akkerman (Groningen, Netherlands)	09:20 - 09:30
	Patient Pathway in an Eastern European Clinic Akaki Abutidze (Georgia)	09:30 - 09:40
	Managing TB/HIV/HCV coinfections: Best practices and challenges Ole Kirk (Copenhagen, Denmark)	09:40 - 09:55
	Navigating drug-drug interactions: HIV-TB-HCV and beyond Catia Marzolini (Switzerland)	09:55 - 10:10
	Social aspects of management of a person with TB: The community perspective Alistair Story (United Kingdom)	10:10 - 10:20
	Panel discussion with Q&A	10:20 - 10:45
<i>Oral Abstract Sessions</i>		
09:15 - 10:45		R3
	OA17 - TB screening and finding TB in marginalised populations Alberto Garcia Basteiro (Manhiça, Mozambique) Christian Wejse (Aarhus N, Denmark) Hongjo Choi (Seoul, Korea, Republic of)	
In	Introduction	09:15 - 09:20
OA17-259-20	Finding TB among children in seemingly safe places: Lessons from multi-sectoral collaboration on TBLON3 in Ogun State, Nigeria Abiola Alege (Lagos, Nigeria)	09:20 - 09:27
OA17-261-20	Finding TB among internally displaced persons: Navigating hard-to-reach underserved communities of Adamawa State, Northeast Nigeria Suraj Abdulkarim (Gombe, Nigeria)	09:27 - 09:34
OA17-262-20	Active TB case finding using digital chest X-ray with artificial intelligence in prisons of Nepal: An initial experience Basundhara Sharma (Thimi, Nepal)	09:34 - 09:41
OA17-263-20	Reaching the unreached: Programmatic innovations for	09:41 - 09:48

	identification of TB among underserved populations in Bangladesh Farhana Nishat Seheli (Dhaka, Bangladesh)	
OA17-264-20	Enhanced diagnosis of asymptomatic TB in vulnerable populations: Impact of the 100 days TB Mukht Bharat Abhiyan compared to previous year Dimpal Panchal (New Delhi, India)	09:48 - 09:55
OA17-265-20	Addressing TB at the nexus of incarceration and conflict: Computer-aided detection-based mobile active case finding in prisons of Haiti and the Central African Republic Margarette Bury (Port-au-Prince, Haiti)	09:55 - 10:02
OA17-266-20	Facilitators and barriers for the implementation of peer-led TB active case finding among people who use drugs in Dar es Salaam, Tanzania Lilian Tina Minja (Mbeya, Tanzania)	10:02 - 10:09
OA17-267-20	Integrated NCD and TB screening to improve active case finding in India Trisha Chandra (New Delhi, India)	10:09 - 10:16
OA17-268-20	Formative evaluation of community wide screening using ultra-portable handheld X-rays in urban slums of Delhi, India Kamalini Mukhopadhyaya (New Delhi, India)	10:16 - 10:23
OA17-260-20	Efficiency of different active TB case finding strategies among coal mine communities in Pakistan Kinz Ul Eman (Islamabad, Pakistan)	10:23 - 10:30
	Q&A	10:30 - 10:45
 <i>Symposia</i>		
	09:15 - 10:45	R4
	SY16-260-16 - CAD-supported chest radiography for TB screening and diagnosis in children as well as young adolescents: Key advances and remaining gaps Martina Casenghi (Geneva, Switzerland) Cecily Miller (Geneva, Switzerland)	
	Introduction	09:15 - 09:20
	Performance of available CAD algorithms for identifying TB in children and adolescents: Results from the CAPTURE Consortium multi-country CXR dataset Megan Palmer (Cape Town, South Africa)	09:20 - 09:35
	Start4All: The evaluation of CAD for childhood TB in Cameroon and Viet Nam Rachel Byrne (Liverpool, United Kingdom)	09:35 - 09:50
	Evaluation of CAD performance for diagnosis of TB in children: Evidence from the multi-country TACTiC study Juno Min (Amsterdam, Netherlands)	09:50 - 10:05
	Evaluating CAD performance in combination with minimally invasive tools for young children with presumed TB: First findings from the NOD-pedFEND study Francesca Basile (Oxford, United Kingdom)	10:05 - 10:20
	Development of a paediatric TB-CAD evaluation framework: Key updates from a consensus building process Irina Aulianisa (Seoul, Korea, Republic of)	10:20 - 10:35
	Q&A	10:35 - 10:45

Short Oral Abstract Sessions

09:15 - 10:45

R5

SOA08 - New TB diagnostics in the pipeline

Claudia Denking (Heidelberg, Germany)

Lina Davies Forsman (Stockholm, Sweden)

In	Introduction	09:15 - 09:18
SOA08-582-20	'Sputum is King', but other TB diagnostics are gaining ground: Exploring perceptions of specimens for TB testing in South Africa through the TUTIPlus study Leisha Genade (Johannesburg, South Africa)	09:18 - 09:25
SOA08-583-20	Healthcare worker acceptance of tongue swabs for TB screening with migrants in Italy: A qualitative study Renee Codsi (Seattle, United States)	09:25 - 09:32
SOA08-584-20	Diagnostic accuracy of MultNAT and PortNAT with Swab Sample compared with Xpert MTB/RIF Ultra for <i>M.tuberculosis</i> detection in Nigeria Timan Taryuta Eliya (Karu, Nigeria)	09:32 - 09:39
SOA08-585-20	Sensitivity of PortNAT TB tongue swabs in adults with confirmed pulmonary TB: Results from a diagnostic study Han T. Nguyen (Ha Noi, Vietnam)	09:39 - 09:46
SOA08-586-20	Evaluation of clinical performances of the PATHFAST TB LAM Ag assay: A new diagnostic test for TB Théo Fouchet (Dijon, France)	09:46 - 09:53
SOA08-587-20	Lipoarabinomannan (LAM) as a biomarker for the diagnosis of TB Steffen Pichlo (Borstel, Germany)	09:53 - 10:00
SOA08-588-20	Performance of Fujifilm SILVAMP TB LAM for detection of pulmonary TB across different healthcare facilities and urban-slum communities in Bangladesh Syed Mohammad Mazidur Rahman (Dhaka, Bangladesh)	10:00 - 10:07
SOA08-589-20	Diagnostic accuracy and reproducibility of the FujiLAM II point-of-care assay to detect TB in stored urine specimens Nestor Biatu (Bamenda, Cameroon)	10:07 - 10:14
SOA08-590-20	Effect of sputum quality on performance of tuberculosis molecular bacterial load assay for tuberculosis diagnosis and treatment monitoring among adults in Uganda Wilber Sabiiti (Glasgow, United Kingdom)	10:14 - 10:21
SOA08-592-20	Xpert MTB/XDR external quality assurance rollout by NTP Bangladesh: A milestone unveiled Umme Tasnim Maliha (Dhaka, Bangladesh)	10:21 - 10:28
SOA08-593-20	Incorporating differential test attributes into population-level models of new TB diagnostics Maria Bekker-Nielsen Dunbar (Heidelberg, Germany)	10:28 - 10:35
	Q&A	10:35 - 10:45

Oral Abstract Sessions

09:15 - 10:45

R6

OA18 - Building sustainable systems and workforce

Nesri Padayatchi (Durban, South Africa)

Andrew Steenhoff (Philadelphia, United States)

Introduction

09:15 - 09:20

OA18-269-20	Leveraging WHO standards to improve TB diagnostic access for universal health coverage in Zambia Judith Mzyece (Lusaka, Zambia)	09:20 - 09:28
OA18-270-20	Building resilient health systems: Enhancing TB prevention and care in Ghana's private sector through capacity building Ernestina Sam (Accra, Ghana)	09:28 - 09:36
OA18-271-20	Capacity building for health workers: Enhancing prevention of mother-to-child transmission (PMTCT) and TB/HIV services in resource-constrained environments based on the Katsina experience Abishai Galadima (Katsina, Nigeria)	09:36 - 09:44
OA18-272-20	Sustaining best practices: An iECHO hub model Kwatekai Lockhart (Houston, United States)	09:44 - 09:52
OA18-273-20	Utilising a grading tool to improve performance of reference laboratories in India's National TB Elimination Programme Jyoti Kayesth (New Delhi, India)	09:52 - 10:00
OA18-274-20	Empowered to power machines: GeneXpert superuser model is optimising TB diagnostics in Kenya Jeremiah Ogoro (Nairobi, Kenya)	10:00 - 10:08
OA18-275-20	Closing the diagnostic gap: How Nigeria's optimised sample transport networks boosted TB detection by 105%: A model for scale-up? Abraham Joseph (Kano, Nigeria)	10:08 - 10:16
OA18-276-20	Scaling-up and optimisation of laboratories for diagnosing drug-resistant TB in Uttar Pradesh, India Bharatesh Karunakar Shetty (Lucknow, India)	10:16 - 10:24
OA18-277-20	Transforming primary healthcare services through strategic mentorship approaches in Machakos County, Kenya Elizabeth Atieno Odhiambo (Machakos, Kenya)	10:24 - 10:32
	Q&A	10:32 - 10:45
 <i>Symposia</i>		
09:15 - 10:45		R7
	SY17-270-17 - Tomorrow is here: Innovative financing for the future of TB funding Lindsay Palazuelos (Boston, United States)	
	Introduction	09:15 - 09:20
	Where are we now: A landscape of TB funding changes and challenges in 2025 Janika Hauser (London, United Kingdom)	09:20 - 09:35
	When aid fails: The impact of USAID terminations on TB affected communities Stephen Anguva (Nairobi, Kenya)	09:35 - 09:50
	Building a new funding order: Reforming TB finance towards domestic driven agendas Luan Nguyen Quang Vo (Ha Noi, Vietnam)	09:50 - 10:05
	Sovereign debt relief and reform as pathway to domestic resource mobilisation for investments in TB Erin McConnell (New York, United States)	10:05 - 10:20
	The untapped potential of Special Drawing Rights (SDRs) in the fight against TB	10:20 - 10:35

	Ivana Vasic-Lalovic (Serbia)	
	Q&A	10:35 - 10:45
	<i>Short Oral Abstract Sessions</i>	
	09:15 - 10:45	R8
	SOA09 - Communities at the centre: Driving TB awareness, support, and science	
	Chelsie Cintron (Providence, United States)	
	Attannon Arnould Fiogbé (Cotonou, Benin)	
In	Introduction	09:15 - 09:18
SOA09-594-20	“Make sure you involve us”: Experiences and care needs among youth with TB in East Africa Leslie Enane (Indianapolis, United States)	09:18 - 09:24
SOA09-595-20	From research conceptualisation to scientific publication: A community actor’s journey with TB research Yuliia Kalancha (Kyiv, Ukraine)	09:24 - 09:30
SOA09-596-20	Aida on WhatsApp: AI-powered support for TB treatment Kristian van Kalmthout (The Hague, Netherlands)	09:30 - 09:36
SOA09-597-20	Community radio stations: A powerful, real and relatable, 'last mile' communications platform, going beyond, resulting in early TB screening and testing Anisha Singh (New Delhi, India)	09:36 - 09:42
SOA09-598-20	Enhancing TB treatment adherence: Evaluation of a digital support tool in Argentina Sarah Iribarren (Seattle, United States)	09:42 - 09:48
SOA09-599-20	Engaging religious leaders to drive active TB case finding at the community level: Implementation outcomes from Enugu State, Nigeria Uchenna Okoye (Enugu, Nigeria)	09:48 - 09:54
SOA09-600-20	Improving knowledge and access to health and development information for illiterate women and girls in three urban slums in Southeast Nigeria Francis Iyama (Enugu, Nigeria)	09:54 - 10:00
SOA09-601-20	Enhancing the detection of people with TB (PwTB) in Mozambique Benedita Jose (Maputo, Mozambique)	10:00 - 10:06
SOA09-602-20	Finding the forgotten: Community-led TB surveillance in fragile, conflict-affected communities in Borno and Adamawa States of Northern Nigeria Olayemi Olupitan (Abuja, Nigeria)	10:06 - 10:12
SOA09-603-20	Strengthening accountability in service delivery and commodity availability through community-led monitoring: A collaborative approach in Kenya Catherine Kamau (Mombasa, Kenya)	10:12 - 10:18
SOA09-604-20	Beyond the pack: Integrating behavioural science to strengthen pictorial health warnings in India Sanjeeta Agnihotri (New Delhi, India)	10:18 - 10:24
SOA09-605-20	Amplifying TB treatment uptake through strategic engagement of corporate laboratories in UP and Delhi, India Sangita Pandey (Noida, Delhi-NCR, India)	10:24 - 10:30
	Q&A	10:30 - 10:45

Community Connect Sessions

10:00 - 10:45

CC

CCS022 - From research conceptualisation to scientific publication: A community actor's journey with TB research

Lesia Tonkonoh (Kyiv, Ukraine)

Yuliia Kalancha (Kyiv, Ukraine)

Introduction

10:00 - 10:02

A practical algorithm for community-led TB research publishing: Lessons and tools

10:02 - 10:09

Yuliia Kalancha (Kyiv, Ukraine)

Community evidence, scientific rigour: Using publication frameworks to amplify voices

10:09 - 10:16

Yuliya Chorna (Toronto, Canada)

Tools and capacity building for community-led publishing: What works

10:16 - 10:23

Amrita Daftary (Toronto, Canada)

Publishing in open access and peer-reviewed journals: What communities should know

10:23 - 10:30

Oxana Rucsineanu (Moldova)

Question and answers

10:30 - 10:45

TBScience Sessions

10:05 - 11:00

TBS

TBS09 - AI design of studies and interventions: Trials and case retention strategies

Willem Hanekom (South Africa)

Timothy Walker (Oxford, United Kingdom)

TBS09-05

Session introduction

10:05 - 10:07

TBS09-10

Artificial intelligence for tuberculosis control: a scoping review of applications in public health

10:07 - 10:27

Sonia Menon (Brussels, Belgium)

TBS09-20

The future of AI in TB - Panel discussion

10:27 - 11:00

Joseph Sugie (United States)

Isabelle Bekerredjian Ding (Germany)

Morten Ruhwald (Copenhagen, Denmark)

Sonia Menon (Brussels, Belgium)

Break

10:45 - 11:00

Main

Break/Networking

Plenary Sessions

11:00 - 12:00

Main

PL03 - Place, politics, morals and equity: Reimagining TB prevention and care

Ashna Ashesh (Patna, India)

Anete Trajman (Rio de Janeiro, Brazil)

Introduction

11:00 - 11:05

What is a in a neighbourhood and how is it measured? Social context and assessment methods in TB epidemiology

11:05 - 11:20

Dustin Duncan (United States)

Where TB occurs: The politics and place of treatment and prevention

11:20 - 11:35

	Diego S. Silva (Sydney, Australia)	
	Centring equity as core to the TB response	11:35 - 11:50
	Amrita Daftary (Toronto, Canada)	
	Panel discussion with Q&A	11:50 - 12:00
<i>Break</i>		
12:00 - 14:10		Main
Break/Networking		
<i>E-Posters</i>		
12:05 - 13:05		B1A
	EP28 - Advances in diagnosis, epidemiology and management of non-tuberculous mycobacterial disease	
	Gisela Unis (Brasilia, Brazil)	
EP28-965-20	A cross-sectional survey of people with NTM pulmonary disease	12:05 - 12:10
	Parvaneh Baghaei Shiva (Tehran, Iran)	
EP28-967-20	Characterisation of NTM isolated in a TB research laboratory using whole genome sequencing, Lusaka, Zambia	12:10 - 12:15
	Brian Shuma (Lusaka, Zambia)	
EP28-968-20	Molecular subspeciation and antimicrobial resistance prediction in <i>M. avium</i> complex by whole genome sequencing	12:15 - 12:20
	Hafid Soualhine (Winnipeg, Canada)	
EP28-969-20	Real-world treatment status of nontuberculous NTM lung disease: Course, restart and regiment switch	12:20 - 12:25
	Chin-Chung Shu (Taipei, Taiwan)	
EP28-970-20	Multiplex targeted peptidome platform for rapid identification of NTM species	12:25 - 12:30
	Jia Fan (New Orleans, United States)	
EP28-971-20	Burden of disease in persons with NTM in three west African countries: A prospective cohort study	12:30 - 12:35
	Elizabeth Tabitha Abbew (Cape Coast, Ghana)	
EP28-972-20	Geographic distribution of most prevalent NTM disease in Brazil	12:35 - 12:40
	Gisela Unis (Brasilia, Brazil)	
	Q&A	12:40 - 12:55
<i>E-Posters</i>		
12:05 - 13:05		B1B
	EP29 - Breaking the cycle of <i>M. tuberculosis</i> infection	
	Shifa Salman Habib (Karachi, Pakistan)	
EP29-973-20	Prevalence and risk factors of latent tuberculosis infection in Rwanda, 2024	12:05 - 12:10
	Byiringiro Rusisiro (Kigali, Rwanda)	
EP29-974-20	Temporal trend of tuberculosis infection incidence in a priority municipality in Brazil (2019-2024)	12:10 - 12:15
	Thiago Nascimento do Prado (Vitória, Brazil)	
EP29-975-20	Epidemiology of tuberculosis infection among general population in a selected district of Bangladesh	12:15 - 12:20
	Mohammad Khaja Mafij Uddin (Dhaka, Bangladesh)	
EP29-976-20	Temporal and geographic variations in TB case detection: A 2023 national analysis from Nigeria	12:20 - 12:25

	Ekoche Juliana Ikeh (Abuja, Nigeria)	
EP29-977-20	Diagnostic integration for sustainability in resource limited countries: A case of Zambia Judith Mzyece (Lusaka, Zambia)	12:25 - 12:30
EP29-978-20	Decentralized nucleic acid amplification testing and systematic active case finding for ending tuberculosis in the Lakshadweep Islands, India Gayathri A. V. (Kochi, India)	12:30 - 12:35
EP29-979-20	Delays in TB treatment among people with pulmonary TB in East Africa: Findings from a prospective cohort study Kirsten Prabhudas-Strycker (Indianapolis, United States)	12:35 - 12:40
EP29-980-20	Building blocks for prevention: A health system strengthening approach to scaling up TB preventive treatment in Pakistan Kinz Ul Eman (Islamabad, Pakistan)	12:40 - 12:45
EP29-981-20	Managing TB in situations of insecurity and conflict: Experiences from West and Central Africa Christ Kevin Houessinon (Cotonou, Benin)	12:45 - 12:50
EP29-982-20	Implementation of cascade monitoring of TB prevention in Ukraine: Achievements and challenges in the context of war Yana Terleieva (Kyiv, Ukraine)	12:50 - 12:55
	Q&A	12:55 - 13:05
<i>E-Posters</i>		
	12:05 - 13:05	B1C
EP30 - Economic evaluations to improve TB care		
Sedona Sweeney (London, United Kingdom)		
EP30-983-20	Global impact of the BPaL/BPaLM regimens on tuberculosis treatment outcomes and costs: A modeling analysis Theresa Ryckman (Baltimore, United States)	12:05 - 12:10
EP30-984-20	Evaluating the clinical and economic impact of isoniazid resistance detection in tuberculosis molecular testing in Indonesia Ahmad Fuady (Jakarta, Indonesia)	12:10 - 12:15
EP30-985-20	Cost impact of improving test performance in community screening Elena Venero-Garcia (London, United Kingdom)	12:15 - 12:20
EP30-987-20	Chest X-ray and Xpert MTB Rif-Ultra more accurate but costlier than symptom-based screening for same day TB screening, diagnosis and treatment initiation Geofrey Amanywa (Kampala, Uganda)	12:20 - 12:25
EP30-988-20	Patient and household costs of DR-TB care-seeking: Results from the Bring BPaL2Me trial in South Africa Kamban Hirasen (Johannesburg, South Africa)	12:25 - 12:30
EP30-989-20	Catastrophic cost of TB-related death: Results from a cluster-randomised controlled trial in South Africa Kamban Hirasen (Johannesburg, South Africa)	12:30 - 12:35
EP30-990-20	Cost-effectiveness of community tuberculosis screening in South Africa Krishna P. Reddy (Boston, United States)	12:35 - 12:40
EP30-991-20	The impact and cost of using mobile digital X-ray units to detect pulmonary tuberculosis in South Africa Lezanie Coetzee (Johannesburg, South Africa)	12:40 - 12:45

EP30-992-20	Cost-effective tuberculosis diagnosis: Evaluating sputum pooling with Xpert MTB/RIF Ultra in Rwanda Francois Hakizayezu (Kigali, Rwanda)	12:45 - 12:50
	Q&A	12:50 - 13:00
<i>E-Posters</i>		
12:05 - 13:05		B1D
EP31 - Everyone exposed deserves a chance: Contact investigation as a gateway to prevention		
Hanif Esmail (London, United Kingdom) Rein Houben (London, United Kingdom)		
EP31-994-20	Uncovering the hidden threat: Contact investigation among clinically diagnosed TB cases in Lagos State Olugbenga Daniel (Ikeja, Nigeria)	12:05 - 12:10
EP31-995-20	The new contact investigation model for comprehensive tuberculosis case finding by community in East Java Province, Indonesia Mochammad Sholehuddin (Surabaya, Indonesia)	12:10 - 12:15
EP31-996-20	Latent tuberculosis infection and life expectancy: A long-term follow-up on a cohort tested with tuberculin skin test Maiken Kruse Kristensen (Aarhus, Denmark)	12:15 - 12:20
EP31-997-20	Enhancing TB contact investigation and TPT uptake through community volunteer engagement: Evidence from the Global Fund N-THRIP grant in Ondo State, Nigeria Olayemi Olupitan (Abuja, Nigeria)	12:20 - 12:25
EP31-998-20	Long-term impact evaluation of the National Latent Tuberculosis Infection Mass Screening Program among adolescents in South Korea Doyoon Kim (Atlanta, United States)	12:25 - 12:30
EP31-999-20	Factors associated with 28-month TB incidence after isoniazid-rifapentine (3HP) among Ugandan adults with HIV Allan Musinguzi (Kampala, Uganda)	12:30 - 12:35
EP31-1000-20	Estimating the prevalence of tuberculosis infection in the EU/EEA: Results of feasibility assessment Christiaan Mulder (The Hague, Netherlands)	12:35 - 12:40
EP31-1002-20	'Ring Survey' - An innovative blending of active case finding and contact tracing activity under National TB Program. An insight from West Bengal, India Biswajit Chaklader (New Delhi, India)	12:40 - 12:45
	Q&A	12:45 - 13:05
<i>E-Posters</i>		
12:05 - 13:05		B1E
EP32 - Building capacity in systems and people to deliver person-centred care		
Onno Akkerman (Groningen, Netherlands)		
EP32-1003-20	Empowering health staff in the peripheral states of Himachal Pradesh and Odisha for better TB data management under national TB Elimination Program, India Quazi Toufique (Delhi, India)	12:05 - 12:10
EP32-1004-20	Accelerating eCBSS access and utilisation to enhance TB/HIV program implementation through multifaceted, district-led quality improvement initiatives in mid-Western Uganda: The Bunyoro region success story!	12:10 - 12:15

	Raymond Kamara Atuhaire (Kampala, Uganda)	
EP32-1005-20	Evaluating the contributions and challenges of community pharmacies and over-the counter medicine shops in tuberculosis case detection and treatment initiation in Ghana Charity Femeyibor (Accra, Ghana)	12:15 - 12:20
EP32-1006-20	Improving tuberculosis knowledge among community health cadres through national training: Evidence from pre- and post-test evaluation in 229 districts in Indonesia Erman Varella (Jakarta, Indonesia)	12:20 - 12:25
EP32-1007-20	Enhancing tuberculosis case manager training through leader-guided discussions in Taiwan I-Wen Chang (Taipei, Taiwan)	12:25 - 12:30
EP32-1010-20	Pathways to enhance presumptive TB examination rate (PTER)/100,000 population and its impact in TB cases notification in the state of Uttar Pradesh (UP), India Bharatesh Karunakar Shetty (Lucknow, India)	12:30 - 12:35
EP32-1011-20	Kanniq, a confluence of rivers: Inuit determine how lay public health workers can lead the transformation towards person-centered TB care in Nunavik, Quebec, Canada Glenda Sandy (Kuujuuaq, Nunavik, Canada)	12:35 - 12:40
EP32-1012-20	Local action for global goals: A tuberculosis education project in southern Brazil Gabriela Tavares Magnabosco (Maringá, Brazil)	12:40 - 12:45
EP32-1013-20	Integrated TB-mental health services in Nigeria: A task-shifting model for underserved communities Martin Njoku (Enugu, Nigeria)	12:45 - 12:50
EP51-1196-21	Bridging the rural TB care gap: Impact of Ayushman Arogya Mandir (AAM) integration into National Tuberculosis Elimination Programme in Uttar Pradesh, India Bharatesh Karunakar Shetty (Lucknow, India)	12:50 - 12:55
	Q&A	12:55 - 13:05
<i>E-Posters</i>		
	12:05 - 13:05	B1F
EP33 - Characterising the drivers and impacts of TB- related stigma across different contexts		
Nancy Bedingfield (McGill, Canada)		
EP33-1014-20	Toward a conceptual understanding of intersectional stigma and resilience in DRTB-HIV coinfection Jacquelyn Yushkov (Montreal, Canada)	12:05 - 12:10
EP33-1015-20	The landscape of TB stigma in Nepal: Contextual evidence of stigma levels, manifestations, and experiences among people with TB Maxine Caws (Kathmandu, Nepal)	12:10 - 12:15
EP33-1016-20	Tuberculosis stigma and health-seeking behavior: Results from the 2022 Nairobi, Kenya tuberculosis prevalence survey Jennifer M. Ross (Seattle, United States)	12:15 - 12:20
EP33-1017-20	Stigma's dual shadow: TB-HIV misconceptions affect patients and health workers in West Nile, Uganda Louis Ocen (Kampala, Uganda)	12:20 - 12:25
EP33-1018-20	Assessing the impact of stigma on access to TB services in Zimbabwe	12:25 - 12:30

	Donald Denis Tobaiwa (Gweru, Zimbabwe)	
EP33-1020-20	Healthcare providers' perception of tuberculosis-related stigma: Drivers and manifestations within Nepal's cultural contexts Raghu Dhital (Kathmandu, Nepal)	12:30 - 12:35
EP33-1021-20	Manifestations of stigma related to unhealthy alcohol use and its impact among people with tuberculosis or HIV coinfection in Pune, India Nishi Suryavanshi (Pune, India)	12:35 - 12:40
EP33-1022-20	Determinants of tuberculosis-related stigma among school-aged adolescents in Bangkok, Thailand David Livingstone (New Delhi, India)	12:40 - 12:45
EP33-1023-20	The change in the level of TB stigma in Ukraine during 2020-2024 Nadiia Savchenko (Kyiv, Ukraine)	12:45 - 12:50
	Q&A	12:50 - 13:05
<i>E-Posters</i>		
12:05 - 13:05		B1G
EP34 - Advanced tools and strategies to enhance detection		
Jeremy Hill (Sydney, Australia) Alvin Kuo Jing Teo (Sydney, Australia)		
EP34-1024-20	Person-centered solution to repeat sputum collection increases TB diagnosis in Manila, Philippines Catherine Hewison (Paris, France)	12:05 - 12:10
EP34-1025-20	Accuracy of computer aided detection (CAD) for TB screening among ex-miners in Mafeteng District, Lesotho Lawrence Oyewusi (Maseru, Lesotho)	12:10 - 12:15
EP34-1026-20	Active TB case finding amidst insecurity: Wellness On Wheels (WOW) experience In Benue State Nigeria Fila Mathew (Benue, Nigeria)	12:15 - 12:20
EP34-1027-20	Chest X-ray referral and financing partnership to enhance TB diagnosis in South Jakarta, Indonesia Nurliyanti Nurliyanti (Jakarta Selatan, Indonesia)	12:20 - 12:25
EP34-1028-20	Enhancing TB prevention and care efforts among high-risk population: Results from hospital-based targeted service delivery point screening in Nasarawa State, Nigeria Chinenye Igwetu (Federal Capital Territory, Nigeria)	12:25 - 12:30
EP34-1029-20	The contribution of screening to global TB notification Cecily Miller (Geneva, Switzerland)	12:30 - 12:35
EP34-1030-20	Mapping margins: A geospatial and programmatic analysis of TB loss-to-follow-up in border districts of Tamil Nadu, India Minitta Maria Regy (New Delhi, India)	12:35 - 12:40
EP34-1031-20	Community health workers as frontline soldiers in TB prevention and care in Anambra State, Nigeria: Successes and challenges Olawumi Olarewaju (Abuja, Nigeria)	12:40 - 12:45
EP34-1032-20	TB incidence and impact of mass screening and treatment for latent tuberculosis infection among North Korean refugees Yerin Yu (Seoul, Korea, Republic of)	12:45 - 12:50
EP34-1033-20	Screening for TB using ultraportable handheld X-ray with AI for early detection of disease in Bihar, India Pranati Das (Patna, India)	12:50 - 12:55

	Q&A	12:55 - 13:05
<i>E-Posters</i>		
	12:05 - 13:05	B1H
EP35 - Integrating systems to improve TB care outcomes		
Amrita Daftary (Toronto, Canada)		
EP35-1034-20	The effectiveness of community engagement in improving drug-resistance TB service delivery and enrolment outcomes in Kogi State Christiana Iye Stephen (Lokoja, Nigeria)	12:05 - 12:10
EP35-1035-20	Challenges, progress and opportunities towards TB elimination in New South Wales, Australia Ben Marais (Sydney, Australia)	12:10 - 12:15
EP35-1036-20	Performance-based incentives to improve quality of TB care at primary healthcare providers in Indonesia Tiffany Tiara Pakasi (South Jakarta, Indonesia)	12:15 - 12:20
EP35-1037-20	Discrete choice experiment suggests that person-centered treatment support could be achieved by offering a choice between two interventions Courtney Yuen (Boston, United States)	12:20 - 12:25
EP35-1038-20	Providers' perceptions of integrating mental health care in TB services in the Free State, South Africa Gladys Kigozi-Male (Bloemfontein, South Africa)	12:25 - 12:30
EP35-1039-20	Strengthening TB drug supply chains to reduce stockouts: Lessons from Nasarawa State, Nigeria Kingsley Obideje (Lafia, Nigeria)	12:30 - 12:35
EP35-1040-20	Exploring and preparing for BPaLM adoption in India: A system-level analysis using the EPIS framework Sandeep Chauhan (New Delhi, India)	12:35 - 12:40
EP35-1041-20	Challenges in TB referral processes and health workers' perspectives in Indonesia: A qualitative study Agus Fitriangga (Pontianak, Indonesia)	12:40 - 12:45
EP35-1042-20	Empowering change: A study on the role of TB champions in strengthening National TB Elimination Programme indicators in Union territory, Chandigarh in India Pooja Kapoor (New Delhi, India)	12:45 - 12:50
EP35-1043-20	Innovative models for TB/HIV integrated service delivery among pregnant women in an unconventional setting in Ogun State, Nigeria Fadeyi Muse (Ibadan, Nigeria)	12:50 - 12:55
	Q&A	12:55 - 13:05
<i>E-Posters</i>		
	12:05 - 13:05	B1I
EP36 - TB and comorbidities including mental health		
Geetanjali Chander (Seattle, United States)		
EP36-1044-20	Optimising TB care: Differentiated TB care on affected person's outcome (Interventional study in Haveri district, Karnataka) Hamsaveni G (New Delhi, India)	12:05 - 12:10
EP36-1045-20	Predictive analysis of all-cause mortality of initial-treated people with pulmonary TB complicated by hypertension	12:10 - 12:15

	Yiping Leng (Changsha, China)	
EP36-1047-20	Computer-aided detection of cardiomegaly during TB screening: Prevalence and association with hypertension Joowhan Sung (Baltimore, United States)	12:15 - 12:20
EP36-1048-20	Clinicopathological features and diagnostic challenges in concurrent intestinal TB and colorectal cancer: A retrospective cohort study from a TB-endemic region Li Shi (Changsha, Hunan, China)	12:20 - 12:25
EP36-1049-20	Substance use prevalence during TB treatment: A systematic review and meta-analysis in the African region Alanna Bergman (Charlottesville, United States)	12:25 - 12:30
EP36-1050-20	Double burden of mental health issues and TB among people with drug-sensitive and drug-resistant TB in rural India Miranda Brouwer (Haren, Netherlands)	12:30 - 12:35
EP36-1051-20	Empowering adults with TB in Indonesia through a community-based, peer-led psychosocial support intervention to reduce stigma and depression: A qualitative study from the TB-CAPS project Ahmad Fuady (Jakarta, Indonesia)	12:35 - 12:40
EP36-1052-20	Pharmacokinetics of concomitant drug-resistant TB and hepatitis C treatment in Georgia: Preliminary results from the DARE TB/HCV study Mariana Buziashvili (Tbilisi, Georgia)	12:40 - 12:45
	Q&A	12:45 - 13:05
 <i>TBScience E-Poster Sessions</i> 12:05 - 13:05		
TBS-EP-05 - TBScience Moderated E-posters V		
Julia Brake (Nijmegen, Netherlands)		
TBS-EP152	M. tuberculosis exosome detection in peripheral blood for pediatric TB Sylvia LaCourse (Seattle, United States)	12:05 - 12:10
TBS-EP155	MAMS_6 - A novel transcriptome-informed quantitative real-time PCR-based signature for monitoring tuberculosis treatment success Kathrin Held (Munich, Germany)	12:10 - 12:15
TBS-EP158	Automated cough frequency monitoring as a predictor of unfavorable TB outcomes Devan Jaganath (San Francisco, United States)	12:15 - 12:20
TBS-EP161	Optimizing approaches to recover high quality M. tuberculosis genome-wide and within-host variation Katharine Walter (Salt Lake City, United States)	12:20 - 12:25
TBS-EP164	Benchmarking surrogate endpoints for relapse in TB trials: A statistical framework for assessing new biomarkers Mark Warden (San Francisco, United States)	12:25 - 12:30
TBS-EP170	CYP3A5 polymorphisms influence bedaquiline and clofazimine pharmacokinetics in clinical trial participants with MDR/RR-TB across six countries Kesia Esther da Silva (Stanford, United States)	12:30 - 12:35
TBS-EP179	Sputum MGIT culture versus lipoarabinomannan (LAM) assay for evaluating regimen activity in phase 2B trials Anthony Geronimo (Makati City, Philippines)	12:35 - 12:40

Guy Marks (Sydney, Australia)
 Zahedul Islam (Kyiv, Ukraine)
 David Jackson (United Kingdom)
 Kavindhra Velen (Geneva, Switzerland)

Questions and answer with the communities 12:50 - 13:20

E-Posters

13:10 - 14:10

B1A

EP37 - Beyond the cure: Addressing TB sequelae, relapse and reinfection in long-term health

Giovanni Battista Migliori (Tradate, Italy)

EP37-1053-20 **Evaluation of sequelae after treatment completion in people with pulmonary TB in Bamako, Mali** 13:10 - 13:15

Bouke Catherine deJong (Antwerpen, Belgium)

EP37-1054-20 **Post-TB lung function among adults screened for chronic obstructed pulmonary disease in Nepal, Peru and Uganda: A post-hoc analysis of the GECO study** 13:15 - 13:20

Nicola Foster (London, United Kingdom)

EP37-1055-20 **Post-TB chronic pulmonary aspergillosis: Phenotypic heterogeneity and independent predictors of adverse treatment outcomes** 13:20 - 13:25

Qing-Luan Yang (Shanghai, China)

EP37-1056-20 **Identifying gaps in post-TB screening through a comparative study of national guidelines in high-burden countries: A scoping review** 13:25 - 13:30

Samyra R. Cox (Baltimore, United States)

EP37-1057-20 **Optimising active detection of recurrent TB: An individual-based modelling analysis informed by Indian cohorts** 13:30 - 13:35

Emily Kendall (Baltimore, United States)

EP37-1058-20 **Unveiling the dynamics of post-TB recurrence screening among TB healthcare workers in Pune, India: A normalisation process theory perspective** 13:35 - 13:40

Prashant Kulkarni (Pune, India)

EP37-1060-20 **Assessment of TB reinfection rates among previously treated people in Nigeria (October 2022 - June 2024): Implications for targeted intervention strategies** 13:40 - 13:45

Uduak Bassey (Makurdi, Nigeria)

Q&A 13:45 - 13:55

E-Posters

13:10 - 14:10

B1B

EP38 - Uniting forces: Collaborative strategies and policies driving TB progress

Olya Klymenko (Kyiv, Ukraine)

EP38-1061-20 **Sustaining the lifeline: Empowering counties to drive costed integrated specimen referral plans for TB diagnostics** 13:10 - 13:15

James Marcomic (Nairobi, Kenya)

EP38-1062-20 **Improving TB detection in vulnerable urban populations through integrated health services: Evidence from two districts in Greater Accra, Ghana** 13:15 - 13:20

Richard Socrate Adzesi (Accra, Ghana)

EP38-1063-20 **Evaluating community-based initiatives on TB knowledge and attitude in Nasarawa, Nigeria: A machine learning comparison of survey responses** 13:20 - 13:25

Nathan Zoakah (Karu, Nigeria)

EP38-1065-20	Words matter: Caregiver-health worker communication when using paediatric TB treatment decision algorithms Sofia Payotte (Paris, France)	13:25 - 13:30
EP38-1066-20	Assessment of the social support available to TB-affected communities in Viet Nam Rachel Forse (Ho Chi Minh City, Vietnam)	13:30 - 13:35
EP38-1067-20	Breaking barriers: Assessing community-led, rights-based, and gender-transformative TB responses in conflict-affected zones of Tigray, Ethiopia Getachew Dessalegn (Addis Ababa, Ethiopia)	13:35 - 13:40
EP38-1068-20	Putting the pedal to the metal by integrating HIV screening services to other health services through community-led initiatives: Results from GFATM supported project in India Kaushik Biswas (Delhi, India)	13:40 - 13:45
EP38-1069-20	Beyond the Pill: Person-centred support for drug-resistant TB treatment adherence in Delhi (Lessons from the Dream Delhi Project) Sudhi Nath (New Delhi, India)	13:45 - 13:50
EP38-1070-20	Stakeholder perspectives on new TB vaccine introduction in Indonesia: Concerns and priorities Ahmad Fuady (Jakarta, Indonesia)	13:50 - 13:55
	Q&A	13:55 - 14:10
<i>E-Posters</i>		
13:10 - 14:10		B1C
EP39 - Engaging private sector to innovate finding TB		
Jinsoo Min (Seoul, Korea, Republic of)		
EP39-1071-20	Leveraging an intermediary organisation to enhance private sector TB detection in Lagos State, Nigeria Ndidiama Umerah-Nwosu (Lagos, Nigeria)	13:10 - 13:15
EP39-1072-20	Finding TB through the intensified Integrating Screen-For-All (SFA) approach in routine primary care services to improve TB detection in Myanmar Medical Association private-public mix clinics Thet Maung (Yangon, Myanmar)	13:15 - 13:20
EP39-1073-20	Making a case for poor-performing facilities in TB disease identification in the private sector: Avoiding throwing the baby out with the bathwater Hauwa Usman Garba (Kaduna, Nigeria)	13:20 - 13:25
EP39-1074-20	STEPS toward excellence: Ensuring quality of TB care at Yashoda Super Speciality Kaushambi, a private hospital in Uttar Pradesh, India Chhavi Gupta (Ghaziabad, Delhi NCR, India)	13:25 - 13:30
EP39-1075-20	Private public mix (PPM) as a key driver of finding TB in Ogun State (2018-2024) Musibau Akande Tijani (Abeokuta, Nigeria)	13:30 - 13:35
EP39-1076-20	Stand-alone lab intervention: A key driver to scaling up TB diagnosis in the Public Private Mix (PPM) model: A KNCV Nigeria experience Idara Edo (Jos, Nigeria)	13:35 - 13:40
EP39-1077-20	Enhancing finding TB and strengthening the cascade of care: A public private mix approach in Ghana	13:40 - 13:45

	Ernestina Sam (Accra, Ghana)	
EP39-1078-20	Private provider-initiated facility based intensified case finding for TB: Experiences from a private hospital in New Delhi, India Rakesh PS (New Delhi, India)	13:45 - 13:50
EP39-1079-20	Innovative approach to finding TB in the private sector: Results from stand-alone (SALs) private laboratories in Benue State Ongbabo A. Joseph (Benue, Nigeria)	13:50 - 13:55
EP39-1080-20	Impact of a large-scale private sector intervention on TB notifications and treatment outcomes in India: A difference in difference analysis Aakshi Kalra (New Delhi, India)	13:55 - 14:00
	Q&A	14:00 - 14:10
<i>E-Posters</i>		
13:10 - 14:10		B1D
EP40 - Burning planet, broken systems: Addressing TB at the crossroads of climate inequality		
Matthew J. Saunders (London, United Kingdom) Salome Charalambous (Johannesburg, South Africa)		
EP40-1081-20	Impact of climate change on TB in East Africa: Development and validation of a conceptual framework Daniel Chemtob (Montpellier, France)	13:10 - 13:15
EP40-1082-20	TB integrated screening at the coalface of climate-change: Lessons about what works from a qualitative study with Pacific-island leaders and donors Mikaela Coleman (Munich, Germany)	13:15 - 13:20
EP40-1083-20	Environmental impact assessments in TB healthcare settings in Nigeria: The gap between identification and action Nkiru Nwokoye (Abuja, Nigeria)	13:20 - 13:25
EP40-1084-20	Early results from a scoping review examining the intersection of TB and climate change through critical social science and One Health perspectives Amrita Daftary (Toronto, Canada)	13:25 - 13:30
EP40-1085-20	Air pollution and its toll: Unmasking the impact on TB in FCT, Kogi, and Nasarawa states Uche Ekwugha (FCT, Nigeria)	13:30 - 13:35
EP40-1086-20	Is TB prevalence higher in cities or rural areas? A systematic review and meta-analysis of prevalence surveys Seyed Alireza Mortazavi (Glasgow, United Kingdom)	13:35 - 13:40
EP40-1087-20	Outdoor air pollutants impair host immunity via TNF-α and IL-8 suppression, elevating pulmonary TB risk: A two-stage study Jianming Wang (Nanjing, China)	13:40 - 13:45
EP40-1088-20	Social-behavioural determinants shaping TB service uptake among household contacts of people with TB in the Eastern Cape, South Africa Nancy Bedingfield (Montreal, Canada)	13:45 - 13:50
EP40-1089-20	Social inequities in TB treatment uptake: Results from a qualitative intersectional gender research study in Eastern Cape province, South Africa Jeremiah Chikovore (Durban, South Africa)	13:50 - 13:55
EP40-1090-20	Structural violence, poverty, and TB/HIV in Cross River State, South-South Nigeria: A social science perspective on health	13:55 - 14:00

	inequities	
	Steven Batur (Abuja, Nigeria)	
	Q&A	14:00 - 14:10
<i>E-Posters</i>		
13:10 - 14:10		B1E
EP41 - What do you need? Innovation to realise the delivery of person-centred care		
Graeme Hoddinott (Sydney, Australia)		
EP41-1091-20	Improved treatment success rate among drug-susceptible people with TB through pre-treatment and routine counselling addressing stigmatisation in Delta State, Nigeria	13:10 - 13:15
	Chike Ezeanya (Abuja, Nigeria)	
EP41-1092-20	NGO experience in expanding video-DOT support for people with TB via smartphone provision in Ukraine	13:15 - 13:20
	Yana Sheremeta (Kyiv, Ukraine)	
EP41-1093-20	Understanding mental health of individuals who successfully complete their anti-TB treatment: A study from Pune City, India	13:20 - 13:25
	Sachin Atre (Pune, India)	
EP41-1094-20	Enhancing drug-resistant TB treatment compliance through community support: Lessons learned from the community-based drug-resistant programme in Indonesia	13:25 - 13:30
	Betty Nababan (South Jakarta, Indonesia)	
EP41-1095-20	The TRIO model: A community-led triad approach to improve TB adherence and psychosocial support in Zambia	13:30 - 13:35
	Emelly Machisa (Shamva, Zimbabwe)	
EP41-1096-20	Barriers and facilitators in TB nutritional support: A CFIR framework-based qualitative study of TB champions' experiences with Nikshay Poshan Yojana and Nikshay Mitra Yojana	13:35 - 13:40
	Atul Shendge (Sonipat, India)	
EP41-1097-20	TB and social protection: Coverage and execution of the Food Assistance Programme in the State of Rio de Janeiro, Brazil	13:40 - 13:45
	Yan Mathias Alves (Ribeirão Preto, Brazil)	
EP41-1098-20	Impact of livelihood support on the treatment of drug-resistant TB: An excerpt from rural India	13:45 - 13:50
	Miranda Brouwer (Haren, Netherlands)	
EP41-1099-20	Leveraging community treatment supporters (CTS) to improve TB treatment outcomes: Evidence from Papua New Guinea's urban TB response	13:50 - 13:55
	Simon Peter Akena (Port Moresby, Papua New Guinea)	
EP41-1100-20	Acceptability of integrated TB, hypertension and diabetes screening in health facilities and active case finding in Cambodia	13:55 - 14:00
	Sokun Chay (Phnom Penh, Cambodia)	
	Q&A	14:00 - 14:10
<i>E-Posters</i>		
13:10 - 14:10		B1F
EP42 - Innovating TB care: Triage, technology, mobility and workforce solutions for better outcomes		
David Moore (LONDON, United Kingdom)		
Dennis Falzon (Geneva, Switzerland)		
EP42-1101-20	Role of triage audit in an ongoing differentiated TB care initiative to reduce TB deaths in Tamil Nadu, India	13:10 - 13:15

	Hemant Deepak Shewade (Chennai, India)	
EP42-1102-20	Why oxygen plants fail: A case study from The Gambia Samson Jarso (Baltimore, United States)	13:15 - 13:20
EP42-1103-20	Digital technology use and perceptions of VDOT in TB care in São Paulo State, Brazil Yan Mathias Alves (Ribeirão Preto, Brazil)	13:20 - 13:25
EP42-1104-20	Evaluation of TB screening coverage among workers in Lagos State Kehinde Akande (Lagos, Nigeria)	13:25 - 13:30
EP42-1105-20	Increasing utilisation rate and access to TB diagnostics through mobile community intervention efforts: A case study of Primary Health Centre, Jaji Valley-lily Temeoweipreye Ovoh (Abuja, Nigeria)	13:30 - 13:35
EP42-1106-20	Enhancing TB treatment outcomes in high mobility, densely populated urban hubs: Scalable lessons from targeted interventions Aldomoro Burua (Kampala, Uganda)	13:35 - 13:40
EP42-1107-20	Role of TB preventive therapy in reduction of incidence of TB disease among health workers in Bungoma County, Kenya Paul Lodi (Bungoma, Kenya)	13:40 - 13:45
EP42-1108-20	Health care workers screening for TB disease over time in relation to TB mortality in Bungoma County, Kenya Paul Lodi (Bungoma, Kenya)	13:45 - 13:50
EP42-1109-20	Strengthening TB detection in high-risk populations: Findings from an intensified screening campaign among Indian mine workers Mrigen Deka (New Delhi, India)	13:50 - 13:55
	Q&A	13:55 - 14:05
 <i>E-Posters</i>		
	13:10 - 14:10	B1G
EP43 - Diabetes and ageing in TB: Breaking barriers to better care		
Reinout van Crevel (Nijmegen, Netherlands)		
EP43-1110-20	Prognostic value of the glycation gap in predicting TB treatment outcomes Chuan-Chin Huang (Boston, United States)	13:10 - 13:15
EP43-1111-20	Investigating the association between TB infection and multimorbidity in people with diabetes Jiahan Kelly Peng (London, United Kingdom)	13:15 - 13:20
EP43-1112-20	Impact of glycemic control on treatment outcomes in rifampicin-resistant people with TB and with diabetes mellitus: Preliminary data from China Yilin Zhang (Shanghai, China)	13:20 - 13:25
EP43-1114-20	Challenges of diabetes mellitus and drug-resistant TB co-management in Indonesia: A qualitative study Bony Wiem Lestari (Bandung, Indonesia)	13:25 - 13:30
EP43-1115-20	Challenges of caregivers of people with TB and diabetes (PwTB-DM) seeking care from the private sector in Chennai - A cross-sectional descriptive study Ramya Ananthakrishnan (Chennai, India)	13:30 - 13:35
EP43-1116-20	TB in the elderly: A growing challenge and the need for specialised care in Anambra State Mercy Chukwu (Abuja, Nigeria)	13:35 - 13:40

EP43-1117-20	TB in older adults (GERIA-TB): Clinical characteristics and outcomes from a low-incidence country Chiara Sepulcri (Genova, Italy)	13:40 - 13:45
	Q&A	13:45 - 14:00
<i>E-Posters</i>		
13:10 - 14:10		B1H
EP44 - Harnessing Innovation: AI, breathomics, and data science for the future of TB detection, prevention and care		
Xavier Padanilam (Johannesburg, South Africa)		
EP44-1118-20	Breath analysis using HPPI-TOF-MS and spatial attention convolutional neural networks for latent TB infection screening: A diagnostic accuracy study Liang Fu (Shenzhen, China)	13:10 - 13:15
EP44-1119-20	Construction and preliminary validation of a breath-based diagnostic model for bacteriologically unconfirmed pulmonary TB using deep anomaly detection Yucheng Chen (Tianjin, China)	13:15 - 13:20
EP44-1120-20	Transforming TB treatment monitoring with breathomics: A prospective cohort study in drug-susceptible pulmonary TB Liang Fu (Shenzhen, China)	13:20 - 13:25
EP44-1121-20	Streamlined 4-zone point-of-care ultrasound (POCUS) exam for pulmonary TB Lydia Nakiyingi (Kampala, Uganda)	13:25 - 13:30
EP44-1122-20	Prediction of TB risk in the elderly population of Eastern China: Development and validation of multiple machine learning models Peng Lu (Nanjing, China)	13:30 - 13:34
EP44-1123-20	Identification of large TB transmission clusters using machine learning models in Taiwan, Kaohsiung Yi-Hsin Chen (Taipei, Taiwan)	13:34 - 13:39
EP44-1124-20	Predicting loss to follow-up among people with TB in Karamoja, Northern Uganda: A machine learning approach Hilary Akatwijuka (Karamoja, Uganda)	13:39 - 13:44
EP44-1125-20	Predicting TB culture contamination using machine learning: The role of sputum transit time and clinical features Timan Taryuta Eliya (Karu, Nigeria)	13:44 - 13:49
EP44-1126-20	Data visualisation using Microreact dashboards to connect next-generation sequencing analysis, comprehensive test result data and demographics of people with M. tuberculosis in New York state Kimberlee Musser (Albany, United States)	13:49 - 13:54
	Q&A	13:54 - 14:09
<i>E-Posters</i>		
13:10 - 14:10		B1I
EP45 - Innovating multi-sectoral engagement to improve TB care		
Erlina Burhan (Jakarta, Indonesia)		
EP45-1127-20	Association between geographic accessibility and use of the private sector among people with TB in Lima, Peru Ana Millones (Lima, Peru)	13:10 - 13:15
EP45-1128-20	Barriers and best practices in TB treatment initiation across public and private providers in Indonesia: A multi-stakeholder qualitative	13:15 - 13:20

	study	
	Agus Fitriangga (Pontianak, Indonesia)	
EP45-1129-20	Enhancing TB care in private sector in India: Role of innovative private sector engagement model under programmatic settings Sandhya Gupta (New Delhi, India)	13:20 - 13:25
EP45-1130-20	Leveraging corporate social responsibility to enhance molecular diagnosis of TB in Uttar Pradesh Bharatesh Karunakar Shetty (Lucknow, India)	13:25 - 13:30
EP45-1131-20	Is private sector challenging to engage on addressing TB? Situation analysis in Bangladesh Rupali Sisir Banu (Dhaka, Bangladesh)	13:30 - 13:35
EP45-1132-20	Disparities in drug-resistant TB detection: A comparative analysis of private healthcare settings and community-based case finding in Katsina State, Nigeria Micheal Sheshi (Abuja, Nigeria)	13:35 - 13:40
EP45-1133-20	Institutionalising multi-ministerial accountability for TB prevention and care: High-level advocacy and subnational monitoring to enhance commitment, TB funding and detection in Indonesia Tiffany Tiara Pakasi (South Jakarta, Indonesia)	13:40 - 13:45
EP45-1134-20	Accelerating TB elimination in Uganda: A multisectoral accountability framework approach Mathius Mwesige (Kampala, Uganda)	13:45 - 13:50
EP45-1135-20	Accelerating Uganda's fight achieving UNHLM targets to end Alex Mulindwa (Kampala, Uganda)	13:50 - 13:55
EP45-1136-20	Bridging the gap in drug-sensitive TB treatment initiation in Indonesia: Insights from a national assessment and pathways for public-private collaboration I Wayan Gede Artawan Eka Putra (Denpasar, Indonesia)	13:55 - 14:00
	Q&A	14:00 - 14:10

TBScience E-Poster Sessions
13:10 - 14:10

TBS-EP-06 - TBScience Moderated E-posters VI

Indu Verma (Chandigarh, India)

TBS-EP182	Deep learning on longitudinal chest CT predicts treatment outcomes in multidrug-resistant tuberculosis: A multicentre retrospective study Li Jie (Nanchang, China)	13:10 - 13:15
TBS-EP185	Development of a biomarker to monitor children treated for non-severe tuberculosis James Seddon (Cape Town, South Africa)	13:15 - 13:20
TBS-EP188	Novel nanoparticle respiratory tract mucosal tuberculosis vaccine Frederick Quinn (Athens, United States)	13:20 - 13:25
TBS-EP191	Adaptation of MBLA for quantification of bacterial load in the clinical routine laboratory Katarina Niward (Linköping, Sweden)	13:25 - 13:30
TBS-EP197	Strain-specific host-pathogen sympatry drives tuberculosis spread and drug resistance dissemination in Nigeria Opeyemi Alayande (Ibadan, Nigeria)	13:30 - 13:35

TBS-EP200	Prominent <i>M. tuberculosis</i> biomarkers among sputum culture-negative patients Yingda Xie (Newark, NJ, United States)	13:35 - 13:40
TBS-EP203	Performance of the <i>DREstimator</i> tool to predict the phenotypic effect of genomic variants in <i>Mycobacterium tuberculosis</i> - A validation study Miguel de Diego Fuertes (Antwerp, Belgium)	13:40 - 13:45
TBS-EP206	Revisiting the mouse model for tuberculosis-malaria co-infections through the natural routes to measure immunopathology and pathogen fitness Tuhina Gupta (Athens, United States)	13:45 - 13:50
TBS-EP209	Can emergence of canonical mechanisms of isoniazid resistance in tuberculosis be predicted? Faramarz Valafar (San Diego, United States)	13:50 - 13:55
TBS-EP212	Assessing the translational value of <i>in vitro</i> time-kill assays in TB drug regimens development Marie Sylvianne Rabodoarivelo (Zaragoza, Spain)	13:55 - 14:00
TBS-EP213	Q&A	14:00 - 14:10

Spotlight Sessions

14:10 - 15:40

Main

SL03 - Tuberculosis: New warriors take on an old enemy

Madhukar Pai (Montreal, Canada)

Introduction

14:10 - 14:15

Stigmatized: A Mongolian girl's journey from stigma & illness to empowerment

14:15 - 14:30

Handaa Enkh-Amgalan (Berlin, Germany)

Everything is Tuberculosis

14:30 - 14:45

John Green (United States)

The Black Angels

14:45 - 15:00

Maria Smilios (Asheville, United States)

Phantom plague: How tuberculosis shaped our history

15:00 - 15:15

Vidya Krishnan (Goa, India)

Q&A from the audience

15:15 - 15:35

Wrap-up

15:35 - 15:40

Symposia

14:10 - 15:40

TBS

SY18-280-18 - Optimising TB screening as a critical gateway to TB care: Recent advances in available and emerging tools and technologies

Cecily Miller (Geneva, Switzerland)

Martina Casenghi (Geneva, Switzerland)

Introduction

14:10 - 14:15

Updated WHO Target Product Profiles for novel TB screening tools and technologies

14:15 - 14:30

Cecily Miller (Geneva, Switzerland)

Head-to-Head comparison of CAD-CXR, LF-LAM and CRP for TB screening: Results from the Start4All study

14:30 - 14:45

	Sayera Banu (Dhaka, Bangladesh)	
	CAD-supported CXR for TB screening: Review of latest evidence and WHO policy update	14:45 - 15:00
	Mikashmi Kohli (Geneva, Switzerland)	
	Advances and challenges in AI-based cough analysis for TB screening	15:00 - 15:15
	Alexandra Zimmer (Heidelberg, Germany)	
	Leveraging oral swab-based molecular diagnostics for scalable TB detection	15:15 - 15:30
	Seda Yerlikaya (Heidelberg, Germany)	
	Q&A	15:30 - 15:40
<i>Short Oral Abstract Sessions</i>		
	14:10 - 15:40	R1
	SOA10 - Reducing risk for close contacts of people with TB: Find, treat, prevent	
	Edson Tawanda Marambire (Harare, Zimbabwe)	
	Yohhei Hamada (London, United Kingdom)	
	Introduction	14:10 - 14:13
SOA10-606-20	Finding TB through community-led interventions: Using clinically diagnosed people with TB to reach their social contacts for TB investigations in Wakiso district, Uganda	14:13 - 14:19
	Lydia Namusisi (Kampala, Uganda)	
SOA10-607-20	Chest radiographic TB screening using human vs. artificial intelligence reads in asymptomatic adult household contacts in South Africa	14:19 - 14:25
	Sarah Nyangu (Cape Town, South Africa)	
SOA10-608-20	Role of cadres to increase finding TB through contact investigation based on household and community outreach in Palangkaraya City and Kotim District	14:25 - 14:31
	Betty Nababan (South Jakarta, Indonesia)	
SOA10-609-20	A novel bioinformatics household linkage technique reveals populations at high risk for TB infection within a multi-state US community health network	14:31 - 14:37
	Jeffrey Campbell (Boston, United States)	
SOA10-610-20	Harnessing digital innovations for enhancing contact tracing, early diagnosis and prevention of TB in 15 selected districts of Sindh, Pakistan	14:37 - 14:43
	Mariam Malik (Lahore, Pakistan)	
SOA10-611-20	Enhancing finding TB through optimized screening: Lessons from the spot to tent onion model (STOM) of contact investigation	14:43 - 14:49
	Iboro Gordon (Abuja, Nigeria)	
SOA10-612-20	The value of contact investigation in a human population affected by bacteriological confirmed <i>M. bovis</i>	14:49 - 14:55
	Sophie Toumanian (Twente, Netherlands)	
SOA10-613-20	Improving contact tracing and TB diagnosis in children in a drug-resistant TB programme in Punjab province, Pakistan	14:55 - 15:01
	Laura Sannino (Paris, France)	
SOA10-615-20	Optimising TB preventive therapy: A comparative study of completion rates for isoniazid (6H) and isoniazid-rifampicin (3HR) regimens, USAID TB LON 3 project experience	15:01 - 15:07
	Ify Genevieve Ifeanyi-Ukaegbu (Lagos, Nigeria)	

SOA10-616-20	Safety monitoring and completion rates of once-daily isoniazid and rifapentine (1HP) among high-risk populations Pei-Chun Chan (Taipei city, Taiwan)	15:07 - 15:13
SOA10-617-20	Risk of progression to incident pulmonary TB among household contacts with abnormal chest X-rays in South Africa Evans Muchiri (Cape Town, South Africa)	15:13 - 15:19
	Q&A	15:19 - 15:40
<i>Oral Abstract Sessions</i>		
14:10 - 15:40		R2
	OA19 - It's all about the money: Optimising TB care Pranay Sinha (Boston, United States) Carrie Tudor (Baltimore, United States)	
	Introduction	14:10 - 14:15
OA19-278-20	TBI tests for contact screening in Brazil: A cost-effectiveness analysis Anete Trajman (Rio de Janeiro, Brazil)	14:15 - 14:22
OA19-279-20	Improving resource allocation for TB programmes: A mechanistic cost function approach for efficient priority setting Andres Madriz (London, United Kingdom)	14:22 - 14:29
OA19-280-20	Cost-effectiveness of utilising CAD in an active case finding community screening programme to detect TB in Tamil Nadu, India Asha Frederick (Chennai, India)	14:29 - 14:36
OA19-281-20	Impact and cost-effectiveness of implementing household contact tracing, including TB preventive treatment in Nepal: A model-based analysis Rajan Paudel (Kathmandu, Nepal)	14:36 - 14:43
OA19-282-20	Cost-effectiveness of replacing 6-9H isoniazid monotherapy with 3HP for TB preventive therapy in Brazil: A national and sub-national analysis Klauss Villalva-Serra (Salvador, Brazil)	14:43 - 14:50
OA19-283-20	Cost effectiveness of 1HP vs 3HP in HIV-negative contact persons with latent TB infection in Brazil David Dowdy (Baltimore, United States)	14:50 - 14:57
OA19-284-20	Cost and impact of decentralising TB testing: Price thresholds for molecular instruments in high-TB-burden settings Brooke Nichols (Boston, Netherlands)	14:57 - 15:04
OA19-285-20	Evaluating the economic impact of low-to mid-throughput multi-disease molecular testing with Cobas MTB and MTB-RIF/INH assays: A case study in the Philippines Tushar Srivastava (London, United Kingdom)	15:04 - 15:11
OA19-286-20	An extended cost-effectiveness and benefit incidence analysis of decentralised TB diagnostic testing with Molbio Truenat MTB/RIF vs. hub-and-spoke GeneXpert MTB/RIF in Mozambique and Tanzania Saima Arif (Manchester, United Kingdom)	15:11 - 15:18
OA19-287-20	Is universal health coverage the solution to protecting TB-affected households from financial and socio-economic burdens: A cross-sectional cost study in South Korea Hongjo Choi (Seoul, Korea, Republic of)	15:18 - 15:25
	Q&A	15:25 - 15:40

Oral Abstract Sessions

14:10 - 15:40

R3

OA20 - Prevalence surveys (TB disease and M. TB infection) and transmission studies

Kavindhran Velen (Geneva, Switzerland)

Edine Tiemersma (The Hague, Netherlands)

In	Introduction	14:10 - 14:15
OA20-288-20	TB infection by age groups in Mongolia Enkhtsetseg Tumur (Ulaanbaatar, Mongolia)	14:15 - 14:23
OA20-289-20	Prevalence and risk factors for tuberculin skin test positivity in Rwanda: A nationwide cross-sectional study Patrick Migambi (Kigali, Rwanda)	14:23 - 14:31
OA20-290-20	Early results of the first subnational TB prevalence survey in Ho Chi Minh City, Viet Nam Luan Nguyen Quang Vo (Ha Noi, Vietnam)	14:31 - 14:39
OA20-291-20	National TB Prevalence Survey in Nepal (2018-2019) Ashish Shrestha (Bhaktapur, Nepal)	14:39 - 14:47
OA20-292-20	Cross-regional transmission of drug-resistant TB in Namibia: Insights from genomic surveillance Olga Shavuka (Windhoek, Namibia)	14:47 - 14:55
OA20-293-20	The role of prisons in the spread of TB over time in Lima, Peru Chuan-Chin Huang (Boston, United States)	14:55 - 15:03
OA20-294-20	Population-wide TB screening in Kiribati: Preliminary results Jeremy Hill (Sydney, Australia)	15:03 - 15:11
OA20-295-20	Quantifying undetected TB in Ethiopia using a novel geospatial modelling approach Haileab Fekadu Wolde (Perth, Australia)	15:11 - 15:19
OA20-296-20	Heterogeneity in M. TB immunoreactivity in a community-based survey of young children in Blantyre, Malawi Hannah M. Rickman (London, United Kingdom)	15:19 - 15:27
	Q&A	15:27 - 15:40

Short Oral Abstract Sessions

14:10 - 15:40

R4

SOA11 - Bridging gaps in TB care: AI solutions for high-risk populations

Leyla Larsson (London, United Kingdom)

Celso Khosa (Maputo, Mozambique)

	Introduction	14:10 - 14:15
SOA11-618-20	How subtle is asymptomatic pulmonary TB? Lessons from using digital chest X-ray with computer aided detection software for TB case finding in communities in Uganda Aldomoro Burua (Kampala, Uganda)	14:15 - 14:21
SOA11-620-20	Enhancing paediatric TB screening: Validation of an enriched artificial intelligence-based computer aided detection model using chest X-rays from children under 15 years Justy Antony Chiramal (Atlanta, United States)	14:21 - 14:27
SOA11-621-20	Adaptive artificial intelligence for TB screening: Automated age prediction from chest X-rays to improve paediatric TB detection in low-resource settings Shibu Vijayan (Bengaluru, India)	14:27 - 14:33

SOA11-622-20	Predicting the burden of undiagnosed TB cases in India using a machine-learning approach Subramanian Potty Rajaram (Bengaluru, India)	14:33 - 14:39
SOA11-623-20	Improving digital TB screening efficiency in remote rural communities in Nigeria through offline and local intranet-based data synchronisation Chidimma Okoye (Abak, Nigeria)	14:39 - 14:45
SOA11-624-20	A retrospective evaluation of the MATCH AI model for prediction of TB positivity rates in active case finding settings of Pakistan Christina Mergenthaler (Amsterdam, Netherlands)	14:45 - 14:51
SOA11-625-20	Technical validation of Swaasa AI platform for detecting likely presence of pulmonary TB among people presenting with cough in India Rakesh Kumar (New Delhi, India)	14:51 - 14:57
SOA11-626-20	Understanding asymptomatic TB: Insights from community-level screening using AI-enabled portable digital X-ray technology in remote rural Nigeria Chidimma Okoye (Abak, Nigeria)	14:57 - 15:03
SOA11-627-20	Development of artificial intelligence lung sound algorithm using pulmonary physician-expert analysis to improve the accuracy of diagnosing paediatric pneumonia in low- and middle-income countries Sunaina Kapoor (Baltimore, United States)	15:03 - 15:09
SOA11-628-20	Scaling up digital X-ray with CAD for TB screening: Implementation challenges, procurement, and regulatory insights from a market access analysis focused on sub-Saharan Africa Vibol Iem (Liverpool, United Kingdom)	15:09 - 15:15
SOA11-629-20	Utilising AI-based risk stratification of TB recurrence for improving post-treatment outcomes Aparna Chaudhary (New Delhi, India)	15:15 - 15:21
	Q&A	15:21 - 15:40

Oral Abstract Sessions

14:10 - 15:40

R5

OA21 - Breaking the TB poverty cycle: Tackling inequality, financial burden and policy gaps for people-powered solutions

Tom Wingfield (Liverpool, United Kingdom)

	Introduction	14:10 - 14:15
OA21-297-20	Does TB research presented at The Union World Conference on Lung Health engage with the conditions of poverty, inequality and undernutrition experienced by TB-affected communities? An abstract review Mikaela Coleman (Munich, Germany)	14:15 - 14:22
OA21-298-20	People with TB challenged with catastrophic healthcare expenses before diagnosis and during treatment in Cambodia Kim Lee Khieu (Phnom Penh, Cambodia)	14:22 - 14:29
OA21-299-20	Beyond the cost of free treatment, people with presumptive TB in Cambodia face financial hardship before TB diagnosis Kim Lee Khieu (Phnom Penh, Cambodia)	14:29 - 14:36
OA21-300-20	Financial burden of people with TB in Nepal: Assessing catastrophic costs and mitigation strategies Rajendra Basnet (Kathmandu, Nepal)	14:36 - 14:43

OA21-301-20	Assessment of social protection for people affected by TB: Development of an indicator matrix for Brazil Melisane Regina Lima Ferreira (Ribeirão Preto, Brazil)	14:43 - 14:50
OA21-302-20	Evaluating social capital of 2382 people with pulmonary TB: A cross-sectional survey nested within the community-randomised controlled CRESIPT trial, Peru Amrita D'Souza (Liverpool, United Kingdom)	14:50 - 14:57
OA21-303-20	People power against TB: Janbhagidari as a transformative force in India's 100-Day TB Elimination campaign Paranjyot Bordoloi (New Delhi, India)	14:57 - 15:04
OA21-304-20	Breaking the cycle: Integrating economic empowerment into TB care for sustainable outcomes in Indonesia Nurliyanti Nurliyanti (Jakarta Selatan, Indonesia)	15:04 - 15:11
OA21-305-20	Cost-effectiveness of conditional cash transfers with pre-test and post-test TB counselling in South Africa: A mathematical modelling study Lara Goscé (London, United Kingdom)	15:11 - 15:18
OA21-306-20	Policy gaps in social protection for people affected by TB: Evidence from high-burden municipalities in Rio de Janeiro, Brazil Yan Mathias Alves (Ribeirão Preto, Brazil)	15:18 - 15:25
	Q&A	15:25 - 15:40

Symposia

14:10 - 15:40

R6

SY19-290-19 - Emerging data in maternal and infant TB

Nicole Salazar-Austin (Baltimore, United States)

Emma Kalk (Cape Town, South Africa)

Introduction	14:10 - 14:15
Emerging data on TB prevention in pregnancy: Where do we go from here? Jyoti Mathad (New York, United States)	14:15 - 14:30
Population pharmacokinetic modelling of second-line TB drugs in pregnancy and lactation: Insights from levofloxacin and delamanid Sharon Sawe (Cape Town, South Africa)	14:30 - 14:45
Impact of pregnancy on TB treatment outcomes: An analysis of national surveillance data Silvia Chiang (Providence, United States)	14:45 - 15:00
Radiant-Moms: Generating evidence to support the evaluation, adoption, and safe practical implementation of novel TB treatment regimens for pregnant and lactating women Mary Christine Castro (Muntinlupa City, Philippines)	15:00 - 15:15
Integrating TB care with maternal and child health: Lessons learned in Papua New Guinea Pauline Masta (Port Moresby, Papua New Guinea)	15:15 - 15:30
Q&A	15:30 - 15:40

Symposia

14:10 - 15:40

R7

SY20-300-20 - Impact of recent and expected reductions in international donor funding for TB prevention and care

Jeremiah Chakaya (Nairobi, Kenya)

Katherine C. Horton (London, United Kingdom)

Introduction 14:10 - 14:15

Impact of US government funding halt on TB responses in high-burden TB countries 14:15 - 14:30

Suvanand Sahu (Switzerland)

Community perspectives on the impact of funding cuts in South Africa 14:30 - 14:45

Phumeza Tisile (Cape Town, South Africa)

Predicting the epidemiological impact of TB funding cuts in low- and middle-income countries 14:45 - 15:00

Rebecca A. Clark (London, United Kingdom)

Predicting the epidemiological impact of HIV and TB funding cuts on TB in South Africa 15:00 - 15:15

Mmamapudi Kubjane (Johannesburg, South Africa)

Reckoning with the roots of TB's funding crisis 15:15 - 15:30

Uzma Khan (Montreal, Canada)

Q&A 15:30 - 15:40

Symposia

14:10 - 15:40

R8

SY21-310-21 - Investment case: Why community engagement is critical to ending TB

Tauhid Islam (Geneva, Switzerland)

Nimalan Arinaminpathy (Geneva, Switzerland)

Introduction 14:10 - 14:15

Community engagement for ending TB: Why it matters and what it takes 14:15 - 14:30

Tauhid Islam (Geneva, Switzerland)

Making it count: Evidence of impact from community engagement in national responses 14:30 - 14:45

Karina Kielmann (United Kingdom)

Insights from a scoping review: Understanding how community engagement drives TB outcomes 14:45 - 15:00

Salla Atkins (Tampere, Finland)

Modeling the health and economic impact of community engagement in TB 15:00 - 15:15

Bikram Pal (Berhampore, India)

Interactive session - Modeling towards an investment case for community engagement 15:15 - 15:30

Q&A 15:30 - 15:40

Community Connect Sessions

14:10 - 14:55

CC

CCS015 - Integrating gender-related knowledge into the national medical training curriculum and healthcare workplace practices

Lesia Tonkonoh (Kyiv, Ukraine)

Lesia Tonkonoh (Kyiv, Ukraine)

Introduction

14:10 - 14:15

How inclusive medical education contributes to a more gender-diverse and equitable health workforce

14:15 - 14:20

Yuliia Kalancha (Kyiv, Ukraine)

Nothing about us without us: Using social science to bridge TB research and community realities

14:20 - 14:25

Yuliya Chorna (Toronto, Canada)

Integrating gender-related knowledge into the national medical training curriculum and healthcare workplace practices: Findings from the conducted assessment in Ukraine

14:25 - 14:30

Lesia Tonkonoh (Kyiv, Ukraine)

Integration of gender-sensitive knowledge into the national medical curriculum and healthcare practices

14:30 - 14:35

Yana Terleieva (Kyiv, Ukraine)

Understanding intersections: How gender interacts with improving TB outcomes

14:35 - 14:40

Amrita Daftary (Toronto, Canada)

Question and answers

14:40 - 14:55

Community Connect

14:10 - 14:40

CCC

CCF003 - Films

Strengthening TB prevention: Advancing TPT through community action in Ghana

14:10 - 14:30

Jerry Amoah-Larbi (Ghana)

Rise of the TB Titan: Inspiring Young Heroes for TB and Lung Health Awareness

14:30 - 14:35

Usman Rasool Lodhi (Islamabad, Pakistan)

New Communication Strategies in Infectious Disease Awareness

14:35 - 14:40

Evgenia Geliukh (Kyiv, Ukraine)

TBScience E-Poster Sessions

14:15 - 15:45

TBS-EP-07 - TBScience Moderated E-posters VII

Nicolas Menzies (United States)

TBS-EP215

Integrating Spatial Modelling and Contextual Data to Optimize the Identification of People Living with TB in Uganda

14:15 - 14:20

Anne-Laure Budts (Cape Town, South Africa)

TBS-EP218

Spread and drug resistance of a lineage-2 *Mycobacterium tuberculosis* subgroup in Hanoi, Vietnam

14:20 - 14:25

Hang Thi-Le Nguyen (Hanoi, Vietnam)

TBS-EP221

Biomarker combinations of TB-MBLA with CFU and TTP give greater biological insight in EBA studies

14:25 - 14:30

Mairi McClean (Germany)

TBS-EP224	Optimizing the thresholds of the computer-aided detection for tuberculosis (CAD4TB) algorithms for tuberculosis screening in Mozambique Eveline Klinkenberg (the Hague, Netherlands)	14:30 - 14:35
TBS-EP227	Machine learning approach identifies distinct clinical phenotypes of HIV-associated pulmonary tuberculosis associated with differences in household transmission risk Palwasha Yousafzai Khan (London, United Kingdom)	14:35 - 14:40
TBS-EP230	A dual-CRISPRi system to probe gene-gene interactions in <i>M. tuberculosis</i> Valwynne Faulkner (London, United Kingdom)	14:40 - 14:45
TBS-EP233	Differential responses of <i>Mycobacterium tuberculosis</i> complex lineages to tuberculosis treatment regimens Fatou Faal (Banjul, Gambia)	14:45 - 14:50
TBS-EP239	The impact of phylogenetic lineages on the drug susceptibility of <i>Mycobacterium tuberculosis</i> Lara Muñoz-Muñoz (Zaragoza, Spain)	14:50 - 14:55
TBS-EP242	The clinical potential of targeting the free fatty acid receptor 4 in COPD and asthma Bethany Strellis (Glasgow, United Kingdom)	14:55 - 15:00
TBS-EP245	Evaluation of locally synthesized silica-coated magnetic nanoparticles for development of a <i>Mycobacterium tuberculosis</i> DNA concentration assay John Meldwin Cuales (Manila, Philippines)	15:00 - 15:05
TBS-EP248	A multiplex Mtb-specific FluoroSpot assay measuring IFNγ, TNF, and IL2-secreting cells can improve accuracy and differentiation across the tuberculosis spectrum Elin Folkesson (Stockholm, Sweden)	15:05 - 15:10
TBS-EP251	Clinical evaluation of the LifeArc Tuberculosis Molecular Bacterial Load Assay (TB-MBLA) for the diagnosis and monitoring of pulmonary tuberculosis Tamara Martin (United Kingdom)	15:10 - 15:15
TBS-EP254	The diagnostic value of interferon-γ and IP-10 in latent and active tuberculosis: A comparative analysis Neelima Sudharshan (Hyderabad, India)	15:15 - 15:20
TBS-EP257	Estimating the national transmission impact of household contact management and tuberculosis preventive treatment for drug-susceptible and multidrug-resistant tuberculosis in South Africa Martin Harker (United Kingdom)	15:20 - 15:25
TBS-EP258	Q&A	15:25 - 15:45

Community Connect

15:00 - 17:00

CCART

CCAT003 - Art therapy, a healing process playing with colors -- Paediatric tuberculosis.

Mohammad Rofiqul (Royal) Islam (Bangladesh)

Introduction about art therapy

15:00 - 15:00

Mohammad Rofiqul (Royal) Islam (Bangladesh)

Art therapy

15:00 - 15:00

Mohammad Rofiqul (Royal) Islam (Bangladesh)

Community Connect Sessions

15:10 - 15:55

CC

CCS016 - Climate, conflict and care: Building TB programme resilience in an era of instability

Usman Rasool Lodhi (Islamabad, Pakistan)

Ghulam Nabi Kazi (Pakistan)

Introduction	15:10 - 15:12
Climate-responsive TB outreach to marginalised communities in Pakistan	15:12 - 15:19
Kinz Ul Eman (Islamabad, Pakistan)	
Local action, global impact: Community resilience to climate and conflict disruptions in Northern Nigeria	15:19 - 15:26
Stephen John (Yola, Nigeria)	
Resilient TB care for flood-affected populations: Lessons learned during floods in Punjab	15:26 - 15:33
Usman Rasool Lodhi (Islamabad, Pakistan)	
Voices from the frontlines: Community-led monitoring of TB services in crisis settings	15:33 - 15:40
Viorel Soltan (Switzerland)	
Question and answers	15:40 - 15:55

Community Connect

15:30 - 17:30

CCC

CCWS009 - Escaping The TB Trap: A Virtual Escape Room

Anisha Singh (New Delhi, India)

Janhavi Mittal (India)

In conversation: Importance of strategic advocacy, communications and social mobilization In the global fight against TB	15:30 - 15:40
Anisha Singh (New Delhi, India)	
Workshop: Welcome and game concept	15:40 - 15:45
Janhavi Mittal (India)	
Pre-assessment survey	15:45 - 15:55
Escaping the TB trap (game play)	15:55 - 16:45
Post survey assessment and synthesising cross learnings	16:45 - 17:00

Break

15:40 - 15:55

Main

Break/Networking

Special Sessions

15:55 - 17:25

Main

SPS05 - Sustaining momentum: Collective strategies for advancing TB innovation

Salome Charalambous (Johannesburg, South Africa)

Dennis Falzon (Geneva, Switzerland)

Kavindhran Velen (Geneva, Switzerland)

Introduction	15:55 - 16:00
EDCTP	16:00 - 16:05
Lara Pandya (Belgium)	
Bill & Melinda Gates Foundation	16:05 - 16:10

	Nina Russell (United States)	
	UNITAID	16:10 - 16:15
	Cherise Scott (Switzerland)	
	Global Fund	16:15 - 16:20
	Eliud Wandwalo (Geneva, Switzerland)	
	Wellcome Trust	16:20 - 16:25
	Florian von Groote-Bidlingmaier (United Kingdom)	
	Fondation Mérieux	16:25 - 16:30
	Jonathan Hoffmann (France)	
	Panel discussion and Q&A	16:30 - 17:25
<i>Symposia</i>		
15:55 - 17:25		TBS
	SY22-320-22 - Charting the course of post-TB lung health and well-being: Advances and opportunities in the field	
	Marieke van der Zalm (Cape Town, South Africa)	
	Stellah Mpagama (Siha, Tanzania)	
	Introduction	15:55 - 16:00
	Advocacy priorities for post-TB care	16:00 - 16:15
	Phumeza Tisile (Cape Town, South Africa)	
	Global consensus on PTLT: A research-focused definition for children, adolescents, and adults	16:15 - 16:30
	Gregory Bisson (Philadelphia, United States)	
	Adolescent post-TB lung disease: Emerging evidence	16:30 - 16:45
	Sylvia Chiang (Providence, United States)	
	Advancing post-TB care through individual participant data meta-analysis	16:45 - 17:00
	Jonathon Campbell (Montreal, Canada)	
	Understanding the early natural history of post-TB lung disease: Insights from the TB aftermath study	17:00 - 17:15
	Akshay Gupte (Boston, United States)	
	Q&A	17:15 - 17:25
<i>Oral Abstract Sessions</i>		
15:55 - 17:25		R1
	OA22 - Understanding the impact of case finding modalities: From the facility to the population	
	David Dowdy (Baltimore, United States)	
	Bruce Kirenga (Kampala, Uganda)	
	Introduction	15:55 - 16:02
OA22-307-20	Closing the gaps in TB detection: Evaluating a novel screening strategy on TB presumption and detection from Kunda Nqob'iTB project in Zimbabwe	16:02 - 16:09
	Sithabiso Dube (Harare, Zimbabwe)	
OA22-308-20	Modelling the epidemiological impact of strengthening intensified TB case-finding in health facilities in India	16:09 - 16:16
	Yashi Aman Raj (Mumbai, India)	
OA22-309-20	Modelling 'targeted universal testing for TB' vs symptom-based screening in South Africa	16:16 - 16:23

	Nicky McCreesh (London, United Kingdom)	
OA22-310-20	Does active case-finding detect people with TB early in programme settings? A national level study from India S. Kiran Pradeep (Chennai, India)	16:23 - 16:30
OA22-311-20	Using geolocation data to inform TB active case finding in the Kulob Zero TB project, Tajikistan Matthew J. Saunders (London, United Kingdom)	16:30 - 16:37
OA22-312-20	Modelling the impact of case finding for TB: The role of infection dynamics Theresa Ryckman (Baltimore, United States)	16:37 - 16:44
OA22-313-20	Simulating the ACT3 trial: How TB natural history determines the durability of community screening Stewart Chang (Seattle, United States)	16:44 - 16:51
OA22-314-20	Potential impact of community-wide screening approaches for TB: A modelling study across the spectrum of disease Katherine C. Horton (London, United Kingdom)	16:51 - 16:51
OA22-315-20	Estimating the epidemiological impact of the CAST TB Uganda: A modelling analysis Alexandra Richards (Glasgow, United Kingdom)	16:51 - 16:58
OA22-316-20	Can temporary mass screening campaigns accelerate declines in TB incidence in high-burden TB/HIV countries? Abigail de Villiers (Heidelberg, Germany)	16:58 - 17:05
	Q&A	17:05 - 17:12
 <i>Oral Abstract Sessions</i>		
	15:55 - 17:25	R2
OA23 - Prevention, diagnosis, and treatment for people living with HIV		
	Daria Podlekareva (Copenhagen, Denmark) Denise Banze (Maputo, Mozambique)	
	Introduction	15:55 - 15:58
OA23-317-20	Assessing TB vaccine confidence in South African adults with HIV Alexa Giovanatti, DO (Seattle, United States)	15:58 - 16:05
OA23-318-20	Point-of-care biomarker-confirmed adherence to the three-month weekly isoniazid plus rifapentine (3HP) regimen in people with HIV Dickens Onyango (Kisumu, Kenya)	16:05 - 16:12
OA23-319-20	Preferred short course TB preventive regimens for adults and adolescents living with HIV Helen Cox (Melbourne, Australia)	16:12 - 16:19
OA23-320-20	Factors associated with high CAD scores among people living with HIV screened for TB using digital chest X-ray with computer-aided detection software in Kenya Grace Kaluai (Nairobi, Kenya)	16:19 - 16:26
OA23-321-20	Diagnostic accuracy of Fujifilm SILVAMP TB LAM II for TB in HIV-positive and HIV-negative adults: A multicenter study in Vietnam Han T. Nguyen (Ha Noi, Vietnam)	16:26 - 16:33
OA23-322-20	Diagnostic accuracy of FujiLAM II point-of-care assay for detecting TB in urine among people with and without HIV in Cameroon Jean Bosco Taya Fokou (Bamenda, Cameroon)	16:33 - 16:40
OA23-323-20	Tongue swab based targeted universal TB testing in people living	16:40 - 16:47

	with HIV in KwaZulu-Natal, South Africa Alaina Olson (Seattle, United States)	
OA23-324-20	A randomised-controlled trial comparing C-reactive protein- to symptom-based TB screening of people with HIV in Uganda: Primary 24-month effectiveness results Christina Yoon (San Francisco, United States)	16:47 - 16:54
OA23-325-20	Early adherence trajectories predict six-month outcomes in people living with HIV and multi-drug-resistant TB: Findings from the PRAXIS study Kevin Guzman (New York, United States)	16:54 - 17:01
OA23-326-20	HIV incidence among people with TB in Israel: A 42-years follow up study Zohar Mor (Ashkelon, Israel)	17:01 - 17:08
	Q&A	17:08 - 17:18
 <i>Short Oral Abstract Sessions</i> 15:55 - 17:25		
		R3
	SOA12 - Making it work for us: Community-led programme design Carol Nawina Nyirenda (Lusaka, Zambia) Kathrin Held (Munich, Germany)	
In	Introduction	15:55 - 15:58
SOA12-630-20	Campus Leaders Program: Fostering youth participation in TB elimination and SDGs implementation in Indonesia through a collaborative hexa-helix stakeholder engagement model Jimmy Muhamad Rifai Gani (Jakarta, Indonesia)	15:58 - 16:04
SOA12-631-20	From data to impact: Reducing TB stigma through digital community-led monitoring in Mozambique Nina Helen Hallstrom (Maputo, Mozambique)	16:04 - 16:10
SOA12-632-20	Leadership matters: Assessing TB stigma among industrial managers in Telangana's high-burden districts Vikas Panibatla (Hyderabad, India)	16:10 - 16:16
SOA12-633-20	Beyond the narrative: Shifting power to communities in driving health research through community led-research strategy in Kenya Christine Mwamsidu (Nairobi, Kenya)	16:16 - 16:22
SOA12-634-20	Building resilient TB interventions: Strengthening community-led monitoring through supervision and mentorship Ifeanyi Okekearu (Abuja, Nigeria)	16:22 - 16:28
SOA12-635-20	Community-led monitoring using real-time data through OneImpact applications in Cambodia Leng Molina (Phnom Penh, Cambodia)	16:28 - 16:34
SOA12-636-20	Community-led monitoring for TB: A human rights based approach using OneImpact Anne Hoejrup (Lusaka, Zambia)	16:34 - 16:40
SOA12-637-20	415 youth-led actions in 2 months: A rapid movement to transform TB awareness and policy in Indonesia Iman Maha Putra Zein (Jakarta Selatan, Indonesia)	16:40 - 16:46
SOA12-638-20	Empowerment of local self-governing bodies to accelerate TB elimination efforts in Kashmir, India Kamesh Venkatesan (Srinagar, India)	16:46 - 16:52
SOA12-639-20	Using design thinking to translate evidence into strategy: A case	16:52 - 16:58

	study on strengthening community health workers in TB prevention and care in Madagascar Onja Gabrielle Ravololohanitra (Antananarivo, Madagascar)	
SOA12-640-20	Uncovering drivers of multi-drug-resistant TB/HIV treatment adherence using natural language processing of routine counselling notes Max R. O'Donnell (New York, United States)	16:58 - 17:04
SOA12-641-20	General and religious coping among people with TB: A systematic enquiry using Brief COPE and Brief RCOPE scales Abhay Kadam (Pune, India)	17:04 - 17:10
SOA09-604-20	Beyond the pack: Integrating behavioural science to strengthen pictorial health warnings in India Sanjeeta Agnihotri (New Delhi, India)	17:10 - 17:16
	Q&A	17:16 - 17:25
<i>Short Oral Abstract Sessions</i>		
	15:55 - 17:25	R4
	SOA13 - Feeding recovery, fueling hope: Nutrition's central role in TB elimination Pranay Sinha (Boston, United States) Gisele Badoum (Ouagadougou, Burkina Faso)	
	Introduction	15:55 - 16:00
SOA13-642-20	Body mass index and TB risk: An updated systematic literature review and dose-response meta-analysis Matthew J. Saunders (London, United Kingdom)	16:00 - 16:05
SOA13-643-20	Diagnostic accuracy of molecular testing on different respiratory specimens for TB diagnosis in children hospitalised with severe acute malnutrition Eden Masama Ngu (Montpellier Cedex 5, France)	16:05 - 16:10
SOA13-644-20	Can we diagnose TB better in nutrition centres? Experience from Maiduguri Nigeria Muhammad Bashir Abdullahi (Maiduguri, Nigeria)	16:10 - 16:15
SOA13-645-20	Weighing the risk: Severe acute malnutrition determinants in children treated for TB in Papua New Guinea Gordon Pukai (Port Moresby, Papua New Guinea)	16:15 - 16:20
SOA13-646-20	Skip the snakes, ladder up: Let the game do the counselling Suresh Bollepogu (Hyderabad, India)	16:20 - 16:25
SOA13-647-20	Enhancing TB treatment outcomes: The role of nutrition education and micronutrient supplementation on immunological markers and quality of life in peri-urban Bangladesh Farzana Zaman (Dhaka, Bangladesh)	16:25 - 16:30
SOA13-648-20	Community-driven nutrition support model to enhance TB outcomes: Insights from Uttarakhand, India Bipra Bishnu (New Delhi, India)	16:30 - 16:35
SOA13-649-20	Impact of nutritional support to the person with TB: A comparative study between Nikshay Poshan Yojna and Nikshay Mitra initiative in West Bengal, India Abhijit Dey (New Delhi, India)	16:35 - 16:40
SOA13-650-20		16:40 - 16:45
	How best to manage TB in households? A modelling analysis of TB preventive therapy and nutritional support in India	

	Sandip Mandal (New Delhi, India)	
SOA13-651-20	Nutritional support for people with or at risk of TB: A systematic review and synthesis of implementation approaches Norma Madden (The Hague, Netherlands)	16:45 - 16:50
SOA13-652-20	Nutritional support improves treatment success, nutritional status, and functional recovery: Findings from the INSTITUT study Mohammed Fall Dogo (Lomé, Togo)	16:50 - 16:55
SOA13-653-20	Empowering TB-affected communities: Savings groups as a social protection strategy Anne Hoejrup (Lusaka, Zambia)	16:55 - 17:00
SOA13-654-20	Assessing the impact of climate change on TB care in Zimbabwe: A mixed-methods evaluation of community and health system needs Canice Christian (San Francisco, United States)	17:00 - 17:05
	Q&A	17:05 - 17:20

Symposia

15:55 - 17:25

R5

SY23-330-23 - Beyond explanatory phase III adult trials: Innovative TB treatment trials for effectiveness in programmatic settings and inclusion of priority populations

Geraint (Gerry) Davies (Liverpool, United Kingdom)

Tiziana Masini (Geneva, Switzerland)

	Introduction	15:55 - 16:00
	Country-led, collaborative platform for clinical trials of TB: A paradigm shift in TB research Samuel Schumacher (Geneva, Switzerland)	16:00 - 16:15
	A platform approach for phase I/II trials of new TB drugs in children Sumati Nambiar (Raritan, United States)	16:15 - 16:30
	Strategy trials in children: Reflecting on the need for randomised, controlled efficacy trials in children Anneke C. Hesselning (Cape Town, South Africa)	16:30 - 16:45
	Inclusion of pregnant women in clinical trials Jyoti Mathad (New York, United States)	16:45 - 17:00
	Beyond efficacy and safety: The importance of person-centred outcomes Oxana Rucsineanu (Moldova)	17:00 - 17:15
	Q&A	17:15 - 17:25

Oral Abstract Sessions

15:55 - 17:25

R6

OA24 - Sustainability in demand: Feasibility, acceptability, cost effectiveness, and TB care approaches

Jacob Creswell (Geneva, Switzerland)

Helen Ruth Stagg (London, United Kingdom)

	Introduction	15:55 - 16:00
OA24-327-20	Evaluation of a fluorescence immunoassay-based IGRA for latent TB diagnosis: A simplified, cost-effective alternative Mohammad Khaja Mafij Uddin (Dhaka, Bangladesh)	16:00 - 16:07
OA24-328-20	Consideration of risks and consequences of TB and its prevention	16:07 - 16:14

	in cost-utility analyses among immigrants to low incidence countries: A systematic review Sammy Robayo (Montreal, Canada)	
OA24-329-20	Cost and cost-effectiveness of household contact investigation of pulmonary bacteriologically confirmed people with TB in sub-Saharan Africa Kobto Koura (Paris, France)	16:14 - 16:14
OA24-330-20	Evaluating the effectiveness of the PDX machine in improving sample quality and reducing costs in TB sample processing in Ekiti State Olatunji Odeyemi (Ado Ekiti, Nigeria)	16:14 - 16:21
OA24-331-20	DronEconomics: The cost of implementing drones to facilitate TB sputum sample collection in hard-to-reach areas in Nepal Anchal Thapa (Kathmandu, Nepal)	16:21 - 16:28
OA24-332-20	Testing more for less: Evidence on pooling specimens for molecular testing at healthcare facilities and by active case finding in communities across seven high-burden countries Tushar Garg (Geneva, Switzerland)	16:28 - 16:28
OA24-333-20	Pooled testing for TB: A cost-saving strategy with trade-offs in detection sensitivity Andrew James Codlin (Ho Chi Minh City, Vietnam)	16:28 - 16:35
OA24-334-20	Implementation of targeted next-generation sequencing for drug-resistant TB detection in Indonesia Bony Wiem Lestari (Bandung, Indonesia)	16:35 - 16:42
OA24-335-20	Cost-effectiveness of targeted next-generation sequencing for TB drug-resistance testing as an alternative to the standard of care in South Africa Alexandra de Nooy (Amsterdam, Netherlands)	16:42 - 16:49
OA24-336-20	Evaluating feasibility and acceptability of TB screening and diagnostic tests: A qualitative study across seven high-burden low- and middle-income countries in the Start4All project Vibol Iem (Liverpool, United Kingdom)	16:49 - 16:56
	Q&A	16:56 - 17:11
 <i>Symposia</i>		
	15:55 - 17:25	R7
	SY24-340-24 - Unveiling TB narratives: The power of storytelling Petra Heitkamp (Ottawa, Canada) Lindsay Palazuelos (Boston, United States)	
	Introduction	15:55 - 16:00
	Techniques in writing and storytelling for targeted impact Vidya Krishnan (Goa, India)	16:00 - 16:17
	Beyond the data: The Art of storytelling in science communication Maria Smilios (Asheville, United States)	16:17 - 16:45
	Framing narratives to empower those affected by TB and directing voices to build empathy and influence decisions Handaa Enkh-Amgalan (Berlin, Germany)	16:45 - 17:13
	Q&A	17:13 - 17:25

Symposia

15:55 - 17:25

R8

SY25-350-25 - Implementation research to prepare for the introduction of new TB vaccines for adults and adolescents

Saskia Den Boon (Geneva, Switzerland)

Vanessa Veronese (Switzerland)

Introduction	15:55 - 16:00
Gavi's Investment Case and Learning Agenda for new TB Vaccines Marta Tufet Bayona (Switzerland)	16:00 - 16:15
Evaluation of the acceptability of new and repurposed tuberculosis vaccines in southern Mozambique Agostinho Lima (Maputo, Mozambique)	16:15 - 16:30
Integrated model of delivery for novel TB vaccines in South Africa Limakatso Lebina (Durban, South Africa)	16:30 - 16:45
Optimizing TB Vaccine Strategies: Harnessing Local Evidence and Modeling Insights in the Indian context Jessy Joseph (Delhi, India)	16:45 - 17:00
Advocacy for policy impact: translating political commitments to action to deliver new TB vaccines Shaun Palmer (Amsterdam, Netherlands)	17:00 - 17:15
Q&A	17:15 - 17:25

Community Connect Sessions

16:10 - 16:55

CC

CCSPS002 - Proofing community action: Aligning with the new global health financing paradigm

Kinz Ul Eman (Islamabad, Pakistan)

Usman Rasool Lodhi (Islamabad, Pakistan)

Introduction	16:10 - 16:15
Localizing Global Shifts: Community-Led Financing Strategies in Low- and Middle-Income Settings Kinz Ul Eman (Islamabad, Pakistan)	16:15 - 16:20
Shaping Community Power in a Shifting Financing Landscape: Lessons from Indonesia's TB Response Erman Varella (Jakarta, Indonesia)	16:20 - 16:25
Protecting Community Voice in the New Era of Donor Realignment Sharonann Lynch (Washington, United States)	16:25 - 16:30
Strategic Global Advocacy: How Civil Society Networks Influence Financing Priorities Robyn Waite (Ottawa, Canada)	16:30 - 16:35
Role of communities in shifting the financial paradigm Tariro Kutadza (Zimbabwe)	16:35 - 16:40
Question and Answer	16:40 - 16:55

Community Connect Sessions

17:10 - 17:55

CC

CCS017 - Engaging lawmakers and judges in Anglophone Africa to promote accountability, access to justice and rights-based laws in the TB response

Peace Okeshola (Abuja, Nigeria)

James Malar (Genève, Switzerland)

Anna Versfeld (South Africa)

Introduction

17:10 - 17:15

Strategic legal advocacy and rights-based lawmaking in Nigeria's TB response: Nigeria's journey towards a rights-based TB legislation

17:15 - 17:20

Rommy Mom (Abuja, Nigeria)

Strengthening people-centred TB response and legal remedies for TB through multisectoral advocacy: Zimbabwe's experience

17:20 - 17:25

Donald Denis Tobaiwa (Gweru, Zimbabwe)

Removal of barriers to care: Integrating TB, judicial dialogues for rights enforcement and legal remedies in Malawi's TB action plan

17:25 - 17:30

Victor Mhango (Malawi)

TB community engagement and collaborative advocacy with legal and health institutions: Ghana's experience

17:30 - 17:35

Rachel Otu Amponsah (Ghana)

Catalysing people-centred TB justice and removal of barriers to care in Kenya: Through judicial and community-led dialogues

17:35 - 17:40

Timothy Wafula (Nairobi, Kenya)

Question and answers

17:40 - 17:55

Break

17:25 - 17:40

Main

Break/Networking

Side Meetings

17:30 - 19:00

ML

Meet the Leadership Event (hosted by American Friends of The Union) - private event - tickets available through registration: [Registration | The Union World Conference on Lung Health 2025](#)

Side Meetings

17:40 - 19:10

TBS

Childhood pneumonia working group

Side Meetings

17:40 - 18:40

R2

TB - Bacteriology & Immunology Sub-section

Side Meetings

17:40 - 18:40

R3

TB - Nurses & Allied Professionals sub-section

Spotlight Sessions

17:40 - 19:10

R4

SL04 - How to get your research published: insights from the IJTLD and The Lancet

Giovanni Battista Migliori (Tradate, Italy)

Hugh Blackburn (United Kingdom)

Session introduction	17:40 - 17:45
Introduction to publishing Giovanni Battista Migliori (Tradate, Italy)	17:45 - 18:00
How to be a good/great author Hugh Blackburn (United Kingdom)	18:00 - 18:15
Navigating the peer review process Giovanni Battista Migliori (Tradate, Italy)	18:15 - 18:30
Insights into publishing at The Lancet Arianna Colosio (United Kingdom)	18:30 - 18:45
Q&A	18:45 - 19:10
 <i>Satellite Sessions</i>	
17:40 - 19:10	R5
SS09 - Country-led strategic and programme planning for tuberculosis	
Guy Stallworthy (United States) Eveline Klinkenberg (the Hague, Netherlands)	
Introduction	17:40 - 17:40
The People-Centred Framework (PCF): translating (routine) data into action for robust TB programming at national and sub-national levels Kathy Fiekert (United Kingdom)	17:40 - 17:55
The role of PRIME-TB and the TB digital platform in strategic planning and prioritization for TB Charalampos (Babis) Sismanidis (Switzerland)	17:55 - 18:10
Using the framework for prioritizing TB data and evidence-related tools for TB strategic and programme planning Rachel Fiorillo (United States)	18:10 - 18:25
Nigeria's experience with national and state-level strategic planning using key TB programme prioritization tools Obioma Chijioke-Akaniro (Abuja, Nigeria)	18:25 - 18:40
Panel discussion	18:40 - 19:10
Closing remarks	19:10 - 19:10
 <i>Satellite Sessions</i>	
17:40 - 19:10	R6
SS10 - Operationalizing TB Elimination: Lessons from the CETA Project in Francophone Africa	
Kobto Koura (Paris, France) Gisele Badoum (Ouagadougou, Burkina Faso)	
Introduction	17:40 - 17:45
Scaling Up Contact Investigation Across 8 African Countries: Programmatic Evidence and Cost-Effectiveness for National TB Response Olivia Mbitikon (BANGUI, Central African Republic)	17:45 - 18:00
Prioritizing Nutrition in TB Care: Evidence from a Multi-Country Study in Francophone Africa Pranay Sinha (Boston, United States)	18:00 - 18:15
Where There's Smoke, There's TB: Addressing Tobacco Use in TB	18:15 - 18:30

Control Efforts	
Abdoul Ouedraogo (Burkina Faso)	
Turning Data into Action: Using Routine TB Data to Drive Program Improvements in Togo	18:30 - 18:45
Mohammed Fall Dogo (Lomé, Togo)	
Building the Next Generation of TB Leaders: Capacity Strengthening and South-South Collaboration through the CETA Project	18:45 - 19:00
Q&A	19:00 - 19:10
<i>Side Meetings</i>	
17:40 - 18:40	R7
Book signing: Maria Smilios & Handaa Enkh-Amgalan	
<i>Side Meetings</i>	
17:40 - 18:40	R8
Zoonotic sub-section	
<i>Community Connect Sessions</i>	
18:10 - 18:55	CC
CCS018 - Advocating integration: Civil society's role in transforming health systems for UHC	
Vlada Rabinova (Ukraine)	
Vlada Rabinova (Ukraine)	
Introduction	18:10 - 18:12
Why integration matters: The case for people-centred health systems in the UHC era	18:12 - 18:19
Zahedul Islam (Kyiv, Ukraine)	
Data into models: Community-led integration of HIV, TB, hepatitis, sexual and reproductive health (within Frontline AIDS partnership)	18:19 - 18:26
Madhava Sai Sivapuram (India)	
Integrated care in practice: Cambodia's experience with strengthening primary-level TB, HIV and NCD services	18:26 - 18:33
Sok Chamreun Choub (Phnom Penh, Cambodia)	
Responding amid war: How Ukraine's communities sustain integrated TB, HIV and mental health services in crisis	18:33 - 18:40
Evgenia Geliukh (Kyiv, Ukraine)	
Question and answers	18:40 - 18:55

Friday, 21. November 2025

TBScience Sessions

08:00 - 09:00

TBS

TBS10 - TB vaccines and immune correlates of risk and protection

Elisa Nemes (South Africa)

Nicole Frahm (Cambridge, United States)

TBS10-05	Session introduction	08:00 - 08:05
TBS10-10	Critical overview of the current clinical TB vaccine pipeline Willem Hanekom (South Africa)	08:05 - 08:20
TBS10-15	Correlates of risk of TB disease following H56 administration to prevent disease recurrence Thomas Scriba (Cape Town, South Africa)	08:20 - 08:35
TBS10-20	Immune correlates of protection from sustained TB infection following BCG revaccination of adolescents Andrew Fiore-Gartland (United States)	08:35 - 08:50
TBS10-25	Q&A	08:50 - 09:00

Meet the Expert Sessions

08:00 - 09:00

R2

MTE-08 - The power of nurses: Brazil is leading cascade of diagnostic, care, and treatment for TB

Archana Trivedi (New Delhi, India)

	Live introduction	08:00 - 08:05
	The power of nurses: Brazil is leading cascade of diagnostic, care, and treatment for TB Gabriela Tavares Magnabosco (Maringá, Brazil)	08:05 - 08:20
	Discussion and Q&A	08:20 - 09:00

Meet the Expert Sessions

08:00 - 09:00

R3

MTE-09 - Severe acute malnutrition and TB in children: New progress in a longstanding battle

Melanie Dubois (United States)

	Live Introduction	08:00 - 08:05
	Severe acute malnutrition and TB in children: New progress in a longstanding battle Bryan Vonasek (East Lansing, United States)	08:05 - 08:20
	Discussion and Q&A	08:20 - 09:00

Meet the Expert Sessions

08:00 - 09:00

R4

MTE-10 - AI in monitoring treatment response in TB clinical trials

Ajoy Kumar Verma (New Delhi, India)

	Live introduction	08:00 - 08:05
	AI in monitoring treatment response in TB clinical trials Mairi McClean (Germany)	08:05 - 08:20
	Discussion and Q&A	08:20 - 09:00

Satellite Sessions

08:00 - 09:00

R6

SS11 - Advances in Host-Directed Therapies for Tuberculosis

Petros Karakousis (United States)

Natalya Serbina (United States)

Introduction	08:00 - 08:02
Bactericidal Potential of Host-Directed Therapies: Lessons from the BALB/c Mouse Model	08:02 - 08:12
Petros Karakousis (United States)	
AI-Powered Discovery of Host-Directed Therapies: Insights from InveniAI Integration	08:12 - 08:22
Natalya Serbina (United States)	
In Silico Trials to Identify and Optimize Host-Directed Therapy Combinations for TB	08:22 - 08:32
Francesco Pappalardo (Italy)	
Engineering Lung Organoids to Model Host Responses to TB and Evaluate HDTs	08:32 - 08:42
Céline Cougoule (France)	
Leveraging the Drosophila Model to Rapidly Screen Host-Directed Therapeutics for TB	08:42 - 08:52
Pere Joan Cardona (Spain)	
Q&A	08:52 - 09:00

TBScience Unmoderated E-Posters

08:00 - 19:00

TBS-EP-FRI - TBScience 2025 Unmoderated E-Posters

TBS-EP362	Toward entropy-based precision monitoring of tuberculosis: A systematic review of immune dysregulation as a predictive framework for treatment innovation	08:00 - 08:00
	Satiti Palupi Purwanto (Hat Yai, Thailand)	
TBS-EP365	Machine learning models reveal predictive signatures of therapy outcome in Phase 3 TB trials	08:00 - 08:00
	Daniel Garger (Munich, Germany)	
TBS-EP368	The use of unmanned aerial vehicles (UAV) on delivering biological samples for tuberculosis and COVID-19 diagnosis: A scoping review	08:00 - 08:00
	Olga Maira Machado Rodrigues (Brasilia, Brazil)	
TBS-EP371	Evaluation of an oral bedaquiline regimen for treating multidrug-resistant TB in China: A randomized trial	08:00 - 08:00
	Jingtao Gao (Beijing, China)	
TBS-EP374	Treatment outcomes and risk factors among tuberculosis patients infected with <i>Mycobacterium tuberculosis</i> Beijing lineage in Ukraine (2020-2023)	08:00 - 08:00
	Dmytro Butov (Kharkiv, Ukraine)	
TBS-EP377	Addressing tobacco industry tactics in university campuses and its impact on tobacco cases in Iraq	08:00 - 08:00
	Thamer Alhilfi (Baghdad, Iraq)	
TBS-EP380	Breath-based pathogen detection technologies for diagnosing respiratory infections: A scoping review	08:00 - 08:00
	Sonal Jain (Heidelberg, Germany)	
TBS-EP383	Leveraging artificial intelligence driven mobile X-ray screening on	08:00 - 08:00

	TB detection in high-risk brick Kiln communities of Punjab, Pakistan Qasim Mehmood (Lahore, Pakistan)	
TBS-EP386	Drug resistance detection from swab samples - A proof of principle pilot study using Molbio Truenat MTB-RIF-Dx and MTB-INH assays Seda Yerlikaya (Heidelberg, Germany)	08:00 - 08:00
TBS-EP389	AI-powered TB screening revolution: Impact of CAD4TB and DELFT portable X-ray machines in Punjab, Pakistan Bilal Ahmed (Lahore, Pakistan)	08:00 - 08:00
TBS-EP395	Preventive practices of pulmonary tuberculosis in Chitwan districts Kamal Kalakheti (Ilam, Nepal)	08:00 - 08:00
TBS-EP398	Genetic pattern of the ST 61 cluster of the Cameroon family among <i>Mycobacterium tuberculosis</i> complex strains collected during the CANTAM I project in Cameroon Alix Kevine G. T. Tchoupe (Yaoundé, Cameroon)	08:00 - 08:00
TBS-EP401	SHIFTING paradigms in DR-TB management: Real-world outcomes of injectable Kanamycin vs. Bedaquiline all-oral regimens using Ni-Kshay surveillance data Zuha Jabeen Shaikh (Mumbai, India)	08:00 - 08:00
TBS-EP404	Analysis of the incidence of tuberculosis lung injury and related factors of lung function after cure of pulmonary tuberculosis: A prospective observational study Wenli Cao (Beijing, China)	08:00 - 08:00
TBS-EP410	Human reader vs CAD4TB: Enhancing TB case detection through AI-supported mobile screening in Cambodia Monyrath Chry (Phnom Penh, Cambodia)	08:00 - 08:00
TBS-EP413	Tuberculosis recurrence prediction: A machine learning approach Olga Zofia Wieromiejczyk (Copenhagen, Denmark)	08:00 - 08:00
TBS-EP416	Bridging the knowledge gap: KAP assessment on tuberculosis among undergraduate health professional students in Baghdad with a focus on tobacco smoke and curriculum adequacy Thamer Alhilfi (Baghdad, Iraq)	08:00 - 08:00
TBS-EP419	Development and evaluation of hydrogel loaded with human amniotic membrane in wound healing Faheem Jan (Islamabad, Pakistan)	08:00 - 08:00
TBS-EP425	Impact of discordant isoniazid and rifampicin susceptibility results between the Anyplex™ II MTB/MDR assay and the BACTEC MGIT 960 system on treatment decisions Kanphai Wongjarit (Bangkok, Thailand)	08:00 - 08:00
TBS-EP428	The role of physiotherapy in demystifying pulmonary tuberculosis in Uganda Sheillah T. Nakisanze (Masaka, Uganda)	08:00 - 08:00
TBS-EP431	Clinical performance of the CAD4TB AI system for pulmonary tuberculosis detection among young adults in Mongolia: A diagnostic screening study Yanjindulam Purevsuren (Ulaanbaatar, Mongolia)	08:00 - 08:00
TBS-EP434	Addressing access to treatment and diagnostic barriers in TB treatment through the Market and Patent Intelligence Study: A focus on intellectual property barrier Duke Otieno (Nairobi, Kenya)	08:00 - 08:00
TBS-EP440	Shortened treatment regimens for drug resistant (DR)-TB patients	08:00 - 08:00

	in Azerbaijan: First results Irada Akhundova (Baku, Azerbaijan)	
TBS-EP443	Concomitant subclinical pulmonary tuberculosis in patients with extra-pulmonary tuberculosis Tejaswini Gude (New Delhi, India)	08:00 - 08:00
TBS-EP446	Evaluation of the second-generation Fujifilm SILVAMP TB-LAM assay for TB diagnosis in Nigerian adults Nadiia Tytarenko (Badalona, Spain)	08:00 - 08:00
TBS-EP449	Novel mutations in genes associated with bedaquiline and linezolid resistance in drug- naive <i>Mycobacterium tuberculosis</i> isolates Chikanshi Sharma (Delhi, India)	08:00 - 08:00
TBS-EP452	Measuring cellular responses against respiratory pathogens can help to guide prophylaxis in immunocompromised patients Irene Latorre (Badalona, Spain)	08:00 - 08:00
TBS-EP455	Radiological features of pulmonary nontuberculous mycobacterial disease depending on the species of the pathogen Anastasiya Gaida (Moscow, Russian Federation)	08:00 - 08:00
TBS-EP458	Estimating the effect of implementing novel diagnostics in adults and children on pediatric TB indicators in KwaZulu-Natal, South Africa Mark Fajans (Seattle, United States)	08:00 - 08:00
TBS-EP461	The iron-vitamin D axis in tuberculosis: Hepcidin modulation as a target for precision host-directed therapy Satiti Palupi Purwanto (Hat Yai, Thailand)	08:00 - 08:00
TBS-EP464	Research on patients with NTM lung disease accompanied by anxiety or depression and related risk factors Xiang Shi (Shang Hai, China)	08:00 - 08:00
TBS-EP467	Reasons for refusal of TB preventive treatment uptake by eligible contacts of TB patients in high TB burden settings Sobia Faisal (Islamabad, Pakistan)	08:00 - 08:00
TBS-EP470	Isolation of non-tuberculous mycobacteria (NTM) from household water of patients with NTM pulmonary disease Wei Sha (Shang Hai, China)	08:00 - 08:00
TBS-EP479	Adherence to isoniazid preventive therapy and its associated factors among HIV patients receiving treatment in five districts in Ghana Mavis Pearl Kwabla (Hohoe, Ghana)	08:00 - 08:00
TBS-EP482	Prospective prediction of TBAJ-876-PaL phase 2 clinical outcomes in NC-009 trial via a multi-model framework Eunsol Yang (San Francisco, United States)	08:00 - 08:00
TBS-EP485	Implementation of TPT with shorter regimens: Experience from Bangladesh Rifat Jahan Khan (Dhaka, Bangladesh)	08:00 - 08:00
TBS-EP488	Empowering National TB Control Program through artificial intelligence-enhanced portable X-ray deployment in Bangladesh Rifat Jahan Khan (Dhaka, Bangladesh)	08:00 - 08:00
TBS-EP491	Lineage identification and mutation profile of <i>Mycobacterium tuberculosis</i>: A study from National Reference Laboratory, India Raj Narayan Yadav (New Delhi, India)	08:00 - 08:00
TBS-EP493	Oral rinse outperforms facemask capture for non-sputum diagnosis	08:00 - 08:00

	of pulmonary TB Simon C Mendelsohn (Cape Town, South Africa)	
TBS-EP503	Trends in tuberculosis detection using GeneXpert in a rural Ghanaian district: A six-year retrospective analysis (2019-2024) Eyram Hanu (Hohoe, Ghana)	08:00 - 08:00
TBS-EP506	Fate of TB treatment among the patients who remained bacteriologically positive after two months of anti-TB drugs Sobia Faisal (Islamabad, Pakistan)	08:00 - 08:00
TBS-EP509	Physiotherapy management in tuberculosis patients with co-existing HIV infection: Challenges in immunocompromised care Elizabeth Nakanwagi (Kampala, Uganda)	08:00 - 08:00
TBS-EP512	Can simple blood tests predict heart disease in patients with pulmonary tuberculosis? - The TB-HEART Study Marcello Scopazzini (London, United Kingdom)	08:00 - 08:00
TBS-EP515	Threat beyond TB: Rising menace of NTM infections and the urgent need for accurate diagnosis Jyotirmayee Turuk (Bhubaneswar, India)	08:00 - 08:00
TBS-EP518	Genomic insights into <i>Mycobacterium tuberculosis</i> lineages and antimicrobial resistance profiles in three Canadian provinces Reema Singh (Saskatoon, Saskatchewan, Canada)	08:00 - 08:00
TBS-EP521	Transcriptomic profiles from animal hosts following infection with <i>Mycobacterium bovis</i>: A systematic review Liliana C. M. Salvador (Tucson, United States)	08:00 - 08:00
TBS-EP524	Assessment of awareness and knowledge of butchers on bovine tuberculosis in the Volta region of Ghana Iddrisu Saliu (Hohoe, Ghana)	08:00 - 08:00
TBS-EP527	Effectiveness of BPaL/BPaLM in central area of Taiwan Yi-Wen Huang (Changhua, Taiwan)	08:00 - 08:00
TBS-EP530	Ibuprofen and acetylsalicylic acid as adjunctive to anti-tuberculosis treatment: Phase II clinical trial Cris Vilaplana (Badalona, Spain)	08:00 - 08:00
TBS-EP533	Pathobionts and antimicrobial resistance in symptomatic people with and without tuberculosis Suventha Moodley (Cape Town, South Africa)	08:00 - 08:00
TBS-EP536	Validation of a DNA methylation signature of active tuberculosis in the buccal mucosa using methylation-specific PCR Isabelle Öhrnberg (Linköping, Sweden)	08:00 - 08:00
TBS-EP539	The Tuberculosis Knowledge and Analytics Platform: TB Nexus Analytics Nibedita Rath (Bangalore, India)	08:00 - 08:00
TBS-EP562	Effect of combined inspiratory and expiratory muscle training in pulmonary rehabilitation of active and post tuberculosis Sheillah T. Nakisanze (Masaka, Uganda)	08:00 - 08:00
TBS-EP565	Establishment of a model for early warning of onset in population exposed to <i>Mycobacterium tuberculosis</i> Jingli Du (Beijing, China)	08:00 - 08:00
TBS-EP568	Nutritional status of tuberculosis patients and its associated factors in four districts in Ghana Mavis Pearl Kwabla (Hohoe, Ghana)	08:00 - 08:00

TBS-EP571	Maternal and infant outcomes in acute hematogenous disseminated pulmonary tuberculosis during pregnancy Huiru An (Beijing, China)	08:00 - 08:00
TBS-EP577	Development of a loop-mediated Isothermal amplification (LAMP) assay for the detection of pepQ gene in Mycobacterium tuberculosis Joannah Marie Bislumbre (Manila, Philippines)	08:00 - 08:00
TBS-EP580	Factors that impact the expansion of coverage for preventive treatment of TB in the Kyrgyz Republic Dinara Madybaeva (Bishkek, Kyrgyzstan)	08:00 - 08:00
TBS-EP583	Clinical features of pulmonary tuberculosis and nanostructural characteristics of multidrug-resistant Mycobacterium tuberculosis strains Natalia Yatskevich (Belarus)	08:00 - 08:00
TBS-EP586	Long term impact of pulmonary TB on health-related functioning and well-being in four African countries Kamban Hirasen (Johannesburg, South Africa)	08:00 - 08:00
TBS-EP589	Enrichment of <i>M. tuberculosis</i> in patient sputa using a limiting dilution assay Dale Liebenberg (Johannesburg, South Africa)	08:00 - 08:00
TBS-EP592	Bridging diagnostic gaps of drug-resistant pulmonary tuberculosis with clinical diagnosis in a low-and middle-income state, Southwest, Nigeria: A secondary data analysis Emmanuel Irek (Ekiti, Nigeria)	08:00 - 08:00
TBS-EP595	Diagnostic potential of hematological counts and ratios in pediatric tuberculosis: A five-year retrospective study Simona Mäsiarová (Martin, Slovakia)	08:00 - 08:00
TBS-EP598	Polystyrene particles alter mycobacterial lipidic cell wall composition Iris Romero-Andrada (Badalona, Spain)	08:00 - 08:00
TBS-EP601	Population pharmacokinetics of isoniazid in TB patients: Accounting for age, sex, weight, diabetes, and HIV Felipe Ridolfi (United States)	08:00 - 08:00
TBS-EP603	Single-cell transcriptomic profiling identifies immune signatures in latent Mycobacterium tuberculosis infection and active tuberculosis Jie Tian (Shanghai, China)	08:00 - 08:00
TBS-EP606	Latent tuberculosis infection retains cytotoxic molecule expression and functionality lost during active disease Carlos Peña Bates (CDMX, Mexico)	08:00 - 08:00
TBS-EP609	Harnessing AI for rapid, consistent, and efficient scientific writing: Large language models for TB trial protocol generation Brian Hiroshi Aldana (San Francisco, United States)	08:00 - 08:00
TBS-EP614	Predictive modeling of tuberculosis prevalence among medical workers in the Vinnitsya Region, Ukraine: Insights from 2007-2029 Artemii Bogomolov (Vinnitsya, Ukraine)	08:00 - 08:00
TBS-EP616	Knowledge of tuberculosis prevention and control among public service vehicle operators in the South Rift Valley, Kenya Cheruiyot Sambu (Eldoret, Kenya)	08:00 - 08:00
TBS-EP618	Is transmission the primary route to bedaquiline resistance? A context specific framework for transmission threshold estimation	08:00 - 08:00

	Abel Kjaersgaard (London, United Kingdom)	
TBS-EP620	Utility of antibody responses in the diagnosis of tuberculosis in rural Papua New Guinea Catherine Rush (Townsville, Australia)	08:00 - 08:00
TBS-EP622	Evaluation of the consistency between phenotypic MIC and genomic mutations in the detection of Bedaquiline and Clofazimine cross-resistance in <i>Mycobacterium tuberculosis</i> isolates from the Philippines Shiomi Yoshida (Kiyose, Tokyo, Japan)	08:00 - 08:00
TBS-EP624	Gastrointestinal parasites and their association with TB immune responses in Rural Papua New Guinea Jeffrey Warner (Townsville, Australia)	08:00 - 08:00
TBS-EP626	Accelerating tuberculosis prevention: Assessing novel TB preventive treatments in a preclinical infection model Andréanne Lupien (Montreal, Canada)	08:00 - 08:00
TBS-EP628	The computer-aided detection software using chest X-ray images in TB screening may have the potential to identify early TB patients in China Wei Liu (China)	08:00 - 08:00
TBS-EP630	Comparing LAM to other sputum-based biomarkers in NC-009 trial Juliano Timm (New York, United States)	08:00 - 08:00
TBS-EP632	Low complexity-manual nucleic acid amplification tests for detection of pulmonary tuberculosis in adolescents and adults with presumptive tuberculosis: A systematic-review and meta-analysis of diagnostic accuracy Adhin Bhaskar (Chennai, India)	08:00 - 08:00
TBS-EP634	Impact of TB preventive therapy at grassroots level in community setting in Pune, India Govinda Narke (Pune, India)	08:00 - 08:00
TBS-EP636	Innovative AI tool for TB diagnosis based on metabolomic detection in urine Jose Dominguez (Barcelona, Spain)	08:00 - 08:00
TBS-EP638	Comparison of different chemicals as an alternative sputum liquefaction reagent to N-acetyl-L-cysteine with Sodium Hydroxide (NALC-NaOH) Jo Mary Lei Majaducon (Manila, Philippines)	08:00 - 08:00
TBS-EP647	Enhancing lung health through physiotherapy for overall well-being Elizabeth Nakanwagi (Kampala, Uganda)	08:00 - 08:00
TBS-EP653	Tissue-specific immune phenotyping reveals divergent responses to BCG vaccination and <i>Mycobacterium tuberculosis</i> challenge Irene Latorre (Badalona, Spain)	08:00 - 08:00
TBS-EP656	Risk of human tuberculosis associated with exposure to livestock in rural Ballabgarh, Haryana: A Case-Control Study Rakesh Kumar (New Delhi, India)	08:00 - 08:00
TBS-EP665	Detection of first-line and second-line Drug-Resistance mediating mutations in <i>Mycobacterium tuberculosis</i> with DNA extracted with different extraction methods directly from sputum using Next-Generation Sequencing Vera Allerheiligen (Nehren, Germany)	08:00 - 08:00
TBS-EP668	Frequency and co-resistance of bedaquiline, clofazimine, delamanid, and pretomanid in MDR-TB isolates at a North Indian	08:00 - 08:00

	reference laboratory Rashmi Ratnam (Lucknow, India)	
TBS-EP674	Breaking resource barriers: Development of portable AIMLAM for active TB diagnosis in the HIV- population Xiang Yang (Guangzhou, China)	08:00 - 08:00
TBS-EP677	Exhaled breath condensate: A new window on aerobiology of <i>Mycobacterium tuberculosis</i> Benjamin Patterson (Cape Town, South Africa)	08:00 - 08:00
TBS-EP680	Assessment of a simplified and portable IGRA-TB platform based on fluorescence immunoassay for the diagnosis of <i>Mycobacterium tuberculosis</i> Infection Jose Dominguez (Barcelona, Spain)	08:00 - 08:00
TBS-EP683	Diagnostic Utility of Fluorescein Diacetate (FDA) Staining for Rapid Tuberculosis Detection: A Comparative Study Against Automated Liquid Culture Rashmi Ratnam (Lucknow, India)	08:00 - 08:00
TBS-EP689	Prevalence and risk factors of anti-tuberculosis drug-induced hepatitis based on liver function tests among TB patients at Hargeisa TB Hospital, Somaliland Mohamed Abdi Hergeye (Hargeisa, Somalia)	08:00 - 08:00
TBS-EP695	Post TB morbidity - What is the optimal management of TB IRIS? Proposal for a clinical trial Kasha Singh (Melbourne, Australia)	08:00 - 08:00
TBS-EP698	Preliminary diagnostic performance of novel LAM antibodies in CSF of HIV negative Vietnamese children with TB meningitis: A SURE substudy Julie Huynh (Ho Chi Minh City, Vietnam)	08:00 - 08:00
TBS-EP701	Investigating the impact of inoculum size on EUCAST methodology for MIC <i>Mycobacterium tuberculosis</i> determinations Deborah Recchia (Pavia, Italy)	08:00 - 08:00
TBS-EP704	Targeting the tryptophan synthase TrpAB to fight <i>Mycobacterium tuberculosis</i> Giovanni Stelitano (Pavia, Italy)	08:00 - 08:00
TBS-EP710	Achieving 100% participant retention in an active tuberculosis cohort Zainab Baig (Durban, South Africa)	08:00 - 08:00
TBS-EP713	Pre-extensively drug-resistant extrapulmonary tuberculosis: A growing threat Manu Singh (Lucknow, India)	08:00 - 08:00
TBS-EP716	Pharmacogenetic insights for tuberculosis treatment using Namibian human genetic diversity Lorraine Boois (Windhoek, Namibia)	08:00 - 08:00
TBS-EP722	Integrated genomic and host-based assessment of a persistent extensively drug resistant <i>M. tuberculosis</i> Beijing strain during therapy Mandira Varma-Basil (Delhi, India)	08:00 - 08:00
TBS-EP725	Optimization of community-based tuberculosis screening informed by Bayesian Latent Class modelling Aquiles R. Henriquez-Trujillo (Antwerp, Belgium)	08:00 - 08:00
TBS-EP734	Neutrophil-to-lymphocyte-ratio and neutrophil-to-monocyte-plus-lymphocyte-ratio in the blood of adolescents with pulmonary	08:00 - 08:00

	tuberculosis	
	Larissa Gorbach (Minsk, Belarus)	
TBS-EP737	Using artificial intelligence for parameterization of mechanistic epidemiological models in tuberculosis control Nishant Chavan (New Delhi, India)	08:00 - 08:00
TBS-EP740	Chronotherapy for tuberculosis: A conceptual framework to harness host circadian rhythms and destabilize mycobacterium tuberculosis physiology Satiti Palupi Purwanto (Hat Yai, Thailand)	08:00 - 08:00
TBS-EP743	Neutrophil, lymphocyte and monocyte ratios in children with active and latent tuberculosis Larissa Gorbach (Minsk, Belarus)	08:00 - 08:00
TBS-EP746	Platelet-to-lymphocyte-ratio in children and adolescents with pulmonary tuberculosis and latent tuberculosis Larissa Gorbach (Minsk, Belarus)	08:00 - 08:00
TBS-EP755	Computer aided diagnostics for TB diagnosis: Overcoming challenges and leveraging opportunities in LMICs Arnold Kennedy Tumuhairwe (Kampala, Uganda)	08:00 - 08:00
TBS-EP761	Alteration in micromineral levels, cluster of differentiation 4+ and gamma glutamyl transferase in subjects on anti-tuberculosis chemotherapy at Infectious Disease Hospital Calabar, Nigeria Raymond Eworo (Calabar, Nigeria)	08:00 - 08:00
TBS-EP767	Targeting TB granulomas to develop HDTs Mohlopheni Jackson Marakalala (Cape Town, South Africa)	08:00 - 08:00
TBS-EP773	Genotypes of <i>Mycobacterium tuberculosis</i> complex isolated from GeneXpert negative PTB patients: Whole genome sequence based comparative study Alem Alemayehu (Addis Ababa, Ethiopia)	08:00 - 08:00
TBS-EP779	Systemic immune inflammation index and systemic inflammation response index in children with pulmonary tuberculosis and latent tuberculosis Larissa Gorbach (Minsk, Belarus)	08:00 - 08:00
TBS-EP782	The impact of information technology on the epidemiological profile of tuberculosis in the socio-economic zones of the Republic of Sakha Aleksey Kazakov (Moscow, Russian Federation)	08:00 - 08:00
TBS-EP785	Modern capabilities of neural network models in the analysis of chest X-rays: A systematic review Aleksey Kazakov (Moscow, Russian Federation)	08:00 - 08:00
TBS-EP788	Characteristics of non-specific microflora in patients with pulmonary tuberculosis Anastasiya Gaida (Moscow, Russian Federation)	08:00 - 08:00

Community Connect Sessions

08:15 - 09:15

CC

CCS019 - From fragility to force: Community resilience and leadership amid TB funding shifts

Madhava Sai Sivapuram (India)

Madhava Sai Sivapuram (India)

Nicola James (United Kingdom)

Introduction

08:15 - 08:20

Context setting: Donor funding freeze

08:20 - 08:25

	Duy Trinh-Hoang (Sydney, Australia)	
	Standing the gap: Community responses to TB service disruptions amid donor withdrawals	08:25 - 08:35
	Zahedul Islam (Kyiv, Ukraine)	
	From crisis to capacity: Rebuilding TB programmes through local ownership and domestic advocacy	08:35 - 08:45
	Ingrid Schoeman (Pretoria, South Africa)	
	Decolonising TB funding: Centring communities in the future of sustainable health systems	08:45 - 08:55
	Kinz Ul Eman (Islamabad, Pakistan)	
	Question and Answer	08:55 - 09:10
<i>Break</i>		
09:00 - 09:15		Main
Break/Networking		
<i>Community Connect Sessions</i>		
09:00 - 10:30		CCC
	CCWS007 - Responding to lived realities-A multisectoral panel dialogue	
	Atul Shendge (Sonipat, India)	
	Ingrid Schoeman (Pretoria, South Africa)	
	Panel Discussion: Responding to Lived Realities - A Multisectoral Panel Dialogue	09:00 - 09:00
	Vikas Panibatla (Hyderabad, India)	
	Blessina Kumar (New Delhi, India)	
	Kerri Viney (Geneva, Switzerland)	
	Evaline Kibuchi (Nairobi, Kenya)	
	Stephan Albani (Germany)	
<i>Community Connect</i>		
09:00 - 17:00		CCART
	CCAE004 - 'Hospitality': Selected Works (Preview) Exhibition by artist and TB survivor Paulina Siniatkina	
	Paulina Siniatkina (Netherlands)	
<i>TBScience Sessions</i>		
09:05 - 09:55		TBS
	TBS11 - Mixed oral abstract presentations IV	
	Kobto Koura (Paris, France)	
	Erica Andersen-Nissen (South Africa)	
TBS11-05	Session introduction	09:05 - 09:07
TBS11-10	Immunogenicity and efficacy of replication-limited or irradiation-inactivated BCG delivered intravenously to rhesus macaques	09:07 - 09:14
	Patricia Darrah (Bethesda, MD, United States)	
TBS11-15	Immunogenicity of the novel TB vaccine H107e/CAF®10b in BCG exposed, Mtb-uninfected adults in South Africa	09:14 - 09:21
	Cecilia Lindestam Arlehamn (Copenhagen, Denmark)	
TBS11-20	Diagnostic performance of tongue swabs for tuberculosis using two sampling durations with the Pluslife MTBC platform	09:21 - 09:28
	Sri Hartati (Bandung, Indonesia)	
TBS11-25	Novel aptamer-based immunoassay targeting gastric lavage antigens for pediatric pulmonary tuberculosis diagnosis	09:28 - 09:35
	Anjali Kashwal (Chandigarh, India)	

TBS11-30	Boosting immunity: Screening immunomodulators for enhanced antimicrobial therapy in tuberculosis Tamia Lawrence (Durban, South Africa)	09:35 - 09:42
TBS11-35	Q&A	09:42 - 09:55
<i>Short Oral Abstract Sessions</i>		
09:15 - 10:45		Main
	SOA14 - A taste for something new: Innovative sampling for mycobacterial testing Morten Ruhwald (Copenhagen, Denmark) Rachel Byrne (Liverpool, United Kingdom)	
In	Introduction	09:15 - 09:18
SOA14-655-21	Evaluation of a novel tongue swab specimen for molecular TB testing on the point-of-care LumiraDx platform Ronit Dalmat (Seattle, United States)	09:18 - 09:25
SOA14-656-21	Positive progress: Development of <i>M. tuberculosis</i> proficiency products for tongue swab testing protocols Lindsey Turnbull (Fishers, United States)	09:25 - 09:32
SOA14-657-21	Non-Invasive diagnosis of pulmonary TB using face mask sampling: A prospective study in adults from Moldova Dariusz Woelk (Borstel, Germany)	09:32 - 09:39
SOA14-658-21	Diagnostic yield of tongue swab- compared to sputum-based molecular testing in four high-burden countries Seke Muzazu (Lusaka, Zambia)	09:39 - 09:46
SOA14-659-21	Test performance of tongue swabs subjected to Xpert MTB/RIF Ultra, collected from high-risk South African adult primary healthcare clinic attendees (TUTTPlus Study) Rebecca Berhanu (Johannesburg, South Africa)	09:46 - 09:53
SOA14-660-21	Testing tongue swab samples by Cepheid Xpert MTB/RIF Ultra: Comparison of two protocols applied to samples from people with low-bacillary load TB Rachel C. Wood (Seattle, United States)	09:53 - 10:00
SOA14-661-21	Multicentre evaluation of tongue swabs using a new molecular point-of-care assay for TB diagnosis in China Junwei Cui (Xinxiang, China)	10:00 - 10:07
SOA14-662-21	Feasibility and diagnostic performance of tongue swab-based qPCR testing for TB in programmatic settings in Vietnam Dr. Nguyen Binh Hoa (Hanoi, Vietnam)	10:07 - 10:14
SOA14-663-21	An ultra-high throughput tongue swab molecular testing platform (NEXAR) for mass TB screening Lesley Scott (Johannesburg, South Africa)	10:14 - 10:21
SOA14-664-21	qPCR batch-processed tongue swabs as screening tool for large-scale community-based case-finding of TB Sharon L. Olifant (Pretoria, South Africa)	10:21 - 10:28
SOA14-665-21	Diagnostic accuracy and feasibility of the AveloMask for non-invasive detection of pulmonary TB via breath aerosol sampling Rouxjeane Venter (Cape Town, South Africa)	10:28 - 10:35
	Q&A	10:35 - 10:45

Short Oral Abstract Sessions

09:15 - 10:45

R1

SOA15 - Zero deaths? Hope dims with funding cuts

Robert Horsburgh (Boston MA, United States)

Hemant Deepak Shewade (Chennai, India)

	Introduction	09:15 - 09:18
SOA15-666-21	The potential impact of reductions in international donor funding on TB incidence and mortality in low- and middle-income countries Rebecca A. Clark (London, United Kingdom)	09:18 - 09:24
SOA15-667-21	Why are people with TB dying? Ndapewa Ngwetuna Jason (Windhoek, Namibia)	09:24 - 09:30
SOA15-668-21	TB associated mortality rate and case fatality ratio in India: A scoping review Adhin Bhaskar (Chennai, India)	09:30 - 09:36
SOA15-669-21	Sex differences in risk factors for unsuccessful TB treatment outcomes: A retrospective cohort study of six Eastern European countries, 2020-2022 Ole Skouvig Pedersen (Aarhus, Denmark)	09:36 - 09:42
SOA15-670-21	Key determinants of loss to follow-up and mortality among people with multi-drug-resistant TB in Papua New Guinea: A multi-province analysis Robin Yasi (Port Moresby, Papua New Guinea)	09:42 - 09:48
SOA15-671-21	Treatment outcomes and post-treatment mortality among adults with drug-resistant TB in Sierra Leone: A national prospective cohort study Tom Wingfield (Liverpool, United Kingdom)	09:48 - 09:54
SOA15-672-21	Unmasking the impact of COVID-19 on TB mortality in Brazil: A Bayesian structural time series analysis with implications for future health crises Reginaldo Bazon Vaz Tavares (Ribeirão Preto, Brazil)	09:54 - 10:00
SOA15-673-21	A cross-sectional study to identify comorbidities contributing to deaths among people with TB using verbal autopsy tool in Tamil Nadu, India Asha Frederick (Chennai, India)	10:00 - 10:06
SOA15-674-21	Preventable TB deaths reported by coroners in England and Wales: A case series and guideline review Ava Milne (Oxford, United Kingdom)	10:06 - 10:12
SOA15-675-21	How does the family perceive TB deaths? Qualitative analysis of TB deaths in the RATIONS trial Madhavi Bhargava (Mangaluru, India)	10:12 - 10:18
SOA15-676-21	Navigating the road to recovery: User journeys and barriers among persons with drug-resistant TB in South Africa Preethi Mistri (Johannesburg, South Africa)	10:18 - 10:24
SOA15-677-21	Six districts with sustained TB death rate reduction following differentiated TB care in Southern India Asha Frederick (Chennai, India)	10:24 - 10:30
	Q&A	10:30 - 10:45

Symposia

09:15 - 10:45

R2

SY26-360-26 - A world without TB must not be a world without ethics: The AI dilemma

Razia Kaniz Fatima (Islamabad, Pakistan)

Nesri Padayatchi (Durban, South Africa)

Introduction

09:15 - 09:20

Ethical considerations in ultrashort TPT trials

09:20 - 09:37

Justin Denholm (Melbourne, Australia)

The ethics of artificial intelligence in health

09:37 - 09:54

Keymanthri Moodley (South Africa)

AI in TB care: Just because the cool kids are doing it doesn't mean you have to do it too

09:54 - 10:11

Diego S. Silva (Sydney, Australia)

Perceptions of TB-affected communities about AI in TB care

10:11 - 10:28

Karuna Devi Sagili (Amsterdam, Netherlands)

Q&A

10:28 - 10:45

Oral Abstract Sessions

09:15 - 10:45

R3

OA25 - Enhancing TB detection and diagnostics in public and private settings

Mohammed Yassin (Geneva, Switzerland)

Deborah Ikeh (Abuja, Nigeria)

In

Introduction

09:15 - 09:20

OA25-337-21

Acceptability and feasibility of an AI-powered care co-ordination tool in TB management in Patient Provide Supporter Agency (PPSA) service implementation model in India: Qualitative insights

09:20 - 09:27

Saniya Pawar (Mumbai, India)

OA25-338-21

Utility of symptom-agnostic chest X-ray for facility-based TB screening in Viet Nam: Secondary analysis of a large-scale public-private mix intervention

09:27 - 09:34

Luan Nguyen Quang Vo (Ha Noi, Vietnam)

OA25-339-21

Impact of private sector involvement in TB case finding: Results from 16 newly-included states in Nigeria

09:34 - 09:41

Kelechi Nzeadibe (Abuja, Nigeria)

OA25-340-21

Strengthening public-private mix (PPM) for TB case finding: Expanding the role of private healthcare providers in Nigeria

09:41 - 09:48

Bethel Nwaogu (Abuja, Nigeria)

OA25-341-21

Turning the tide: Five years of enhanced TB detection in Southwestern Nigeria (FY20-FY25)

09:48 - 09:55

Olugbenga Daniel (Ikeja, Nigeria)

OA25-342-21

Wheels of change: Strengthening TB sample referral and diagnosis through public-private collaboration Meru County experience (2022-2023)

09:55 - 10:02

Winnie Tole (Nairobi, Kenya)

OA25-343-21

Enhancing TB detection using innovative screening technologies: Programmatic impact of mobile application for TB screening integration in private healthcare sector in Katsina State, Nigeria

10:02 - 10:09

Innocent Tidisha Lawrence (Katsina, Nigeria)

OA25-344-21

Driving efficiency in TB notification: The impact of DHIS2 in Pakistan's private sector

10:09 - 10:16

	Abdullah Latif (Islamabad, Pakistan)	
OA25-345-21	Building TB diagnostic infrastructure in Uttarakhand State in India: A joint effort by government and corporate social responsibility Bipra Bishnu (New Delhi, India)	10:16 - 10:23
OA25-346-21	Intensified TB case finding in private hospitals in India: Transforming the incidental screening pathway with computer-aided detection Saniya Pawar (Mumbai, India)	10:23 - 10:30
	Q&A	10:30 - 10:45
 <i>Symposia</i>		
09:15 - 10:45		R4
	SY27-370-27 - Bridging the gap: Accelerating development and approval of priority formulations for children with TB Anneke C. Hesseling (Cape Town, South Africa) Catherine Hewison (Paris, France)	
	Introduction	09:15 - 09:20
	CHasing Expedited and Equitable Treatment Access (CHEETA) for children Anthony Garcia-Prats (Madison, United States)	09:20 - 09:35
	State-of-the-art pharmacometric approaches to paediatric trials Elin Svensson (Uppsala, Sweden)	09:35 - 09:50
	Child-friendly formulations and acceptability: Not an afterthought Tiziana Masini (Geneva, Switzerland)	09:50 - 10:05
	Towards regulatory approval: Paediatric investigation plans Laura Fregonese (A, Netherlands)	10:05 - 10:20
	Ganfeborole: Status of paediatric development programme Simon Tiberi (London, United Kingdom)	10:20 - 10:35
	Q&A	10:35 - 10:45
 <i>Special Sessions</i>		
09:15 - 10:45		R5
	SPS06 - Smarter, shorter, stronger: Advancing paediatric TB care through science Sangeeta Sharma (India) James Seddon (Cape Town, South Africa)	
	Introduction	09:15 - 09:20
	TB Survivor Nur-Kamila Kandela (Denmark)	09:20 - 09:30
	Smarter decision, earlier diagnosis: The evolving landscape of pediatric TB Celso Khosa (Maputo, Mozambique)	09:30 - 09:45
	An update on current approaches to treatment and preventive regimens for childhood TB Megan Palmer (Cape Town, South Africa)	09:45 - 10:00
	Special Group: Children with Severe Acute Malnutrition Chishala Chabala (Lusaka, Zambia)	10:00 - 10:15
	TB in teens: An update on research findings and their implications	10:15 - 10:30

	for care Silvia Chiang (Providence, United States)	
	Discussion and Q&A	10:30 - 10:40
 <i>Oral Abstract Sessions</i>		
09:15 - 10:45		R6
	OA26 - Advancing TB care: Innovations in drugs, vaccines, diagnostics and treatment Michael Hoelscher (Munich, Germany) Kelly Dooley (Nashville, United States)	
	Introduction	09:15 - 09:18
OA26-347-21	Early bactericidal activity of oral Sanfetrinem cilexetil against pulmonary TB Melissa Murphy (Cape Town, South Africa)	09:18 - 09:25
OA26-348-21	Early efficacy and preliminary safety of a novel 6-month regimen containing contezolid, delamanid, bedaquiline (CODA) and fluoroquinolones for Chinese rifampin-resistant people with TB Wenjuan Nie (Beijing, China)	09:25 - 09:32
OA26-349-21	Safety and efficacy of TBAJ-876 In combination with pretomanid and linezolid: Week 8 analysis result of NC-009 Morounfolu Olugbosi (Sandton, South Africa)	09:32 - 09:39
OA26-350-21	Safety of the novel TB vaccine H107e/CAF®10b in BCGexposed, M.tuberculosis-uninfected adults in Gauteng, South Africa: First in human trial Vaneshree Govender (Johannesburg, South Africa)	09:39 - 09:46
OA26-351-21	Enhancing the acceptability of a phase three TB vaccine trial in the Matlosana sub-district of South Africa: Using the Social Marketing Model Blossom Napoleon (Klerksdorp, South Africa)	09:46 - 09:53
OA26-352-21	Imprecision in TB infection outcomes: Implications for non-inferiority vaccine trials Daniel Grint (London, United Kingdom)	09:53 - 10:00
OA26-353-21	Refining research outcomes: Lessons from the setup of an endpoint review committee in TB observational diagnostic studies Leyla Larsson (Munich, Germany)	10:00 - 10:07
OA26-354-21	TRIDORE: Intensive-phase-throughout regimen is safer and more efficacious than triple-dose regimen for retreatment of rifampicin-susceptible TB Mahamadou Bassirou Souleymane (Niamey, Niger)	10:07 - 10:14
OA26-355-21	Multi-method monitoring of response to individualised all-oral drug-resistant TB therapy reveals rapid conversion to negative in three high burden countries Wilber Sabiiti (Glasgow, United Kingdom)	10:14 - 10:21
OA26-356-21	Nebulised bronchodilator-enhanced sputum induction in presumed smear-negative pulmonary TB: A randomised controlled trial (NeB-TB) Pichanon Mingchay (Bangkok, Thailand)	10:21 - 10:28
OA26-357-21	UNITE4TB - DECISION: A BTZ-043 phase IIB dose-ranging trial in combination with bedaquiline and delamanid Michael Hoelscher (Munich, Germany)	10:28 - 10:35
	Q&A	10:35 - 10:45

Symposia

09:15 - 10:45

R7

SY28-380-28 - Global political and financial shifts: Impact on TB communities and a collective action response

Petra Heitkamp (Ottawa, Canada)

Introduction	09:15 - 09:20
Assessing the USAID fallout: Comprehensive survey insights on TB programme impacts	09:20 - 09:35
Kinz Ul Eman (Islamabad, Pakistan)	
TB lives disrupted: The human cost of interrupted support in Ukraine	09:35 - 09:50
Olya Klymenko (Kyiv, Ukraine)	
TB Healthcare workers furloughed: The impact and experience in Cambodia	09:50 - 10:05
Sok Chamreun Choub (Phnom Penh, Cambodia)	
TB Programmes in distress: Experiences from Kenya	10:05 - 10:20
Evaline Kibuchi (Nairobi, Kenya)	
TB Community Coordination Hub: The TB community takes collective action to lead a response in crisis	10:20 - 10:35
Robyn Waite (Ottawa, Canada)	
Q&A	10:35 - 10:45

Symposia

09:15 - 10:45

R8

SY29-390-29 - Addressing TB in migrant populations: Challenges, evidence, and strategies for action

Delia Goletti (Italy)

Daria Podlekareva (Copenhagen, Denmark)

Introduction	09:15 - 09:20
Overview of TB in migrant populations: Epidemiology and barriers to care	09:20 - 09:37
Lorenzo Guglielmetti (Verona, Italy)	
Re-emergence of drug-resistant TB because of instable geopolitics	09:37 - 09:54
Ignacio Monedero-Recuero (Vilanova i la Geltrú, Spain)	
TB and refugees: Challenges and solutions from a global perspective	09:54 - 10:11
Christian Wejse (Aarhus N, Denmark)	
Consensus-based recommendations for TB prevention and care in migrants	10:11 - 10:28
Raquel Duarte (Porto, Portugal)	
Q&A	10:28 - 10:45

Community Connect Sessions

09:30 - 11:00

CC

CCS021 - Empowering communities: Our children should not die of TB!

Stijn Deborggraeve (Belgium)

Stijn Deborggraeve (Belgium)

Sabine Verkuijl (Geneva, Switzerland)

Introduction	09:30 - 09:35
Messages from a TB survivor and mother of a child who survived	09:35 - 09:47

TB

Ani Herna Sari (Indonesia)

Providing TB care in high food insecure settings: From policies to implementation 09:47 - 09:59

Oumarou Farouk Moussa Mamane (Niger)

Engaging communities in advocacy for nutrition in paediatric TB care and prevention 09:59 - 10:11

Aman Shukla (India)

Building a community of civil society for children with TB 10:11 - 10:23

Gloriah Moses (Kenya)

Innovative strategies for finding TB in children: The Nigerian experience 10:23 - 10:35

Urhioke Ochuko (Nigeria)

Question and Answer 10:35 - 11:00

TBScience Sessions

10:00 - 11:00

TBS

TBS12 - What should we prioritise for prevention of TB? Vaccines vs. antimycobacterials vs. nutritional intervention?

Willem Hanekom (South Africa)

Puck Pelzer (Amsterdam, Netherlands)

TBS12-05 **Session introduction** 10:00 - 10:03

TBS12-10 **What would communities like to see?** 10:03 - 10:10

Oanh Khuat Thi Hai (Vietnam)

TBS12-15 **What can nutritional intervention do?** 10:10 - 10:17

Anurag Bhargava (Mangaluru, India)

TBS12-20 **What are the prospects of long-acting TB drug formulations for prevention?** 10:17 - 10:24

Eric Nuermberger (United States)

TBS12-25 **How do we do TB vaccine trials in the era of preventive antimicrobials and nutritional intervention?** 10:24 - 10:31

Frank Cobelens (Amsterdam, Netherlands)

TBS12-30 **What does modelling teach us about likely effectiveness of different interventions?** 10:31 - 10:38

Rebecca A. Clark (London, United Kingdom)

TBS12-35 **Panel discussion** 10:38 - 11:00

Community Connect Sessions

10:00 - 10:50

WS-PGC

CCMC002 - Meeting with communities and The Union Community Advisory Panel (UCAP)

Madhava Sai Sivapuram (India)

Introduction 10:00 - 10:05

Building Community Connect (CC) and its challenges 10:05 - 10:20

Zahedul Islam (Kyiv, Ukraine)

Priyanka Aiyer (Delhi, India)

Kinz Ul Eman (Islamabad, Pakistan)

Tariro Kutadza (Zimbabwe)

Erman Varella (Jakarta, Indonesia)

Phumeza Tisile (Cape Town, South Africa)

	Question and answer with the communities	10:20 - 10:50
<i>Break</i>		
10:45 - 11:00		Main
Break/Networking		
<i>Plenary Sessions</i>		
11:00 - 12:00		Main
PL04 - Addressing chronic lung disease across the life course in low- and middle-income countries		
Guy Marks (Sydney, Australia)		
Chen-Yuan Chiang (France)		
	The Stephen Lawn TB-HIV Research Leadership Prize	11:00 - 11:05
	Introduction	11:05 - 11:07
	Global Asthma Network	11:07 - 11:12
	Chen-Yuan Chiang (France)	
	Out of breath: Confronting the hidden burden of asthma	11:12 - 11:27
	Chakaya Muhwa (Kenya)	
	Diagnose, treat, adapt: Confronting COPD in a warming, inequitable world	11:27 - 11:42
	David MG Halpin (United Kingdom)	
	Small lungs, big impact: Early-life risks for lifelong lung disease	11:42 - 11:57
	Rebecca Nantanda (Kampala, Uganda)	
	Panel discussion with Q&A	11:57 - 12:00
<i>Break</i>		
12:00 - 14:10		Main
Break/Networking		
<i>E-Posters</i>		
12:05 - 13:05		B1A
EP46 - Asymptomatic TB - reports from the field		
Anna Coussens (Melbourne, Australia)		
Hanif Esmail (London, United Kingdom)		
EP46-1137-21	Asymptomatic TB: A new challenge	12:05 - 12:10
	Marina Tadolini (Bologna, Italy)	
EP46-1138-21	Effectiveness of hospital-based active case finding using chest X-rays for early detection of asymptomatic TB in Chiangrai, Thailand	12:10 - 12:15
	Worarat Imsanguan (Chiangrai, Thailand)	
EP46-1139-21	Enhancing asymptomatic TB detection through active case finding initiatives using PDX machines and mobile X-ray vans in Lagos, Nigeria	12:15 - 12:20
	Taiwo Osatuyi (Lagos, Nigeria)	
EP46-1140-21	Prevalence and factors associated with asymptomatic pulmonary TB: A secondary data analysis of Uganda TB prevalence survey conducted in 2014-2015	12:20 - 12:25
	Aldomoro Burua (Kampala, Uganda)	
EP46-1141-21	Breaking the symptom barrier in ACF: Targeting high risk vulnerabilities for efficient asymptomatic TB detection in India	12:25 - 12:30
	Adhiraj Shekhawat (Delhi, India)	

EP46-1142-21	Diagnosis of asymptomatic TB during the nationwide hundred days campaign and the strategies for additional detection: Evidence from West Bengal, India Abhijit Dey (New Delhi, India)	12:30 - 12:35
EP46-1143-21	Tongue swab qPCR for asymptomatic TB screening: A high-accuracy alternative to sputum RMT and AI-based CXR in the general population Yang Li (Shanghai, China)	12:35 - 12:40
EP46-1144-21	Bio-phenotyping undetected TB: Is asymptomatic TB infectious and what is the role of chest radiography? Alex John Scott (Cape Town, South Africa)	12:40 - 12:45
EP46-1145-21	Evaluation of the PATHFAST TB LAM Ag assay in minimally symptomatic and subclinical TB cases and assessing its performance against established laboratory diagnostic tests Tahlia Perumal (Cape Town, South Africa)	12:45 - 12:50
EP46-1146-21	Improving diagnosis of asymptomatic TB among people living with HIV using digital chest X-ray with computer-aided detection in Nigeria Chidubem Ogbudebe (Abuja, Nigeria)	12:50 - 12:50
	Q&A	12:50 - 13:00
<i>E-Posters</i>		
12:05 - 13:05		B1B
EP47 - Enhancing TB care: Innovations in drug therapy, pharmacokinetics and treatment strategies Rovina Ruslami (Bandung, Indonesia)		
EP47-1147-21	Geographical representativeness of participants enrolled in randomised trials for TB treatment: A systematic review Ilaria Motta (London, United Kingdom)	12:05 - 12:10
EP47-1148-21	Population pharmacokinetic modelling of standard- and high-dose rifampicin for TB preventive therapy in the 2R² randomised controlled trial Fajri Gafar (Montreal, Canada)	12:10 - 12:15
EP47-1149-21	Is rifampin as part of fixed-dose combination tablet optimal for people in the with TB? A population pharmacokinetic study Francisco Beraldi-Magalhaes (Curitiba, Brazil)	12:15 - 12:20
EP47-1150-21	Could first-line anti-TB drugs in fixed-dose combination tablets be administered through a nasogastric tube? A pharmaceutical technology assay Francisco Beraldi-Magalhaes (Curitiba, Brazil)	12:20 - 12:25
EP47-1151-21	Cerebrospinal fluid penetration of pyrazinamide, levofloxacin and linezolid in people with pulmonary TB Jose Miguel Calderin Miranda (Cape Town, South Africa)	12:25 - 12:30
EP47-1152-21	Improving phase 2a efficacy predictions through parent/metabolite analysis: Insights from bedaquiline Belen P. Solans (San Francisco, Spain)	12:30 - 12:35
EP47-1153-21	Pretomanid exposure is not increased by severely impaired renal function Maria Beumont (New York, United States)	12:35 - 12:40
EP47-1154-21	Effectiveness and safety of a shortened oral regimen for multi-drug-resistant/rifampicin-resistant in Peru Edwin Herrera-Flores (Lima, Peru)	12:40 - 12:45

EP47-1155-21	Linezolid pharmacokinetics among people with TB receiving the newly-introduced BPaL/BPaLM regimen in Georgia Nikoloz Shurgaia (Tbilisi, Georgia)	12:45 - 12:50
EP47-1156-21	Establishment and application of a method for determination of plasma concentration of sodium aminosalicylate Haiyan Cui (Shanghai, China)	12:50 - 12:55
	Q&A	12:55 - 13:05
<i>E-Posters</i>		
12:05 - 13:05		B1C
EP48 - Surveillance of drug-resistant TB		
Jim Werngren (Stockholm, Sweden)		
EP48-1157-21	Characterisation of <i>M. tuberculosis</i> drug resistance using targeted next-generation sequencing: Observations from Indonesia Bony Wiem Lestari (Bandung, Indonesia)	12:05 - 12:10
EP48-1158-21	Phenotypic and genotypic comparison of anti-TB drug-resistant <i>M. tuberculosis</i> in Thailand Kraisorn Tohtubtiang (Bangkok, Thailand)	12:10 - 12:15
EP48-1159-21	Genomic variants and associated drug resistance profiles revealed by whole genome sequencing in drug-resistant <i>M. tuberculosis</i> clinical isolates from Limpopo province Kabelo Kaapu (Polokwane, South Africa)	12:15 - 12:20
EP48-1160-21	Prevalence of <i>katG</i> and <i>inhA</i> mutations in genes associated with isoniazid resistance in <i>M. tuberculosis</i> clinical isolates in Kazakhstan Nurlan Takenov (Almaty, Kazakhstan)	12:20 - 12:25
EP48-1161-21	Prevalence and distribution of genomic drug-resistance of anti-TB drugs in West Java, Indonesia Bony Wiem Lestari (Bandung, Indonesia)	12:25 - 12:30
EP48-1162-21	Trends in drug-resistant TB in the Democratic Republic of Congo: A 6-year retrospective analysis (2018-2023) Mawete Fina (Kinshasa, Congo (Democratic Republic))	12:30 - 12:35
EP48-1163-21	Shifting narratives of drug-resistant TB enrolment challenges Temitope Adetiba (Abuja, Nigeria)	12:35 - 12:40
EP48-1164-21	Surveillance of drug-resistant TB, including bedaquiline and delamanid, in Kazakhstan (2020-2024) Nurlan Takenov (Almaty, Kazakhstan)	12:40 - 12:45
EP48-1165-21	Resistance patterns among treatment-naive drug-resistant people with TB in Nigeria James Awotoye (Abuja, Nigeria)	12:45 - 12:50
EP48-1166-21	Baseline and emergent delamanid and pretomanid resistance in people exposed to delamanid in KwaZulu-Natal, South Africa Camus Nimmo (London, United Kingdom)	12:50 - 12:55
EP48-1167-21	The correlation between isoniazid resistance-related gene mutations and resistance levels in <i>M. tuberculosis</i> in Shanghai Wenjing Xiao (Shanghai, China)	12:55 - 13:00
	Q&A	13:00 - 13:05

E-Posters

12:05 - 13:05

B1D

EP49 - Journeys through TB: Stories of hope, resilience and recovery

Evaline Kibuchi (Nairobi, Kenya)

Phumeza Tisile (Cape Town, South Africa)

EP49-1168-21	Breaking the silence: Assessing and addressing TB-related stigma in Zimbabwe Kudzaishe Mutungamiri (Gweru, Zimbabwe)	12:05 - 12:10
EP49-1169-21	Here is my story! TB Champions on air and unafraid Suresh Bollepogu (Hyderabad, India)	12:10 - 12:15
EP49-1170-21	Enhancing TB knowledge and reducing stigma among private healthcare providers through virtual learning platforms in Lagos, Nigeria Ndidiama Umerah-Nwosu (Lagos, Nigeria)	12:15 - 12:20
EP49-1171-21	Assessing TB prevention in university freshmen: An IMB model-based survey on knowledge, motivation, behavioural skills, stigma, and information channels Jianming Wang (Nanjing, China)	12:20 - 12:25
EP49-1172-21	Documenting rights violations associated with TB in Nigeria: Impact on community rights and gender Rommy Mom (Abuja, Nigeria)	12:25 - 12:30
EP49-1173-21	Leveraging community-led monitoring to identify and address stigma and discrimination through the iMonitor ATM+ system in Kenya Caren Mutai (Eldoret, Kenya)	12:30 - 12:35
EP49-1174-21	Feasibility and impact of behaviour change solutions for TB response among vulnerable populations: Insights from 'Breaking the Barriers' community engagement project (A NIMHANS-led study) Rehana Begum (Delhi, India)	12:35 - 12:40
EP49-1175-21	"You will never be the same": A photovoice study with TB survivors in Uganda Wincelous Katagira (Kampala, Uganda)	12:40 - 12:45
EP49-1176-21	Indigenising TB professional development and education through researcher continuity and storytelling: Lessons from Inuit community public health worker training in Nunavik (Quebec, Canada) Anna Dunn-Suen (Montreal, Canada)	12:45 - 12:50
	Q&A	12:50 - 13:05

E-Posters

12:05 - 13:05

B1E

EP50 - Sick because they are poor: Undernutrition poverty and the TB crisis

Pranay Sinha (Boston, United States)

EP50-1177-21	Placing a nutritional lens on paediatric TB risk: Variability in definitions and their association with TB Meredith Brooks (Boston, United States)	12:05 - 12:10
EP50-1178-21	High prevalence of TB among Malawian children aged <5 years hospitalised with severe acute malnutrition Bryan Vonasek (East Lansing, United States)	12:10 - 12:15
EP50-1179-21	Poor nutrition increases the mortality risk in children treated for TB in sub-Saharan Africa	12:15 - 12:20

	Anca Vasiliu (Houston, United States)	
EP50-1180-21	Rifampin dosing and exposure in undernourished people with TB in India Pranay Sinha (Boston, United States)	12:20 - 12:25
EP50-1181-21	Improving the diagnosis of TB among children with malnutrition in Niger, Nigeria and South Sudan Helena Huerga (Brussels, Belgium)	12:25 - 12:30
EP50-1183-21	Carbohydrate dominance and gender inequity in diets of TB-affected households in India Chelsie Cintron (Providence, United States)	12:30 - 12:35
EP50-1184-21	Food with medicines: Impact of nutritional support on nutritional status, body composition, and grip strength in people nested within the RATIONS trial Anurag Bhargava (Mangaluru, India)	12:35 - 12:40
EP50-1185-21	Beyond the diagnosis: Using social determinants to drive targeted TB interventions in South Africa's West Rand District Nelisiwe Mhlabane (Pretoria, South Africa)	12:40 - 12:45
EP50-1186-21	Eureka: Evidence of links between financial help and TB disease and recovery in Victoria, Australia Justin Denholm (Melbourne, Australia)	12:45 - 12:50
	Q&A	12:50 - 13:05
 <i>E-Posters</i>		
	12:05 - 13:05	B1F
EP51 - Finding those missing: Responding to differentiated screening need		
Nora Engel (Amsterdam, Netherlands)		
Ashna Ashesh (Patna, India)		
EP51-1187-21	Accelerating drug-resistant diagnosis and ending the gap of missing cases in urban India Aakshi Kalra (New Delhi, India)	12:05 - 12:10
EP51-1188-21	Active TB detection in nomadic populations: Insights from hard-to-reach communities of Adamawa State, Northeast Nigeria Stephen John (Yola, Nigeria)	12:10 - 12:15
EP51-1189-21	Strengthening cross-border TB prevention and care through a one health approach among nomadic pastoralist communities in Kenya and Uganda Irungu Karuga (Nairobi, Kenya)	12:15 - 12:20
EP51-1191-21	Leaving no one behind: Targeted TB case finding in correctional facilities in Niger State, Nigeria Isah Ibrahim (Minna, Nigeria)	12:20 - 12:25
EP51-1192-21	Transforming TB preventing and care in prisons through policy and person-centered active case finding: A case from Padang City, Indonesia Rizanda Machmud (Padang, Indonesia)	12:25 - 12:30
EP51-1194-21	Impact of alcohol use on treatment outcomes amongst drug-resistant people with TB in Kenya Michael Odhiambo (Nairobi, Kenya)	12:30 - 12:35
EP51-1195-21	Leaving no one behind: Experience of piloting TB diagnosis and treatment service delivery to the conflict affected population in Myanmar Htun Myay Latt (Maesot, Thailand)	12:35 - 12:40

	Q&A	12:40 - 13:05
<i>E-Posters</i>		
12:05 - 13:05		B1G
EP52 - Preventing and finding TB in children and household contacts		
Anete Trajman (Rio de Janeiro, Brazil)		
Sabine Verkuijl (Geneva, Switzerland)		
EP52-1197-21	Reaching children where they are: The role of community and school-based TB screening during World Tuberculosis Day 2025 activities in Rivers State, Nigeria Nera Kadiri-Eneh (Port Harcourt, Nigeria)	12:05 - 12:10
EP52-1198-21	Finding TB in children living with HIV: Results using the WHO-recommended algorithms in Conakry, Guinea Emily Briskin (Paris, France)	12:10 - 12:15
EP52-1199-21	Improving childhood TB diagnosis and notification through advanced sample collection technologies intervention: An insight from Malawi Knox Banda (Blantyre, Malawi)	12:15 - 12:20
EP52-1200-21	The socio-cultural challenges affecting diagnosis of drug-resistant TB in children aged 0-4 years: Insights from KNCV Nigeria's experience Chinenye Igwetu (Federal Capital Territory, Nigeria)	12:20 - 12:25
EP52-1201-21	Prevalence of TB infection in school-going children in India: A scoping review Rebecca Calderara (Baltimore, United States)	12:25 - 12:30
EP52-1202-21	Integrated approach on case detection in children with unknown TB history in Nigeria: RAISING study Ugochukwu Chukwulobelu (Awka, Nigeria)	12:30 - 12:35
EP52-1203-21	Isoniazid preventive therapy (IPT) and TB infection in intrahousehold contacts: Results from a cohort in Peru Megan Murray (Boston, United States)	12:35 - 12:40
EP52-1204-21	Cracking the code: How local leadership and smart collaboration boosted contact investigation and TB prevention in Indonesia Erman Varella (Jakarta, Indonesia)	12:40 - 12:45
EP52-1205-21	Enhancing TB prevention and care through innovative contact tracing: Evaluating the effectiveness of the 2 km radius Spot-to-Tent Onion Model in Akwa Ibom State, Nigeria Blessing Noah (Uyo, Nigeria)	12:45 - 12:50
	Q&A	12:50 - 13:05
<i>E-Posters</i>		
12:05 - 13:05		B1H
EP53 - Mobilising communities: The heartbeat of TB response		
Robyn Waite (Ottawa, Canada)		
EP53-1206-21	Community-led monitoring for TB services in Geita, Tanzania: Lessons from the OneImpact TB Kiganjani approach Rabia Abeid Khaji (Kahama Municipal Council, Tanzania)	12:05 - 12:10
EP53-1207-21	A systematic TB screening to improve notification rates in vulnerable and high-risk populations in Kathmandu Urban, Nepal Ram Sharan Gopali (Kathmandu, Nepal)	12:10 - 12:15
EP53-1208-21	Designing effective TB programmes through community	12:15 - 12:20

	engagement: Lessons from TB REACH projects in South Asia Abhijith Njarattil Parameswaran (Amsterdam, Netherlands)	
EP53-1209-21	Addressing TB diagnostic delays in urban marginalised and unhoused populations of Delhi, India in project LEAD (Leveraging, Engaging, and Advocating to Disrupt TB Transmission) Jahangir Alam (Delhi, India)	12:20 - 12:25
EP53-1210-21	Accelerating cures: The race to fast-track BPaL access in Indonesia Yeremia Runtu (Jakarta, Indonesia)	12:25 - 12:30
EP53-1211-21	Faith, culture and artificial intelligence in action: A people-centered community-led approach to TB elimination in hard-to-reach tribal communities of Mizoram, India Agniswar Das (Aizawl, India)	12:30 - 12:35
EP53-1212-21	Empowering youth in TB detection and linkage to care: Lessons from community-driven interventions in Turkana County, Kenya Vivian Faith (Nairobi, Kenya)	12:35 - 12:40
EP53-1213-21	Stakeholders' absolute engagement: A proven approach towards increasing community TB notification in rural Nigeria Uchenna Ebenezer (Abakaliki, Ebonyi State, Nigeria)	12:40 - 12:45
EP53-1214-21	Leveraging health and wellness centres to strengthen decentralised TB services: A successful model in Himachal Pradesh, India Kamesh Venkatesan (New Delhi, India)	12:45 - 12:50
	Q&A	12:50 - 13:05
 <i>E-Posters</i>		
12:05 - 13:05		B11
EP54 - Understanding tobacco use in a changing world: Insight on policy, risk and communication		
Tara Singh Bam (Singapore, Singapore)		
EP54-1215-21	Communicating tangible research findings to non-statisticians: A case study of Tanzania GATS-2018 Elieza Milonga (Shinyanga MC, Tanzania)	12:05 - 12:10
EP54-1216-21	The effectiveness of quitline intervention on knowledge of harmful effects of smokeless tobacco use among residents of Ebonyi State, Nigeria Uzochukwu Ofonakara (Asaba, Nigeria)	12:10 - 12:15
EP54-1218-21	Dissecting Article 5.3: Understanding stakeholders' perspectives on tobacco industry interference and gaps in governance Jatina Vij (Chandigarh, India)	12:15 - 12:20
EP54-1219-21	Oral nicotine pouches: A summary of potentially applicable laws and regulatory challenges in India Tara Singh Bam (Singapore, Singapore)	12:20 - 12:25
EP54-1220-21	TAPS exposures, smoke-free area policies, and individual factors influence the intention and smoking behaviour among adolescents in Central Java, Indonesia Anung Sugihantono (Semarang, Indonesia)	12:25 - 12:30
EP54-1221-21	Vaping and pregnancy in the last decade: Mapping scientific progress, research gaps, and evolving themes (2014-2025) Nandita Bhatnagar (Chandigarh, India)	12:30 - 12:35
EP54-1222-21	Digital epidemiology of tobacco consumption: A Google Trends analysis of lung cancer and e-cigarette interest in India Jatina Vij (Chandigarh, India)	12:35 - 12:40

EP54-1223-21	Smoke and strain: A global bibliometric exploration of smoking's impact on TB treatment outcomes Diksha Walia (Chandigarh, India)	12:40 - 12:45
	Q&A	12:45 - 13:05

TBScience E-Poster Sessions
12:05 - 13:05

TBS-EP-08 - TBScience Moderated E-posters VIII

Marshlin Delon Naicker (Durban, South Africa)

TBS-EP260	Comparative transcriptomics uncover the mechanisms of transcripts regulation by coding and non-coding RNAs within the <i>Mycobacterium tuberculosis</i> complex strains Asanda Nyide (Durban, South Africa)	12:05 - 12:10
TBS-EP263	Tongue and rectal swab samples processed by manual qPCR enhance clinical decision-making in paediatric patients with presumptive tuberculosis Sharon L. Olifant (Pretoria, South Africa)	12:10 - 12:15
TBS-EP266	Mutational profiling and phylogenetic analysis of <i>Mycobacterium tuberculosis</i> strains from Pakistan Nazia Khursheed (Karachi, Pakistan)	12:15 - 12:17
TBS-EP269	Using affinity proteomics to understand the host response and identify diagnostic signatures of TB infection and disease Christopher Sundling (Stockholm, Sweden)	12:17 - 12:22
TBS-EP272	Evaluation of the WHO Mutation Catalogue (second edition) for genomic characterization of bedaquiline-, pretomanid- and linezolid-resistant <i>M. tuberculosis</i> isolates in South Africa Lavania Joseph (Johannesburg, South Africa)	12:22 - 12:27
TBS-EP275	Assessing diagnostic delays in tuberculosis testing: Turnaround time from computer-aided diagnostic X-ray to GeneXpert in selected Ugandan health facilities Dennis Mujuni (Kampala, Uganda)	12:27 - 12:32
TBS-EP278	Real-time predictive modelling for TB hotspots at the barangay level in the Philippines Anne-Laure Budts (Cape Town, South Africa)	12:32 - 12:37
TBS-EP284	The use of chest X-ray computer-aided detection scores in assessing post-TB lung disease in children Claire Hulsman (Cape Town, South Africa)	12:37 - 12:42
TBS-EP287	The accuracy of an infrasound vibroacoustic signature to screen for tuberculosis disease Hayley Poore (Irvine, United States)	12:42 - 12:47
TBS-EP288	Q&A	12:47 - 13:00

Satellite Sessions
12:15 - 13:45

R1

SS12 - Accelerating Country Readiness for Introduction of Novel TB Vaccines for Adults and Adolescents: Perspectives from High-Burden TB Countries

Yogan Pillay (South Africa)

Tereza Kasaeva (Switzerland)

Welcome and introduction from Co-Chairs 12:15 - 12:20

Mobilizing Communities for Future TB Vaccine Access and Uptake 12:20 - 12:30
Ramya Ananthakrishnan (Chennai, India)

	Country in Focus: Indonesia's Path to TB Vaccine Introduction	12:30 - 12:40
	Erlina Burhan (Jakarta, Indonesia)	
	Country in Focus: South Africa's role in Shaping Access and Financing for New TB Vaccines	12:40 - 12:50
	Norbert Ndjeka (South Africa)	
	Laying the Groundwork: Regulatory and Manufacturing Readiness	12:50 - 13:00
	Lucia Rizka Andalusia (Indonesia)	
	From Readiness to Access: Market Shaping and System Preparedness for TB Vaccines	13:00 - 13:10
	Frauke Uekermann (Netherlands)	
	Panel Discussion	13:10 - 13:30
	Audience Q&A	13:30 - 13:40
	Closing remarks and reflections from Co-chairs	13:40 - 13:45
<i>Side Meetings</i>		
12:30 - 13:30		R2
Tuberculosis Section		
<i>Side Meetings</i>		
12:30 - 13:30		R3
TB in prisons working group		
<i>Side Meetings</i>		
12:30 - 13:30		R4
Adult and Child Lung Health Section		
<i>Side Meetings</i>		
12:30 - 13:30		R5
HIV Section		
<i>Side Meetings</i>		
12:30 - 13:30		R7
TB and ethics working group		
<i>Side Meetings</i>		
12:30 - 13:30		R8
TB and mental health working group		
<i>E-Posters</i>		
13:10 - 14:10		B1A
EP55 - Novel diagnostics and treatment monitoring methods		
	Claudio Köser (Cambridge, United Kingdom)	
EP55-1224-21	Rapid detection of drug-resistant <i>M.tuberculosis</i> using a multiplexed CRISPR droplet platform	13:10 - 13:15
	Bo Ning (New Orleans, United States)	
EP55-1225-21	A CRISPR-Cas13a-based molecular assay for rapid and accurate detection of <i>M. tuberculosis</i>	13:15 - 13:20
	Uma Devi Ranganathan (Chennai, India)	
EP55-1226-21	One-pot CRISPR gel assay for urine-based diagnosis of TB	13:20 - 13:25

	Mayu Hikone (Nairobi, Kenya)	
EP55-1227-21	Utility of Nanopore sequencing for the detection of drug-resistant TB in Kyrgyzstan Aizat Kulzhabaeva (Bishkek, Kyrgyzstan)	13:25 - 13:30
EP55-1228-21	Nanopore targeted next-generation sequencing for the timely prediction of drug resistance in <i>M. tuberculosis</i> complex clinical specimens in Tanzania Togolani Maya (Dar es Salaam, Tanzania)	13:30 - 13:35
EP55-1230-21	Evaluation of urine lipoarabinomannan and host transcriptional molecular biomarkers for diagnosing TB in symptomatic individuals with negative culture results Robert Reiss (Newark, United States)	13:35 - 13:40
EP55-1231-21	Microfluidic-based molecular rapid diagnosis for tongue swab and sputum samples: A multicentre study Yu Chen (Zhengzhou, China)	13:40 - 13:45
EP55-1232-21	Machine learning combined with plasma multi-omics analysis helps diagnose TB progression in high-risk populations Mengqing Qian (Shanghai, China)	13:45 - 13:50
EP55-1233-21	Development and clinical validation of a novel method for simultaneous rapid molecular drug susceptibility testing of rifampicin, isoniazid and fluoroquinolones Junwei Cui (Xinxiang, China)	13:50 - 13:55
EP55-1234-21	TB-MBLA: Design and development of TB molecular bacterial load assay, a monitoring tool for treatment response Rowan Gray (Edinburgh, United Kingdom)	13:55 - 14:00
	Q&A	14:00 - 14:10
<i>E-Posters</i>		
	13:10 - 14:10	B1B
EP56 - From policy to practice: Strategic alignment to fight TB		
Robyn Waite (Ottawa, Canada)		
EP56-1235-21	Collaboration practices in TB research in Peru: Perspectives from TB researchers and clinicians Luz Villa-Castillo (Lima, Peru)	13:10 - 13:15
EP56-1236-21	A global survey of TB management policies in prisons Amy Zheng (Boston, United States)	13:15 - 13:20
EP56-1237-21	Improving grants management through business central systems to fight TB, leprosy and lung diseases in Kenya John Mungai (Nairabi, Kenya)	13:20 - 13:25
EP56-1238-21	Inequities in the production of TB-related social protection policies across municipalities in Rio de Janeiro, Brazil (2014-2024) Reginaldo Bazon Vaz Tavares (Ribeirão Preto, Brazil)	13:25 - 13:30
EP56-1239-21	Institutionalising nutritional support for people with TB into the local self-governance annual plans in Kerala, India: A policy reform initiative Aparna Mohan (Thiruvananthapuram, India)	13:30 - 13:35
EP56-1240-21	Strategies for managing global shortages of first-line anti-TB medicines: A case study of the National TB Programme in Nigeria Raji Mobolaji (Abuja, Nigeria)	13:35 - 13:40
EP56-1241-21	Translating evidence into policy: A mixed-methods approach to	13:40 - 13:45

	guideline development for differentiated TB care in India Sanjay Mattoo (New Delhi, India)	
EP56-1242-21	What happens when people with drug-resistant TB are not supported by the community? A survival analysis in Indonesia Qonita Nur Salamah (Jakarta, Indonesia)	13:45 - 13:50
EP56-1243-21	Accelerated BPaLM scale-up in high burden multi-drug-resistant/rifampicin-resistant TB setting: A mixed methods study on health-system strengthening through capacity building in India Sanjay Mattoo (New Delhi, India)	13:50 - 13:55
EP56-1244-21	Social protection and TB: Policy production before, during, and after the COVID-19 pandemic in Rio de Janeiro, Brazil Reginaldo Bazon Vaz Tavares (Ribeirão Preto, Brazil)	13:55 - 14:00
	Q&A	14:00 - 14:10
<i>E-Posters</i>		
	13:10 - 14:10	B1C
	EP57 - Rapid diagnostic and resistance testing Thomas Schön (Kalmar, Sweden)	
EP57-1245-21	Validating proficiency testing panels for Xpert® MTB/XDR assay using CDC's DTS technology for EQA PT program Shipra Bhargava (New Delhi, India)	13:10 - 13:15
EP57-1246-21	Sinapi Specimen Cups to reduce Xpert MTB/RIF testing rejection rate in Mali	13:15 - 13:20
EP57-1247-21	Implementing Bangladesh's first EQA program for GeneXpert MTB/XDR: Ensuring quality diagnosis of drug-resistant TB Iffat Ara Ifa (Dhaka, Bangladesh)	13:20 - 13:25
EP57-1248-21	Innovo GenMax MTB-RIF/INH: A moderate-complexity automated NAAT for rapid simultaneous detection of <i>M. tuberculosis</i> complex and rifampin/isoniazid resistance Huiwen Zheng (Beijing, China)	13:25 - 13:30
EP57-1249-21	Evaluation of the STANDARD M10 MTB-RIF/INH assay: A rapid solution for drug-resistant TB detection Anura David (Johannesburg, South Africa)	13:30 - 13:35
EP57-1250-21	Real-time monitoring of performance of GeneXpert machines through a locally developed web-based application Ashish Shrestha (Bhaktapur, Nepal)	13:35 - 13:40
EP57-1251-21	Operational feasibility of 'TB Concentration & Transport' and 'TB DNA Extraction' kits for bio-safe dry sputum transport for drug resistance detection using Line Probe Assay Sagarika Halder (Chandigarh, India)	13:40 - 13:45
EP57-1252-21	Drug-resistance characterisation of <i>M. tuberculosis</i> using ONT in Mongolia Baasansuren Erkhembayar (Ulaanbaatar, Mongolia)	13:45 - 13:50
EP57-1253-21	Equivalency for HIV: Tongue swabs offer robust alternative to sputum testing for PLHIV Kelsey Heard (Fishers, United States)	13:50 - 13:55
	Q&A	13:55 - 14:10

E-Posters

13:10 - 14:10

B1D

EP58 - Outcomes of drug-resistant TB

Christian Kraef (Copenhagen, Denmark)

EP58-1255-21	Predicting delayed culture conversion in people receiving treatment for rifampicin-resistant TB Annelies Van Rie (Antwerp, Belgium)	13:10 - 13:15
EP58-1256-21	Treatment outcomes of rifampicin-resistant TB under programmatic conditions in Vietnam in 2021 - 2022 Thi Mai Phuong Nguyen (Hanoi, Vietnam)	13:15 - 13:20
EP58-1257-21	Comparative analysis of bedaquiline-based treatment outcomes in people who are HIV-positive and HIV-negative with rifampicin-resistant TB in Gauteng Province, South Africa Charles Rhea (Nashville, United States)	13:20 - 13:25
EP58-1258-21	Outcomes of short-course regimens in the treatment of drug-resistant TB in people with TB & HIV, TB & hepatitis, TB & HIV & hepatitis, and TB in Kazakhstan Yerkebulan Algozhin (Almaty, Kazakhstan)	13:25 - 13:30
EP58-1259-21	PZA resistance and treatment outcome among people with drug-resistant TB at Respiratory Referral Hospital in Indonesia in 2020-2024 Salsabila Hulwani (Jakarta, Indonesia)	13:30 - 13:35
EP58-1260-21	Treatment success rate of people with drug-resistant TB on BPaL regimen in the Democratic Republic of Congo Mawete Fina (Kinshasa, Congo (Democratic Republic))	13:35 - 13:40
EP58-1261-21	Treatment outcomes of bedaquiline-resistant TB: A retrospective and matched cohort study Johanna Kuhlin (Cape Town, South Africa)	13:40 - 13:45
EP58-1262-21	Long-term efficacy and safety of 9-month all-oral regimens for multi-drug-resistant and pre-extensively drug-resistant TB: A multicentre, prospective cohort study in China Senlin Zhan (Shenzhen, China)	13:45 - 13:50
EP58-1263-21	The hidden challenge: Impact of <i>M. tuberculosis</i> strains With <i>rpoB</i> I491F mutation on outcomes of the BPaLM regimen Debrah Vambe (Mbabane, Eswatini)	13:50 - 13:55
	Q&A	13:55 - 14:05

E-Posters

13:10 - 14:10

B1E

EP59 - Digital and AI-driven approaches to integrated TB and respiratory health management

Rachel Byrne (Liverpool, United Kingdom)

EP59-1264-21	Integrated, community-centered screening for chronic respiratory diseases in high-risk Nairobi hotspots using digital chest X-rays with artificial intelligence (AI) Elizabeth Mueni (Nairobi, Kenya)	13:10 - 13:15
EP59-1265-21	Reimagining integrated screening: Preliminary findings from an AI-driven TB and lung health initiative in Pakistan Sabira Tahseen (Islamabad, Pakistan)	13:15 - 13:20
EP59-1266-21	Artificial intelligence-driven increase in TB preventive treatment in prison settings in Mozambique Amadin Olotu (Atlanta, United States)	13:20 - 13:25

EP59-1267-21	Perceptions of smartphone-based cough-audio TB triage among health facility clients: Findings from qualitative implementation research in CAGE-TB Hanlie Myburgh (Cape Town, South Africa)	13:25 - 13:30
EP59-1268-21	Active case finding and detection of TB infection among incarcerated populations using an artificial intelligence-aided portable handheld X-ray machine in Himachal Pradesh, India Shruthi Rajan (New Delhi, India)	13:30 - 13:35
EP59-1269-21	A quarter of a century of TB-CAD research: A bibliometric overview of themes, tools, and global partnerships Irina Aulianisa (Seoul, Korea, Republic of)	13:35 - 13:40
EP59-1270-21	Evaluating CAD software performance in handling erroneous chest radiograph images Betty Bonass (Kenya)	13:40 - 13:45
EP59-1271-21	Use of multimodal computer aided detection software for optimisation of lung health services in Kenya Immaculate Kathure (Nairobi, Kenya)	13:45 - 13:50
EP59-1272-21	Accuracy of computer-aided detection systems for identifying specific non-TB pulmonary findings Betty Bonass (Kenya)	13:50 - 13:55
EP59-1273-21	Radiology a high-risk section for airborne infections including TB: Array of possible interventions in India Deepak Khismatrao (Delhi, India)	13:55 - 14:00
	Q&A	14:00 - 14:10
<i>E-Posters</i>		
13:10 - 14:10		B1F
EP60 - Innovations in TB Modelling for vaccination, diagnosis and treatment		
Katherine C. Horton (London, United Kingdom) Sandip Mandal (New Delhi, India)		
EP60-1274-21	Modelling the Covid-19 pandemic impact on the diagnosis of child and adolescent TB in South Africa Karen Du Preez (Cape Town, South Africa)	13:10 - 13:15
EP60-1275-21	Targeted TB vaccination strategies in India: Impact of risk-based vs. geographic approaches using mathematical modelling Ruchita Jalal (Gurugram, India)	13:15 - 13:20
EP60-1276-21	The potential epidemiological impact of TB screening among previously incarcerated individuals for TB in Brazil Lily O'Brien (London, United Kingdom)	13:20 - 13:25
EP60-1277-21	The delivery of new TB vaccines to people living with HIV: When to vaccinate? Tom Sumner (London, United Kingdom)	13:25 - 13:30
EP60-1278-21	Impacts of diagnostic sensitivity on mortality in paediatric TB Radhika P. Tampi (Boston, United States)	13:30 - 13:35
EP60-1279-21	Potential long-acting TB treatment for people with HIV in South Africa: Cost-effectiveness benchmarks Krishna P. Reddy (Boston, United States)	13:35 - 13:40
	Q&A	13:40 - 13:50

E-Posters

13:10 - 14:10

B1G

EP61 - Bold actions advancing TB elimination

Mikaela Coleman (Munich, Germany)

EP61-1280-21	Impact of person-centred care on treatment outcomes in drug-resistant TB: A case study from Mozambique a low-middle-income country Pereira Zindoga (Maputo, Mozambique)	13:10 - 13:15
EP61-1282-21	Coach Mpilo: Men supporting men through TB and HIV treatment journeys in South Africa Kelly Rutt (East London, South Africa)	13:15 - 13:20
EP61-1283-21	Cash or calories: Preferences for nutritional support among persons with TB in South India Sadie B. Cowan (Boston, United States)	13:20 - 13:25
EP61-1284-21	Harnessing the power of private providers: Scaling up TB notification in Niger State Deborah Philip (Minna, Nigeria)	13:25 - 13:30
EP61-1285-21	TB-Free Desert Initiative in Rajasthan: A multi-sectoral and diagnostic network optimisation approach in the Thar region Shikha Gupta (New Delhi, India)	13:30 - 13:35
EP61-1286-21	Current realities: Benefits of a diversified project portfolio and adaptive implementation for programme resiliency Mamman Bajehson (Kano, Nigeria)	13:35 - 13:40
EP61-1287-21	Harnessing rural governance for TB elimination: Findings from a multi-tiered approach to achieving TB-free status in rural India Mrigen Deka (New Delhi, India)	13:40 - 13:45
EP61-1288-21	Enhancing TB case-holding through effective pre-treatment and continuous counselling in Delta State, Nigeria Chike Ezeanya (Abuja, Nigeria)	13:45 - 13:50
	Q&A	13:50 - 14:10

E-Posters

13:10 - 14:10

B1H

EP62 - M. tuberculosis infection and preventive treatment

Andrew Steenhoff (Philadelphia, United States)

EP62-1289-21	High TB infection rates in two rural districts of Ethiopia: Implications for enhanced TB preventive treatment Oumer Ali (Addis Ababa, Ethiopia)	13:10 - 13:15
EP62-1290-21	Prevalence of TB infection among household contacts aged 18 years and above of persons with pulmonary TB: A secondary analysis of Cy-TB test data from West Bengal, India Biswajit Chaklader (New Delhi, India)	13:15 - 13:20
EP62-1291-21	TB infections among rifampicin-resistant TB household contacts: A multi-central prospective cohort study (TCCT study) Qing-Luan Yang (Shanghai, China)	13:20 - 13:25
EP62-1292-21	Evaluation of TB infection prevention and control measures in China's designated medical institutions: A comparative analysis of 2014 and 2022 Lijie Zhang (Beijing, China)	13:25 - 13:30
EP62-1293-21	Impact of household TB contact investigation on detecting TB: TB-LON 3 project experience	13:30 - 13:35

	Chukwuemeka Uzoigwe (Lagos, Nigeria)	
EP62-1294-21	Revisiting index contact households: Evidence for structured repeat testing among TB contacts in Khana LGA, Rivers state Nigeria Excellent Ade (Port Harcourt, Nigeria)	13:35 - 13:40
EP62-1295-21	Finding the missing people with TB through expanded public-private mix (PPM) engagement in Lagos State, Nigeria Vivian Okafor (Lagos, Nigeria)	13:40 - 13:45
EP62-1296-21	Treatment uptake among people with TB infection detected by community-based screening in rural Vietnam Khanh Luu (Ho Chi Minh, Vietnam)	13:45 - 13:50
EP62-1297-21	Digital health interventions in improving initiation and completion of TB preventive treatment among household contacts: A systematic review and meta-analysis Gistane Ayele (Arba Minch, Ethiopia)	13:50 - 13:55
	Q&A	13:55 - 14:05
 <i>E-Posters</i>		
	13:10 - 14:10	B11
EP63 - TB uncovered: Advocacy and awareness in action		
Peter Ngo'la Owiti (Makueni, Kenya) Priyanka Aiyer (Delhi, India)		
EP63-1299-21	Empowering mothers of children living with HIV to promote TB preventive therapy: A community-based approach in high-burden districts of Sindh, Pakistan Syed Sharaf Ali Shah (Karachi, Pakistan)	13:10 - 13:15
EP63-1300-21	From villages to victory: Empowering PRIs to declare TB Mukht Gram Panchayats in Moga District, Punjab (A scalable model for India) Ramesh Dasari (Hyderabad, India)	13:15 - 13:20
EP63-1301-21	HIV and TB are not the same: Rethinking how to tailor community engagement for TB Duy Trinh-Hoang (Sydney, Australia)	13:20 - 13:25
EP63-1302-21	Empowering TB survivor-led networks in India to adopt CRGS approaches Anupama Srinivasan (Chennai, India)	13:25 - 13:30
EP63-1303-21	Coalition-driven advocacy to improve access to TB medicines in Canada: Using provider perspectives to create change Yassen Tcholakov (Montreal, Canada)	13:30 - 13:35
EP63-1304-21	Eliminating barriers to TB care: Lessons from the 100-day intensified TB elimination campaign in remote tribal areas of Arunachal Pradesh, India (Dec 2024-Mar 2025) Nidhi Sumnyan (New Delhi, India)	13:35 - 13:40
EP63-1305-21	Evidence based advocacy to enhancing integrated TB and HIV service provision among persons with disabilities (PWDs) in Uganda Nissy Namuyomba (Masaka city, Uganda)	13:40 - 13:45
EP63-1306-21	Empowering TB survivors as champions of change: A community-led approach to advancing TB elimination efforts in India Amitabh Das (Delhi, India)	13:45 - 13:50
EP63-1307-21	Utilising the 'Duare Sarkar' (Government at doorstep) camp for TB information, education and communication, as well as screening:	13:50 - 13:55

Outputs of such a camp in a district of West Bengal, India

Abhijit Dey (New Delhi, India)

EP63-1308-21	EduClowns for TB awareness: Creative community engagement for early detection and behavioural change in Tamil Nadu, India Mercy Annapoorani (Virudhunagar, India)	13:55 - 14:00
	Q&A	14:00 - 14:10

TBScience E-Poster Sessions

13:10 - 14:10

TBS-EP-09 - TBScience Moderated E-posters IX

Limakatso Lebina (Durban, South Africa)

TBS-EP290	Possible role of amino acid synthesis suggested in contributing to tolerance under BDQ pressure in <i>Mycobacterium tuberculosis</i> (Mtb) clinical isolates Dania Saeed (Karachi, Pakistan)	13:10 - 13:15
TBS-EP293	Host driven evolution of antimicrobial resistance in mycobacteria Catherine Rush (Townsville, Australia)	13:15 - 13:20
TBS-EP296	Polymer microparticles surface functionalized with phages to improve intracellular efficacy of phage therapy Daria Smalchuk (Badalona, Spain)	13:20 - 13:25
TBS-EP299	Identification of bacterial cell envelope factors that influence tuberculosis treatment outcome Jérôme Nigou (Toulouse, France)	13:25 - 13:30
TBS-EP305	Long-acting bedaquiline: A novel preventive strategy against tuberculosis in a murine model Nicolas Veziris (Paris, France)	13:30 - 13:35
TBS-EP308	Shifts in <i>Mycobacterium tuberculosis</i> complex lineages and drug resistance patterns in Georgia: A whole genome sequencing-based cohort study (2014-2020) Dmytro Butov (Kharkiv, Ukraine)	13:35 - 13:40
TBS-EP311	Sputum microbiome among newly admitted patients with HIV in a high TB prevalence setting: A study from a teaching hospital in Ghana Prince Asare (Legon, Ghana)	13:40 - 13:45
TBS-EP314	Plasma metabolites of tryptophan catabolism and reduced lung function during and after TB treatment Joshua Chandler (Atlanta, United States)	13:45 - 13:50
TBS-EP317	Collagen-targeted PET/CT for evaluation of post-TB lung disease in adults with TB Alvaro A. Ordonez (Philadelphia, United States)	13:50 - 13:55
TBS-EP318	Q&A	13:55 - 14:10

Community Connect

13:15 - 14:00

CCC

CCBS001 - Book signing with Author of [STIGMATIZED: A Mongolian girl's journey from stigma and illness to empowerment](#) -- Handaa Enkh-Amgalan

Introduction and moderators impression of the book Petra Heitkamp (Ottawa, Canada)	13:15 - 13:20
Live reading from the book	13:20 - 13:30

	Handaa Enkh-Amgalan (Berlin, Germany)	
	Question and answer with the author	13:30 - 13:40
	Petra Heitkamp (Ottawa, Canada)	
	Book signing & meet and greet with Handaa Enkh Amgalan	13:40 - 14:00
	Handaa Enkh-Amgalan (Berlin, Germany)	
<i>Symposia</i>		
14:10 - 15:40		Main
	SY30-400-30 - Accelerating the introduction of new sample types and near point of care platforms to close gaps in TB diagnosis	
	Nazir Ismail (Johannesburg, South Africa)	
	Tejaswini Dharmapuri Vachaspathi (New York, United States)	
	Introduction	14:10 - 14:15
	Performance of tools in the pipeline using oral swabs for TB detection	14:15 - 14:30
	Alfred Andama (KAMPALA, Uganda)	
	Trade-offs and considerations: Sample types and placement	14:30 - 14:45
	Andrew Kerkhoff (San Francisco, United States)	
	Country perspectives: Planning to Introduce a new near-point of care test	14:45 - 15:00
	The Global Fund next-generation market shaping strategic initiative: Early demand estimations for near-point of care tests to support affordable access to new TB diagnostics	15:00 - 15:15
	Grania Brigden (Switzerland)	
	The Diagnostics Equity Consortium: A civil society-led mechanism for ambition and accountability for closing diagnostic gaps	15:15 - 15:30
	Tapiwanashe Kujinga (Harare, Zimbabwe)	
	Q&A	15:30 - 15:40
<i>Oral Abstract Sessions</i>		
14:10 - 15:40		TBS
	OA27 - Institutional hotspots: Addressing TB transmission in hospitals and prisons	
	Xiaolin Wei (Toronto, Canada)	
	In Introduction	14:10 - 14:13
OA27-358-21	Spatial distribution of TB among healthcare workers in Brazil: High-density areas and occupational risk (2013-2023)	14:13 - 14:20
	Fernando Augusto Dias e Sanches (Rio de Janeiro, Brazil)	
OA27-359-21	Beyond the workplace: A qualitative study of the impact of TB-related stigma on the private lives of healthcare workers in Indonesia	14:20 - 14:27
	Agus Fitriangga (Pontianak, Indonesia)	
OA27-360-21	The uptake of TB preventive therapy among primary healthcare practitioners: A retrospective cohort study from Montreal	14:27 - 14:34
	Mojdeh Azimi (Montreal, Canada)	
OA27-361-21	Lessons from occupational screening for TB disease using chest radiography in health workers in South Africa	14:34 - 14:41
	Ananja van der Westhuizen (Cape Town, South Africa)	
OA27-362-21	Evaluating TB treatment outcomes among healthcare workers in Zambia (2018-2022): A key strategy for enhancing healthcare	14:41 - 14:48

	workers' safety Jonathan Mpundu Chama (Lusaka, Zambia)	
OA27-363-21	TB preventive treatment among health workers in Pakistan: Cross-country comparison of outcomes and gaps Kinz Ul Eman (Islamabad, Pakistan)	14:48 - 14:55
OA27-364-21	Feasibility and acceptability of chest X-ray with computer aided detection (CAD) among health care workers Paul Bako Adogo (Karu, Nigeria)	14:55 - 15:02
OA27-365-21	Standards behind bars: Review of TB policies for incarcerated populations in six countries Sharonann Lynch (Washington, United States)	15:02 - 15:09
OA27-366-21	Human rights-based and inmate-led TB prevention and care in prisons Anne Hoejrup (Lusaka, Zambia)	15:09 - 15:16
OA27-367-21	Enhancing TB prevention and care as well as early diagnosis in Zambia's correctional facilities: The Building Bridges Model Nawa Sanjobo (Kitwe, Zambia)	15:16 - 15:23
OA27-368-21	Effectiveness of latent TB infection treatment among individuals in correctional facilities, Taiwan Pin Hui Lee (Taipei, Taiwan)	15:23 - 15:30
	Q&A	15:30 - 15:40
 <i>Oral Abstract Sessions</i>		
	14:10 - 15:40	R1
	OA28 - Lung health in children and adolescents James Seddon (Cape Town, South Africa) Elizabeth Obimbo (Nairobi, Kenya)	
In	Introduction	14:10 - 14:15
OA28-369-21	Challenges and stethoscope preferences among healthcare workers in diagnosing paediatric pneumonia: A qualitative study in South Africa Abenathi Mcinziba (Cape Town, South Africa)	14:15 - 14:23
OA28-370-21	Evidence synthesis: RSV burden and the future of respiratory infection surveillance in Pakistan Mahnoor Tariq (Karachi, Pakistan)	14:23 - 14:31
OA28-371-21	Assessing acute cough in pre-schoolers through TB symptomatic screening: Insights from a five-year retrospective study Yekumah Wali (Awka, Nigeria)	14:31 - 14:39
OA28-372-21	Assessing lung function impairment in children and adolescents post-TB treatment: Case of Mama Lucy Kibaki Hospital Kajuju Juliet (Nairobi City, Kenya)	14:39 - 14:47
OA28-374-21	The TB aftermath: Uncovering the hidden respiratory burden in children Joy Githua (Nairobi, Kenya)	14:47 - 14:55
OA28-375-21	Bidirectional screening approach for TB and pertussis: Lessons learnt from West Bengal, India Abhijit Dey (New Delhi, India)	14:55 - 15:03
OA28-376-21	The performance of CAD4TB to distinguish radiological TB from not-TB in a paediatric population in South Africa Megan Palmer (Cape Town, South Africa)	15:03 - 15:11

OA28-377-21	AI-enabled X-ray for childhood TB detection: Early implementation results from school-based TB screening activities in remote rural communities in Nigeria Chidimma Okoye (Abak, Nigeria)	15:11 - 15:19
OA28-378-21	Feasibility, tolerability, and yield of nasopharyngeal aspirate and stool samples for molecular TB detection in children with severe pneumonia Mikaela Coleman (Munich, Germany)	15:19 - 15:27
	Q&A	15:27 - 15:40
 <i>Oral Abstract Sessions</i>		
14:10 - 15:40		R2
OA29 - Equity at the doorstep: Community health workers for lung health		
Zahedul Islam (Kyiv, Ukraine) Emma Smith (Darwin, Australia)		
In	Introduction	14:10 - 14:15
OA29-379-21	Strengthening community health workers' engagement in TB prevention and care in Madagascar: Recommendations from the workforce themselves Onja Gabrielle Ravololohanitra (Antananarivo, Madagascar)	14:15 - 14:23
OA29-380-21	Incentivising community action: A results-based approach to TB detection, prevention and care Donald Denis Tobaiwa (Gweru, Zimbabwe)	14:23 - 14:31
OA29-381-21	Boosting TB prevention: The role of community volunteers in increasing uptake of TB preventive treatment among household contacts in Haryana, India Kritika Bansal (Gurugram, India)	14:31 - 14:39
OA29-382-21	TB notifications by community-based volunteers in communities serviced by mission health facilities in Zambia: Translating WHO guidance into practice Ernest Mwila Bwalya (Lusaka, Zambia)	14:39 - 14:47
OA29-383-21	Comparative yields of TB preventive therapy from community contact tracing and facility based contact invitation strategies: Implications for programmatic implementation Susan Mutua (Nairobi, Kenya)	14:47 - 14:55
OA29-385-21	Enhancement of TB infection prevention through task shifting to community health volunteers (CHVs) Johnson Diara (Makurdi, Nigeria)	14:55 - 15:03
OA29-384-21	Targeting the golden years: Finding missing people with TB among the elderly through targeted outreaches in Siaya County, Kenya Alice Wanyonyi (Nairobi, Kenya)	15:03 - 15:11
OA29-387-21	Community-based tobacco cessation intervention among chronic smokers in urban slums: A public health approach Deepika S (Chennai, India)	15:11 - 15:19
OA29-388-21	Enhancing TB detection through community-led hybrid contact investigation: A scalable model for hard-to-reach populations Donald Denis Tobaiwa (Gweru, Zimbabwe)	15:19 - 15:27
	Q&A	15:27 - 15:40

Short Oral Abstract Sessions

14:10 - 15:40

R3

SOA16 - Geospatial analytics and mapping for TB prevention, detection and care

Pete Dodd (Sheffield, United Kingdom)

Stewart Chang (Seattle, United States)

Zaidi Asad (London, United Kingdom)

In	Introduction	14:10 - 14:15
SOA16-678-21	Leveraging artificial intelligence to predict potential TB hotspots at the community level in Bangui, Republic of Central Africa Caroline Cauwelaert (Brussels, Belgium)	14:15 - 14:23
SOA16-679-21	Spatial analysis of TB disease and infection: Identifying priority areas for active contact management in Brazil Anete Trajman (Rio de Janeiro, Brazil)	14:23 - 14:31
SOA16-680-21	Spatiotemporal dynamics and hotspot identification of TB in Eswatini: A national analysis from 2017 to 2024 Sandile Ndabezitha (Houston, United States)	14:31 - 14:39
SOA16-681-21	Exploring added value of novel data sources for small area prediction of TB burden in Pakistan: Private sector sales, telecom mobility and satellite imagery data Ente Rood (Amsterdam, Netherlands)	14:39 - 14:47
SOA16-682-21	Mapping BCG vaccination coverage in Africa, 1990-2022: A novel spatiotemporal modelling study Alemneh Liyew (Perth, Australia)	14:47 - 14:55
SOA16-683-21	Mapping TB preventive therapy in Ethiopia: Geospatial analysis Alemneh Liyew (Perth, Australia)	14:55 - 15:03
SOA16-684-21	Geospatial patterns of loss to follow-up from TB treatment: A gender-based analysis in Brazil Reginaldo Bazon Vaz Tavares (Ribeirão Preto, Brazil)	15:03 - 15:11
SOA16-685-21	Geospatial intelligence using QGIS tool for localised TB elimination: A multi-sectoral approach in Kasargod district, Kerala, India Gayathri A. V. (Kochi, India)	15:11 - 15:19
SOA16-686-21	Emerging hotspots of TB in Uganda: Insights from spatiotemporal analysis Geofrey Amanywa (Kampala, Uganda)	15:19 - 15:27
	Q&A	15:27 - 15:40

Oral Abstract Sessions

14:10 - 15:40

R4

OA30 - Environmental determinants of lung health: From fossil fuel to filter tips

Lin Yan (Beijing, China)

Finn McQuaid (London, United Kingdom)

In	Introduction	14:10 - 14:13
OA30-389-21	Climate change and TB: An analytical framework Matthew J. Saunders (London, United Kingdom)	14:13 - 14:21
OA30-390-21	Tuberculosis and climate emergency: Community analysis on access to TB services during the floods in 2024 in Porto Alegre, Brazil Carla de Almeida (Porto Alegre, Brazil)	14:21 - 14:29
OA30-391-21	Asthma and air pollution in Benin: Symptoms' frequency and	14:29 - 14:37

	impact of the harmattan period in adolescents from A4A Project study in Cotonou Attannon Arnauld Fiogbé (Cotonou, Benin)	
OA30-393-21	Effect of food insecurity on TB incidence in climate sensitive Karamoja region of Uganda Basant Joshi (Montpellier, France)	14:37 - 14:45
OA30-394-21	Factors contributing to delayed TB diagnosis in Somalia: Survey data identifies poverty, malnutrition, displacement, and low awareness as key factors delaying TB diagnosis in Somalia Amatarahman Isse Omar (Garowe, Somalia)	14:45 - 14:53
OA30-395-21	Ten-year trends in second hand smoking (SHS) in Europe 2012-2023: A snapshot review Aarthy Aravind (Buckingham, United Kingdom)	14:53 - 15:01
OA30-396-21	A comprehensive bibliometric exploration on the health impact of e-cigarettes Diksha Walia (Chandigarh, India)	15:01 - 15:09
OA30-397-21	Global trends and industry influence in tobacco harm reduction research: A bibliometric analysis (2014-2024) Nancy Satpathy (Bhubaneswar, India)	15:09 - 15:17
OA30-398-21	Heated tobacco product use and tobacco abstinence: A prospective cohort study Tomohiko Ukai (Kiyose, Japan)	15:17 - 15:25
	Q&A	15:25 - 15:40
 <i>Oral Abstract Sessions</i> 14:10 - 15:40		
	OA31 - Informing evidence-based TB policies Rein Houben (London, United Kingdom) Pei-Chun Chan (Taipei city, Taiwan)	R5
In	Introduction	14:10 - 14:15
OA31-399-21	Power, players and politics: Who are the power brokers of TB control in Pakistan - International donors or national leadership? Shifa Salman Habib (Karachi, Pakistan)	14:15 - 14:22
OA31-400-21	Comparing the relative epidemiological impact, costs and cost-effectiveness of TB interventions across three countries Katherine C. Horton (London, United Kingdom)	14:22 - 14:29
OA31-401-21	New drugs, diagnostics and vaccines in India: Their potential impact on TB burden, and priorities for their development Sandip Mandal (New Delhi, India)	14:29 - 14:36
OA31-402-21	Combination strategies to control the TB epidemic in the Karamoja subregion of Uganda: A modelling analysis Stella Zawedde-Muyanja (Kampala, Uganda)	14:36 - 14:43
OA31-403-21	What will it take to achieve the End TB targets in South Africa? Leigh Johnson (Cape Town, South Africa)	14:43 - 14:50
OA31-404-21	TBMod: A flexible, open-source framework for modelling TB Roel Bakker (London, United Kingdom)	14:50 - 14:57
OA31-405-21	Large notification impact of a multi-component active case finding and person-centered care intervention in urban Viet Nam: The Erase TB case study Lan Phuong Nguyen (Ha Noi, Vietnam)	14:57 - 15:04

OA31-406-21	Potential impact, costs, and benefits of population-wide screening interventions for TB in Viet Nam Alvaro Schwalb (London, United Kingdom)	15:04 - 15:11
OA31-407-21	Community-driven TB elimination in India: Lessons from VHAI's multi-state interventions Binoy Mathew (Delhi, India)	15:11 - 15:18
OA31-408-21	Impact of US government funding cessation on TB prevention and care: An African multicountry survey Kobto Koura (Paris, France)	15:18 - 15:25
	Q&A	15:25 - 15:40
 <i>Oral Abstract Sessions</i>		
	14:10 - 15:40	R6
	OA32 - Person-centred quality care for all Razia Kaniz Fatima (Islamabad, Pakistan)	
	Introduction	14:10 - 14:15
OA32-409-21	Private healthcare sector-led initiative to end TB in India Rakesh P S (Delhi, India)	14:15 - 14:22
OA32-410-21	Longitudinal single patient viewer (SPV) usage, awareness, and training for integrated patient management in South Africa Lario Viljoen (Cape Town, South Africa)	14:22 - 14:29
OA32-411-21	Development and validation of a TB provider trust scale: A pilot study Stephanie Law (Montreal, Canada)	14:29 - 14:36
OA32-412-21	Measuring the efficiency of TB care in Korea's public-private mix project: A data envelopment analysis approach Donghoon Kim (Seoul, Korea, Republic of)	14:36 - 14:43
OA32-413-21	People-centred care for culturally diverse people with drug-resistant TB in Norway: Healthcare strategies and challenges Eline Storvig (Trondheim, Norway)	14:43 - 14:50
OA32-414-21	A mixed-methods evaluation of the acceptability, implementation and effectiveness of a gender-specific TB intervention in Uganda Jasper Nidoi (Kampala, Uganda)	14:50 - 14:57
OA32-415-21	Gender-specific predictors of TB mortality among adolescents and young adults in Kenya: A national surveillance study Rhoda Pola (Nairobi, Kenya)	14:57 - 15:04
OA32-416-21	Understanding knowledge gaps challenges access to TB care for gender-diverse individuals in India Atul Shendge (Sonipat, India)	15:04 - 15:11
OA32-417-21	Navigating dual burdens: Intersectionality of TB and social stigma among transgenders, MSM, female sex workers, and people living with HIV in India: Findings from a qualitative study Atreyee Sinha (Bengaluru, India)	15:11 - 15:18
OA32-418-21	Understanding TB transmission driven by alcohol sharing behaviours and venues: A comparative cross-sectional social network survey in Puducherry, India Charutha Retnakumar (Puducherry, India)	15:18 - 15:25
	Q&A	15:25 - 15:40

Oral Abstract Sessions

14:10 - 15:40

R7

OA33 - The future of TB screening: Integrating AI, economic modelling, and community-based approaches

Hongjo Choi (Seoul, Korea, Republic of)
Emily Kendall (Baltimore, United States)

	Introduction	14:10 - 14:15
OA33-419-21	Ensuring diagnostic accuracy: Real-time quality control for AI-driven chest X-ray screening in resource-limited settings Justy Antony Chiramal (Atlanta, United States)	14:15 - 14:23
OA33-420-21	Time-to-treatment-initiation studies of a randomised controlled trial in community-based active case-finding for TB Tahlia Perumal (Cape Town, South Africa)	14:23 - 14:31
OA33-421-21	CAD4TB trajectory modelling in a cohort of household contacts and association with socio-demographic and clinical characteristics Leyla Larsson (London, United Kingdom)	14:31 - 14:39
OA33-422-21	Differentiated TB abnormality thresholds for artificial intelligence interpretation of chest X-rays Tushar Garg (Geneva, Switzerland)	14:39 - 14:47
OA33-423-21	Factors affecting the performance of chest X-ray artificial intelligence-based computer-aided diagnosis for TB in a primary health centre Celso Khosa (Maputo, Mozambique)	14:47 - 14:55
OA33-424-21	Mathematical modelling of TB transmission and intervention effectiveness: Evaluating age-specific control measures across epidemiologically diverse regions in China Zexuan Wen (Shanghai, China)	14:55 - 15:03
OA33-425-21	A Bayesian cost-effectiveness model of TB screening and diagnosis in seven high TB burden low- and middle-income countries Tushar Garg (Geneva, Switzerland)	15:03 - 15:11
OA33-426-21	Cost-effective diagnostic strategies for targeted mass screening campaigns: Pooled GeneXpert vs. TB-LAMP testing in Ethiopia Tamiru Assefa (Addis Ababa, Ethiopia)	15:11 - 15:19
OA33-427-21	Cost-effectiveness of clinic-based and community-based active case finding in South Africa Sedona Sweeney (London, United Kingdom)	15:19 - 15:27
	Q&A	15:27 - 15:40

Symposia

14:10 - 15:40

R8

SY31-410-31 - It takes a village: Advancing late-stage TB vaccine trials in adults and adolescents through global collaboration

Elana Van Brakel (Stellenbosch, South Africa)
Alexander Schmidt (Germany)

	Introduction	14:10 - 14:15
	M72/AS01E Phase 3 design considerations, trial progress update, and learnings Alemnew Dagneu (Cambridge, United States)	14:15 - 14:30
	Epidemiology in support of late-stage TB vaccine trials Puck Pelzer (Amsterdam, Netherlands)	14:30 - 14:45

Asymptomatic TB: Unique opportunities in tuberculosis vaccine trials	14:45 - 15:00
Keertan Dheda (Cape Town, South Africa)	
Recruitment of adolescents for late-stage TB vaccine trials	15:00 - 15:15
Elizabeth Hellström (Paarl, South Africa)	
Vaccine hesitancy and TB vaccine development	15:15 - 15:30
Anastacia Koch (Cape Town, South Africa)	
Q&A	15:30 - 15:40

Community Connect Sessions

14:10 - 14:55

CC

CCSPS004 - From pilots to global impact: Communities driving the TB prevention revolution (2018-2025)

Mike Frick (New York City, United States)

Blessina Kumar (New Delhi, India)

Makaita Gombe (Harare, Zimbabwe)

Opening remarks on where TPT stood in 2018, and how communities drove progress to today	14:10 - 14:14
Mike Frick (New York City, United States)	
Blessina Kumar (New Delhi, India)	
Introducing the IMPAACT4TB community small grants model	14:14 - 14:20
Lynette Mabote (United States)	
Patient journeys	14:20 - 14:25
Frontline health workers	14:25 - 14:28
Community panel	14:28 - 14:43
Makaita Gombe (Harare, Zimbabwe)	
Aisha Linatu Abdulrahman (Nigeria)	
Edna Tembo (Malawi)	
Melody Mukundwi (Zimbabwe)	
Question and answer	14:43 - 14:48
The future of TPT	14:48 - 14:52
Gavin Churchyard (Isando, South Africa)	
Dennis Falzon (Geneva, Switzerland)	
Closing - creative expression	14:52 - 14:55

TBScience E-Poster Sessions

14:15 - 15:45

TBS-EP-10 - TBScience Moderated E-posters X

Matthys Gerhardus Potgieter (Cape Town, South Africa)

TBS-EP320	Long-term morbidity after tuberculosis treatment in a high-burden country	14:15 - 14:20
Reiko Miyahara (Tokyo, Japan)		
TBS-EP326	The ability of patients with TB disease to control mycobacterial replication in vitro is not impaired by diabetes	14:20 - 14:25
Alessandra Aiello (Rome, Italy)		
TBS-EP329	Population impact of new TB vaccines may depend on efficacy against infectious asymptomatic TB: A modelling study	14:25 - 14:30
Rebecca A. Clark (London, United Kingdom)		
TBS-EP332	Comparison of phylogenetic metrics of transmission in symptomatic and asymptomatic tuberculosis	14:30 - 14:35

	Kesia Esther da Silva (Stanford, United States)	
TBS-EP335	A new blood-based RNA signature (R7), effectively identifies TB disease and predicts response to therapy Bernadette Saunders (Sydney, Australia)	14:35 - 14:40
TBS-EP338	Granulysin antimicrobial activity promotes dormancy in <i>Mycobacterium tuberculosis</i> Sarah Schmidiger (Allschwil, Switzerland)	14:40 - 14:45
TBS-EP341	Peripheral CD34+ cells as a potential niche for <i>Mycobacterium tuberculosis</i> Tonino Alonzi (Rome, Italy)	14:45 - 14:50
TBS-EP344	<i>Mycobacterium tuberculosis</i> complex lineage 1: A frequent but neglected cause of tuberculosis with implications for vaccine design Venus Marie Rojas (Allschwil, Switzerland)	14:50 - 14:55
TBS-EP347	Targeted sequencing directly on sputum samples for optimizing detection of <i>M.tuberculosis</i> Michaela Jonsson Nordvall (Linköping, Sweden)	14:55 - 15:00
TBS-EP350	Distinct macrophage subsets associate with varying roles that contribute to human lung tissue damage during TB disease Thabo Mpotje (Durban, South Africa)	15:00 - 15:05
TBS-EP353	Oral rinse outperforms facemask capture for non-sputum diagnosis of pulmonary TB Simon C Mendelsohn (Cape Town, South Africa)	15:05 - 15:10
TBS-EP356	Lineage identification and mutation profile of <i>Mycobacterium tuberculosis</i>: A study from National Reference Laboratory, India Raj Narayan Yadav (New Delhi, India)	15:10 - 15:15
TBS-EP359	Comparison of different chemicals as an alternative sputum liquefaction reagent to N-acetyl-L-cysteine with Sodium Hydroxide (NALC-NaOH) Jo Mary Lei Majaducon (Manila, Philippines)	15:15 - 15:20
TBS-EP360	Q&A	15:20 - 15:45
 <i>Community Connect</i>		
	14:15 - 14:45	CCC
CCF002 - Films		
	Life is beautiful Anisha Singh (New Delhi, India)	14:15 - 14:30
	Health worker stigma training Intervention Phumeza Tisile (Cape Town, South Africa)	14:30 - 14:45
 <i>Community Connect Sessions</i>		
	15:00 - 17:30	CCC
CCWS003 - Community Consultation: Way forward for the TB Community Coordination Hub		
	Robyn Waite (Ottawa, Canada)	
	Community Consultation: Way forward for the TB Community Coordination Hub Robyn Waite (Ottawa, Canada) Kinz Ul Eman (Islamabad, Pakistan) Petra Heitkamp (Ottawa, Canada) Shailly Gupta (Switzerland)	15:00 - 17:00

Community Connect Sessions

15:10 - 15:55

CC

CCS023 - Generating community demand for the best available treatments and comprehensive packages of care for drug-resistant tuberculosis

Kathy Fiekert (United Kingdom)

Mariam Toure (Switzerland)

Introduction	15:10 - 15:15
Harnessing traditional and new media to increase demand for drug-resistant TB diagnosis and treatment in the community	15:15 - 15:20
Aisha Linatu Abdulrahman (Nigeria)	
A dual-lens approach to TB care: Integrating people with TB and provider perspectives on short regimens (Findings from a community-designed survey conducted in Ukraine)	15:20 - 15:25
Lesia Tonkonoh (Kyiv, Ukraine)	
Developing a community curriculum on drug-resistant TB treatment and role-playing exercise for healthcare workers to understand perspectives of people with TB	15:25 - 15:30
Dwi Lestari (Indonesia)	
Training former people with drug-resistant TB to be community health agents and participate in community-led monitoring	15:30 - 15:35
Jonas Maunde (Mozambique)	
Using art as a tool for trauma-informed community engagement	15:35 - 15:40
Paulina Siniatkina (Netherlands)	
Question and answers	15:40 - 15:55

Break

15:40 - 15:55

Main

Break/Networking

Late Breaker Oral Abstract Sessions

15:55 - 17:25

Main

LB03 - The Union/CDC late-breaker - TB Detection and Transmission: New Diagnostic Approaches and Study Insights

Sadia Shakoor (Pakistan)

Celso Khosa (Maputo, Mozambique)

In	Introduction	15:55 - 15:58
LB03-1322-21	Asymptomatic ≠ less infectious: School-based study highlights critical role of asymptomatic TB in transmission	15:58 - 16:07
	Shijia Ge (Shanghai, China)	
LB03-1324-21	Diagnostic accuracy of Pluslife MiniDock MTB using sputum and tongue swabs	16:07 - 16:16
	Tessa Mochizuki (United States)	
LB03-1325-21	Evaluating the performance of computer-aided detection systems for pediatric tuberculosis: Results from the CAPTURE consortium	16:16 - 16:25
	Mikashmi Kohli (Geneva, Switzerland)	
LB03-1326-21	Towards child-friendly TB diagnosis: An interim diagnostic accuracy analysis of SMaRT-PCR: A noninvasive mask-based TB diagnostic workflow	16:25 - 16:34
	Ambreen Shaikh (Mumbai, India)	
LB03-1327-21	Pooling sputum specimens of people at high risk of TB reduces costs of Xpert Ultra TB testing without compromising concordance	16:34 - 16:43

	(TUTTPlus Study)	
	Shaheed Vally Omar (Johannesburg, South Africa)	
LB03-1328-21	Smarter screening, lower costs: A seven-country mixed-methods evaluation of novel TB diagnostic strategies from the Start4All consortium	16:43 - 16:52
	Tom Wingfield (Liverpool, United Kingdom)	
LB03-1329-21	The diagnostic TB overture: Deep listening to hear what CXR can and can't see	16:52 - 17:01
	Devan Jaganath (San Francisco, United States)	
LB03-1330-21	Intensive screening reduces tuberculosis transmission over time in prisons	17:01 - 17:10
	José Bampi (Campo Grande, Brazil)	
	Q&A	17:10 - 17:25
<i>Symposia</i>		
15:55 - 17:25		TBS
	SY32-420-32 - Ensuring global access to shorter, better regimens for multi-drug-resistant/rifampicin-resistant TB for children, adolescents and pregnant women	
	Martina Casenghi (Geneva, Switzerland)	
	Jennifer Furin (Boston, United States)	
	Introduction	15:55 - 16:00
	Treatment as short as six months for drug-resistant TB in children, adolescents and pregnant/lactating women: An update on global guidance	16:00 - 16:15
	Sabine Verkuijl (Geneva, Switzerland)	
	Early experiences with shorter, all-oral multi-drug-resistant TB regimens in children and adolescents in Papua New Guinea	16:15 - 16:30
	Gordon Pukai (Port Moresby, Papua New Guinea)	
	Introducing shorter drug-resistant TB treatment regimens for children and pregnant/lactating women in South Africa: Key lessons learned	16:30 - 16:45
	Jennifer Hughes (Cape Town, South Africa)	
	Using shorter all-oral regimens for children and adolescent with multi-drug-resistant/rifampicin-resistant TB: Experience from Peru	16:45 - 17:00
	Antonietta Alarcon (Lima, Peru)	
	Ensuring access to shorter multi-drug-resistant/rifampicin-resistant TB regimens for children using a novel web-based costing tool	17:00 - 17:15
	Anthony Garcia-Prats (Madison, United States)	
	Q&A	17:15 - 17:25
<i>Oral Abstract Sessions</i>		
15:55 - 17:25		R1
	OA34 - From households to health systems: Innovations, ethics, and integration in TB prevention and contact care	
	Uzma Khan (Montreal, Canada)	
	Christopher Sundling (Stockholm, Sweden)	
	Introduction	15:55 - 16:00
OA34-428-21	Is household contact investigation a missing link for TB care in Chhattisgarh, India? Operational research using programmatic data	16:00 - 16:08

	Chetanya Malik (Ambikapur, India)	
OA34-429-21	Severity of TB disease in people diagnosed through systematic screening Cong Minh Nguyen (Munich, Germany)	16:08 - 16:16
OA34-430-21	Breaking the chain: A community-based intervention for screening and TB preventive treatment in household contacts Kinz Ul Eman (Islamabad, Pakistan)	16:16 - 16:24
OA34-431-21	Breaking barriers: Healthcare workers' perspectives on strengthening TB prevention therapy (TPT) implementation in Indonesia and the Philippines Prashant Kulkarni (Pune, India)	16:24 - 16:32
OA34-432-21	Missed opportunities for HIV prevention, diagnosis and treatment in TB-affected households: Evidence from a household contact cohort study Edson Tawanda Marambire (Harare, Zimbabwe)	16:32 - 16:40
OA34-433-21	Diagnostic performance of novel TB infection skin tests and interferon-γ release assays (IGRAs) to detect TB infection in Ndola, Zambia: A pragmatic cluster randomised trial Richard Mwape (Lusaka, Zambia)	16:40 - 16:48
OA34-434-21	Feasibility and acceptability of integrating TB-specific skin testing into home-based household contact investigation for TB infection in Uganda Alex Kityamuwesi (Kampala, Uganda)	16:48 - 16:56
OA34-435-21	mTST: An AI-based approach for quality assurance and measurement of tuberculin skin test administration and reading Aariana Lopes (Montreal, Canada)	16:56 - 17:04
OA34-436-21	Beyond specificity: A bioethical frameworks essay on the ethical imperatives in choosing between PPD Rt23 and recombinant tuberculin tests Fernando Augusto Dias e Sanches (Rio de Janeiro, Brazil)	17:04 - 17:12
	Q&A	17:12 - 17:25
 <i>Symposia</i>		
	15:55 - 17:25	R2
	SY33-430-33 - Lymph node TB: Identifying priorities, challenges, and finding better treatments faster Graeme Meintjes (United Kingdom) Conor Tweed (London, United Kingdom)	
	Introduction	15:55 - 16:00
	The perspective of persons affected by lymph node TB Blessina Kumar (New Delhi, India)	16:00 - 16:15
	Missing nodes: A systematic review of representativeness of lymph node TB in randomised treatment trials Ilaria Motta (London, United Kingdom)	16:15 - 16:30
	The immunology of lymph node TB and the host-pathogen interaction Virginie Rozot (Cape Town, South Africa)	16:30 - 16:45
	Untangling paradoxical reactions: What, when, who and where? Sabine Hermans (Amsterdam, Netherlands)	16:45 - 17:00
	Lymph node TB clinical trials: How do we pick the low-hanging fruit?	17:00 - 17:15

Francesca Conradie (Johannesburg, South Africa)

Q&A 17:15 - 17:25

Symposia

15:55 - 17:25

R3

SY34-440-34 - Generating social science evidence alongside TB trials: Opportunities and impacts

Rovina Ruslami (Bandung, Indonesia)

Samuel Schumacher (Geneva, Switzerland)

Introduction 15:55 - 16:00

Community engagement in TB trials: How to optimise impact and overcome challenges 16:00 - 16:15

Ingrid Schoeman (Pretoria, South Africa)

Integrating mixed-methods research in a paediatric TB diagnostic accuracy trial in Uganda and Peru 16:15 - 16:30

Francesca Basile (Oxford, United Kingdom)

Laying the groundwork for the ethical implementation of genomic sequencing for TB in Botswana 16:30 - 16:45

Stephen Molldrem (Galveston, United States)

Methodological and resource considerations for the successful execution of social science studies alongside TB treatment trials 16:45 - 17:00

Amrita Daftary (Toronto, Canada)

Bringing social science evidence on novel TB interventions to global guideline development 17:00 - 17:15

Nora Engel (Amsterdam, Netherlands)

Q&A 17:15 - 17:25

Symposia

15:55 - 17:25

R4

SY35-450-35 - TB in an era of arctic self-determination

Jennifer Munick-Watkins (Canada)

Faiz Ahmad Khan (Montreal, Canada)

Introduction 15:55 - 16:00

Inuit Tuberculosis Elimination Working Group: A space for Canadian Inuit self-determination and learning 16:00 - 16:15

Raymond Obed (Ottawa, Canada)

Parnasimautik: A Nunavik Inuit story of reclaiming self-governance applied to TB 16:15 - 16:30

Maggie Emudluk Sr. (Kangiqsualujjuaq, Canada)

Community-based research to action: Inuit experiences with TB in Nunavik shaping a community public health worker programme 16:30 - 16:45

Glenda Sandy (Kuujuuaq, Nunavik, Canada)

Kalaallit (Inuit) on the frontline of TB care in Kalaallit Nunaat (Greenland) 16:45 - 17:00

Michael Olsen-Morch (Denmark)

A historical and epidemiological overview of TB and its elimination strategies in Greenland and in Inuit in Denmark 17:00 - 17:15

Anders Koch (Copenhagen, Denmark)

Q&A 17:15 - 17:25

Oral Abstract Sessions

15:55 - 17:25

R5

OA35 - Tiny-people, big challenges: Emerging diagnostics for paediatric TB

Chishala Chabala (Lusaka, Zambia)

Toyin Togun (London, United Kingdom)

	Introduction	15:55 - 16:00
OA35-437-21	Chest X-ray artificial intelligence for detection of paediatric pulmonary TB: A multi-site retrospective diagnostic accuracy study from rural and peri-urban India Saniya Pawar (Mumbai, India)	16:00 - 16:09
OA35-438-21	Generation of paediatric chest X-rays with TB-related findings using deep generative models Daniel Capellán-Martín (Madrid, Spain)	16:09 - 16:18
OA35-439-21	Diagnostic performance of an optimised computer-aided diagnosis (CAD) for TB algorithm on chest radiographs from an exclusively paediatric population in The Gambia Victory F. Edem (Fajara, Gambia)	16:18 - 16:27
OA35-440-21	Evaluating the performance of CAD4TB software using photographs of digital chest X-rays in children with pulmonary TB Heidi Van Deventer (Cape Town, South Africa)	16:27 - 16:36
OA35-441-21	The comparison of Roche Cobas and Xpert Ultra on induced sputum to detect childhood pulmonary TB Juaneta Luiz (Cape Town, South Africa)	16:36 - 16:45
OA35-442-21	Point-of-care ultrasound to support the new WHO treatment decision algorithms in the diagnosis of TB in children Helena Huerga (Brussels, Belgium)	16:45 - 16:54
OA35-443-21	Evaluating the diagnostic accuracy of the TAM-TB assay for paediatric TB in the RaPaed-TB study Alia Razid (Münich, Germany)	16:54 - 17:03
OA35-444-21	Urine lipoarabinomannan concentrations among children living with and without HIV with clinically diagnosed TB disease in KwaZulu-Natal, South Africa Mark Fajans (Seattle, United States)	17:03 - 17:12
	Q&A	17:12 - 17:25

Symposia

15:55 - 17:25

R6

SY36-460-36 - Scaling-up community-wide TB screening irrespective of symptoms: Recognising and overcoming the barriers

Hanif Esmail (London, United Kingdom)

Anna Coussens (Melbourne, Australia)

	Introduction	15:55 - 16:00
	Show me the money: Making the investment case for community-wide screening Luan Nguyen Quang Vo (Ha Noi, Vietnam)	16:00 - 16:15
	Participation is key: Community sensitisation Tejaswini Dharmapuri Vachaspathi (New York, United States)	16:15 - 16:30
	To X-Ray or not to X-Ray: That is the question Thu-Anh Nguyen (Ho Chi Minh city, Vietnam)	16:30 - 16:45
	The health system: Challenges in scaling up and scaling down	16:45 - 17:00

	Obioma Chijioke-Akaniro (Abuja, Nigeria)	
	Do no harm: Evaluating the risk of over-treatment in community screening	17:00 - 17:15
	Rein Houben (London, United Kingdom)	
	Q&A	17:15 - 17:25
<i>Symposia</i>		
15:55 - 17:25		R7
	SY37-470-37 - A forgotten population: Finding TB and disparities within prisons	
	Jason Andrews (Stanford, United States)	
	Salome Charalambous (Johannesburg, South Africa)	
	Introduction	15:55 - 16:00
	Providing access to TB care in prisons: Lessons learned from MSF experience in unstable and limited resource settings (Malawi, Kazakhstan, Ukraine)	16:00 - 16:15
	Ana Paula Cavalheiro (United Kingdom)	
	Modelling TB preventive Therapy in Brazil's prisons	16:15 - 16:30
	Lara Goscé (London, United Kingdom)	
	Experience of use of Chest X-ray and CAD4TB for TB screening in Paraguay	16:30 - 16:45
	Cécile Magis-Escurra (Nijmegen, Netherlands)	
	Experience of policy change to integrate prison infirmaries in the district health system in Cameroon	16:45 - 17:00
	Juergen Noeske (Cameroon)	
	Experience of TB testing in Ethiopia: Introduction of molecular testing for all	17:00 - 17:15
	Negussie Beyene (Ethiopia)	
	Q&A	17:15 - 17:25
<i>Short Oral Abstract Sessions</i>		
15:55 - 17:25		R8
	SOA17 - Innovations and insights in tobacco control: From community action to policy reform	
	Lin Yan (Beijing, China)	
	Tara Singh Bam (Singapore, Singapore)	
	In Introduction	15:55 - 16:00
SOA17-687-21	Who speaks for the margins? Indigenous communities, tobacco, and policy representation in India: A qualitative analysis of parliamentary questions from India (1952-2022)	16:00 - 16:08
	Shilpi Sikha Das (Bengaluru, India)	
SOA17-688-21	A challenging intervention success: Tobacco use reduction in hard-to-reach communities in Sri Lanka	16:08 - 16:16
	Amaranath Oswald Bandara Tenna (Colombo, Sri Lanka)	
SOA17-689-21	Effects of new pictorial cigarette pack warnings on Vietnamese smokers' perceptions and smoking behaviours: A single-factor, between-subjects experimental study	16:16 - 16:24
	Thi Phuong Thao Tran (Hanoi, Vietnam)	
SOA17-690-21	Leveraging online media for the Tobacco Free Youth Campaign increased the visibility of tobacco control efforts among youth in India	16:24 - 16:32
	Bakul Sharma (Indore, India)	

SOA17-691-21	Decoding public perception: Knowledge, attitudes, and practices on WHO FCTC Articles 9 and 10 in India Diksha Walia (Chandigarh, India)	16:32 - 16:40
SOA17-693-21	Data-driven regulation: Prioritising hazardous constituents in smokeless tobacco in India Chirag Goel (Chandigarh, India)	16:40 - 16:48
SOA17-694-21	Restoring FCTC shadow reporting with the Global Tobacco Control Progress Hub Les Hagen (Edmonton, Canada)	16:48 - 16:56
SOA17-695-21	Innovative financing for sustaining tobacco control in low resource settings in the state of Himachal Pradesh, India Gopal Chauhan (Himachal Pradesh (Shimla), India)	16:56 - 17:04
	Q&A	17:04 - 17:25
<i>Community Connect Sessions</i>		
16:10 - 16:55		CC
CCSPS003 - Continuity amid chaos: Sustaining TB responses in times of crisis		
Vlada Rabinova (Ukraine) Yana Terleieva (Kyiv, Ukraine)		
	Introduction	16:10 - 16:12
	Impact of emergencies on TB response: Community-led responses in conflict and fragile settings Muhammad Bashir Abdullahi (Maiduguri, Nigeria)	16:12 - 16:19
	Innovating through crisis: Adaptive tools and peer support for TB continuity Evgenia Geliukh (Kyiv, Ukraine)	16:19 - 16:26
	Global health system adaptations - WHO Askar Yedilbayev (Denmark)	16:26 - 16:33
	Operating in the shadows - Sustaining TB services amidst an unrelenting cycle of crises Kelland Stevenson (Myanmar)	16:33 - 16:40
	Question and Answers	16:40 - 16:55
<i>Break</i>		
17:25 - 17:40		Main
Break/Networking		
<i>Closing Session</i>		
17:40 - 18:55		Main
CS01 - Closing Session		
	Part I	17:40 - 17:40
	Introduction Cassandra Kelly-Cirino (Switzerland)	17:40 - 17:42
	Introduction to conference reflections Katharina Kranzer (United Kingdom)	17:42 - 17:45
	Panel discussion: Reflections and road ahead for the TB Community Katharina Kranzer (United Kingdom)	17:45 - 18:04

Stephan Albani (Germany)
Anete Trajman (Rio de Janeiro, Brazil)
Ashna Ashesh (Patna, India)

Part II	18:04 - 18:04
Introduction	18:04 - 18:07
Cassandra Kelly-Cirino (Switzerland)	
Early Career Researcher Award	18:07 - 18:14
Princess Chichibu Award	18:14 - 18:21
Karel Styblo Public Health Award	18:21 - 18:28
Christmas Seals	18:28 - 18:35
Announcement of The Union World Conference on Lung Health 2026	18:35 - 18:45
Closing remarks	18:45 - 18:55